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ABSTRACT 
 
 
THE EPIDEMIOLOGY AND CLINICAL IMPORTANCE OF FOREFOOT BURSAE IN PATIENTS 
WITH RHEUMATOID ARTHRITIS 
By Lindsey Hooper 
 
The epidemiology of foot complications in patients with rheumatoid arthritis (RA) is poorly 
understood. A number of patients report ongoing foot-related pain, impairment, footwear 
restriction and activity limitation, despite developments in pharmacological disease 
management. Forefoot bursae (fluid filled sacks, FFB) have been previously shown to be highly 
prevalent and related to foot complications in patients with RA. However, the longitudinal 
epidemiology and clinical importance of FFB in this patient population remains unclear.  
  It is anticipated that an improved understanding of the mechanisms by which FFB are 
responsive to, or contribute to, fluctuations in RA disease activity will inform future evaluation of 
foot health and novel therapeutic targets. 
  Through a series of four experimental studies this work has shown that ultrasound (US) 
detectable FFB are highly prevalent in patients with RA compared to healthy volunteers (HV) 
and are clinically relevant. The natural history of FFB remains consistent longitudinally in a 
cohort of patients with established RA disease at baseline. US-detectable FFB were determined 
to be significant prognostic indicators of foot-related disability after three years. Furthermore, the 
distribution of US-detected FFB across forefoot sites was identified as significantly different 
between HV and patients with predominantly inflammatory or degenerative arthritis; uniquely 
patients with RA have a number of FFB within the central forefoot region, in addition to those 
located laterally, which were frequently present in all comparative groups. Thus, in patients with 
RA ~50% of US-detected FFB may be of greatest clinical relevance, due to their positioning 
within the central forefoot region.  
  Detection of FFB using MRI defined a series of FFB characteristics of clinical relevance in 
patients with RA. The presence of plantar forefoot fluid lesions or intermetatarsal soft tissue 
lesions was significantly related to RA disease activity. The presence of plantar soft tissue 
lesions was significantly related to increased biomechanical impairment. However, a high 
proportion of plantar predominantly soft tissue FFB was also noted to be actively inflamed whilst 
other MRI-based markers of disease activity within the forefoot were minimal.   ii 
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Chapter one  
Introduction 
 
1.0 Introduction 
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory polyarthritis affecting multiple 
tissues and organs (Elliott and O'Dell 2002). The disease is typified by symmetrical, diarthrodial 
joint damage that particularly affects the peripheral joints of the hands and feet (Elliott and O'Dell 
2002). Historically pharmacological intervention sought to slow RA disease progression while 
total remission was uncommon (Shaver et al. 2008, van Tuyl et al. 2009). This is exemplified by 
radiographical works of the time which document progressive cortical bone erosion at the 
metacarpophalangeal or metatarsophalangeal joints (Lawrence 1965, Wittenborg and Creutzig 
1973, Fischer 1976, Limido et al. 1985, Akerman et al. 1991). However, advances in the 
pharmacological treatment of RA disease have heralded a new era in disease management 
(Singh et al. 2009, Edwards et al. 2005, Edwards 2005). Remission is the current target for all 
healthcare practitioners and their patients (Aletaha and Smolen 2011). Accordingly, new ways of 
assessing disease activity or its progression are sought and evaluation of bone erosion or joint 
destruction considered too slow an indication (Shaver et al. 2008, Aletaha et al. 2011, Aletaha 
and Smolen 2011). Recent research has utilised alternate imaging methods, such as 
musculoskeletal ultrasound (US) or magnetic resonance imaging (MRI), in order to identify 
earlier manifestations of disease activity in both bone and soft tissue structures (Wakefield 2006, 
Wakefield 2007, Wakefield et al. 2008, Ostergaard 2008, Ostergaard et al. 2011, Cohen et al. 
2011, Conaghan et al. 2003). The use of these modalities has raised the concept of minimal 
disease activity, where it is increasingly apparent that systemic serological or composite 
indicators may be insensitive to ongoing subtle activity within the peripheral joints of the hands 
and feet (van der Heijde et al. 1992, van der Leeden et al. 2007, van der Leeden et al. 2008). As 
such localised investigation of disease activity within both the bone and of tissue structures in 
the peripheral joints is warranted (Haraoui et al. 2011, Aletaha et al. 2011, Aletaha et al. 2010).  
 
Disease progression within the foot may be compounded by its’ functional role during daily 
weight bearing activity (Turner et al. 2008, van der Leeden et al. 2008, van der Leeden et al. 
2006). The biomechanical or inflammatory stresses arising within the anatomical structures of 
the foot in patients with RA are unclear (Turner et al. 2008, Helliwell et al. 2000). However, it is 
known that patient-reported foot-related disability is high in this population (Grondal et al. 2008, 
Rojas-Villarraga et al. 2009, Turner et al. 2006). Additionally, foot complications and foot-related 
disability have been shown to persist despite the current advances in pharmacological disease 
management (Nagasawa et al. 2010, Otter et al. 2009, Grondal et al. 2008). Thus, the patient 
and clinician goal of disease remission is not always met. There is a need to identify factors 
contributing to the propagation of foot-related disability in this patient group and to better target 2 
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intervention. Previous cross-sectional studies have suggested that forefoot bursae (fluid filled 
sacks: FFB) are associated with RA disease activity and patient-reported foot-related disability 
(Bowen et al. 2009, Bowen et al. 2010c). However, it is unclear whether these are spurious 
relationships, confounding effects or true physiological responses. None the less, FFB arguably 
represent a much needed potential indicator of localised disease activity or therapeutic target. 
The determination of the natural history and clinical importance of FFB in patients with RA will 
potentially facilitate improved disease management or disability prevention.  
1.1 Main thesis aim  
This thesis, therefore aims to utilise novel US and MRI imaging techniques for the determination 
of the epidemiology and clinical importance of FFB in patients with RA. It is intended that the 
findings of the four experimental studies completed as part of this thesis will: 1) contribute to the 
current understanding of the clinical importance of US-detectable FFB, 2) contribute to the 
current understanding of the biological mechanisms by which US-detectable FFB are clinically 
relevant, 3) provide a robust tool for the identification and characterisation of FFB and 4) 
contribute to the current understanding of which FFB are pathological and why, providing an 
evidence-based framework for future clinical intervention. The research hypothesis central to 
this thesis, and underpinning the basis of study, is therefore: 
 
H1: ‘FFB are clinically relevant in patients with RA’ 
H0: ‘FFB are not clinically relevant in patients with RA’ 
 
The thesis has been structured thus: 
 
Chapter 2: ‘Background & literature review’. This chapter details the background literature 
informing the research topic. An overview of current concepts within rheumatology regarding the 
aetiology, diagnosis, prevalence, monitoring and management of RA are discussed. An 
overview of foot specific complications reported in patients with RA is given and differentiation 
between articular and extra-articular manifestations of disease made. In particular the 
epidemiology, characterisation, diagnosis and clinical importance of FFB are discussed.  
 
Chapter 3: ‘Methodology’. This chapter presents and justifies the overall philosophical approach 
and methodological design employed in this thesis. An overview of the aim and objectives for 
each experimental chapter is given. The ethical considerations related to this body of work are 
presented and discussed. A summary of the studied populations, outcome measures and 
analysis techniques used throughout the body of work are also presented and justified. 
 
Chapter 4: ‘The epidemiology & clinical importance of US-detectable forefoot bursae in patients 
with rheumatoid arthritis’. This chapter draws upon previously reported cross-sectional data and 
data collected as part of this research project in order to uniquely determine the natural history 3 
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of US-detectable FFB in patients with RA. Potential associations between FFB and disease 
activity or patient-reported foot-related disability are explored. The clinical importance of FFB, 
both cross-sectionally and longitudinally is considered. Differences in the US-characteristics of 
observed FFB are discussed and the potential relevance of these considered. The hypothesis 
that FFB presence is related to both biomechanical impairment and inflammation is proposed. 
 
Chapter 5: ‘The relationship between FFB & inflammation or biomechanical impairment’. This 
chapter seeks to further explore the potential relationship between US-detectable FFB and 
biomechanical impairment of the lower limb or disease mediated inflammation. This is achieved 
via comparative investigation of FFB epidemiology between healthy volunteers, patients with 
medial knee OA (considered as a surrogate primarily degenerative non-inflammatory cohort) 
and patients with RA (considered as a primarily inflammatory cohort). Potential associations 
between FFB presence and markers of inflammation or biomechanical impairment are 
determined. Differences in the distribution of FFB across forefoot sites between participant 
groups are reported and their potential clinical importance explored. The findings of this study 
provide additional evidence to support the hypothesis that FFB are related to both inflammation 
and biomechanical impairment in patients with RA. The need for a reliable, user-independent 
method of identifying and characterising FFB is proposed.  
 
Chapter 6: ‘Detecting forefoot bursae in patients with rheumatoid arthritis using MRI: 
Development of the ‘FFB-Score’’. This chapter presents the rationale, justification for, and 
process of MRI-based score development for the identification and characterisation of FFB in 
patients with RA. The collaborative process of score design, implemented by a team of 
rheumatologists, radiologists, and a podiatrist from centres within the UK and Germany, is 
presented. The reliability and validity of the proposed score is reported.  
 
Chapter 7: ‘The epidemiology & clinical importance of MRI-detectable forefoot bursae in patients 
with rheumatoid arthritis’. This chapter documents the observed presence, distribution and 
characteristics of MRI-detected FFB in patients with rheumatoid arthritis. The relationship 
between FFB MRI characteristics and inflammation or biomechanical impairment is explored. 
The clinical importance of the presence of MRI-detectable FFB, and the characteristics thereof, 
in patients with rheumatoid arthritis, is considered.   
 
Chapter 8: ‘Discussion, conclusions & future research’. This chapter draws together the findings 
of the four previous experimental studies, discussing the findings in the context of an integrated 
programme of research. The advancement in knowledge and contribution towards clinical 
practice made by this research programme is considered. The conclusion is made that ‘FFB are 
clinically relevant in patients with rheumatoid arthritis’ and the alternate thesis hypothesis is 
accepted. Limitations within the reported studies are acknowledged and recommendations for 
future research proposed.  4 
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1.2 Scope of the thesis 
The four experimental studies that form this thesis were conducted over a 27 month period from 
October 2009 to January 2012. All data collection was completed within either the Southampton 
Biomedical Research Centre, within University Hospital Southampton NHS Foundation Trust or 
the MRI suite at the Spire Hospital, Southampton. Please note, the baseline and one-year 
follow-up data used for the longitudinal evaluation of FFB, presented in Chapter four, has been 
previously reported and is not presented as the author’s own work (Bowen et al. 2009, Bowen et 
al. 2010b).  5 
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Chapter two 
Background & literature review 
 
2.0 Introduction 
This chapter provides a critical overview of the academic literature pertinent to the diagnosis, 
classification, evaluation and treatment of rheumatoid arthritis (section 2.1). The complications 
associated with RA are discussed with particular reference to those which are related to the foot 
(section 2.2). Forefoot bursae (FFB) are highlighted as a key soft tissue complication present in 
patients with RA (section 2.3). The clinical importance, epidemiology, characterisation and 
identification of FFB are subsequently reviewed and need for future research in this area is 
highlighted (summary).  
2.1 Rheumatoid arthritis  
Rheumatoid arthritis (RA) is a chronic, systemic, inflammatory polyarthritis that affects multiple 
body tissues and organs, although is typified by symmetrical, peripheral, diarthrodial joint 
damage (figure one), (Elliott and O'Dell 2002). Those joints frequently affected include the 
metacarpophalangeal joints of the hand and metatarsophalangeal joints of the feet (40-50%, 30-
50% of initial presentation respectively) (van der Leeden et al. 2008, Otter et al. 2009, 
Woodburn and Helliwell 1997, Silman and Hochberg 2001). At the point of diagnosis, these 
joints present clinically with swelling, redness and tenderness (Silman and Hochberg 2001). 
Joint subluxation, tissue degradation and fixed deformity can occur latterly (figure one: c-d, f-g), 
leading to difficulties in walking or manual dexterity tasks (Silman and Hochberg 2001, Otter et 
al. 2009, Helliwell et al. 2007).  
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Figure 1: The clinical presentation of RA 
Where 1a illustrates a child’s perception of the experience of having arthritis, 1b-d illustrate mild, moderate 
and severe examples of RA disease in the feet, and 1e-g illustrate mild, moderate and severe examples of 
RA disease in the hands. Images reproduced with permission from Peterson (2011) in association with the 
National Rheumatoid Arthritis Society (NRAS), Dr Mechanik (1998), Dr Agnihotri (2010), Medscape.com 
(2011)  and Rumatory-Arthritis.com (2010). 
 
 
RA disease activity was traditionally assessed clinically using composite measures of disease 
activity (Anderson et al. 2012, Dougados and Gossec 2007). These include evaluation of 
multiple joint swelling or tenderness, (although not typically including the feet), serological 
markers of systemic inflammation and patient reported overall wellbeing (Anderson et al. 2012, 
Arnett et al. 1988). Disease activity was traditionally managed using disease modifying anti-
rheumatic drugs (DMARDs) which aim to suppress inflammation, thereby easing the burden of 
disease on the patient (NICE 2009a, NICE 2009b, Edwards et al. 2005). The aim of 
pharmacological treatment was to suppress inflammation responsively and slow joint decay 
(Edwards et al. 2005, Brown et al. 2008). The aim of adjunctive podiatric treatment was to 
accommodate deformity where possible and provide palliative care of ulcerative sites or callus 
lesions (Rome et al. 2009, Turner et al. 2007, Williams et al. 2011, Mejjad et al. 2004). However, 
recent advances in the understanding of the aetiology and pathophysiology of RA have been 
made (Soderlin et al. 2011, van de Sande et al. 2011). Differing inflammatory pathways have 
been mapped and pharmacological treatment now aims to suppress inflammation early in the 
disease process preventing joint decay (Toonen et al. 2012, Mantovani 2000, Daikh and St Clair 
2012, Singh et al. 2012).  
 7 
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While great progress in the management of RA has been made, a number of limitations to 
complete remission from disease for all patients remain (Kekow et al. 2011, Zhang et al. 2011, 
Tak and Kalden 2011). There is a need to identify and monitor minimal disease activity, to 
differentiate between those patients who have aggressive disease and have greater likelihood of 
developing life limiting complications, and to tailor and deliver targeted therapies for the 
individual patient in a timely manner (Tak and Kalden 2011, Schett et al. 2011, Breedveld and 
Combe 2011). Evaluation of disease activity within the foot may inform these current limitations. 
2.1.1 Aetiology & pathophysiology 
The monitoring and regulation of RA is inhibited by the unknown immunological pathways by 
which the disease is mediated; to date the precise aetiology of RA remains unclear (Choy and 
Panayi 2001, Edwards 2005, Feldmann et al. 1996, Jenkins et al. 2002, Panayi 1993a, Schett 
and Firestein 2010). Some authors have suggested a genetic predisposition (MacGregor et al. 
2000, Macgregor and Steer 2006), others suggest environmental triggers, while the predominant 
current hypothesis is a combination of such factors (MacGregor et al. 2002). However, the 
greatest recent development in our understanding of RA has been made in the field of 
immunology, and thus this area forms the basis of this review (Zimmerman and Weyrich 2010, 
Schett and Firestein 2010, McGonagle and Georgouli 2008, Jenkins et al. 2002).    
 
In RA, tissue and joint damage occur via the immuno-regulated invasion of synovial tissue by a 
milieu of inflammatory cells and cytokines (figure two) (Jenkins et al. 2002, Athanasou et al. 
1988). There is a certain amount of synergy between inflammatory modulators, resulting in over-
expression of cytokines and a primarily up-regulatory effect (figure two) (Athanasou et al. 1988, 
Choy and Panayi 2001). Of note is the positive feedback mechanism, characteristic of this type 
IV delayed hypersensitivity reaction, between T-cells and macrophages via the release of and 
activation by TNFα cytokines (Takaya 2000). TNFα is a key pro-inflammatory cytokine produced 
by T-cells (Jenkins et al. 2002, Panayi 1993a), which has received a lot of research attention 
because of the tremendous beneficial effect of anti-TNFα pharmacological treatments (Houkin et 
al. 1994, Feldmann and Maini 2003, Kogutt et al. 1994). However, as illustrated in figure two, 
this is one of many up-regulatory cytokines which may contribute to RA disease or equally 
represent further therapeutic targets (American College of Rheumatology Subcommittee on 
Rheumatoid Arthritis Guidelines 2002, Panayi 2005, Edwards and Cambridge 2005, Keystone 
2005, Marston et al. 2010). In particular, B-cells have been demonstrated to display antigen 
presenting behaviour, produce both TNFα cytokines and antibodies, in addition to their well-
documented role in autoantibody production in sero-positive RA patients (Panayi 2005, Di Paolo 
et al. 2011, Marston et al. 2010). Destruction of joint cartilage and bone occur latterly and are 
typically mediated via the adaptive immune system (Athanasou et al. 1988, Houkin et al. 1994, 
Choy and Panayi 2001, Martel-Pelletier et al. 2001, McHugh et al. 2010, Paradowska-Gorycka 
et al. 2010). Those factors which mediate activation and control of down-regulatory cellular 
responses, or maintenance of cellular ‘tolerance’, remain unclear.   
   
                                  
Figure 2: Patho-physiological cellular activity within an active rheumatoid joint 
Where A= Antigen, B= B-cell (‘bursal-cell’), CD= cellular surface recognition molecules – T-cells have either CD4 or CD8, CRP= C-reactive protein, D= dendritic cell, Fi= 
Fibroblast, Ig region= membrane bound immunoglobulin acting as B-cell receptor with aid of ITAMS, IL= Interleukin, Interferon ϒ= interferon gamma, ITAMs= immuno-
receptor tyrosine-based activation motifs, Ma=Macrophage, MHC= major histocompatibility complex (also known as human leukocyte antigen (HLA) in humans), MMP = 
matrix metallo-proteases, NK= natural killer cell, T= T-cell (‘thymus-cell’), TCR= T-cell receptor, Th1= Differentiated T helper cell, TNFα= tumour necrosis factor alpha. 
Image author’s own; information collated from Segal et al., (2000), Athanasou et al., (1988), Choy and Panayi (2001), Edwards (2005), Feldman et al., (1996), Panayi 
(1993b) and Schett and Firestein (2010). 9 
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Of particular relevance to this thesis is the up-regulated formation of pannus (chronically 
hypertrophied synovial tissue), granuloma or rheumatoid nodules (Athanasou et al. 1988, Choy 
and Panayi 2001). In granuloma formation, as illustrated in figure two, Lymphocytes and 
Macrophages mature into giant or epitheloid cells, following stimulation from localised interferon-
ϒ and other cytokines in response to chronic stress (Athanasou et al. 1988, Takaya 2000). 
Athanasou (1988) demonstrated that rheumatoid nodules and hypertrophied (or hyperplastic) 
synovium also demonstrate a high prevalence of several Monocyte-Macrophage markers and 
HLA-DR. This suggests that similar patho-physiological processes may be involved in the 
development of extra-articular nodules as intra-articular pannus. However, there is relatively little 
histological literature exploring the possibility of shared patho-physiological pathways common 
to hypertrophied synovial tissues. None the less, it is plausible to suggest the presence of a self-
propagating positive-feedback mechanism within the extra-articular synovial tissues. There is 
therefore a plausible biological mechanism by which synovial structures of the forefoot may 
become problematic in patients with RA. 
  
An improved understanding of the cellular mechanisms underpinning the development of soft 
tissue pathology within the forefoot may further inform management strategies; as shown in 
figure three, understanding the concept of the pathway between cellular activity and disability, 
and identifying potential causative mechanisms or therapeutic targets will help improve patient 
outcome. Thus there is clear benefit in the early diagnosis and management of RA. 
 
 
 
Figure 3: A theoretical concept of RA disease progression and management 
Image author’s own. 
 
2.1.2 Diagnosis & classification 
The use of diagnostic criteria allow early identification of a disease with good sensitivity 
(Dougados and Gossec 2007).  Conversely, the use of classification criteria within a 
rheumatological research study allows repeatable cohort definition, with good specificity at a 
group level, particularly in late stage disease (Banal et al. 2009). However, until the recent 
publication of the American College of Rheumatology (ACR)/European League Against 
Rheumatism (EULAR) RA diagnosis guidelines (Aletaha et al. 2010, Anderson et al. 2012, 
Felson et al. 2011), few diagnostic criteria had been proposed or externally validated. As such 
research classification criteria were adopted for use clinically (Aletaha et al. 2011). 
Consequently, the majority of RA cohort studies have been based upon the superseded 1987 10 
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ACR disease classification criteria (table one), (Visser et al. 2002, Arnett et al. 1988, Moens et 
al. 1992), about which much discontent has been published. 
 
 
Table 1: Disease classification  
ACR 1987 classification criteria for Rheumatoid Arthritis (Arnett et al. 1988). 
 
Criteria  Definition 
Morning stiffness  Morning stiffness in and around the joints, lasting for at least 1hour 
Arthritis of ≥3 joint areas  Soft tissue swelling or fluid in at least 3 of the following areas: the left 
or right MCP, wrist, elbow, knee, ankle or MTP joints 
Arthritis of the hand joints  Swelling of the wrist, MCP or PIP joints 
Symmetrical arthritis 
Simultaneous involvement of the same joint areas (as above) on both 
sides  of  the  body  (at  least  50%  of  affected  joint  areas  affected 
symmetrically) 
 
Rheumatoid nodules 
 
Subcutaneous nodules present 
Rheumatoid factor  Detected by a method which yields positive findings in <5% of normal 
controls 
Radiographic changes  Erosions or  unequivocal  decalcification  localised to  the  joints of  the 
hands and wrists 
 
 
 
The composite design of the criteria reflects the multifaceted presentation of rheumatoid 
disease, allowing a diagnosis to be made based on the cumulative presentation of some of the 
many possible associated symptoms or serological markers. However, a recent meta-analysis of 
19 peer-reviewed publications (N=7438pts, 3883 with RA), has questioned the sensitivity and 
specificity of the criteria, noting that these are of little benefit in identifying early stage RA (Banal 
et al. 2009). Banal et al (2009) have captured and summarised a widely reported range in 
sensitivity (25-95%) and specificity (50-90%) and what was arguably a recurring theme of 
discontent regarding classification over the last decade (Saraux et al. 2001, Liao et al. 2008, 
Aridogan et al. 2008, Banal et al. 2009, Levin et al. 1996). 
  
With an improved understanding of the immunological mechanisms of disease, numerous 
authors called for a review of RA diagnostic criteria. This is to reflect the biological advances in 
antibody detection, specifically anti-cyclic citrullinated peptide antibodies (anti-ccp), with a 
concomitant introduction of exclusion criteria and removal of markers associated with chronicity 
such as nodule formation (Berthelot et al. 2001, Berthelot et al. 2002, Caro-Oleas et al. 2008). 
Ironically however, authors continuing to compare the predictive value of different criteria, for 
example rheumatoid factor or specific antibody presence, continue to use the ACR criteria to 
define their sample populations (Aridogan et al. 2008, Lemos et al. 2007), or to retrospectively 
review sensitivity (Hulsemann and Zeidler 1999). This does render the question, ‘how can we 
determine if these markers are really more applicable in early RA detection?’ This highlights the 
current paradigm regarding classification; the criteria are limited yet there is a notable absence 11 
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of a more palatable alternative. Similarly, the crossover and merging of diagnostic and 
classification criteria has further confused this literature. 
 
As Emery et al. (1997) suggest, a pathognomic feature of RA is persistence, therefore it is 
perhaps unsurprising that cumulatively the ACR criteria are reported as more sensitive and 
specific for those patients with early but aggressive disease than for those with an initially more 
subtle presentation, but who may gain a positive diagnosis in time (Jacobsson et al. 1994). This 
perhaps reflects a more pertinent question; ‘is diagnosis enough?’ Current literature suggests a 
trend towards diagnosis with identification of predictors of disease severity/aggression and 
prognosis (Rantapaa-Dahlqvist 2005). Tissue typing and a greater understanding of cellular 
activity, along with improved clinical imaging may be a positive step towards identifying early 
and/or aggressive disease. That is until prospective studies such as ‘SERA’ (Studies of the 
Etiology of RA), currently in its infancy, can provide further information (Kolfenbach et al. 2009, 
Knoss et al. 2007, Rantapaa-Dahlqvist 2005).  
 
The ACR/EULAR 2010 criteria incorporate synovitis, serological markers of inflammation and 
symptom duration, in an attempt to facilitate earlier diagnosis without the need to identify 
features associated with later stage disease. The use of a weighted grading system for these 
three key features is arguably a response to the previously discussed criticisms of the 1987 ACR 
criteria (Aletaha et al. 2010). However, the ability of the criteria to achieve their additional aim of 
distinguishing between those newly diagnosed patients with more aggressive erosive disease is 
yet to be demonstrated. The implications for research design are that where possible the 
inclusion of an inception cohort of patients, presenting initially with undifferentiated inflammatory 
arthritis, would continue to be of benefit for the longitudinal evaluation of disease pathogenesis 
(Liao and Costenbader 2009). 
2.1.3 Monitoring 
The fluctuant nature of rheumatoid disease activity requires careful regular evaluation of disease 
state (Aletaha et al. 2008, Shaver et al. 2008). However, given the complexities of diagnosing 
and classifying disease previously mentioned, achieving rigour in disease state evaluation can 
pose a clinical challenge (Rintelen et al. 2009, Wolfe et al. 2009). Furthermore, the need to 
determine disease activity within research participants is particularly important for the 
determination of disease progression or treatment evaluation (Shaver et al. 2008, van Tuyl et al. 
2009, Felson and Anderson 2001). Unsurprisingly therefore, common clinical and research tools 
for the determination of disease state are often composite measures with varying focus, again 
reflecting the multifaceted nature of RA (van Tuyl et al. 2009, Linde et al. 2008).  
 
The 28 part disease activity score (DAS 28 (Van der Heijde et al. 1990)) is arguably the most 
commonly used composite measure of disease activity in both research and clinical practice 
(Leeb et al. 2007). However, since the advent of this tool the variability of scores, dependent 12 
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upon the individual component parts, has been a recurrent criticism by numerous authors (Leeb 
et al. 2007, Kirwan et al. 2009, Kievit et al. 2006, Neogi and Felson 2008). Măkinen (2007) 
attempted to quantify such variability, identifying that erythrocyte sedimentation rate (ESR), 
tender joint count (TJC), general health (GH) and swollen joint count (SJC) had the greatest 
effect on overall score respectively (mean score=0.71, 0.23, 1.56, 0.28 respectively, N=195) 
(MÃkinen et al. 2007). However, this criticism is not unique to the DAS 28, indeed most 
alternative disease activity measures do inherently have the same complication due to their 
composite design (Balsa et al. 2004, Aletaha et al. 2005).  
 
The search for independent indicative variables has identified that patient reported outcome 
measures such as ‘general health’ and ‘disease activity’ visual analogue scales (VAS) may be 
good indicators of disease state (Linde et al. 2008, Shaver et al. 2008). These variables are also 
becoming increasingly identified as key in emerging alternative patient centred assessment tools 
such as the RADAI-5 and CDAI (Leeb et al. 2008), where traditional measures such as joint 
count are excluded. Arguably, the emerging tools are starting to reflect the current government 
emphases on early detection, intervention and preservation of activity discussed earlier, as well 
as consistency in outcome measures for clinical trials (The National Audit Office 2009, Molenaar 
et al. 2000). However, despite a growing body of evidence in support of these outcome 
measures, they still remain highly contended within the current literature (Shaver et al. 2008).  
 
Particular contention surrounds the definition or classification of remission and minimal disease 
activity (MDA) (Aletaha et al. 2012, Lafeber and Van der Laan 2012, Khan et al. 2012, Anderson 
et al. 2012). Currently, the ACR and EULAR bodies are collaborating in an attempt to define 
criteria for remission and MDA, “so that we are all saying the same thing” (van Tuyl et al. 2009). 
Until such a time, for the purposes of this study the DAS 28, with CRP composite (Wolfe and 
Michaud 1994, Wolfe et al. 2001, Anderson et al. 2012), is arguably the most appropriate tool. 
Importantly though, while the overall theme within the current literature suggests the use of a 
composite tool, the additional identification of physiological phenomena within a clinical setting 
that help indicate minimal disease activity (MDA) would be a valuable asset to patient care.  
2.1.4 Management 
The management of RA has undergone a recent paradigm shift away from the gradual and 
progressive use of medicines towards earlier more aggressive pharmacological intervention with 
a number of relatively newer biological agents (Edwards et al. 2005, Singh et al. 2009, Singh et 
al. 2012). Indeed there is an increasing number of new biologics with differing immunological 
targets being identified and tested, reflecting the improved understanding of molecular 
processes involved in RA pathogenesis (Singh et al. 2009). Table two documents some of the 
current immunological (biologic) therapies and their intended molecular targets for inhibition.  
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Table 2: Current therapeutic biologic agents 
 
  Agent:  Generic  drug  name 
(market name)  Molecular target  Mode of action 
T
N
F
α
 
i
n
h
i
b
i
t
o
r
s
 
Infliximab (Remicade) (Janka et 
al. 2000, Weiger et al. 2000) 
TNFα/T-cell 
activation 
Mouse derived monoclonal TNFα 
antibody 
Etanercept (Embrel) (Holland et 
al. 2000, Westenberg et al. 
2000) 
TNFα  Modulation of membrane-bound receptors 
bound to Fc portion of IgG antibody  
Adalimumab (Humira) 114, 115]  TNFα  Fully human monoclonal TNFα antibody 
(Moller Dohn et al. 2009) 
Certolizumab Pegol (Cimzia) 
(Kaushik and Moots 2005)  TNFα 
Fully human monoclonal TNFα antibody 
(Connock et al. 2010, Patel and Moreland 
2010) 
Abatacept (Orencia) (Teng et al. 
2005, Kremer et al. 2005) 
T-cell co-
stimulation 
modulation 
Inhibits co-stimulation thereby preventing 
secondary messenger activation of B and 
T-cells (Genant et al. 2008, Maxwell and 
Singh 2010, Schiff and Bessette 2010) 
Golimumab (Simponi) (Zhou et 
al. 2007)  TNFα  Fully human monoclonal TNFα antibody 
(Voulgari 2010) 
B
-
c
e
l
l
 
i
n
h
i
b
i
t
o
r
s
 
Rituximab (MabThera) (Shaw et 
al. 2003) 
CD20 (B-cell 
surface molecule) 
CD20 antibody thereby preventing B-cell 
immunoglobulin recognition/ activation & 
thus initiation of immune cascade (Tanaka 
2009) 
Ocrelizumab (Genovese et al. 
2008, Genovese et al. 2010) 
(Genovese et al. 2008, 
Genovese et al. 2010) 
CD20 (B-cell 
surface molecule) 
CD20 antibody thereby preventing B-cell 
immunoglobulin recognition of antigens & 
thus activation and initiation of immune 
cascade 
C
y
t
o
k
i
n
e
 
i
n
h
i
b
i
t
o
r
s
 
Anakinra (Okuda and Takasugi 
2006, Guntinas-Lichius et al. 
2000) 
IL-1 
IL-1 receptor antagonist inhibiting 
endogenous binding of IL-1 & thus 
cytokine messenger activity 
MRA (Nishimoto et al. 2003)  IL-6 
Anti-IL-6 receptor monoclonal antibody- 
acting as IL-6 antagonist thus inhibiting 
cytokine messenger activity 
Tocilizumab (Roactemra) (Maini 
et al. 2006)  IL-6 
Anti-IL-6 receptor monoclonal antibody- 
acting as IL-6 antagonist thus inhibiting 
cytokine messenger activity (Schafer et al. 
2010) 
O
t
h
e
r
  Fostamatinib Disodium (Baluom 
et al. 2011) 
Syk kinase (T-cell 
specific) 
Spleen Tyrosine kinase inhibition – 
inhibiting intra-cellular messages of 
surface activation to lymphocyte cell 
nucleus (binds to ITAM sequences) 
(Genovese et al. 2010) 
 
 
 
As documented in table two, a number of these medicines have been demonstrated as 
efficacious when compared to the management ‘norm’ of Methotrexate. However, the relative 
efficacy of comparative biologic agents remains unclear (Tak and Kalden 2011, Devine et al. 
2011). Perhaps this is partly because the head-to-head trials have not been completed but also 
partly because of the difficulty in evaluating minimal disease activity, discussed previously in 
section 2.1.3. Alternative outcome measures of intervention effectiveness would be of 
considerable benefit in this area of study. In particular, outcome measures that help inform 
which regimen best suits individual patients are required.  14 
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2.1.5 Prevalence, incidence & impact 
It is currently unclear what effect the new diagnostic guidelines have had on the reported 
prevalence of RA. The current documented prevalence of RA is globally inconsistent (Alamanos 
et al. 2006, Andrianakos et al. 2006, Gabriel 2001) and the reported UK national variation is 
between 0.44% and 1.16%, with a 3:1 female to male ratio (MacGregor et al. 1994a, Symmons 
et al. 2002). These ranges are however, similar to those reported for Northern Europe, North 
America and Greece, but higher than for Asia or for developing countries (Andrianakos et al. 
2006). Reasons for such variation have been extensively discussed although a conclusive 
rationale remains elusive. MacGregor et al. (1994b), previously identified ethnic variation within 
the Norfolk region of England. However, despite ongoing work using this Norfolk Arthritis 
Register (NOAR) further explanation for regional or ethnic variation remains hypothetical to date.  
 
The overall incidence of RA is reportedly declining in the UK to around 0.8% (N=26,000) 
(Symmons et al. 2002, Kvien et al. 2006, The National Audit Office 2009). However, the overall 
decline reported by Symmons et al. (2002) is somewhat skewed by the reduction in female 
incidence, a proportionally larger group; where further exploration of the male cohort shows no 
significant decline over the same period. It remains unclear why such gender related differences 
in incidence may occur. A further methodological complication in RA incidence analysis is the 
time taken to ascertain a positive diagnosis. For example, Wiles et al. (1999) highlight how a 5-
year retrospective review of incidence based on the American College of Rheumatology (ACR) 
1987 criteria can significantly adjust the reported incidence values (from 30.8/100,000 to 
54/100,000 for females and 12.7/100,000 to 24.5/100,000 for males). Furthermore, despite the 
growing age of this publication few subsequent researchers appear to have adopted this 
approach and as such any published values for incidence and prevalence can only be 
considered a guide towards the current actual disease burden. Arguably the differences are 
contextually slight, however, when considering the burden of disease not just to patients but also 
their friends, family, co-workers, or care-workers the difference in impact is significant (Lajas et 
al. 2003).  
 
The direct cost of RA to the NHS has risen considerably over the past decade to ~£560million 
with the increased use of biologic therapy (The National Audit Office 2009). The estimated 
indirect national economic cost of RA through sick leave and work related disability has risen 
from ~£1billion to ~£2billion since the turn of the century (The National Audit Office 2009), this is 
exclusive of further ‘household’ losses (Verstappen et al. 2005). However, such a snapshot does 
demonstrate the overall economic situation; indeed estimations from the national audit office’s 
annual review (The National Audit Office 2009) suggest that if the number of patients treated 
within the first three months of diagnosis rises from the current 10% to 20%, the initial direct cost 
of treatment will increase by £11million over a 5 year period. However, the economic productivity 
gained through reduction in sick leave and work related disability is ~£31million. Furthermore, 
each patient has an estimated 4% increase in quality adjusted life years (QALYs) (The National 15 
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Audit Office 2009). This highlights the importance of early diagnosis and management, 
particularly for the retention of quality of life and the maintenance of activity. 
 
It is unclear what proportion of the reported impact of RA disease is attributable to foot-related 
disability. There is increasing evidence that foot problems in patients with RA are highly 
prevalent, even when classical measures of disease activity, such as the DAS 28 score, suggest 
clinical remission (van der Leeden et al. 2010, Rome et al. 2009, Otter et al. 2010, Katz et al. 
2006). A population survey by Otter et al. (2010) demonstrated that this is true for many patients 
with RA, regardless of disease duration or therapy, and may even be evident in those receiving 
biologic therapy (Grondal et al. 2008, Nagasawa et al. 2010). It appears that despite great 
advances in disease management, a large proportion of patients remain significantly affected by 
foot complications (van der Leeden et al. 2007, van der Leeden et al. 2010). This potentially has 
a major continued impact on a patients’ ability to return to work or complete tasks of daily living 
(Klareskog et al. 2009, Katz et al. 2008, Puolakka et al. 2006). Furthermore, the natural history 
of foot related disability in patients with RA has received little investigation to date. Despite 
recent advances in systemic disease management, the longitudinal relationship between the 
prevalence of foot complications, disease state and disability remains unclear (van der Leeden 
et al. 2008). There is an ongoing need to determine the natural history and prognostic indicators 
of foot-related disability in patients with RA. 
2.2 Complications of RA in the foot 
Arguably, foot related complications in patients with RA are arguably poorly understood by both 
clinicians and researchers in comparison to problems with the hand or systemic disease, as 
evidenced by the comparative lack of reported literature (Williams and Graham 2012, Grondal et 
al. 2008, Wechalekar et al. 2012). Of those complications which are documented, metatarsal 
head erosion, metatarsophalangeal joint deformity and midfoot collapse are amongst the most 
frequent (figure four) (Loveday et al. 2012, van der Leeden et al. 2008, Otter et al. 2009).  
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Figure 4: Deformities of the foot associated with RA 
Where  4a  illustrates  bilateral  colour-enhanced  radiograph  of  the  foot,  note  the  extensive  peripheral 
osteopenia and destruction to nearly all forefoot joints, 4b illustrates right foot deformity, note the grade 
three  hallux  abducto  valgus  deformity  and  lesser  digit  retraction,  4c  illustrates  a  left  foot  sagittal  plain 
radiograph (COFAS 2010), note the collapse of the midfoot joints, and 4d illustrates left midfoot deformity 
(COFAS 2010), note the prominent bulging of the navicular, classically associated with progressive midfoot 
medial-longitudinal arch collapse. Images reproduced with permission from the London Science Museum 
(Song  et  al.  2010,  Wellcome  2010)  Medscape.com  (2011),  Dr  Agnihotri  (2010)  and  the  Canadian 
Orthopaedic Foot and Ankle Society (2010). 
 
 
It is largely hypothesised and accepted by most reporting authors that the pathological 
processes of RA disease common to the hand, are likely similar and equally applicable to the 
foot (van der Leeden et al. 2006, Helliwell et al. 2007, Costa et al. 2004, Woodburn and Helliwell 
2004). Helliwell et al (2000) amongst other authors (Turner et al. 2006, Turner and Woodburn 
2008, Costa et al. 2004, Fuhrmann 2002), have documented that early aggressive involvement 
of the metatarsophalangeal (MTP) joints  was as frequent as that of the metacarpals of the hand 
in a subset of 93 RA participants. It is estimated that within this sample population approximately 
eight forefoot joints were affected by pain, swelling or erosion in early disease, progressing to a 
statistically increased 15 or more after just one year (p≤0.001). This demonstrates the often 
rapid onset and progression of early disease in the foot, highlighting this as an area warranting 
further investigation. Importantly, patients with mild to moderate RA disease affecting their feet 
become significantly disabled when compared with the general population (Wickman et al. 
2004).   
 17 
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Conversely, Van der Leeden et al. (2008) note a reduction in reported symptoms in one or more 
forefoot joints from 70% of participants to 45% after one year, in an inception cohort of patients 
with RA (N=848). This is on trend with similar studies of early disease activity in the hand. A 
reduction in reported mild walking disability was also noted from 57% to 40% after one year. 
This suggests that there may be potential for early patient-reported foot-related complications to 
be interrupted (van der Leeden et al. 2008). After eight years however, it was noted that MTP 
joint erosion had dramatically progressed from 19% to 60% presence. In addition a trend 
towards foot deformity in the mid and rearfoot joints, with significantly associated walking 
disability, was again increasing (p=0.02-0.001), a finding reinforced by other authors (Mizumura 
et al. 2000, van der Leeden et al. 2007, Turner et al. 2008). This is in contrast to sustained 
reductions in disease activity reported in studies of the hand. The extent to which disease 
activity continues within the foot compared to the hand remains unclear as does the rationale for 
such differences in treatment response. It is possible that improvements in overall wellbeing 
result in greater physical activity, therefore placing greater biomechanical demand upon the foot. 
Thus, generalised systemic improvement is reported while foot complications are exacerbated. 
Conversely, episodes of high systemic disease activity may result in increased rest periods and 
reduced functional demand upon the foot. There is a need therefore to consider the patient-
reported complications of RA disease alongside the biomechanical and structural articular or 
extra-articular complications.  
2.2.1 Patient reported foot complications 
Reported foot complications in patients with RA are typically multifactorial in nature and include 
pain, deformity, functional impairment and activity limitation (Landorf and Radford 2008, Otter et 
al. 2004, Walmsley et al. 2010). As such, patient-reported complications are typically evaluated 
using multi-domain questionnaires (Walmsley et al. 2010, Otter et al. 2004). These facilitate 
patient-focused reporting of disease impact, providing an adjunct to the OMERACT (outcome 
measures in rheumatology) influenced biomedical model, classically used in the evaluation of 
disease state (DoH 2005, DoH 2003a). There are however relatively few appropriate and 
validated tools available for use in this patient group. In a review by Walmsley et al. (2010), 11 
tools appropriate for the assessment of foot health in RA were identified. Of these, the Foot 
Impact Scale (FIS) was the only tool specifically validated for use in patients with RA (Helliwell et 
al. 2005). The remaining tools explore various domains in an aged or general ailing population. 
As shown in table three, the domains explored ranged from functional impairment, footwear 
limitation and social isolation to anxiety and depression, although the predominant constructs 
are those of pain and activity limitation (Bazzichi et al. 2005). 
   
 
Table 3: Foot-specific patient-reported outcome tools  
Patient reported outcome tools applicable to the evaluation of foot health status. 
 
Primary 
Author  Year  Sample 
size  Tool  Domains  Number of 
items  Benefits  Limitations 
Barnett 
(Barnett et 
al. 2005) 
2005  400  BFS: Bristol Foot 
Score 
Pain 
Function  15  Sensitive to change  Limited evidence to support 
item validation 
Bennett 
(Bennett et 
al. 1998) 
1998  111 
FHSQ: Foot 
Health Status 
Questionnaire 
Pain 
Function 
Footwear 
General foot health 
13 
Sensitive to change (intended for 
post-op evaluation). Includes 
psychometric properties. 
Comprehensive and well 
validated, with additional footwear 
component available. 
Not condition specific 
Budiman-
Mak 
(Budiman-
Mak et al. 
1991) 
1991  87  FFI: Foot 
Function Index  Function  23  Three subscales all 
independently validated 
No patient involvement in 
generation. Therefore poor 
construct validity. 
Budiman-
Mak 
(Budiman-
Mak et al. 
2006) 
2006  92 
FFI-R: Revised 
Foot Function 
Index 
Function 
Footwear and related 
psycho-social impact 
 
Short: ~20 
Long: ~30 
Construction better allied with ICF 
recommendations 
No psychometric evaluation 
included, therefore evaluation 
limited to pain and activity 
limitation 
Garrow 
(Garrow et 
al. 2000) 
2000  1,078 
MFPDQ: 
Manchester Foot 
Pain and 
Disability 
Questionnaire 
Pain 
Disability  19  Good construct validity  Psycho-social impact not 
evaluated 
Helliwell 
(Helliwell et 
al. 2005) 
2005  192 
FIS: Foot Impact 
Scale 
Impairment/footwear 
Activity 
limitation/participation 
restriction 
51 
Specifically designed for use in 
foot evaluation in RA populations. 
Closely associated with ICF 
domains. Well validated. Potential 
application for intervention 
evaluation or change in foot 
health status evaluation. 
Little reported evaluation of 
sensitivity to change 
Johanson 
(Johanson 
et al. 2004) 
2004  290 
FAM: Foot and 
Ankle  
Module 
Pain 
Stiffness 
Swelling 
Function 
10 ± ~10 
Acute and long-term impact 
reviewed. Developed for broad 
application to musculoskeletal 
pathology and intervention. 
Modifiable upon user needs. 
Focuses mainly on structure 
and function domains  
 
 
Macran 
(Macran et 
al. 2003) 
2003  2,361 
PHQ: Podiatry 
Health 
Questionnaire 
Pain 
Function 
Foot hygiene 
Nail care 
Quality of life 
8  Well validated, with extensive 
patient engagement 
Podiatry focussed but with 
little applicability to a 
rheumatoid population 
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2.2.1.1 Foot pain, impairment & activity limitation 
Of the symptoms most frequently reported at both the onset and throughout RA disease, pain 
appears paramount. The forefoot presents as the initial symptomatic region in approximately 
15% of all cases (Rojas-Villarraga et al. 2009), and was cited as the primary cause for walking 
impairment, four times more often than knee or hip joint complications, in 71% of patients with 
RA (N=1000), when surveyed by Grondal et al. (2008). Furthermore, a cross sectional survey of 
patients with RA completed by Otter et al. (2009) (disease duration 12.7yrs ±12.5yrs, N=585), 
reported 93.5% of respondents to have experienced severe foot pain at some point, with this 
pain being most prevalent in the forefoot (63.9%, n=376) and ankle (42.7%, n=251). This finding 
is reinforced by previous authors also noting a similarly high frequency of reported pain across 
the forefoot (range 65-86%; (Shi et al. 2000, Grondal et al. 2008)) and rearfoot/ankle (range 52-
66%; (Shi et al. 2000, Grondal et al. 2008)). Interestingly the main predictive factors for 
increased forefoot pain identified by Otter et al. (2009) were longer disease duration (p=0.009) 
and increased body mass index (BMI; p≤0.001). There again appears to be an interesting 
juxtaposition of increased inflammatory stress and increased biomechanical stress; disease 
chronicity has been demonstrated to be associated with perpetuated inflammation while 
increased BMI has been suggested to pathologically raise lower limb integral joint forces during 
weight bearing activity.  
 
The reported close association between pain and functional impairment in musculoskeletal 
disease is not novel, with themes of this kind echoed throughout the rheumatological literature 
(van der Waal et al. 2003, Badlissi et al. 2005, Barton et al. 2008, Hamilton et al. 2001). For 
example, Rojas-Villaraga et al. (2009) report a significant association between a positive 
metatarsal squeeze test (pain on medial-lateral compression of the forefoot at the level of the 
MTPJs), and patient reported disability. These two themes are also echoed throughout the 
various patient-reported outcome measures (PROMs) developed to evaluate an individual’s 
perception of the impact of disease (Landorf and Radford 2008, Otter et al. 2004, Walmsley et 
al.). Of the available PROMS, the Manchester Foot Pain and Disability Questionnaire (MFPDQ 
(Garrow et al. 2000)), Bristol Foot Score (BFS; (Barnett et al. 2005)), Rowan Foot Pain 
Assessment Questionnaire (ROFPAQ (Rowan 2001)) and the American Academy of 
Orthopaedic Surgeons Foot and Ankle Module (FAM (Johanson et al. 2004)) all closely integrate 
pain and activity limitation sub-scales. Much of the merging of these constructs is reportedly as a 
consequence of patient engagement during item development, as recommended by the 2001 
World Health Organisation (WHO) guidelines for the international classification of functioning, 
disability and health (World 2001). Conversely, the authors of the MFPDQ used an alternative 
approach of principal component analysis to derive the final three included constructs: pain 
intensity, functional limitation and personal appearance (Garrow et al. 2000).  
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It would appear that foot pain and activity limitation are inextricably linked. However, further 
review of the MFPDQ protocol for item development demonstrates a bias in design through the 
non-uniform weighting of factors. The latter use and evaluation of the modified MFPD Index by 
Menz et al. (2006) continued to demonstrate high internal consistency of the tool (Cronbach’s 
alpha=0.89), whilst also demonstrating a significant association between the three primary 
constructs and depression or mental health status as assessed by the Goldberg Anxiety and 
Depression Scale (Goldberg et al. 1988) or Medical Outcomes Study Short Form–36 (McCallum 
1995) respectively. However, this inadvertently reinforces the summative statement proposed by 
Otter et al. (2004) that at present no single tool is both specific and sensitive to the patient 
reported impact of foot complications in RA. Arguably, even fewer tools are sensitive to change 
in foot health status, despite a number being designed in response to the need for post-
operative surgical evaluation, as highlighted in table 2. Indeed the Bristol Foot Score and FHSQ 
are the only tools that have been evaluated for sensitivity to change (Barnett et al. 2005).  
 
While the FIS has not been validated for the evaluation of change in foot health status, it has 
been validated in accordance with ICF criterion (N=192, test-retest ICC analysis for each 
subscale=0.84, CI=0.75-0.9 and ICC=0.96, CI=0.93-0.98 respectively) (Helliwell et al. 2005, 
World 2001). The two subscales of the FIS questionnaire facilitate comprehensive evaluation of 
foot impairment (including pain), footwear restriction, activity limitation, participation restriction 
and psycho-social impact. Turner et al. (2007) have suggested a meaningful change in FIS 
score of 3 or more (with mean SD≤5) in the longitudinal use of this tool. However, the data upon 
which this is inferred is not presented for review, although it is cited as a clinically beneficial 
indicator sensitive to changes in foot health status. None the less, with the overall rounded 
appraisal of foot health status and baseline validation, this is arguably the most appropriate 
measure of disability for use in patients with RA at present.  
2.2.2 Biomechanical foot complications 
Biomechanical studies of the pedal articular manifestations of RA disease also note associations 
between reported pain and function (Bal et al. 2006, Helliwell et al. 2007, van der Leeden et al. 
2008, Hamilton et al. 2001, Anders et al. 2007, Wickman et al. 2004). It has been extensively 
demonstrated that both foot deformity and activity limitation are significantly associated with 
extended disease duration or chronicity (p≤0.001 (Helliwell et al. 2000), p≤0.001 (Turner et al. 
2008, Turner and Woodburn 2008) respectively). Rearfoot eversion, reduced ankle joint range of 
motion and excessive subtalar joint pronation are amongst the most frequently reported static 
biomechanical complications of RA in various cohort studies (Woodburn et al. 2002b, Khazzam 
et al. 2007, Turner et al. 2008, van der Leeden et al. 2008). Particularly clinically evident 
features include the characteristic reduction in medial longitudinal arch height, hallux-abducto-
valgus deformity and forefoot metatarsal abduction (figure four) (Woodburn et al. 2002b). 
Reported functional biomechanical complications include a reduction in overall walking speed, 
from 1.28-1.30m/s in healthy controls to 0.96-1.05m/s in patients with RA (Turner et al. 2006, 22 
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Khazzam et al. 2007, van der Leeden et al. 2008), increased stance phase of gait from 62% to 
66% of the gait cycle and increased periods of double limb support from 15.8% to 19.3% of the 
gait cycle (Khazzam et al. 2007, Turner et al. 2006, Woodburn et al. 2002a). It is suggested that 
these temporal changes are likely related to altered biomechanical loading patterns (centre of 
force trajectory or segmental rotational sequencing) through the foot (Semple et al. 2007, Turner 
et al. 2006, Lundgren et al. 2008, Wolf et al. 2008, Nester et al. 2007). However, the precise 
nature of these changes is yet to be fully understood. Indeed, while these latter stage 
biomechanical features of RA are well reported, their pathogenesis remains unclear. There is a 
paucity of longitudinal studies of foot disease in patients with RA; the current evidence base is 
mainly comprised of cross-sectional investigations of mid/rearfoot deformity and kinematic 
function in patients with established RA. It is unclear at present which patients are at greatest 
risk of developing adverse biomechanical function, which factors contribute to this, and which 
factors may be therapeutically modifiable. The relationship between adverse biomechanical 
function and inflammation in the foot remains unknown but it is thought to be potentially 
synergistic in nature.  
2.2.2.1 Clinical assessment of foot alignment 
A number of investigative techniques have been proposed to evaluate foot joint alignment and 
congruency with inferred implications for biomechanical function (Wolf et al. 2008, Turner et al. 
2008, Nester et al. 2007, Woodburn et al. 2005, Fuller 2000, Dananberg 2000, Cavanagh et al. 
1997). Clinically used static postural measures include navicular height, arch height and valgus 
index (Weiner-Ogilvie and Rome 1998, Menz and Munteanu 2005). However, these have been 
demonstrated to have poor inter-rater reliability (p=0.001-0.005) (Weiner-Ogilvie and Rome 
1998, Menz and Munteanu 2005). Conversely the foot posture index (FPI-6) is a clinical static 
postural tool that has been validated using Rasch analysis (Redmond et al. 2006, Keenan et al. 
2007). The authors acknowledge that the original FPI-8 was only able to predict 64% of the 
variance in static standing position and 41% of the postural variance during the stance phase of 
gait in patients with RA. None the less, with subsequent re-validation and removal of two items 
the tool has been shown to have good internal consistency (Cronbach’s alpha=0.83) and allows 
multi-segment, multi-plane evaluation in a clinical setting. To our knowledge the FPI is the only 
validated measure of foot joint alignment published at the time of this investigation.   
2.2.3 Articular foot complications 
The prevalence of RA articular manifestations within the foot is high, reportedly affecting 90% of 
patients at some point (Michelson et al. 1994), and typically occurs in the forefoot 
metatarsophalangeal (MTP) joints (van der Leeden et al. 2008, Akerman et al. 1991, Bal et al. 
2006, Costa et al. 2004). However, there is also limited evidence of articular involvement in 
other mid and rearfoot joints (Woodburn et al. 2002c, Helliwell et al. 2007). In analogue to the 
hand, synovitis and concomitant articular degradation (cartilage loss, joint space narrowing and 
marginal erosions) reportedly occur across all MTP joints, although a greater prevalence is 
reported in the more lateral joints (Umans and Elsinger 2001, Miller 2001, van der Leeden et al. 23 
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2006). Overall, the prevalence of MTP joint affectation is reportedly equal to or greater than the 
corresponding metacarpophalangeal hand joints in early RA disease (Hulsmans et al. 2000, van 
der Heijde et al. 1992, Mottonen 1988). A longitudinal study by Van der Leeden et al. (2006), 
however, demonstrated that, unlike the hand, a greater proportion of participants (40-50%) 
continued to have MTP joint erosive degradation after the first two years of disease despite 
continued treatment. Furthermore, Van der Leeden et al. (2010) have subsequently 
demonstrated that 40% of participants had active disease in one or more MTP joints despite 
achieving remission according to DAS 28 criteria, with an increase from 19-60% of participants 
reportedly having one or more MTP joint erosions from baseline to eight years. Conversely, 
recent data reported by Van Tuyl et al. (2012) suggests that inclusion of the forefoot joints does 
not alter identification of patients in remission from RA disease. This recent paper does appear 
to be in contrast with the majority of previous works, although further research into the added 
benefit of reviewing disease activity within the forefoot is warranted (Priolo et al. 1997).   
 
Those factors which predict an individual patient’s likelihood of developing greater articular 
involvement with disease chronicity are unclear. However, there does appear to be increasing 
evidence of continued, subclinical, minimal disease activity within the forefoot despite ongoing 
management (Felson et al. 2011, van der Heijde et al. 1992, van der Leeden et al. 2010). 
Continued biomechanical irritation through weight bearing activity and continued inflammation 
within extra-articular foot structures have been cited as potential causes (Shi et al. 2000, Platto 
et al. 1991, Turner et al. 2008, OBrien et al. 1997). There is a need therefore to consider the role 
of extra-articular features in the pathogenesis of foot complications in patients with RA.  
2.2.4 Extra-articular foot complications  
The forefoot is a relatively complex anatomical region housing a number of extra-articular 
structures with potential to be affected by the progress of RA disease (figure five) (Mahana-
Borges et al. 2003). This may be as a consequence of excessive inflammation or adverse 
biomechanical function. However, there is notable obscurity within physiological or histological 
texts that document the anatomical detail of the adult forefoot. Figure five is an illustrative 
representation of the most frequently agreed structural anatomy of the forefoot, which will be 
used as the accepted anatomical reference for subsequent work presented within this thesis. It 
should be noted therefore that the obscurity in anatomical detail has posed a diagnostic 
challenge; abnormal tissues or structures have potentially been overlooked or misinterpreted by 
previous authors because of a lack of a standardised anatomical reference (Mahana-Borges et 
al. 2003, Chauveaux et al. 1987, Zanetti et al. 1997).   
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Figure 5: A transverse illustration of forefoot anatomy 
Where 1= abductor hallucis tendon, 2 = extensor hallucis longus tendon, 3 = extensor hood, 4 = extensor 
hallucis  brevis  tendon,  5  =  adductor  hallucis  tendon,  6  =  dorsal  interosseous  tendon,  7  =  extensor 
digitorum longus tendon, 8 = extensor digitorum brevis tendon, 9 = plantar interosseous tendon, 10 = deep 
transverse metatarsal ligament, 11 = section of plantar plate, 12 = abductor digiti minimi tendon, 13 = 
vertical fibres of plantarfascia, 14 = superficial transverse metatarsal ligament, 15 = flexor digitorum brevis 
tendon, 16 = flexor digitorum longus tendon, 17 = lumbrical tendon, 18 =  neurovascular bundle, 19 = 
sesamoid ligament, 20 = flexor hallucis longus tendon. S = sesamoid bone, M1-5 = head of metatarsal 
bone 1-5. Image author’s own; anatomical detail collated from Mahana-Borges et al. (2003), Zanetti et al. 
(1997), Chauveaux et al. (1987). 
 
 
 
Table four details the known extra-articular complications of the forefoot that may be evident in 
patients with RA. The variety of differential diagnoses for complications of the forefoot in patients 
with RA is perhaps reflective of the anatomical complexity of the region.   
 
Table 4: Differential diagnoses of the forefoot in RA 
Differential diagnoses for commonly reported complications of the forefoot. 
 
Diagnostic 
category  Differential diagnoses  Method of diagnosis  Reported clinical presentation in RA 
Neurological 
Neuroma (Ashman et al. 2001, 
Iagnocco et al. 2001, 
Zielaskowski et al. 2000, 
Alexander et al. 1987) 
MRI (Ashman et al. 2001, 
Zielaskowski et al. 2000) 
US (Iagnocco et al. 2001) 
Pain on medial to lateral compression of the forefoot. ‘Sharp, shooting pain’, 
regional numbness of the lesser digits.  
Neurofibrosis (Bossley and 
Cairney 1980, McElvenny 
1943) 
 
Dissection (Bossley and Cairney 
1980) 
Radiography (Bossley and 
Cairney 1980) 
Surgical exploration (McElvenny 
1943) 
May be asymptomatic. Plantar capsulated, non-fluctuant swelling may be 
present in some cases.  
Ganglia (Ashman et al. 2001)  MRI (Ashman et al. 2001)  Small capsular, non-fluctuant swelling, typically dorsal and asymptomatic. 
Tendonous 
Tendonosis/enthesopathy 
(Ashman et al. 2001, Aronow 
2005, Canoso 1998, Stiskal et 
al. 1997, Slobodin et al. 2007, 
Coakley et al. 1994, Falsetti et 
al. 2003) 
Radiography (Falsetti et al. 
2003) 
MRI (Ashman et al. 2001, Stiskal 
et al. 1997) 
US (Coakley et al. 1994, Falsetti 
et al. 2003) 
Surgical exploration (Aronow 
2005) 
Chronic manifestation at sites of tendon insertion. Low grade inflammation 
may be present. ‘Dull ache on movement’.  
Tenosynovitis (Ashman et al. 
2001, Suzuki et al. 2009, Baan 
et al. 2007, Caprotti et al. 
1993) 
Radiography (Baan et al. 2007) 
MRI (Ashman et al. 2001) 
US (Suzuki et al. 2009, Baan et 
al. 2007, Caprotti et al. 1993) 
Acute manifestation along tendon tracks. Inflammation typically present. 
Regional tenderness on palpation or with movement. Estimated 7% 
prevalence in RA (Lauzon et al. 1987, Coakley et al. 1994), this although may 
be higher.  
Rupture/partial tear (Canoso 
1998, Wanivenhaus 2007, 
Jernberg et al. 1999, Baan et 
al. 2007) 
Radiography (Baan et al. 2007) 
MRI (Jernberg et al. 1999) 
US (Baan et al. 2007) 
Surgical exploration (Canoso 
1998, Wanivenhaus 2007) 
Acute manifestation along tendon tracks with associated regional 
inflammation. Extreme point tenderness on palpation. Functional impairment 
dependent upon degree of rupture. 
Synovial 
Synovitis (Mutlu et al. 2006, 
Burra and Katchis 1998, 
Joshua et al. 2007, Maillefert et 
al. 2003, Mulherin et al. 1996, 
MRI (Mutlu et al. 2006, Maillefert 
et al. 2003) 
US (Joshua et al. 2007, Pascual-
Ramos et al. 2009, Iagnocco et 
Pain, swelling and erythema, local to synovial joints. Movement restricted. 
Typically affecting the MCP or MTP joints of the hands and feet.   
   
Diagnostic 
category  Differential diagnoses  Method of diagnosis  Reported clinical presentation in RA 
Pascual-Ramos et al. 2009, 
Sattar 1990, Iagnocco et al. 
2001) 
al. 2001) 
Physical examination (Burra and 
Katchis 1998, Mulherin et al. 
1996, Sattar 1990) 
Haematology (Mulherin et al. 
1996) 
Synovial cyst (Ashman et al. 
2001, Bancroft et al. 2008)  MRI (Ashman et al. 2001)  Fluctuant, nodular swelling. Often located adjacent to DIP joints. Red/blue 
colouration. Typically asymptomatic.  
Peri-articular joint pannus 
(Caprotti et al. 1993)  US (Caprotti et al. 1993) 
Subcutaneous, soft tissue masses extruding from the joints affected by RA 
(typically the MCP or MTP joints). Pannus itself may appear asymptomatic 
however is typically present alongside additional joint complications 
associated with RA. 
Pigmented villo-nodular 
synovitis (Sharma et al. 2005) 
Histopathology (Sharma et al. 
2005) 
Sudden onset joint swelling, often disproportionate to the pain experienced. 
Less frequent slow onset manifestations, with gradual increases in tenderness 
may occur. Presentation is typically within the larger joints of the hip and knee, 
however the ankle or forefoot may be affected.  
Vascular 
Vasculitis (Maher and Wilson 
2006, Iyngkaran et al. 2003, 
Pascual-Ramos et al. 2009) 
US (Maher and Wilson 2006, 
Pascual-Ramos et al. 2009) 
Purpura (red/purple discolouration), non-blanching with the application of 
pressure, noted. Systemic symptoms including, fever, weight loss and myalgia 
may be present. Glomerulonephritis and raised inflammatory markers 
indicated with further testing.  
Endarteritis (Bossley and 
Cairney 1980) 
Dissection (Bossley and Cairney 
1980) 
Radiography (Bossley and 
Cairney 1980) 
Localised tissue necrosis, due to the collapse of small arterial vessel lumen. 
Severe pain and pallor on initial presentation, progressing to neuropathy and 
dark blue/black tissue discolouration.  
Angiofibromatosis 
(McElvenny 1943) 
Surgical exploration (McElvenny 
1943) 
Small red/brown papules, apparent in only a few cases. Typically 
asymptomatic.  
Vascular calcification 
(Whiddon et al. 2008) 
Radiography (Whiddon et al. 
2008) 
Often entirely asymptomatic unless severe, in which instance symptoms of 
peripheral vascular disease may be noted. Typically bilateral. 
Bone  
Bony neoplasm (Ashman et 
al. 2001)  MRI (Ashman et al. 2001)  Point tenderness present in some cases in addition to bony outgrowths or 
nodules. May be entirely asymptomatic. Unilateral. 
Freiberg’s infarction (Ashman 
et al. 2001)  MRI (Ashman et al. 2001) 
Point tenderness around the second or third metatarsal head region, often 
with small volumes of associated joint effusion. Pain on movement or 
palpation. Increased frequency of presentation in females (5:1) (Katcherian 
1994). Typically unilateral.  
 
Diagnostic 
category  Differential diagnoses  Method of diagnosis  Reported clinical presentation in RA 
Osteonecrosis (Berger et al. 
2004)  Radiography (Berger et al. 2004)  Often localised to the epiphysis of long bones. Reduced joint congruency. 
Unspecified regional calcific 
deposition (Berger and Ziter 
1972) (Whiddon et al. 2008) 
Radiography (Berger and Ziter 
1972, Whiddon et al. 2008) 
Pain and swelling in one or more joints. Calcium deposition identified with 
further imaging or histological examination.  
Fibrous 
Fibromatosis/plantar 
fibromatosis (Ashman et al. 
2001, Oliva et al. 2005) 
Radiography (Oliva et al. 2005) 
MRI (Ashman et al. 2001) 
Physical examination (Oliva et al. 
2005)  
Nodular lesions associated with the deep plantar fascial tissue. May be benign 
at onset, however can functionally impair lesser digit extension in time.   
Granuloma (Knoss et al. 2006, 
Ashman et al. 2001, Caprotti et 
al. 1993, Campbell and 
Montgomery 2005) 
MRI (Ashman et al. 2001) 
US (Caprotti et al. 1993) 
Histopathology (Knoss et al. 
2006) 
Small, spherical nodular mass. Histological examination further specifies sub 
type based upon necrotization and cell infiltration type.  
Dermatological 
Ulceration (Firth et al. 2008, 
Firth et al. 2007, Firth et al. 
2006) 
Physical examination (Firth et al. 
2008, Firth et al. 2007, Firth et al. 
2006) 
Break in dermal tissue. May or may not have associated pain or inflammation.  
Pyoderma-gangrenosum 
(Pacifico et al. 2009) 
Physical examination (Pacifico et 
al. 2009) 
Histopathology (Pacifico et al. 
2009) 
Small papules on initial presentation that may progress to large necrotic 
lesions, with yellow/green wound exudate.  
Other 
Gouty tophi/cyst (Canoso and 
Yood 1979a) 
Combined physical examination 
& Histopathology (Canoso and 
Yood 1979a) 
Swelling and erythema often local to a single joint, described as being 
exquisitely painful. Typically the first MTP joint of the foot is the primary site of 
manifestation. In chronic cases small white tophi may exude from the affected 
area.  
Infection (Ashman et al. 2001)  MRI (Ashman et al. 2001)  Swelling, erythema and tenderness local to the site of infection noted. May 
appear asymptomatic in heavily immune-compromised patients.  
Plantar plate disruption 
MRI (Ashman et al. 2001, 
Umans and Elsinger 2001) 
US(Gregg et al. 2008) 
Definitive presentation unknown. May be associated with unspecified 
metatarsalgia and forefoot instability.  
Sesamoiditis  Radiography (Kanatli et al. 2006) 
US (Ashman et al. 2001) 
Inflammation local to the sesamoid bones, located plantar to the first MTP 
joint. Pain increased with weight-bearing activity.  28 
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The relative prevalence of the extra-articular complications of the forefoot in patients with RA is 
unclear. However, structures which incorporate a synovial membrane, such as joint linings, 
tendon sheaths or intermetatarsal bursae, are amongst the most frequently affected (Helliwell et 
al. 2007, Woodburn and Helliwell 2004, Shi et al. 2000, OBrien et al. 1997); as discussed in 
section 2.1, synovial structures may be preferentially responsive to excessive, disease-
mediated, inflammation in patients with RA (OBrien et al. 1997).  
 
Those factors which predict an individual patient’s likelihood of developing greater extra-articular 
involvement with disease chronicity are unclear. However, as with the articular manifestations of 
RA, there appears to be increasing evidence of continued, subclinical, minimal disease activity 
within the extra-articular forefoot structures despite ongoing management (Wechalekar et al. 
2012, van Tuyl et al. 2012, van der Leeden et al. 2010). In particular US-detected forefoot 
bursae (FFB) have been reported to be highly prevalent in patients with RA when compared to 
healthy volunteers (Bowen et al. 2009). Furthermore, Bowen et al. (2010c) have demonstrated a 
significant association between an increased US-detected presence of FFB and patient-reported 
foot-related disability. The rationale for this association remains hypothetical to date; FFB may 
be responsive to increased inflammation, or adverse biomechanical function, or both. The 
clinical importance of FFB longitudinally remains unclear. None the less, FFB do represent a 
potential prognostic indicator of foot-related disability, beyond existing measures of disease 
state, which warrant further investigation. 
2.3 Forefoot bursae 
Bursae are typically defined as encapsulated fluid filled spaces, often situated adjacent to 
synovial joints (Warwick et al. 1973). Their anatomical function is thought to be that of 
mechanical support by facilitating movement between closely aligned structures, enabling 
localised tissue compression or retraction when under pressure (Aguiar et al. 2005, Canoso et 
al. 1988, Meurman 1982). Within the forefoot however, the precise anatomical features of 
bursae remain contentious within the current literature (Awerbuch et al. 1982, Bossley and 
Cairney 1980, Chauveaux et al. 1987, Claustre et al. 1983). FFB are of particular interest in 
patients with RA, as they are potentially responsive to both disease mediated inflammation and 
adverse biomechanical function. Previous authors have reported the presence of synoviocytes 
lining the inner margins of intermetatarsal bursae, which may be responsive to RA in a similar 
manner to the synovium of joint linings (Jaganathan et al. 2012, Kachlik et al. 2008, Mutlu et al. 
2006, Boutry et al. 2003a). Conversely, other researchers report fibrous connective tissue 
changes that encapsulate various fluid filled cavities across the intermetatarsal or plantar 
forefoot regions, which may be responsive to adverse mechanical function (Studler et al. 2008, 
Ahmed et al. 1994). None the less, preliminary work suggests that the presence of FFB may 
inform clinicians about changes in foot health or foot related disability (Bowen et al. 2009). 
Furthermore, it is also a biologically plausible hypothesis that FFB may themselves become 29 
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pathological. Further evaluation of the epidemiology and clinical importance of FFB in patients 
with RA is therefore warranted (Koski 1998).  
2.3.1 Clinical importance of FFB 
The clinical importance of FFB has been commented upon by only a few authors (Hertzler 1926, 
Iagnocco et al. 2001, Bowen et al.). Both Hertzler et al. (1926) and Iagnocco et al. (2001) report 
symptomatic bursae presenting as generalised metatarsalgia in patients with no comorbidity, 
where the majority of symptoms were characterised as ‘burning’ or ‘walking on marbles’. 
Enlarged intermetatarsal bursae coexisting with neuroma have also been reported (Theumann 
et al. 2001). However, in all reports neurofibrosis is the primary pathological manifestation of 
interest and the bursa is frequently noted as an incidental but interesting finding, the relative 
clinical importance of which is unclear (Bossley and Cairney 1980, Chauveaux et al. 1987, 
Theumann et al. 2001, Alexander et al. 1987, Ashman et al. 2001, Scotti 1957). Bowen et al. 
(2009), document similar reported pain sensations in patients with RA, although again it is 
unclear to what extent these symptoms can be directly attributed to FFB. However, they do note 
a significant association between FFB presence and patient-reported foot-related disability (foot 
impairment p=0.026, activity limitation p=0.009). The reported relationship is independent of 
systemic markers of inflammation, suggesting perhaps a more biomechanical association. This 
would appear contrary to the findings of Hertzler et al. (1926) where reported pain is 
hypothesised to be directly related to actively inflamed bursae. Conversely, Bottger et al. (1998) 
as a result of their study of calcaneal bursae, hypothesise that an increase in the size of the 
bursal cavity is proportional to the pain experienced by the patient, without regard to 
inflammation presence or absence.  
 
In the forefoot distinction between pathological tissues has perhaps been made more difficult 
because of the complex anatomical nature and close association of many structures. There is 
confusion within the available literature regarding the anatomy, physiology, aetiology and clinical 
presentation of FFB (Theumann et al. 2001, Studler et al. 2008, Chauveaux et al. 1987). The 
clinical importance of FFB in patients with RA is therefore unknown at present. It remains 
unclear as to whether size, location, tissue characterisation or inflammation is, either 
independently or in combination, clinically important in the manifestation of problematic FFB. 
Determination of the clinical importance of FFB and the factors which contribute to this will be 
beneficial in developing future management strategies for improving foot health or disability in 
patients with RA. 
2.3.2 Epidemiology of FFB 
The reported prevalence of one or more FFB in healthy volunteers ranges from 70-90% 
(Lohman et al. 2001, Studler et al. 2008, Zanetti et al. 1997). Similarly, the reported prevalence 
of one or more FFB in patients with RA ranges from 63-93% across authors (Boutry et al. 2003a, 
Bowen et al. 2009, Koski 1998). The natural history of FFB has not been detailed to date. None 
the less, FFB appear to be consistently reported as highly prevalent across cohort studies. 30 
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However, there is less consistency between authors regarding the distribution of observed FFB 
across forefoot sites, as illustrated in figure six (Roberts 1929, Bowen et al., Boutry et al. 2003b, 
Koski 1998, Studler et al. 2008, Theumann et al. 2001, Bowen et al. 2009, Bowen et al. 2010b).  
 
 
Figure 6: Previously reported forefoot bursae distribution 
The reported frequency of forefoot bursae presence is illustrated and classified according to anatomical 
location.  Where  S  =  plantar  metatarsophalangeal  joint  region,  IM  =  inter-metatarsophalangeal  region. 
Image author’s own.  
 
 
 
Of note, Chauveaux et al. (1987) have a far greater overall estimation of FFB presence, which is 
relatively evenly distributed across intermetatarsal sites. In contrast, Studler et al. (2008) report 
a particularly high FFB presence plantar to the first and fifth metatarsal heads. Discrepancies 
between reports could be attributable to differences in observed populations, recruitment 
strategy or method of identification. Conversely, as suggested by Studler et al. (2008), 
discrepancies could be indicative of differences between natural anatomical and acquired FFB. 
It is suggested that altered or acquired FFB can be distinguished from anatomical FFB, 
becoming either advantageous or problematic in nature (Ahmed et al. 1994, Studler et al. 2008). 
No further work has been completed to date to systematically explore the characterisation of 
FFB in patients with RA. Characterising FFB may improve treatment targeting, where those FFB 
identified as clinically relevant can be reliably differentiated and preferentially treated.   31 
 
Chapter 2: Background & literature review 
2.3.3 Characterisation of FFB 
Various methods of characterising FFB have been adopted in previous works and have largely 
centred on the perceived importance or aetiology of the identified FFB. The differing methods of 
proposed characterisation can be grouped into three main categories:  
 
  Anatomical FFB 
  Mechanical/adventitial FFB 
  Symptomatic/pathological FFB 
 
Within each category, the further characterisation of FFB has arguably become a complex 
exercise. As demonstrated in table five, a number of different subtypes of FFB have been 
proposed. 
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Table 5: Summary of FFB characterisation strategies 
 
Classification  Definition  Sub-classification  Definition 
Anatomical  
Fluid filled sacks, 
developed during 
intrauterine life 
(Warwick et al. 
1973). Contain a 
synoviocytic 
cellular 
membrane. 
Sub-tendonous 
(Warwick et al. 1973, 
Aguiar et al. 2005, 
Hernandez et al. 
1991) 
Facilitate distinct separation 
between tendons and adjacent 
structures 
Sub-muscular 
(Warwick et al. 
1973) 
Facilitate distinct separation 
between muscle fibres and 
adjacent structures 
Sub-fascial (Warwick 
et al. 1973, Siciliano 
and Mozen 1993, 
Theumann et al. 
2001) 
Facilitate distinct separation 
between fibrous tissues and 
adjacent structures – typically 
bone 
Inter-ligamentous 
(Warwick et al. 
1973) 
Facilitate distinct separation 
between ligaments and typically 
superior adjacent structures 
Between adjacent  
bones/joint 
structures 
(Chauveaux et al. 
1987, Hernandez et 
al. 1991, Siciliano 
and Mozen 1993)  
Facilitate distinct separation 
between adjacent bony 
structures 
Mechanical/adventitial 
Fluid filled 
cavities, 
developed in 
response to 
mechanical tissue 
stress (Studler et 
al. 2008, Ahmed 
et al. 1994) 
Fibrous (Studler et 
al. 2008, Ahmed et 
al. 1994) 
Fluid filled regions present at 
areas of fascial tearing, lacking a 
synovial lining 
Hypertrophied 
synovial (Harper 
2003, Claustre et al. 
1983, Lohman et al. 
2001) 
Enlarged synovially lined bursae. 
May be anatomical or acquired – 
aetiology unknown. 
Symptomatic/pathological 
Fluid filled sacs, 
the presence of 
which may be 
construed as 
negative indicator 
(Awerbuch et al. 
1982) 
Fibrous (Scotti 1957) 
Large fluid filled regions, lacking 
a synovial lining. May contain 
floating elements of fibrous or 
necrotic tissue. 
Hypertrophied 
synovial (Canoso et 
al. 1988, Koski 
1998, Meurman 
1982, Scutellari and 
Orzincolo 1998, 
Awerbuch et al. 
1982, Bottger et al. 
1998) 
Enlarged synovially lined bursae. 
May be anatomical or acquired – 
aetiology unknown. 
Associated with 
Neuroma (Bossley 
and Cairney 1980, 
Reed and Bliss 
1973, Scotti 1957, 
Zanetti et al. 1997, 
Alexander et al. 
1987) 
Synovial lining may or may not 
be present. Fluid filled region 
closely associated with the 
presence of a neuroma, linear 
relationship between neuroma 
and bursae unknown. 
 
 
 
A lack of standardisation in the characterisation of FFB makes comparative evaluation of studies 
in this area challenging. Figure seven summarises the various proposed FFB relative to 
anatomical reference positions of the forefoot, as previously depicted in figure five. 33 
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Figure 7: Forefoot anatomy & identification of reported bursae 
Where 1 = 1-2 intermetatarsal bursa coursing adjacent to adductor hallucis tendon that may extend beyond 
the deep transverse intermetatarsal ligament, 2 = intermetatarsal bursae that may become hypertrophied 
extending beyond the deep transverse intermetatarsal ligament, 3 = bursae associated with neurovascular 
bundle,  4  =  bursae  associated  with  superior  aspect  of  flexor  digitorum  brevis  tendon,  5  =  plantar 
mechanical bursae. Image author’s own; detail collated from Mahana-Borges et al. (2003), Zanetti et al. 
(1997), Chauveaux et al. (1987). 
 
 
 
Accurate characterisation of FFB may be of particular relevance when attempting to determine 
their relative clinical importance. In order to fully evaluate the role of FFB in RA, differentiation 
between closely associated anatomical structures, bursal hypertrophy, bursal fibrosis, bursitis, or 
inflammation in adjacent structures is required. There is a clear need for a standardised method 
of FFB characterisation, the use of which would allow better synthesis of clinical and research 
data in this area. The basis for future characterisation criteria can however be informed by 
previous literature.  
2.3.3.1 Anatomical FFB 
A generalised definition of anatomical FFB is that of an encapsulated, spherical or ellipsoid, fluid 
filled space situated between the metatarsal heads (Hernandez et al. 1991, Theumann et al. 
2001). The FFB are situated superior to the deep transverse intermetatarsal ligament (DTML), 
which divides the intermetatarsal (IM) spaces into inferior and superior regions in the transverse 
plane (figure five) (Theumann et al. 2001). Based predominantly upon the findings of cadaveric 
studies it is thought that anatomical FFB do not typically extend beyond the head and base of 
the metatarsal (M) and proximal phalanx (PP) bones respectively, as shown in figure eight 
(Chauveaux et al. 1987, Claustre et al. 1983, Theumann et al. 2001).  
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Figure 8: An anterior-posterior contrast enhanced right forefoot radiograph 
The contrast media depict the IM bursae (arrows). Note the contrast leakage (arrowheads) distal to the 
second, third, and fourth bursae and proximal to the fourth bursa. Image reproduced with permission from 
Professor Theumann (Theumann et al. 2001). 
 
 
 
Theumann et al. (2001) reported all IM FFB as situated superior to the DTML adjacent to the 
interosseous muscles, tendons and MTPJ collateral ligament complexes in non-pathological 
healthy cadaveric specimens (N=8), (figure nine: a). This is quite distinct from the neurovascular 
bundles (NVB) which are found plantarly. However as illustrated in figure nine (b), once distal to 
the DTML a closer association between the FFB and NVB may be seen. Indeed, as illustrated 
by Mohana-Borges et al. (2003) (figure nine: c), the uniformity of FFB positioning demonstrated 
by Theumann et al. (2001) may not always be the case, where the IM2-3 FFB appears far 
superiorly positioned than the IM1-2 FFB in this example. Conversely, Chauveaux et al. (1987) 
describe the IM1-2 bursa as uniquely and closely aligned with the adductor hallucis tendon in 
most cases, perhaps accounting for the presentation demonstrated by Mohana-Borges et al. 
(2003) in figure nine (c). 
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Figure 9: Cadaveric anatomical sections of the forefoot 
Where 9a illustrates a transverse section of the forefoot, taken from the region proximal to the distal edge 
of the metatarsal head. The IM bursae (thin straight black arrows) lie between both interosseous tendons 
(straight white arrows). The collateral accessory ligaments (white arrowheads), arise in the depressions on 
the medial and lateral sides of the third and fourth metatarsal heads,(M3 & M4), and extend to the plantar 
plate  (curved  black  arrows)  below  the  interosseous  tendons.  The  black  arrow  heads  depict  the  flexor 
digitorum  longus  muscle.  The  neurovascular  bundle  is  depicted  by  the  thick  straight  white  arrow 
(Theumann et al. 2001). 9b illustrates a transverse section of the forefoot, taken from the region distal to 
the base of the third and fourth proximal phalanx (PP3 & PP4 respectively). The IM bursa (straight black 
arrow) lies between both interosseous tendons (straight white arrows). Note the close relationship between 
the  neurovascular  bundle  (curved  arrow)  and  the  bursa  (actual  size  =  smaller  than  1mm).  Proximal 
phalanges of the third (PP3) and fourth (PP4) rays are shown (Theumann et al. 2001). 9c illustrates a 
transverse  section  of  the  forefoot,  taken  at  the  middle  inferior  one-third  of  the  metatarsal  heads  in  a 
cadaveric left foot. The arrow heads show the phalangeal attachment of the main collateral component of 
the collateral ligament complex. The IM bursae (white arrows) are situated between the depressions of the 
metatarsal heads (M2 & M3) bordered by interosseous tendons (black arrows) which insert further into the 
phalangeal  bases  (Mahana-Borges  et  al.  2003).  Images  reproduced  with  permission  from  Professor 
Theumann, and Dr Resnick on behalf of Dr Mohana-Borges et al. and the Journal of Radiology. 
 
 
 
Similarly, Chauveaux et al. (1987) and Bossley et al. (1980) also note the IM 2-3 and 3-4 bursae 
to be situated centrally and superiorly over the DTML, reporting these to arc either dorsally or 
plantarly once distal to the DTML, with the proximal fourth remaining at some distance from the 
NVB. In further contrast to Theumann (2001), Chauveaux et al. (1987) note that the IM 4-5 
bursa may advance plantar to the DTML communicating directly with the subjacent plantar 
space, although reported findings are from a subset of participants presenting with neuroma-like 
symptoms. None the less, such plantar projections are not reported to protrude beyond the level 
of the plantar nerves or lumbrical muscles in any cases (N=25). In addition, various authors 
have also documented FFB as being located plantar to the metatarsal heads (Hernandez et al. 
1991, Studler et al. 2008, Boutry et al. 2003b, Bowen et al., Bowen et al., Zanetti et al. 1997, 
Bowen et al. 2010b). However, the latter appear in imaging and pathological studies only and 
none to date have been reported in any non-pathological cadaveric human dissection works. 
2.3.3.2 Hypertrophied synovial FFB 
Bossley et al. (1980), among other authors, propose that anatomical bursae may become 
hypertrophied with excessive protrusion either dorsally or plantarly. Bossley et al. (1980), 
hypothesise that the synovial lining, proposed as common to all anatomical bursae (Hernandez 
et al. 1991, Bottger et al. 1998, Haller et al. 1988, Weston 1970b, Weston 1970a), may be 
susceptible to the processes of hypertrophy in a similar manner to the synovial tissues of MTP 36 
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joints in inflammatory joint disease (Scutellari and Orzincolo 1998, Awerbuch et al. 1982, 
O'Brien et al. 1997, Palmer 1995, Palmer 1970). Indeed, a number of authors have documented 
the presence of either an inner synovial membrane with projecting villi (Hernandez et al. 1991), 
or a fibro-collagenous membrane present with some superficial synoviocytic cellular elements, 
within anatomical bursae (Chauveaux et al. 1987, Meenagh et al. 2006). 
 
Claustre et al. (1983), first explicitly report the possible association between hypertrophied IM 
FFB and RA specifically, a theory reinforced by the earlier work of Awerbuch et al. (1982) who 
demonstrated 20% (N=10) of RA patients to have histopathological changes within the synovial 
bursae consistent with inflammatory disease. Interestingly, the histopathological works by Koski 
et al. (1998) (N=25) identified 14 RA patients with inflamed IM FFB (bursitis), 8 with associated 
inflammation within the adjacent synovial tissue structures, thus 6 with inflammation local to the 
FFB only and no instances of inflammation in adjacent structures without the involvement of 
FFB. This is reinforced by the FFB findings of Scutellari et al. (1998) and Harper et al. (2003), in 
their studies of retrocalcaneal bursae, whereby bursitis is present in isolation. Despite this, the 
rationale for bursae affectation remains unclear. 
 
Of note, the presence of connective tissue or integrated fibrosis appears to be as frequently 
reported as that of synovium (Chauveaux et al. 1987, Meenagh et al. 2006, Hernandez et al. 
1991). Bossley et al. (1980) describe the bursal wall as often showing fibrinoid necrosis (in 
conjunction with lymphocytic infiltration). Perhaps, as both Palmer et al. (1995) and Reed et al. 
(1973) suggest, the distinction between rheumatoid nodules and hypertrophied synovial/fibrous 
lesions is less clear than initially thought in this population. Alternatively, Reed et al. (1973) 
propose links between the pathogenesis of vasculitic disease in RA and bursal lesion 
development, documenting hypertrophied synovial/fibrous FFB as being closely associated with 
the localised vasculature via hyalinised fronds. However, 38 years on, no further authors have 
documented this phenomenon. 
 
Jahs et al. (1972) suggest that the frequently reported fibrosis is an additional traumatic 
response of anatomical bursae generated by chronic external compressive/torsional forces or 
inflammation. Both Alexander et al. (1987) and Coackley et al. (1994) hypothesise that 
distension of the DTML or adjacent ligamentous/tendonous structures, secondary to MTP joint 
deformity or inflammation respectively, causes attenuation of the bursal cavity, thus distorting 
the IM FFB. However the exact longitudinal cause and effect relationship between changes in 
forefoot structure has not been demonstrated to date and this does not appear to satisfactorily 
explain the hypertrophy previously demonstrated in the absence of other structural change. In 
contrast, Dedrick et al. (1990) hypothesises that IM FFB hypertrophy in RA exerts compressive 
force thereby distorting the neighbouring tissues and joints. Again, however, there is no 
longitudinal evidence to support this hypothesis. Conversely, the close integration between FFB 37 
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and fibrous or connective tissues has also led to the development of an entirely alternative 
hypothesis for the generation and hypertrophy of FFB. 
2.3.3.3 Biomechanical FFB 
A number of authors propose that a subset of bursae are generated following biomechanical 
irritation (Aguiar et al. 2005, Claustre et al. 1983, Meurman 1982, Studler et al. 2008). For 
example, Ahmed et al. (1994) report the development of biomechanical bursae at the socket 
interface in four below knee amputation patients. In such instances biomechanical bursae are 
often referred to as advantageous, allowing compression or torsion between otherwise densely 
fibrous rigid tissues. The proposed aetiology is mechanically induced separation of the fibro-
collagenous tissues resulting in the accumulation of extra-cellular fluid in these spaces 
(Hernandez et al. 1991). Indeed, Ahmed et al. (1994) also note that with socket repositioning, 
the presence of bursae in two patients fully resolved. Studler et al. (2008) describe such bursae 
as slit-like cavities of fluid when observed within the forefoot, that manifest predominantly in 
areas of torsional stress and lack a synovial membrane.  
 
Chauveaux et al. (1987) observe that the anatomical region in which biomechanical FFB are 
most frequently reported (inferior to the superior transverse IM ligament and superior to the 
DTML) is often referred to as the fibrous channel. It is hypothesised that the pathological 
changes within the local fibrous tissues of this region play an important role is the development 
of biomechanical FFB. The proposed pathological process is quite distinct from the hypertrophy 
of synovial tissue. The historical works of Scotti et al. (1957) appear to support this hypothesis, 
documenting evidence of fibrin within bursal cavities in this region. Additionally, the MRI work of 
Studler et al. (2008) (figures ten: a-c) appears to offer preliminary support for this hypothesis, 
demonstrating 90% of participants to have plantar fibrosis (>14mm), and 75% to have plantar 
FFB. The accompanying histopathological analysis supports these findings (figure ten: d). 
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Figure 10: MRI & histological specimen comparison 
Where figures 10a and 10b illustrate plantar fat pad signal alterations detected with MRI in a 35-year-old 
asymptomatic  female;  (a)  Transverse  T1-weighted  image  (400/15)  showing  continuous  signal  intensity 
alterations with blurred margins (white arrows) in plantar fat pad under the first and fifth metatarsal head 
regions of the right forefoot. (b) Transverse T2-weighted image (4500/119) showing similar signal intensity 
alterations  (white  arrows).  Figures  10c  and  10d  illustrate  the  correlation  between  MRI  findings  and 
histological tissue sample removed plantar to the first metatarsal head region in a cadaveric specimen; (c) 
Transverse  T1-weighted  MRI  (470/20)  showing  fat  pad  signal  intensity  alterations  (white  arrows)  with 
blurred  margins  under  the  first  metatarsal  head.  (d)  Histopathologic  specimen  demonstrating  fibrosis 
(arrowheads) and a slit-like cavity within collagen sheets that represents an adventitial bursa (black arrow), 
(Hema-toxylin-eosin stain, original magnification x 1) (Studler et al. 2008). Images reproduced with the 
permission of Dr Studler. 
 
 
In a study of marathon runners (N=19), Lohman et al. (2001) similarly identified 68% of runners 
as having excessive fluid in the retrocalcaneal bursae. However, 53% of non-running healthy 
participants also had increases in bursal fluid volume. Perhaps therefore, the differing volume of 
bursae may be nothing more than a natural physiological characteristic. In pathological 
populations however, the presence of excessive fluid may inhibit an anatomical synovial bursa’s 
mechanical function. For example, Canoso et al. (1988) discuss the inhibited movement of the 
rearfoot in a patient with inflammatory spondyloarthropathy, for whom the retrocalcaneal bursa 
has become hypertrophied, preventing the typical upward movement of the tongue-like 
projection of the plantar fat pad of the heel with ankle joint plantarflexion. Arguably, in such 
instances the hypertrophy may interfere with the mechanical role of the bursae, in contrast to 
generation of bursae to facilitate mechanical function. However, this poses the question of how 
one might differentiate between when a bursa, either anatomical synovial or mechanical, is 
advantageous or problematic. 
2.3.3.4 Pathological FFB 
Clinically, excessively hypertrophied FFB are considered to present symptomatically in most 
cases, as a sharp shooting pain, burning pain or the sensation of walking on marbles (Hertzler 39 
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1926, Iagnocco et al. 2001, Koski 1998). Associated visible plantar swelling, such as that shown 
in figure 11, has also been reported.  
 
 
 
Figure 11: Plantar forefoot swelling in a patient with RA 
Note the distal shift of the plantar fibro-fatty padding tissue with particular bulging distal to the second and 
third MTP joint regions bilaterally (black arrows). Large, fluctuant subcutaneous fluid-filled pouches are 
palpable plantar to the first MTP joint of the right foot and the fifth MTP joints bilaterally (black *). Image 
author’s own. 
 
 
In patients with RA, it is unclear to what extent FFB are pathological or just indicative of 
associated pathology. Furthermore it is unclear which particular FFB characteristics could result 
in an FFB being considered pathological.  
 
A number of authors hypothesise that FFB are symptomatic because of their close association 
with the intermetatarsal neurovascular bundle, particularly in the region of common plantar 
digital nerve bifurcation in the IM 3-4 space (Zanetti et al. 1997, Awerbuch et al. 1982, Bossley 
and Cairney 1980, Chauveaux et al. 1987, McGlamery 1987). Awerbuch et al. (1982) reported 
10 case-based symptomatic examples of close associations between neuroma and 
hypertrophied anatomical bursae (with histologically demonstrated synovial lining). Awerbuch et 
al. (1982) propose that the symptomatic development of a neuroma may be co-linear with 
increasing FFB volume, and that the resultant dorso-plantar pressure of the enlarged lesion 
contributes to reported pain. However, following excision of the neurofibrotic lesions, patchy de-
myelination of the nerve tissue was evident in all cases (n=20) and was considered to be the 
primary symptomatic factor. Nissen et al. (1951) alternatively hypothesise that physiological 
damage to the nerve tissue is entirely secondary to bursal hypertrophy and inflammation. After 
extensive literature review, no further epidemiological studies of FFB to provide support or 40 
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counter-argument to these previously proposed hypotheses have been reported. As such, the 
symptomatic relevance of FFB remains unclear.  
 
In contrast, Studler et al. (2008) suggest that plantar FFB are not associated with neuroma but 
instead are biomechanically mediated and occur advantageously. The FFB demonstrated by 
Studler et al. are located inferior to the superficial transverse IM ligament, and thus beyond the 
region of the neurovascular bundle. This may account for the asymptomatic presentation 
reported within the observed cohort, despite the reported high prevalence of bursa-like lesions. 
There is limited further evidence to support or refute the hypothesis that plantar FFB are 
adventitial and not pathological. Thus previous literature would appear to suggest that IM FFB 
are the most likely to be pathological, while plantar FFB may be indicative of biomechanical 
function but are themselves advantageous. Such hypotheses have not been definitively 
explored to date. 
2.3.4 Identification 
Within rheumatology, the traditional use of radiography to identify disease progression is being 
surpassed with the greater uptake of musculoskeletal ultrasound (US) and magnetic resonance 
imaging (MRI) (Cimmino 2008a, Cimmino et al. 2008, Meenagh et al. 2009, Suter et al. 2010). 
Both US and MRI have been shown to have improved efficacy of use relative to radiography in 
the determination and evaluation of early inflammatory arthritis (Cimmino 2008a, Brown 2007b, 
Joshua et al. 2007, katz et al. 2009, Meenagh et al. 2007, Szkudlarek et al. 2006). These 
modalities enable the imaging of soft tissue pathology, active inflammation and bone marrow 
oedema as well as changes within bone structure associated with RA progression (Varsamidis 
et al. 2005, Wakefield 2007). However, there remains a paucity of data regarding the intra and 
inter-rater reliability of image acquisition and interpretation for these modalities (Wakefield 2007, 
Koski 2006, Naredo 2006, Ostergaard et al. 2005b). Additionally there is scarce documentation 
of appropriate imaging techniques for the identification of FFB or other soft tissue lesions of the 
forefoot (Cimmino 2008a, Fessell and van Holsbeeck, Gregg et al. 2008, Iagnocco et al. 2001, 
Koski 1998, Bowen et al.). To date, there is no standardised method of identifying and 
characterising FFB in patients with RA. Bowen et al. (2009) have demonstrated that a number of 
clinically relevant FFB may be undetectable by clinical palpation alone and therefore the use of 
imaging techniques is warranted and development of robust methodologies required.  
2.3.4.1 Musculoskeletal ultrasound 
As noted by Wakefield et al. (2007), the uptake of US has been marred by a persistent paucity 
of data regarding the metric properties of US as an outcome measure in the evaluation of 
inflammatory disease. However, as shown in table six, while there is concerted international 
effort to address these issues, there are few studies to date demonstrating the use of US as a 
longitudinal evaluative tool. None the less, US-determined disease activity is emerging as an 
outcome measure, particularly in early disease or minimal disease activity (Cimmino 2008b).  
 41 
 
Chapter 2: Background & literature review 
 
Table 6: The development of musculoskeletal ultrasound as an outcome measure 
Adapted from the findings of the OMERACT 7 and 8 working group for US (Wakefield 2007). 
 
  Timeline  Event   
2
0
0
4
 
OMERACT US SIG 
formed 
The group was formed to address the metric qualities of US as a potential 
outcome measure in rheumatology (Wakefield 2003). 
2
0
0
4
 
Systematic 
literature review 
Highlighted deficiencies 
in the following areas 
Intra-rater reliability 
Inter-rater reliability 
Inter-machine reliability 
Learning and teaching requirements 
Detecting and scoring synovitis 
Scanning protocol standardisation 
2
0
0
4
 
OMERACT 
agreement 
Agreement that the OMERACT filter (incorporating truth, discrimination and 
feasibility) should be applied to developed US methodologies 
2
0
0
4
 
Pilot pathology 
definitions agreed 
Definitions by US findings for erosion, synovitis, tenosynovitis and 
enthesopathy agreed (Wakefield et al. 2005) 
2
0
0
5
-
1
0
 
Intra/inter-rater 
reliability studies 
Scheel (2005), (N=14): Good agreement with MRI (82%). Inter-rater 
reliability of foot and ankle low (kappa=0.28). Conclusion=standardised 
techniques required.  
D’Agostino (2005), (N=17): Binary agreement good. Synovitis grading (0-3) 
had poor inter-rater reliability; attributed to lack of standardisation in 
scanning technique, particularly for semi-quantitative values. 
Naredo (2006), (N=23): Good general agreement (kappa: 0.61-0.54), 
however, synovitis grading system and pathology definitions required 
Cheung (2010), (N=35): Inter-rater reliability high, intra-rater reliability of 
image acquisition poor 
Dougados (2010), (N=76): intra and inter-rater reliability grey-scale US high. 
Reliability of synovitis grading no better than clinical examination. 
2
0
0
6
 
Efficacy of clinical 
use 
Szkudlarek (2006), (N=60): US more sensitive, specific & accurate than 
clinical examination (kappa: 0.7, 0.78, 0.76 vs. 0.4, 0.85, 0.72 respectively, 
MRI=reference method) 
2
0
0
6
 
US pathology 
definitions agreed 
Final definitions agreed 
by expert consensus 
published (Wakefield 
2007, Wakefield 2006). 
Erosion: intra-articular discontinuation of bone 
surface apparent in 2 planes 
Synovial fluid: hypo or anechoic intra-articular 
material, compressible, without PD signal 
Synovial hypertrophy: hypoechoic non-
displaceable, poorly compressible, may have PD 
signal apparent 
Tenosynovitis: hypo or anechoic thickened 
tissue, with or without fluid within the tendon 
sheath, apparent in 2 perpendicular planes, may 
have PD signal 
Enthesopathy: hypoechoic with loss of normal 
fibrillar architecture and/or thickened tendon or 
ligament at its bony attachment. May contain 
hyperechoic foci consistent with calcification, 
apparent in 2 perpendicular planes. May have 42 
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PD signal, enthesophytes, erosion or irregularity 
at attachment. 
2
0
0
7
 
OMERACT 
synovitis scoring  
OMERACT US group review synovitis scoring methodologies. Systematic 
review completed; highlighted lack of reliability and standardisation 
measures (D'Agostino et al. 2005, Taylor et al. 2004). 
2
0
0
7
 
OMERACT group 
meeting 
Current status and research agenda formalised by OMERACT US SIG. To 
focus on US protocol standardisation (Wakefield 2007). 
2
0
0
9
 
OMERACT 9  Current status and research objectives reviewed. Further meeting 
documentation pending (D'Agostino et al. 2009). 
 
 
 
Indeed, while the first report of the use of US in RA treatment evaluation was by Cooperberg in 
1978 , the uptake of this modality as a routine methodology did not begin until the mid-late 
1990s, with formal recognition only occurring in 2004. None the less, US is consistently reported 
to be advantageous in comparison to MRI due to its real-time imaging capabilities, chair-side 
accessibility, reduced scanning time, low acquisition cost and ability to simultaneously scan 
bone and soft tissues in grey-scale or with enhanced inflammatory feedback (Wakefield et al. 
2008, Wakefield 2007, Szkudlarek et al. 2004, Cimmino 2008a, Grassi and Cervini 1998, katz et 
al. 2009). Comparative sensitivity, specificity and accuracy of US versus MRI range from 80-
97% across various anatomical pathological details to 60-98% respectively, suggesting 
comparable clinical and research usage (Wakefield et al. 2008, Wakefield 2007, Szkudlarek et 
al. 2004, Cimmino 2008a, Grassi and Cervini 1998, katz et al. 2009).  
 
A number of recent training recommendations for the use of US within rheumatological practice 
have been debated (Backhaus et al. 2001, Brown 2005, Brown 2006, Filippucci 2003, Filippucci 
2007, Naredo 2008), although despite such proposals there remains no formal training route for 
rheumatologists or allied health professionals within rheumatology to date (Brown 2007a, Brown 
2007b). However, Bowen et al. (2008) have demonstrated the efficacy of US use for the 
evaluation of forefoot structures by a podiatrist. Similarly, Riente et al. (2006) provide detailed 
documentation of a proposed scanning protocol for the foot and ankle. Thus, despite the well 
documented limitations, US use has potential efficacy in the evaluation of FFB in patients with 
RA, although careful demonstration of user reliability is required. 
 
A particular challenge, consistently highlighted throughout the training literature, is that of tissue 
typing and structural recognition or differentiation (Bianchi et al. 2005, Ernst 1993, Gregg et al. 
2008). As highlighted by Riente et al. (Riente et al. 2006) and Bianchi et al. (2005), this is 
particularly relevant to the complex anatomical structure of the forefoot. Classical grey-scale US 
appearances of joint structures demonstrate hyper-echogenicity at the bony margins due to the 
increased refraction of sound waves off the dense cortical bone, with hypoechoic joint centres 
(Cimmino 2008b, Hau et al. 1999). Comparative early and late pathological rheumatoid joint 
appearances are illustrated in figure 12.   
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Figure 12: Classical grey-scale US appearances in RA 
Where 12a and 12b illustrate right and left comparison of metacarpal head, with dorsal transverse linear 
transducer orientation, showing thinning of the cartilage layer (<), 12c illustrates synovial proliferation, with 
hypertrophy extending proximally from the joint cavity (*), with longitudinal linear transducer orientation 
over  the  second  MCP  joint,  12d  illustrates  an  erosion  of  the  metacarpal  head  <1  mm  in  size,  with 
longitudinal  orientation  of  the  linear  transducer.  M=metacarpal  head;  p=proximal  phalanx.  Images 
reproduced with permission from Professor Cimmino and the Journal of Best Practice and Research in 
Clinical Rheumatology (2008b). 
 
 
 
Such images demonstrate uniformity in acoustic feedback, where there is homogeneity across 
the cortical bone surface, despite marginal cartilage loss (figure 12a; <), erosion (figure 12d; 
white arrow), or throughout the fibrillar superficial tendon structures, despite small linear 
fissuring (figure 12b and c; ^) (Cimmino 2008b, katz et al. 2009, Ernst 1993). However, with 
inaccurate transducer orientation complications such as anisotropy (excessive acoustic 
feedback), shadowing (altered signal loss due to changing tissue densities) or ghosting 
(refracted non-perpendicular sound waves giving the false appearance of the presence of 
hyperechoic tissues) can occur (Hau et al. 1999, Gregg et al. 2008, Riente et al. 2006). User 
techniques such as transducer non-perpendicular orientation or ‘heel-toeing’ (the rocking of the 
transducer to displace soft tissues) may be used beneficially to enhance tissue recognition 
(Riente et al. 2006). It is also recommended that real-time dynamic imaging and tissue 
compression are used to improve US scanning specificity (Riente et al. 2006, Jousse-Joulin et 
al. 2010). Tissues such as the plantar flexor digitorum brevis tendons (appearing as fibrillar 
structures with or without superficial acoustic shadowing) or fibrous tissue around the 
neurovascular bundles (a complex anechoic mass with regions of hyperechogenicity consistent 
with non-pathological nerve tissue) are particularly susceptible to user error, making the clear 
diagnosis of FFB challenging (Riente et al. 2006, D'Agostino et al. 2005, Falsetti et al. 2006, 
Gregg et al. 2008). In these instances the use of real-time dynamic imaging for the assessment 
of compressibility may also improve diagnostic accuracy. 
 
Furthermore, there are few textual references clearly depicting the US presentation of FFB. 
Iagnocco et al. (2001) demonstrate grey scale comparison of FFB and neuroma (figure 13) 44 
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however, the image quality in the printed text is poor and structural differentiation is challenging. 
Furthermore, FFB have not been included within the agreed depiction of structures by the 
EULAR/OMERACT expert consensus panel (Wakefield 2003). 
 
 
 
Figure 13: US appearance of an intermetatarsal neuroma & bursa 
Where 13a illustrates a grey-scale transverse linear scan from the plantar aspect with identification of a 
centralised hypoechoic mass (neuroma is indicated by the white arrows) between metatarsal heads, 13b 
illustrates  a  grey-scale  transverse  linear  scan  from  the  plantar  aspect  with  identification  of  a  non-
homogenous, anechoic signal (bursa is indicated by the white arrows) between metatarsal heads. Images 
reproduced with permission from Professor Iagnocco and the Journal of Rheumatology  (Iagnocco et al. 
2001).   
 
 
 
Koski et al. (1998) summarise the commonly reported differentiating characteristics of US 
detectable FFB, whereby identification of a compressible mass with anechoic central body 
during dynamic imaging is reported as a key diagnostic feature. However, echoed throughout 
much of the imaging literature is the need for continued training to allow reliable dynamic 
differentiation of anatomical structures and clear characterisation of the tissue of interest a priori 
(Brown 2006, Cimmino 2008b, Filippucci et al. 2006, Naredo 2008, Taggart 2006, Valentin and 
Jager 2003). Thus, for the purposes of this thesis and in accordance with published 
recommendations, US detectable FFB will be declared present if: 
 
  A  hypoechoic  discontinuation  (with  or  without  an  anechoic  centre),  within  the 
homogenous  intermetatarsal  or  plantar  fibro-fatty  tissue  is  observed  in  two 
perpendicular planes. 
 
Where FFB extend across multiple joint regions, the region containing the largest volume of FFB 
in the transverse scanning plane will be noted as the primary location, as recommended by 
Chauveaux et al. (1987). Additionally, given the complexity of classification, the appearance and 
association of FFB with adjacent structures will be noted, however FFB will not be classified at 
the data collection stage.  45 
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2.3.4.2 Magnetic resonance imaging 
Unlike US, MRI has been considered the gold standard imaging modality for much of 
musculoskeletal medicine since its advent (Hornak 1996, Suter et al. 2010, Ostergaard and 
Szkudlarek 2003). The gold standard label is arguably given because of the ability of MRI to 
provide detailed, multi-planar, anatomical images which allow differentiation and characterisation 
of the tissues under scrutiny (Ostergaard et al. 2005b). As demonstrated in table seven (a), the 
development of MRI as a diagnostic tool within rheumatology is marked by the ability of MRI 
scans to both differentiate and characterise adjacent tissues. A large proportion of the literature 
pertaining to the use of MRI within rheumatology focuses upon systematic tissue differentiation 
or the development of the ‘rheumatoid arthritis magnetic resonance imaging score’ (RAMRIS) 
(Ostergaard et al. 2005a, Ostergaard et al. 2003). Only in recent years have longitudinal 
evaluations of MRI efficacy in inflammatory disease been reported.  
 
Conversely, the chronological literature documenting the application of MRI to the study of the 
foot, summarised in table seven (b), demonstrates an altogether different trend; the focus of this 
research appears to be the identification of a single pathology and its diagnostic criteria. To 
date, no tools or systematic scoring methods have been proposed for use in the foot. However, 
Baan et al. (2011) have reported user reliability when applying RAMRIS to the foot joints.  
 
 
Table 7a: The development of magnetic resonance imaging in RA  
 
Timeline 
Article 
type  Event 
1
9
9
8
 
Scutellari 
(1998) 
RA 
evaluation 
MRI  reported  as  useful  in  the  differentiation  of  synovial  fluid  from 
inflammatory pannus in RA soft tissue pathology 
1
9
9
9
 
Weishaupt 
(1999)  Diagnosis  MRI reported to provide good tissue differentiation in RA 
2
0
0
3
 
Ostergaard 
(2003)  Tool 
OMERACT-RAMRIS tool proposed: initial core set of sequences and 
definitions are published which detail a methodological approach to MRI 
use in RA 
Conaghan 
(2003)  Tool  RAMRIS proposed: inter-rater reliability of the tool published 
Lassere 
(2003)  Tool  RAMRIS MCP inter-rater reliability published 
2
0
0
4
 
Ostergaard 
(2004)  Review 
Review:  value of MRI in peripheral joint  exam; MR is beneficial in RA 
Review: the validity of imaging synovium – MR is proposed as the gold 
standard modality 
2
0
0
5
 
Conaghan 
(2005a)  Tool  RAMRIS: image atlas specific to the hand published 
Woertler 
(2005)  Diagnosis  Appearances of soft tissue masses on MRI characterised 
Ostergaard 
(Ostergaard et 
al.  2005a, 
Ostergaard  et 
al. 2005c) 
Tool 
OMERACT-RAMRIS: introduction to the associated image atlas for the 
wrist and MCP joints 
Review: update on research priorities 
Haarvardshol
m(2005)  Tool  RAMRIS: sensitivity to change analysis completed – determined to be 
suitable for use in RA monitoring 
Conaghan 
(2005b)  Review  Review: MRI as an outcome measure – rigour in studies completed to 
date is reported to be of a poor standard 46 
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Bird (2005)  Tool  OMERACT-RAMRIS; reliability of proposed scoring system published 
Ejbjerg (2005)  Tool  OMERACT-RAMRIS wrist specific score published 
2
0
0
8
  Dohn (2008)  RA 
evaluation  Semi-quantitative MRI of the wrist in RA proposed 
Cimmino 
(2008a)  Review  Review:  RAMRIS  good  tool,  bone  oedema  strongest  independent 
predictor of radiographic progression at two years 
2
0
0
9
 
Conaghan 
(2009)  Tool  OMERACT MRI inflammatory group meeting: future research priorities 
should include feasibility studies and the imaging of remission 
Duer-Jensen 
(2008)  Use  Use of extremity MRI: efficacy of use unclear 
Boesen 
(2009)  Use  Protocol guidelines for the semi-quantitative analysis of MRI in RA 
Haavardsholm 
(2009) 
RA 
evaluation 
MRI shown to be a highly responsive method of determining biologic 
treatment effect in RA 
Katz (2009)  Review  Review:  MRI  3D  volumetric  measures  may  be  a  useful  outcome 
measure 
Kubassova 
(2010) 
RA 
evaluation  Semi-quantitative MRI use in the evaluation of synovitis 
Machado 
(2010) 
UIA 
evaluation 
3E  initiative  launched:  review  and  expert  consensus  regarding  the 
investigation and follow-up of UIA. 
Boyesen 
(2011) 
RA 
evaluation 
Comparison of evaluative modalities: MRI is superior to other imaging 
modalities and serological markers of disease state in the evaluation of 
RA activity 
2
0
1
0
 
Suter (2010)  Review  Review: a lack of good research to support the use of MRI as either a 
diagnostic or prognostic tool in RA is reported 
 
 
 
Table 7b: The development of magnetic resonance imaging of the foot & ankle  
Timeline 
Article 
type  Event 
1
9
9
4
 
Schweitzer 
(1994)  Diagnosis  MRI  use  proposed  for  tendon  pathology  evaluation  in  the  foot  and 
ankle  
1
9
9
7
 
Zanetti (1997)  Diagnosis  MRI use proposed for forefoot neuroma detection – demonstrated to 
be a highly accurate tool when validated with histology 
Stiskal (1997)  Diagnosis  MRI use proposed for chronic heel pain evaluation – patients with RA 
all had retrocalcaneal bursitis and no tendon abnormalities 
Forslind (1997)  RA 
evaluation 
MRI  in  early  RA:  MRI  of  fifth  MTP  joint  showed  earliest  detectable 
structural change, therefore MRI of the forefoot proposed as highly 
efficacious in patients with RA 
1
9
9
9
 
Kainberger 
(1999)  Review  Review: imaging the foot with MRI 
2
0
0
1
  Theumann 
(2001)  Diagnosis 
Detailed account of MRI findings in the forefoot of non-pathological 
feet  –  documentation  of  forefoot  bursae  verified  with  histological 
samples 
Ashman (2001)  Diagnosis  MRI  protocol  guidelines  for  the  differential  diagnosis  of  forefoot 
structures proposed 
2
0
0
3
 
Boutry (2003a)  Diagnosis  Common MRI findings in the hands and feet: FFB noted as common 
Maillefert (2003)  Diagnosis  MRI of hind foot in RA: criteria for synovitis identification proposed 
Mohana-Borges 
(2003)  Diagnosis  MRI and Bursography: MRI good for differentiating between structures 
2
0
0
4
 
Ostergaard 
(2004)  Review 
Review:  value of MRI in peripheral joint  exam: MR is beneficial in RA 
Review: the validity of imaging synovium  – MR is proposed as the 
gold standard modality 47 
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Ostendorf 
(2004) 
RA 
evaluation 
MRI  revealed  RA  activity  in  the  forefoot  but  not  the  hands  – 
recommends  the  forefoot  is  included  in  clinical  evaluation  of  RA 
disease 
2
0
0
5
 
Falsetti (2006)  Diagnosis  Imaging  the  heel  in  RA:  comparison  of  MR  and  PD-US;  PD-US 
determined to have better clinical utility 
2
0
0
8
 
Wakefield 
(2008) 
Diagnosis 
and use 
Optimal assessment of the rearfoot with MRI: MRI used as reference 
modality - reader variability highlighted as an important consideration  
Gregg (2008)  Diagnosis 
MRI of metatarsalgia: MRI reported to be a highly valuable tool, with 
good  differentiation  between  anatomical  structures  and  areas  of 
inflammation 
Bancroft (2008)  Diagnosis  Methodological considerations  for  imaging  soft  tissue  lesions  in  the 
foot  
2
0
1
1
 
Baan (2011)  Tool  RAMRIS can be reliably applied to the foot 
 
 
 
The use of MRI for the identification of FFB has been reported by only a few authors (Gregg et 
al. 2008, Narvaez et al. 2002, Boutry et al. 2003a, Boutry et al. 2005, Studler et al. 2008) and 
there is currently no standardised protocol or technique for doing so. Despite this, MRI has 
provided useful insight regarding the contentious area of FFB characterisation; authors such as 
Mohana-Borges et al. (2003) and Studler et al. (2008) have both accurately demonstrated MRI 
determined FFB which are consistent with concomitant anatomical or histological examination 
respectively (figure 14).  
 
 
                                     
Figure 14: Imaging and anatomical section comparisons 
Correlation between anatomical section (a) and MRI (b) findings in the transverse plane at the level of the 
metatarsal heads (M1-M3 depicted), in a cadaveric foot (a) 3mm thick gross anatomic section and  (b) 
combined MR arthrographic and bursographic T1  weighted spin echo MR image (500/12) showing the 
phalangeal attachment of the main collateral component of the collateral ligament complex (arrowheads). 
The interosseous tendons (black arrows) insert further into the phalangeal bases and border the collateral 
ligament complex. Note the intermetatarsal bursa (white arrow) between the interosseous tendons, with 
leakage  of  the  contrast  agent  in  14b.  Images  reproduced  with  permission  from  Mohana-Borges  et  al. 
(2003).  
 
 
Boutry et al. (2003a) clearly describe the hypertrophied synovium of intermetatarsal bursae 
(figure 15). Interestingly Chauveaux et al. (1987) demonstrated in eight patient cases, that 
injection with a contrast medium highlighted direct communication between the bursal cavity of 
interest and the MTP joints, a presentation quite distinct from that shown by Boutry et al. 48 
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(2003a).  However, despite disagreement between the reported findings both authors conclude 
that there are distinct anatomical variations in position, physiology and associated 
characteristics of FFB. 
 
 
 
Figure 15: MRI appearance of forefoot bursae in patients with RA  
Where 15a illustrates an axial, fat suppressed, gadolinium enhanced, three-dimensional, FLASH MR image 
of MTP joints in a 45-year-old man with early RA, revealing bilateral intermetatarsal bursitis (arrows). It is 
also noteworthy that no abnormality was found in the wrists (15b). Images reproduced with permission from 
Boutry et al. (2003a). 
 
 
In contrast, Studler et al. (2008) clearly detail the fibrotic changes associated with plantar 
metatarsal bursae (figure 16). Such lesions are reported as distinct masses, occurring plantar to 
the inferior aspect of the deep transverse intermetatarsal ligament, with a fluid element 
encapsulated within an enhancing fibrotic mesh. 
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Figure 16: Plantar fat pad signal alterations with MRI and histological comparison 
MRI findings of plantar fat pad signal alterations in a 59-year-old symptomatic male. Where 16a illustrates 
a  transverse  T1  weighted  image,  (600/15),  showing  a  signal  intensity  alteration  (white  arrows)  with 
indistinct margins in the plantar fat pad beneath the first metatarsal head region of the right forefoot. On a 
T2 weighted image (figure 16b), (4500/96), the majority of the signal intensity alteration (white arrows) is 
hyper-intense. Band-like structures of low signal intensity (black arrowhead) are apparent within the fat pad 
alteration.  16c  illustrates  a  T1  weighted,  contrast  enhanced,  fat  suppressed  image  (735/15),  showing 
peripheral  enhancement  (black  arrows).  16d  is  a  photomicrograph  of  a  histological  specimen  showing 
fibrous collagen bundles (black *). Within the cavity, fibrin-lined papillary projections (black arrowhead) are 
seen  and  correspond  to  the  band-like  structures  in  image  16b.  (Elastin-van  Gieson  stain;  original 
magnification x 32). Images and annotation reproduced with permission from Studler et al. (2008). 
 
 
The aetiology and clinical importance of differences in FFB tissue characteristics remains 
unclear. However MRI does appear to offer a potential method of further FFB epidemiological 
study. MRI has potential to provide an observer-independent, multi-planar, reliable and valid 
method of characterising FFB in patients with RA.  
 
Characterisation of tissues is achieved by translating the different magnetic properties of tissue 
into differing radio frequency signals (Hornak 1996). These are subsequently Fourier 
transformed to generate grey scale images (Hornak 1996). The principles underpinning image 
generation are of particular relevance to this thesis, where the manipulation of magnetic fields is 
of paramount importance to the resultant accurate characterisation of FFB; the relaxation 
properties of excited hydrogen nuclei in water (for example bursal fluid) and lipids (for example 
plantar adipose tissue), after  alignment using large magnetic field gradients which orientate the 
precessing isocromats to be either parallel (longitudinal magnetism) or antiparallel (transverse 50 
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magnetism) to the B0 axis, generate the signal to be Fourier transformed into an image (figure 
17) (Hornak 1996).  
 
 
 
Figure 17: MRI T1 processes 
Where  x/y/z  =  orthoganol  field  gradients;  Mo  =    equilibrium  of magnetisation  within the  rotating  frame 
(perspective of isocromat orientation); Bo = orientation of overall magnetic field. Image reproduced with 
permission from JP Hornak (1996). 
 
 
The strength of the magnetic field gradients (Tesla), in addition to the magnitude, number and 
length of secondary magnetisation (radio frequency pulse) and length of relaxation time 
(longitudinal: T1 and transverse: T2) will therefore all lead to differences in the generated image 
contrast (Lisle 1996). The image contrast can be adjusted by changing the flip angle (direction of 
RF pulse), time of applied magnetisation, or number of applied pulses (Lisle 1996). This will re-
orientate the precessing isocromats, and thus the signal generated by their return characteristics 
towards B0 is altered (Lisle 1996). Image contrast is therefore a result of TR/TE relaxation 
parameters (figure 18), and importantly an increased flip angle will improve tissue differentiation 
but will take longer and therefore there will also be more signal decay and loss of image clarity 
(Hornak 1996, Reiser et al. 2008). 51 
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Figure 18: MRI TR/TE relaxation ratios & image contrast 
Where TR=Relaxation time; TE=Echo time; T1=Longitudinal magnetisation; T2=Transverse magnetisation. 
Image reproduced with permission from JP Hornak (1996).  
 
 
 
The differing response rate of tissues to magnetisation, because of their variable hydrogen 
content, improves image contrast (Hornak 1996). In the case of FFB characterisation, a good 
sequence of images will therefore be selected in order to show sharp anatomical detail (avoiding 
excessive signal decay), the presence/absence of inflammation, the presence/absence of fluid, 
and differentiation between synovium and fibrous tissue. To date, there is no standardised 
definition of MRI-detected FFB and as such, for the purposes of this thesis, a fluid collection was 
defined as: 
 
  A homogeneous hyperintense mass with fluid-equivalent signal on pd/T2 sequence and 
homogenous  hypo-intensity  in  contrast  to  true  ‘mass’  defined  as  non-fluid 
equivalent/intermediate signal on T1 and T2.  
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Differentiation between fluid/fibrous intermetatarsal lesions and neuroma was determined 
primarily by anatomical location, in addition to review of lesion margins and T1/T2 characteristics 
as above. 
2.4 Summary  
RA is a systemic, complex disease affecting multiple body tissues and organs that has a 
significant impact on the lives of patients and their families. The disease is typified by painful 
swelling and deformity of the joints of the hands and feet. However, the exact epidemiology of 
RA foot complications is unclear and under-reported in comparison to those of the hand. None 
the less, there is a growing body of evidence highlighting the epidemiology of foot problems in 
this patient group. Furthermore, evaluation of the presence of disease activity within the foot 
may help inform the new therapeutic target of complete remission from RA disease. In particular 
forefoot bursae have recently been highlighted as associated with RA disease activity and as 
potentially clinically relevant based upon cross sectional study. However, the natural history and 
longitudinal clinical importance of FFB in patients with RA remains unclear. Furthermore the 
biological mechanisms by which FFB are clinically relevant requires further investigation. This 
could improve the targeting of future intervention strategies. There is currently a clinical need for 
a user-independent, reliable and valid method of identifying and characterising potentially 
pathological and non-pathological FFB. There is confusion within the current literature regarding 
the exact epidemiology, aetiology and clinical importance of FFB in patients with RA. Further 
investigation of this area is warranted in order to inform future treatment strategies. 
2.5 Research aim & hypothesis 
This thesis aims to utilise novel US and MRI imaging techniques to determine the epidemiology 
and clinical importance of FFB in patients with RA. The four experimental studies completed as 
part of this thesis will: 1) contribute to the current understanding of the clinical importance of US-
detectable FFB, 2) contribute to the current understanding of the biological mechanisms by 
which US-detectable FFB are clinically relevant, 3) provide a robust tool for the identification, 
characterisation and evaluation of pathological FFB, and 4) contribute to the current 
understanding of which FFB are pathological and why, providing an evidence-based framework 
for future clinical intervention. The research hypothesis central to this thesis, and underpinning 
the basis of study, is therefore: 
  H1: ‘FFB are clinically relevant in patients with RA’ 
  H0: ‘FFB are not clinically relevant in patients with RA’ 
 
The main research question is thus: 
What is the epidemiology and clinical importance of forefoot bursae in patients 
with rheumatoid arthritis? 53 
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Chapter three 
Methodology 
 
3.0 Introduction 
The preceding chapter has identified an area of unmet clinical need in patients with rheumatoid 
arthritis (RA) who experience foot complications. The literature review completed has identified 
forefoot bursae (FFB) as a potential clinically relevant factor in the development or propagation 
of foot complications in this patient group. However, to date little is known about the longitudinal 
epidemiology, aetiology and clinical importance of FFB in patients with RA. This chapter 
therefore discusses the philosophical approach and research methodology used in the four 
experimental studies that form this thesis, the overall aim of which was to determine the 
epidemiology and clinical importance of forefoot bursae in patients with RA.  
 
In order to achieve the main study aim a series of four experimental studies were completed. 
The methods for the completion of the experimental studies were thus designed to address the 
following objectives: 1) to describe the natural history of musculoskeletal ultrasound (US) 
detectable forefoot bursae (FFB) over a three-year period in patients with RA (Chapter four), 2) 
to describe and compare the presence of US-detectable FFB between patients with RA, OA and 
healthy individuals (Chapter five), 3) to create and evaluate a novel MR imaging methodology for 
use in the identification of FFB in patients with RA (Chapter six) and 4) to determine the clinical 
importance of MR detectable FFB in patients with RA (Chapter seven).  
3.1 Main thesis aim & objectives  
The main aim of the thesis was to determine the epidemiology and clinical importance of forefoot 
bursae in patients with rheumatoid arthritis (RA). The main objectives were thus: 
 
1.  To determine the natural history and clinical importance of US-detectable FFB in 
patients with RA (Chapter four) 
2.  To explore the relationship between US-detectable FFB and inflammation or 
biomechanical impairment in patients with RA (Chapter five)  
3.  To determine the reliability and validity of a novel MRI-based score for the identification 
and characterisation of FFB in patients with RA (Chapter six) 
4.  To determine the epidemiology and clinical importance of MRI-detectable FFB in 
patients with RA (Chapter seven) 
3.1.1 Rationale for overall study design 
A positivistic philosophical approach to this work was adopted (Giddings and Grant 2007, Silman 
and Hochberg 2001, Segura del Pozo 2006). As such, a prospective cohort study design was 
selected as the main methodological approach. Subsequently the methodologies developed are 54 
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reductionist in nature and grounded within a quantitative analytical approach, to facilitate the 
objective exploration of observed phenomena.  
 
A step-wise pragmatic determination of the appropriate methodology was used, following the 
algorithm outlined in table eight. Arguably the majority of this work is based within the field of 
epidemiology (the study of the distribution of disease and its determinants) (Silman and 
Macfarlan 1995), and thus may be considered inductive. However, the methodological design is 
such that the research hypotheses may be tested, and therefore the completed research can be 
considered as deductive. None the less, it is anticipated that a substantial contribution of this 
work may be towards theory generation via the determination of disease occurrence and 
associated factors in a sequence of four novel experimental studies. 
 
 
Table 8: Methodological design  
Considerations in epidemiological research design (Silman and Macfarlan 1995). 
 
Consideration factor  Example 
Study design  What is the question posed – what type of study can best answer 
the question and is most practicable? 
Population selection  Who should be studied? 
How many should be studied? 
Information gathering 
How should the information be obtained? 
Is the information obtained correct? 
Is the method used to obtain the information consistent? 
Analysis  How should the data gathered be prepared for analysis? 
What are the appropriate analytical methods? 
Interpretation of results 
Can any associations observed be explained by confounding? 
Are the results explained by bias? 
Are the results generalisable? 
Logistics  Is the research ethical? 
Is the research affordable? 
 
 
3.2 Study specific research aims, objectives & methodological designs 
To achieve the overall thesis aim a series of four experimental studies were completed:  
 
Experimental study one: The main aim of this study was to determine the natural history and 
clinical importance of FFB in patients with RA. To achieve this aim the following objectives were 
set: 
1.  To determine the natural history of US-detectable FFB over three years  
2.  To describe potential differences in the US characteristics of identified FFB 
3.  To determine the clinical importance of US-detectable FFB  
Experimental study one is a longitudinal, prospective three year follow-up study of US-
detectable FFB, in a known cohort of patients with rheumatoid arthritis, for whom baseline and 
year-one follow-up phenotypic data have previously been collected (Bowen et al. 2009, Bowen 
et al. 2010c, Bowen et al. 2010b).  55 
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Experimental study two: The main aim of this study was to explore the potential relationship 
between US-detectable FFB and inflammation or biomechanical impairment in patients with RA. 
To achieve this aim the following objectives were set:  
1.  To compare the prevalence and distribution of US-detectable FFB between patients with 
medial knee osteoarthritis (OA), as a surrogate biomechanically impaired patient group, 
and healthy volunteers (HV) 
2.  To compare the prevalence and distribution of US-detectable FFB between patients with 
Rheumatoid arthritis (RA), as a surrogate inflammatory and biomechanically impaired 
patient group, and HV 
3.  To compare the prevalence and distribution of US-detectable FFB between patients with 
RA and OA 
4.  To explore the potential relationship between FFB distribution and biomechanical 
impairment or inflammation  
Experimental study two is a comparative, cross-sectional, observational study of US-detectable 
FFB in participants with RA, OA or HV.  
 
Experimental study three: The main aim of this study was to determine the reliability and 
validity of a novel MRI-based score for the identification and characterisation of FFB in patients 
with RA. The following study objectives were set:  
1.  To complete an iterative process of MRI-based semi-quantitative score design: 
development of the FFB-Score 
2.  To collate an FFB-score reference image atlas  
3.  To determine the reliability and validity of the FFB-score 
Experimental study three utilises a collaborative process of score design by a team of 
rheumatologists, radiologists, and a podiatrist from centres within the UK and Germany. A cross-
sectional cohort study design was used, with repeated MRI data generation by multiple readers. 
 
Experimental study four: The main aim of this study was to determine the epidemiology and 
clinical importance of MRI-detectable FFB in patients with RA. To achieve this aim the following 
objectives were set: 
1.  To determine the prevalence of MRI-detectable FFB  
2.  To describe differences in the MRI characteristics of identified FFB 
3.  To determine the clinical importance of MRI-detectable FFB in patients with RA 
Experimental study four is a cross-sectional observational study of MRI-detectable FFB in 
patients with RA.  
 
The overall contribution of each experimental study towards the main thesis aim was 
subsequently considered in the final discussion chapter.  56 
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3.3 Ethical considerations & research governance  
Southampton University Hospitals NHS Trust (SUHT) agreed sponsorship of all patient related 
studies in May 2009 (see appendix section A1). Professional indemnity insurance was also 
granted at this time (see appendix section A1). The programme of work was accepted onto the 
NIHR portfolio register in June 2009. The study was also registered with the UK central research 
network at this time in accordance with the declaration of Helsinki of the World Medical 
Association (2008), and reported on the central research network database. Full ethical approval 
for the program of work entitled ‘The clinical importance of forefoot bursae in patients with 
rheumatoid arthritis’ was obtained from the South Central Local Research Ethics Committee (B) 
in August 2009 (see appendix section A2). The study was accepted for completion within the 
Wellcome Trust Clinical Research Facility (WTCRF) in August 2009. Full approval from the local 
research and development department within SUHT was obtained in December 2009 (see 
appendix section A3). Approval for the additional completion of MRI works, reported in 
experimental studies three and four, was sought from the South Central Local Research Ethics 
Committee (B) and granted in December 2010 subsequent to the submission and approval of a 
substantial amendment request (see appendix section A3). 
 
The University of Southampton agreed sponsorship of the study entitled ‘The prevalence of 
forefoot bursae in healthy volunteers’ in July 2011 (see appendix section A1). Ethical approval 
for this study was granted in July 2011 by the University of Southampton, Faculty of Health 
Sciences ethics committee (see appendix section A2). Insurance for the study was granted by 
the University of Southampton research governance office in July 2011 (see appendix section 
A1). 
3.3.1 Study specific considerations 
The following were identified and acknowledged as potential ethical issues applicable to the 
experimental studies included within this thesis: 
 
1. Human participants were required as part of this population based study, and therefore 
appropriate informed consent procedures were adhered to. The year-three follow-up study was 
dependent upon the use of a previous cohort within which gender inequality had been 
demonstrated. However, this inequality was considered to be reflective of the gender inequality 
present within this regional population.  
 
2. Data collected contained sensitive personal information regarding patient care. However, only 
clinicians and researchers actively involved in the study had access to this information, which 
was anonymised and held in a secure cabinet on the hospital site or on encrypted 
hardware/software. Patient anonymity was observed in all publications arising from this study. 
All participants were seen within the Wellcome Trust Clinical Research Facility (WTCRF), in an 
individually dedicated consultation room. 57 
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3. There is currently no formal training route, with associated assessment of  competency, in the 
use of US or MRI by allied health professionals. As such, it is possible that error or bias may 
have been introduced into the study results by poor acquisition or interpretation of the imaging 
data. To minimise this, the study researcher (LH) completed a series of nationally recognised 
training courses  and a programme of supervised training (as recommended by the lead 
radiologist contributing to this work). Inter-rater agreement between LH and a previous 
investigator (for US) or experienced radiologist (for MRI) was established and further training 
completed until satistfactory agreement was demonstrated.  
 
4. Previous studies have shown a risk of tissue damage with US use, although this is related to 
levels of exposure never used within clinical practice. To ensure patient safety, all US exposure 
was managed in accordance with 'ALARA' principles of use (Fitzpatrick et al. 1998).  
 
5. In patients with poor renal function there is a known risk of nephrogenic systemic fibrois 
associated with the use of gadolinium-based contrast agents during the acqusition of MR 
images. The renal function of all participants was screened prior to the undertaking of the MRI 
data collection, in line with MHRA guidance (MHRA 2007). All participants were also screened 
for additional contra-indications to MRI prior to final recruitment.  
 
6. It was possible that lesions other than those associated with rheumatoid arthritis may have 
been identified during image analysis of the forefoot. Such lesions were reviewed by a senior 
radiologist/ rheumatologist for their evaluation, action and further discussion with the patient 
where applicable. Identification of these lesions was not made apparent to the patient at the time 
of image acquisition. However, a subsequent imaging session was arranged in conjunction with 
clinical follow-up by other medical specialists if appropriate. 
 
7. Participant involvement in this study provided no direct benfit or gain to any patient, although 
did facilitate the development of new knowledge, that is applicable to the larger rheumatological 
community. Participants were able to have layman access to the findings of this study at key 
stages of completion. Participant involvement or withdrawal from the study was fully discussed, 
optional at any time, and had no direct consequence to ongoing clinical care.  
3.3.2 Consent 
Formal consent to participate in a study was obtained in writing on the day of data collection 
(see appendix section A4). Prior to this, participants were issued with a written information sheet 
(see appendix sections A5 and A6), asked to consider their participation and encouraged to 
discuss this with a friend/family member. At the time of obtaining consent participants were 
given the opportunity to discuss any concerns or questions with the investigator. Participants 
were reminded at this time that withdrawal from the study was possible at any stage, for any 58 
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reason, and that this would have no adverse consequence to their ongoing rheumatological 
care.  
3.3.3 Data coding, handling & storage 
The NHS code of confidentiality was adhered to during recruitment, data collection, analysis, 
dissemination or any other activity pertaining to the conduct of this study. All participants were 
anonymised at the time of recruitment, using an alpha-numerical code that was used on all 
subsequent documentation. Access to the coding criteria was limited to the immediate research 
team. All data and anonymisation details were kept in a locked cabinet within the hospital site if 
in hard copy or on encrypted, password protected hardware/software in accordance with the 
Data Protection Act (1998). Access to confidential information was permitted only to recognised 
persons for monitoring/audit/quality assurance or research purposes. Access to patient medical 
records was required to facilitate the review of relevant medical information (for example past 
pharmacological therapy). Participants were advised of this and were asked to acknowledge this 
directly as part of the process of granting informed consent. The principal investigator for the 
study (LH) was nominated as chief custodian of all collected data.   
3.3.4 Conflicts of interest 
The PhD candidature completed in conjunction with this thesis was supported by a clinical 
doctoral research fellowship award from the National Institute of Health Research (NIHR). The 
epidemiological work completed in experimental studies one and two was supported by a 
research grant from the Southampton Rheumatology Research Trust. The MRI-based 
investigations completed in experimental studies three and four were supported by a project 
grant from Pfizer UK. No personal benefits of any form were or will be received from any 
commercial party as a consequence of direct or indirect association with this research.  
3.4 Study population 
The main study population that forms the focus of this thesis is a cohort of consecutively, 
prospectively recruited patients with rheumatoid arthritis (RA) who have contributed to the 
‘FeeTURA’ programme of work from 2007–2011. Two additional participant groups, including 
those with medial knee osteoarthritis (OA) or healthy volunteers (HV) were also included in a 
comparative study, reported in chapter five.  
3.4.1 Target populations & recruitment strategy 
Experimental study one: This study is a longitudinal evaluation of patients with RA who have 
contributed to the ‘FeeTURA’ research project over three-years, for whom baseline and one-
year follow-up data has been previously reported (Bowen et al. 2010c, Bowen et al. 2009). At 
baseline, patients with a consultant confirmed diagnosis of RA, (according to 1987 ACR criteria 
(Arnett et al. 1988)), attending a Southampton based outpatient rheumatology clinic, were 
prospectively, consecutively recruited to the study between July 2006 and January 2007. 
Patients were given information about the study at the time of their clinical appointment and 59 
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invited to contact the research team for further information or to declare their interest in 
participation. Participants who completed the baseline appointment were invited to return for 
subsequent year-one follow-up by way of letter of invitation. Participants who attended both 
baseline and year-one appointments were considered eligible for entry into the year-three 
follow-up study and again contacted by way of a letter of invitation and reply slip (see appendix 
section A6).  
 
Experimental study two: This study is a comparative evaluation of patients with RA, medial 
knee osteoarthritis (OA) or healthy volunteers (HV). Those patients with RA who contributed to 
experimental study one, were also included within this study. Patients with a consultant 
confirmed diagnosis of medial compartment knee OA of Kellgren and Lawrence grade≥2, in at 
least one knee, were recruited from a known cohort who had previously participated in a trial of 
vitamin D supplementation (the ‘VIDEO’ study). Participants were originally consecutively, 
prospectively recruited to the VIDEO study from a population of patients attending a general 
rheumatology outpatient clinic in Southampton between December 2005 and April 2009. 
Participants from the VIDEO study were consecutively, retrospectively identified from those 
completing the final episode of data collection within the trial and invited to participate within this 
study by way of letter of invitation. Recruitment of patients with OA to this study was completed 
in phases, from December 2009 to December 2010, until the target sample size was achieved. 
Healthy volunteers were recruited from staff and students attending the University of 
Southampton between July 2011 and November 2011. Potential participants were informed of 
the study by way of poster displays which contained researcher contact information. Following 
receipt of an expression of interest the researcher contacted the potential participants to 
complete eligibility checks and arrange an appointment. 
 
Experimental studies three and four: Those patients with RA who contributed to experimental 
study one, were eligible for screening to studies three and four. Eligible participants were invited 
to complete this study by way of letter of invitation and reply slip, and accompanying patient 
information sheet (see appendix sections A5 and A6). Upon receipt of the reply slip, participants 
were contacted by the researcher to complete final screening checks and to arrange an 
appointment.  
 
3.4.2 Inclusion and exclusion criteria  
The inclusion and exclusion criteria for the patient groups contributing to this thesis were defined 
as follows: 
 
Inclusion criteria 
For RA participants, patients were included who:  
  had a diagnosis of RA according to the ACR criteria   
  were attending a SUHT rheumatology outpatients’ clinic between Jul 2006 and Jan 2007 
  took part in the baseline FeeTURA study 60 
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  were aged between 18-80 years at the time of initial recruitment into the previous baseline 
FeeTURA study 
 
For OA participants, patients were included in who: 
  had radiological evidence of early OA disease at medial tibio-femoral knee compartment 
(based upon a modified Kellgren and Lawrence score of 2-3 (Lawrence et al. 1966), and 
Joint space width of >1mm) 
  were able and willing to attend or comply with treatment and follow-up 
  had pain in the knee for most days of the previous month 
  were ambulatory at the time of recruitment into the VIDEO study 
  were aged 50 years or over at the time of initial recruitment into the VIDEO study  
  had taken part in the baseline VIDEO study 
 
For HV, individuals were included who: 
  have no diagnosis of a musculoskeletal condition 
  are a student or staff member at Southampton University 
  are willing to participant in the study, providing full informed consent 
 
Exclusion criteria 
For RA participants, patients were excluded who: 
  had received corticosteroid injection therapy to the forefoot within the 12 weeks prior to the 
commencement of the initial FeeTURA study 
  were unable to walk a distance of 5metres 
  had concomitant musculoskeletal disease (e.g. primary osteoarthritis, gout, Paget’s disease, 
systemic lupus erythematous) 
  had a serious medical or psychological disorder that would prevent compliance with the 
study protocol 
  were unable to provide informed consent  
 
Additional exclusion criteria applicable to patients with RA otherwise eligible to complete MRI 
included: 
  have a pacemaker fitted 
  have other electronically, magnetically or mechanically activated medical device or implant 
that may be adversely affected by the MRI procedure 
  have a history of eye injury involving metal fragments 
  have a cochlear implant 
  have renal dysfunction 
  were pregnant 
  are claustrophobic 61 
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  have a history of forefoot surgery with metallic fixation devices still in situ 
 
For OA participants, patients were excluded who: 
  had secondary OA subsequent to any of the following: septic arthritis, gout, pseudo-gout, 
Wilson’s disease, Paget’s disease, hyperparathyroidism, hypothyroidism, sarcoidosis, 
osteomalacia, osteoporotic fracture, a history of inflammatory disease, hypercalcaemia or 
hypercalciuria 
  were using any of the following at the time of initial recruitment into the VIDEO study: 
glucosamine or chondroitin within the 12 weeks prior to recruitment, bisphosphonates, 
vitamin D supplementation with at total vitamin D content>200iµ, any anti-epileptic 
medication 
  had received any intra-articular corticosteroid injection therapy within the 12 weeks prior to 
recruitment into the VIDEO study 
  had received injection of Hyalgan within the 24 weeks prior to recruitment into the VIDEO 
study 
  had undergone any surgical procedure to the knee in the 24 weeks prior to recruitment into 
the VIDEO study  
  were pregnant at the time of recruitment into the VIDEO study 
 
For HV, individuals were excluded who: 
  Have had corticosteroid injection therapies to the forefoot within the previous 3 months prior 
to commencement of the study 
  Have a musculoskeletal/rheumatological disease (e.g. primary osteoarthritis, rheumatoid 
arthritis, gout, Paget’s disease, systemic lupus erythematous) 
  Have a serious medical or psychological disorder that would affect the study protocol 
  Are unable to comply, understand or are unwilling to participate in the requirements of this 
investigation 
  Are unable to give informed consent 
3.4.2 Withdrawal of participants 
Participants were able to withdraw from the study at any time without providing a reason for 
doing so. At the time of consent all participants were reminded that they were able to withdraw 
at any point and that, if applicable, this would have no adverse consequence to their ongoing 
clinical care.  
 
In the event of a participant with RA wishing to withdraw from the study they would not be 
replaced because all possible participants from the original FeeTURA study will already have 
been invited to participate. In the event of a participant with OA wishing to withdraw from the 
study, it was possible to fill this opportunity to participate via further consecutive, retrospective 62 
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recruitment from the VIDEO study population. In the event of a healthy volunteer wishing to 
withdraw from the study, they could be replaced by continued recruitment.  
3.5 Sample size determinants 
The following sections discuss the calculation, clinical reasoning and previously reported 
literature considered when determining the appropriate sample size for each experimental study.  
3.5.1 Experimental study one  
The sample size calculation used for independent group analysis with binary data (bursa 
presence/absence) was as follows: 
 
    N (per group)   =   2 x [z (1-α / 2) + z (1-β)]
2 
   
                                  Δ
2 
  Where α = level of statistical significance, β = power, Δ
2 = proportional difference,  
  adjusted for variability between groups (effect size).  
  Calculation 1: Sample size  
 
However, for this longitudinal investigation the target population is known and has been 
previously reported (Bowen et al. 2010b). This initial sample size was constructed using 
Pearson’s correlation coefficient estimates of association between patient reported foot 
complications and bursae presence/absence (PCC=0.211; p=0.371). At baseline 150 
participants were enrolled into the study with a subsequent recruitment rate of 86% (N=129) at 
the one-year follow-up visit. With a continued annual trend in loss to follow-up rates, the 
estimated recruitment for this study was approximately 90 participants. Therefore, with a known 
population size, the above calculation can be simultaneously equated thus (assuming the 
estimate of effect size obtained at baseline is consistent): 
 
    Z (1-β)   =   √     NΔ
2   – z(1-α / 2) 
                   2 
   
  Where α = level of statistical significance, β = power, Δ
2 = proportional difference,  
  adjusted for variability between groups (effect size).  
Calculation 2: Statistical power  
 
Assuming a sample size of 90, there will be over 95% power to detect a difference of 0.55 in the 
proportion of participants with one or more bursae, using a two-sided 5% significance level. This 
power is greatly increased due to the large proportional difference between groups in 
presence/absence of bursae (effect size) observed at baseline. Thus the likelihood of detecting 
a false positive or incorrectly omitting a true positive finding is reduced. 
3.5.2 Experimental study two  
There is currently no known data regarding the prevalence of FFB in patients with OA. It was not 
possible therefore to estimate proportional effect in order to calculate a required sample size for 
this population, thus a pragmatic sample of 50 candidates was selected. Similarly, there is 
limited evidence available regarding the prevalence of US-detectable FFB in healthy volunteers 
and therefore a comparative control sample of 50 participants was recruited. This sample size 63 
 
Chapter 3: Methodology 
was reflective of the sample size of non-arthritic populations previously reported in studies of 
FFB (Bowen et al. 2010b). 
3.5.3 Experimental study three  
Previous research regarding the development of MRI-based tools, designed for use in patients 
with rheumatological conditions, have ranged from 10 in a developmental study for a semi-
quantitative OA hand MRI score (Haugen et al. 2011), to 32 in an evaluative study of semi-
quantitative MRI modalities for the assessment of knee OA (Roemer et al. 2010). However, 
previous research has also highlighted that an increased sample size is beneficial in imaging 
studies of inflammatory or erosive disease, in which distortion of anatomical features is common 
(Bird et al. 2003, Boesen et al. 2009, Cohen et al. 2011, Ostergaard et al. 2005c). As such, a 
target sample size of 50 participants was considered appropriate for this study. However, the 
potential size of the targeted population is bounded by the number of participants who are both 
eligible to undergo MRI and have completed the year-three follow-up appointment in 
experimental study one. 
3.5.4 Experimental study four 
The size of the potential sample available for analysis within this study is dependent upon those 
participants who completed experimental studies one and three. However, based upon the 
proportional difference in US-detectable FFB presence/absence a sample size of approximately 
20 participants would be required, assuming 80% power and 5% significance level, for the 
determination of FFB presence or absence. These estimations are potentially of academic value 
only, as the prevalence of MRI-detectable FFB has not been previously reported to date.  
3.6 Study outcome measures 
A number of variables were recorded in order to achieve the proposed experimental study 
outcomes. The outcome measures were selected to provide information on the following: 
participant demographical information, the presence/absence of forefoot bursae or other forefoot 
soft tissue lesions, the evaluation of disease state, foot health or posture, and the determination 
of patient-reported foot-related disability. The following sections provide further detail regarding 
the methodological considerations for each identified outcome measure. 
3.6.1 Demographical information 
The demographical information collected includes age (years), height (centimetres/cm), weight 
(kilograms/Kg), gender (male/female), arthritis diagnosis and disease duration (years), and 
current pharmacology. These measures were obtained either by the review of patient records on 
the day of data collection, participant interviewing or by using standardised laboratory measures. 
The information was recorded on the participant demographical information sheet (see appendix 
sections A7a and A7b), to be used in subsequent analyses of interactions or confounding.  64 
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3.6.2 Monitoring of disease state 
As discussed in Chapter two (section 2.1), a number of tools for the evaluation of disease state 
in RA have been developed. However for the purposes of this thesis both the DAS 28-CRP and 
DAS 28-ESR scores were used. These measures are consistent with those reported as routinely 
used within current rheumatological clinical practice and allow the evaluation of fluctuations in 
disease state (Wolfe et al. 2001).  
 
Participants were asked to complete a visual analogue scale indicating their perceived overall 
well-being on the day of assessment. This was transformed linearly from a millimetre scale into 
a score of 0-100. The 28 joints assessed included both shoulders, both elbows, both radiocarpal 
joints, metacarpophalangeal joints 1-5 of both hands, proximal interphalangeal joints 1-5 of both 
hands, distal interphalangeal joints 2-5 of both hands and both knees (Van der Heijde et al. 
1990). The joints were palpated for fluctuant swelling using a standardised technique and the 
patient was asked to report any tenderness felt during this process. Figure 19a-d illustrates the 
palpation techniques used for some of the upper body joints. Figure 19e-f illustrates the 
additional ankle and proximal interphalangeal joint palpation completed as part of the 
assessment of disease activity within the foot.  
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Figure 19: Joint Palpation 
Joint palpation technique at a) the right 3
rd proximal interphalangeal joint, b) the left radiocarpal joint, c) the 
left elbow joint, d) the right knee, e) the right 2
nd proximal interphalangeal joint and f) the right talo-crural 
joint. Images author’s own. 
 
 
Blood samples were taken using standardised venesection techniques by the study researcher 
(LH), in accordance with local trust policy and good clinical practice guidelines (Bird et al. 2005). 
Samples were then labelled for ESR/CRP calculation or spun for plasma and serum separation 
(using a Beckman Coulter centrifuge, Allegra 6R
® model, at 5,000rpm, 5°C, for 10 minutes), and 
prepared for storage (figure 20). 
 
 
 
 
Figure 20: Sample preparation 
Sample preparation where, 20a illustrates venesection technique, 20b illustrates plasma/serum separation 
via centrifuge at 5,000rpm, 5°C, for 10minutes, and 20c illustrates sample transfer into aliquots for storage. 
Images author’s own. 
 
 
Further to the joint swelling and tenderness count, visual analogue scale (VAS) of overall 
wellbeing completion and CRP or ESR analysis, the composite DAS 28-CRP or DAS 28-ESR 66 
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scores were calculated. All information was recorded on the disease activity assessment form 
(see appendix section A14d), (Lynch et al. 2010). The DAS 28 scores and change in scores 
were subsequently interpreted in accordance with the guidelines listed in table nine. 
 
 
Table 9: The scoring of disease activity in RA  
DAS 28 scoring and interpretation (Lynch et al. 2010, Hayashi et al. 2010, Ostergaard et al. 2005a) 
DAS score at baseline  Change in DAS score after baseline 
DAS score  Interpretation  >1.2  >0.06 + ≤1.2  ≤0.06 
≤3.2  inactive  good 
improvement 
moderate 
improvement  no improvement 
 
>3.2 ≤5.1  moderate activity  moderate 
improvement 
moderate 
improvement  no improvement 
>5.1  high activity  moderate 
improvement  no improvement  no improvement 
 
 
3.6.3 Musculoskeletal ultrasound 
A Diasus
® diagnostic musculoskeletal ultrasound (US) scanner (System 8, Dynamic imaging, 
Livingston, Scotland, UK), was used for both studies one and two (figure 21a). Scanning was 
completed in B-Mode to provide real-time grey-scale images, sampled at a maximum frame rate 
of 30 frames per second. The return echo signals were automatically processed using Diasus
® 
2D spline filtering. Image pixilation was standardised at 640 x 440 pixels, the optimum settings 
for fine image resolution available using this software. The overall transmit power and gain was 
set at ≤50 and ≤30 respectively, in accordance with the European League Against Rheumatism 
(EULAR) working group for US in rheumatology scanning recommendations (Backhaus 2001). 
However, grey-scale contrast was continually adjusted during image acquisition in real-time 
using multiple fine gain control and focus points. Where possible the least amount of focus 
points were used and centred at the intermetatarsal level for plantar foot scans and the upper 
third of the joint space for dorsal foot scans. This enabled the transmit frequency to be as high 
as possible to achieve good image resolution whilst also maintaining a suitable wave 
penetration depth aimed at the level of anatomical interest. 
 
All US scanning was performed in accordance with the British Medical Ultrasound Society 
(BMUS) guidelines for safe use (Fitzpatrick et al. 1998). In addition, the image acquisition 
protocol was designed to reflect the ALARA principles (as low as reasonably achievable) 
reported by the American Institute of Ultrasound in Medicine (AIUM), (Fitzpatrick et al. 1998). 
Thus, the minimum amount of US exposure was used to reasonably fulfil the objectives of the 
US scan.  
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Figure 21: US equipment 
Where 21a illustrates the Diasus
® portable US unit, system 8, 21b illustrates the 5-10MHz ultra wideband 
linear-array transducer, active length 40mm (left) and the 8-16MHz transducer, active length 26mm (right). 
Images author’s own. 
 
 
 
The dual probe system operates with two linear array transducers (figure 21b). This enabled 
specific sound wave frequency use and thus optimised image resolution where possible whilst 
also ensuring accurate wave penetration depth when required, as demonstrated in figure 22. For 
example, the 8-16MHz transducer was not sufficient to accurately review the intermetatarsal 
spaces at the level of the deep transverse intermetatarsal ligament and therefore the 5-10MHz 
transducer was used for these scans. 
 
 
                    
Figure 22: US transducer frequency & tissue depth penetration 
A Longitudinal skin section demonstrating US frequency compared to depth of tissue penetrated in a large 
joint. Image reproduced with permission from RH09 schematic design, Southampton (2009) 
 
3.6.3.1 US protocol 
The US foot scan was completed prior to the podiatric assessment or evaluation of disease 
state, to minimise the potential for observer bias; the researcher completed the scan without 
prior knowledge of the participant’s foot health or disease activity status. An overview of the US 68 
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scanning protocol is shown in figure 23. Hypo-allergenic, alcohol free coupling gel was liberally 
used throughout to improve transducer to skin contact.  
 
 
Figure 23: US scanning protocol 
1. Participant is seated on a flatbed plinth, with their feet facing towards the researcher 
2. The transducer is applied to the plantar forefoot region, at the level of the first metatarsal head, 
orientated in the transverse plane 
3. Structural landmarks are identified (sesamoid bones) for anatomical orientation 
4.The US scan is completed, using the 5-10MHz ultra wideband linear array transducer, moving 
proximally to distally in this region 
5.  The  transducer  is  sequentially  relocated  medially  to  laterally,  with  proximal  to  distal  scan 
sequences repeated. The central portion of the transducer is positioned over the MTP joint region. 
6. The transducer is applied to the plantar forefoot region, at the level of the first metatarsal head, 
orientated in the longitudinal plane 
7.  Structural  landmarks  are  identified  (base  of  metatarsal  head  and  proximal  phalanx)  for 
anatomical orientation. The centre of the transducer is aligned with the MTP joint space. 
8. The US scan is completed, moving medially to laterally in this region 
9. The longitudinal plantar scanning sequence is repeated plantar to all MTP joint regions and 
intermetatarsal regions at the level of the MTP joint  
9b.  Observed  plantar  lesions  must  be  scanned  in  both  the  transverse  and  longitudinal  planes 
before a positive identification is recorded 
10. The transducer is applied to the dorsal forefoot region, at the level of the first MTP joint, 
orientated in the longitudinal plane 
11. Steps 8-10 are repeated in this scanning orientation, using the 8-16MHz linear array transducer 69 
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Forefoot bursae were noted as present if detectable in both the transverse and longitudinal 
planes, when scanning from a plantar approach, as illustrated in figures 24a and 24b. There are 
no standardised documented approaches for the determination of intermetatarsal or plantar 
bursae in the forefoot. However, common differential diagnoses include intermetatarsal neuroma 
and flexor digitorum longus tenosynovitis, for which a plantar US approach is recommended 
(Backhaus 2001, Baker et al., Brown 2005, Fitzpatrick et al. 1998, Koski 1998, Chauveaux et al. 
1987).  The proposed plantar approach is consistent with that used by Bowen et al. (Bowen et 
al. 2008, Bowen et al.), who demonstrated reliable detection of FFB in the baseline and year-
one follow-up studies.  
 
 
 
 
Figure 24: US transducer orientations 
Where 24a illustrates the plantar transverse scan at the level of the MTP joint region, 24b illustrates the 
plantar  longitudinal  scan  at  the  level  of  the  second  MTP  joint  region,  and  24c  illustrates  the  dorsal 
longitudinal scan at the level of the third MTP joint region. Images author’s own. 
 
 
 
MTP joint synovitis was noted as present if detectable in both the transverse and longitudinal 
planes when scanning from a dorsal approach (figure 24c). The selected approach conforms to 
those proposed by the EULAR working group for US in rheumatology (Backhaus 2001). 
Metatarsal head erosion was noted as present if detectable in either the dorsal or plantar 
scanning approach. However, a positive annotation was only given if the erosion was detectable 
in both the transverse and longitudinal plane, in accordance with EULAR guidelines (Backhaus 
2001). Findings were recorded on the US assessment form (see appendix section A7c).   
3.6.3.2 Benefits & limitations of US 
Real-time multi-planar grey-scale US, in B-Mode, allows accurate detection of bone and soft 
tissue lesions within the forefoot. The use of Power Doppler would provide additional benefit for 
the identification of active inflammation. However, this Power Doppler was not available in this 
study. Image artefact, particularly anisotropy (disparity in acoustic feedback with changes in 
transducer orientation) was problematic when scanning plantarly due to the large number of 
converging, differently orientated, anatomical structures. To overcome this, the transducer was 
applied perpendicularly to the sole of the foot and then angled over a range of -45° to +45° 
about this original 90° position thus altering acoustic enhancement. The use of positional 
acoustic variation over striated tendonous structures provided further clarification regarding 
tissue detection and differentiation. Where fluid filled cavities were detected, the transducer was 70 
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held in a still position for a minimum of 5 seconds to observe any potential blood vessel 
pulsation. Gentle pressure was applied to the transducer to compress observed fluid to identify 
capsulation or distribution.  
 
For dorsal MTP joint scanning, good transducer to skin contact was often difficult due to the 
presence of forefoot deformity, particularly lesser digit retraction or subluxation. The use of a 
smaller ‘hockey-stick’ transducer may have improved image acquisition in this area by improving 
transducer to skin coupling (Backhaus 2001). However, this transducer was not available in this 
study. Stand-off pad use was trialled prior to data collection in order to improve transducer to 
skin coupling over the lesser digits (Warner et al. 2008, Brown 2005, Riente et al. 2006). 
However the frequency reduction required to image at sufficient depth when using a stand-off 
pad noticeably reduced image quality. Thus, the smaller linear 8-16MHz transducer was 
preferentially chosen.  
3.6.4 Magnetic resonance imaging 
A 1.5 Tesla (T) whole body scanner (Siemens AG Medical Solutions, Germany), was used for all 
magnetic resonance image (MRI) acquisition (figure 25). A four channel flex extremity radio 
frequency (RF) surface coil (Siemens AG Medical Solutions, Germany; circularly polarised 
array), was used to image the mid and forefoot region only.  
 
 
 
 
Figure 25: MRI hardware  
The Siemens Avanto Syngo
® scanner. Images courtesy of Spire Healthcare Southampton. 
 
 
Prior to data collection initial capacitor tuning was completed to ensure that the RF coil 
frequency was synchronised with the magnetic field (B0). Overall system calibration was 
completed as per the standard protocol for the radiology department. An extremity RF surface 
coil was selected in order to minimise the field of view to the region of interest only, thereby 
reducing the signal to noise ratio (SNR) during image acquisition and thus potential image 
artefact. As illustrated in figure 26, the region of interest (ROI) was centralised within the 71 
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superconducting magnet, reducing eddy current noise (external electrical signal interference), 
with the aid of a light localiser.  
 
 
 
B
Superconducting Magnet
Superconducting Magnet
Gradient Coil
Gradient Coil
RF Coil
Gx
Gy
Gz
B0
 
 
Figure 26: Schematic diagram of magnetic field gradient & coil arrangement 
Where Gx= reference vertical (also the read direction); Gy= reference coronal (also the phase encode 
direction); Gz= reference horizontal; B0=horizontal magnetic field about which isocromats precess prior to 
RF pulse exposure; B=applied static magnetic field; RF=Radio frequency. The alternate spin directions in 
the gradient coil create polarisation in the linear bore. Image author’s own. 
 
 
 
Figure 26 also demonstrates the arrangement of the magnetic fields, where B0 (horizontal static 
magnetic field), about which the isocromats precess prior to the application of a RF pulse, is 
orthogonal to B1 (transverse field after RF pulse is applied perpendicularly). The ROI is therefore 
defined in the read direction by Gx and in the phase encode direction by Gy. Overall, two-
dimensional and three-dimensional sequences, of between 29 and 96 slices with 3mm to 0.6mm 
slice thickness respectively, were completed after orientation with a T1 sagittal localiser image. 
Alignment and positioning was manually orientated by the study radiologist (LK); coronal scans 
were orientated with the metatarsal parabola, sagittal scans were approximately orientated 
perpendicular to the coronal slice profile and with the shaft of the third metatarsal. The field of 
view (FoV) in the read direction was determined as the base of first metatarsal to the distal 
aspect of the hallux. The FoV in the phase-encode direction was defined as extending from the 
medial to the lateral foot borders. 
3.6.4.1 MRI protocol 
In order to establish a sufficient matrix of sequences to adequately identify soft tissue and bony 
structures with sufficient image clarity, a number of sequences were used. The protocol used 
adhered to International Radiation Protection Association (IRPA) (1991) recommendations and 
Medicines and Healthcare Products Regulatory Agency (MHRA) guidance (2007). However, to 72 
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date there are no published guidelines for the MRI of the forefoot in patients with RA. As such, a 
proportion of this thesis is devoted to the development of an appropriate MRI sequence protocol. 
The iterative development process and efficacy of the proposed semi-quantitative score are 
discussed in Chapter six. The main focus of sequence design was the accurate differentiation 
between soft tissue structures of the forefoot, achieved by review of the following: 
 
  Sample properties (proton density/T1 or T2 characteristics of tissues; non-adjustable) 
  Pulse sequence type (inversion recovery/spin echo etc.; adjustable) 
  Pulse sequence timing (TR/TE; adjustable) 
 
Pulse sequence type and timing were therefore selected to visualise a) anatomical structure 
(sequence 1: coronal T1 SE) b) high contrast between fluid and soft tissue (sequence 2: coronal 
STIR), and c) synovial inflammation (sequences 3 and 4: coronal and sagittal T1 weighted, fat 
suppressed, sequences after intravenous contrast administration). The 3D volumetric sequence 
allowed the three-dimensional reconstruction of identified lesions and orientation with adjacent 
features (sequence 5). Coronal scans were orientated with the metatarsal parabola and sagittal 
scans were approximately orientated perpendicular to the coronal slice profile and with the shaft 
of the third metatarsal. The field of view (FoV) in the read direction was determined as the base 
of first metatarsal to the distal aspect of the hallux. The FoV in the phase-encode direction was 
defined as extending from the medial to the lateral foot borders. The TE/TR ratios were adjusted 
in an iterative process by the radiologist until appropriate image clarity or contrast was achieved. 
For sequences 1-4 k-space was mapped linearly, and for sequence 5 was mapped using a 
sequential multi-slice selection method.  
3.6.4.2 MR image reading 
Images were viewed using Siemens Syngo
© Fast view software (Siemens AG 2004-2006) and 
clinically reported by a consultant radiologist (LK) at the time of acquisition, in accordance with 
the ethical protocol. Images were read by two consultant radiologists (LK and MT) and a 
podiatrist (LH). All readers were blinded to each other’s findings, unless explicitly stated as part 
of an educational or reliability exercise, to the corresponding patient clinical data. The protocol 
for image reading is discussed fully in Chapter six (section 6.3).  
3.6.4.3 Safety in MR image acquisition 
All imaging was completed in accordance with guidance from IRPA (1991). Contra-indications 
for MRI were reviewed with participants to confirm inclusion eligibility (see section 3.4 for 
participant inclusion/exclusion details). In accordance with MHRA guidance (2007) all 
participants completed a Glomerular Filtration Rate (GFR) screening test prior to the 
administration of  IV Gadolinium. Gadolinium is a commonly used contrast agent however its 
dissociated form is toxic. Therefore renal function needs to be sufficient to filter the contrast 73 
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agent before it dissociates to avoid side effects such as nausea, headache, or in severe cases 
nephrogenic systemic fibrosis.  
 
Highly concentrated absorption of RF energy at a single focal point, resulting in deep tissue 
burn, is a previously reported adverse event for MRI (Knopp et al. 1996, Dempsey et al. 2001). 
In order to minimise the risk of RF burn, the operating radiologist checked that no current loops 
were formed inside the magnetic bore during image acquisition, either by external wires or by 
touching extremities. Foam padding was used to secure the RF coil away from contact with the 
patient’s skin as well as ensuring the feet were not touching during image acquisition.  
3.6.4.4 Benefits & limitations of MRI 
The use of paramagnetic contrast agents provides a rapid pathway for nearby water protons to 
give up longitudinal magnetisation, effectively reducing T1. Thus highly perfused tissues appear 
brighter on T1 weighted images. However, with time delay the contrast agent will diffuse across 
tissues, blurring anatomical tissue margins. It was important that post-contrast sequences are 
performed in a timely manner to allow adequate differentiation between highly vascularised 
synovium and fluid located within the bursal cavity. MR acquired images are vulnerable to 
distortion as a consequence of external RF interference. To overcome this, all image acquisition 
was performed within a Faraday cage. The use of a flex extremity RF coil allowed reduction in 
SNR by increasing the coil fill factor; the flex coil was closely aligned to the ROI only. Aliasing, 
where an image outside of the FoV is mapped over the ROI can occur when there is a 
demodulated signal frequency; the sampling frequency is unable to differentiate between high 
and low image frequencies. To overcome this, a low pass filter was applied to remove 
frequencies outside of the read direction FoV.  
3.6.5 Foot & ankle assessment 
All foot health information was recorded on the assessment sheet (see appendix section A7d). 
Tissue viability was reviewed and current or previous ulcer presence recorded. Participants were 
asked to report any current foot health concerns, episodes of podiatric or lower limb surgical 
intervention (past or present) or bespoke footwear/orthotic use (past or present).  
 
Foot function was reviewed and range, direction and quality of motion in the ankle, subtalar, 
mid-tarsal (calcaneo-cuboid and talo-navicular joints), and first MTP joints bilaterally recorded. 
Foot structure was reviewed and the presence of hallux abducto-valgus deformity, fifth MTP joint 
exostoses, lesser digital retraction or MTP joint subluxation (2-4 only) was recorded. Foot 
posture was assessed using the foot posture index (Redmond et al. 2006). The FPI provided a 
composite measure of overall foot posture, (-12 to +12), based upon the degree of adjacent joint 
alignment (figure 27). 
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Figure 27: The foot posture index 
Example images of right foot posture used for FPI calculation, where 27a illustrates an inverted rearfoot 
relative to leg (-1), 27b illustrates a rectus rearfoot relative to leg (0), 27c illustrates an everted rearfoot 
relative to leg (+2), 27d illustrates forefoot adduction relative to the rearfoot (-1), 27e illustrates straight 
forefoot  to  rearfoot  alignment  (0),27  f  illustrates  forefoot  abduction  relative  to  the  rearfoot  (+2),  27g 
illustrates  a  high  arched  foot  position  (-1),  27h  illustrates  a  medium  arched  foot  position  (0),  and  27i 
illustrates a low arched foot position (+1). Images author’s own. 
 
 
3.6.6 Patient-reported foot-related disability 
Patient-reported foot-related disability was evaluated using the two subscales of the Foot 
Impairment Score (FIS); a) FISIF, 0-21: foot impairment and footwear restriction, b) FISAP, 0-29: 
activity limitation and participation restriction (Helliwell et al. 2005). An elevated FISIF or FISAP 
score indicates greater foot impairment or activity limitation respectively. For FISIF, scores ≤6 
were considered mild, 7-13 moderate and ≥14 severe. For FISAP, scores ≤9 were considered 
mild, 10-19 moderate and ≥20 severe. Score ranges were pragmatically derived by the division 
of the total score in to approximate thirds. The FIS score has not been validated for longitudinal 
use. However, Turner et al. (2007) suggest that a score change of three or more, in either 
direction is clinically meaningful, and as such these margins will be used to evaluate clinically 
meaningful change in reported disability. For the purposes of reporting, the FISIF subscale will 
be referred to as ‘foot impairment’ and the FISAP subscale as ‘activity limitation’. The FIS 
questionnaire was selected as the primary measure of disability because this is the only tool to 
our knowledge, with foot-related disability subscales that differentiate between disability and 
pain, which has been validated for use in patients with RA.  75 
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3.6.7 Summary of outcome measures 
A summary of the outcome measures used throughout this thesis is given in table ten.  
 
 
Table 10: Summary of outcome variables  
Summary of outcomes including factors, measures, tests and expected results. 
 
Factor  Outcome measure 
Population to 
whom test is 
applicable 
Test  Expected result 
Demographical 
information 
age  all  record review  continuous score; 
years 
gender  all  record review  nominal; 
male/female 
height  all 
standardised 
laboratory 
measure 
continuous score; 
cm 
weight  all 
standardised 
laboratory 
measure 
continuous score; Kg 
BMI  all  standardised 
calculation 
continuous score; 
Kg/m
2 
disease duration  RA and OA  record review  continuous score; 
years 
Dependent 
variable of 
interest 
forefoot bursae (FFB) 
US: all 
MRI: RA 
US determined 
presence/absence 
cumulative 
continuous score; 0-
18 
US: all 
MRI: RA 
MRI determined 
presence/absence 
and 
characteristics 
cumulative 
continuous score; 0-
18 
Clinical 
variables 
joint hypertrophy (JH)  US: all 
MRI: RA 
US/MRI 
determined 
presence/absence 
cumulative 
continuous score; 0-
10 
erosion (ER)  US: all 
MRI: RA 
US/MRI 
determined 
presence/absence 
cumulative 
continuous score; 0-
10 
overall score for 
disease state  all  DAS 28-CRP  continuous score; 0-
5 
systemic inflammation  RA and OA  ESR and CRP  continuous score;  
Mechanical 
variables 
forefoot deformity  all  podiatrist 
examination 
categorical score; 1-
3 
foot and ankle joint 
ranges of motion 
(ROM) 
all  podiatrist 
examination 
cumulative 
continuous score; 0-
6 
overall foot alignment 
and posture  all  FPI  continuous score; -
12 to +12 
Impact 
variables 
patient-reported foot 
impairment  all  FISIF  continuous score; 0-
21 
patient-reported 
activity limitation  all  FISAP  continuous score; 0-
29 
Overall wellbeing  All  VAS  continuous score; 0-
100 
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3.7 Quality assurance & control 
Throughout this thesis, care has been taken to identify, consider, adjust for and interpret 
potential errors or biases inherent within the design of each experimental study. The following 
section documents potential sources of error or bias, methods used to negate these, and where 
possible the steps taken to quantify likely inaccuracy (Silman and Macfarlan 1995). 
3.7.1 Agreement in data collection & interpretation 
Estimations of reporting error, as a consequence of longitudinal researcher variability, have 
been estimated for both imaging modalities and completion of the FPI. The term agreement has 
been used throughout the following text to refer to the quantifiable extent to which scores taken 
on two occasions by the same researcher or by two researchers are the same or differ.  
3.7.1.1 Agreement in US data 
Within the limits of the study protocol it was not possible to recall patients or extend their visit to 
include multiple scans, in order to determine the intra-reader reliability of US for the study 
investigator (LH). Inter-rater reliability regarding the US detection of FFB was established 
between the investigator who collected the baseline and year-one follow-up data reported in 
Chapter four (CB) and the current investigator (LH). Ten participants were consecutively, 
prospectively recruited from those attending the year-three data collection appointment. Both 
raters independently completed an US scan of the same sequence of patients using a 
predefined standard operating procedure, without prior knowledge of the participant’s disease 
state or reported foot health. After completion of the first three participants, raters were given 
opportunity to justify their reported findings and to discuss any potential discrepancies. Raters 
were then blinded to each other’s reports for the remaining participants. FFB were recorded as 
either present or absent. If present, observed FFB were recorded as occurring in one of nine 
pre-defined forefoot regions. Inter-rater agreement regarding FFB presence/ absence at each 
site was evaluated using kappa analysis. Thus, the inter-rater agreement regarding the location 
of bursae, when both raters identified a bursae as being present, was moderate to substantial 
(left foot: kappa=0.8; right foot: kappa=0.8; both feet combined: kappa=0.71), (see appendix 
section A10 for details). 
3.7.1.2 Agreement in MRI data 
Intra-reader agreement for the study investigator (LH) was established. This was considered as 
representative of the potential for learning and transference of skills from a radiologist (LK) to 
podiatrist (LH), particularly with regard to the interpretation and synthesis of a number of key 
MRI sequences. Evaluation of intra-rater agreement was completed on two occasions after 
progressive stages of training. A potential learning effect was noted and agreement continued to 
improve to moderate levels with training (table 11). However, the grading or identification of 
metatarsal erosion and bone marrow oedema was reported to be consistently challenging 
respectively. Difficulty in the synthesis of multiple sequences and optimum slice selection were 
cited as the main reasons for this.   77 
 
Chapter 3: Methodology 
 
Table 11: MRI reading intra-reader agreement (LH)  
Where PEA= percentage exact agreement; PCA= percentage close agreement; IM= intermetatarsal 
region; PL= plantar region. For all factors N=10.  
Factor 
After initial training  After additional training 
Mean score 
(range)  PEA  PCA 
Mean 
score 
(range) 
PEA  PCA 
Metatarsal erosion  8.2, (2-19)  0  50  7.5, (2-19)  20  40 
Bone marrow oedema  -  -  -  -  -  - 
Synovitis  1.2, (0-4)  30  100  1.1, (0-3)  80  100 
IM – fluid 
Presence  1.7, (0-4)  30  100  1.6, (1-3)  50  90 
Shape  1.8, (0-4)  30  100  1.7, (1-4)  50  100 
Enhancement  1.8, (0-5)  40  90  1,  (0-3)  20  90 
T1  3.4, (0-8)  30  90  3.2, (2-9)  50  50 
T2  4.6, (0-10)  20  30  4.8, (2-9)  50  100 
IM - soft 
tissue 
Presence  0.1, (0-3)  20  100  1.8, (0-6)  50  50 
Shape  1.7, (0-6)  30  70  0.8, (0-3)  40  100 
Enhancement  0.7, (0-3)  40  100  1.8, (0-6)  60  90 
T1  1.5, (0-6)  30  80  2.1, (0-9)  50  80 
T2  1.9, (0-9)  20  50  0, (0)  30  100 
PL – fluid 
Presence  0, (0)  100  100  0, (0)  100  100 
Shape  0, (0)  100  100  0, (0)  100  100 
Enhancement  0, (0)  100  100  0, (0)  100  100 
T1  0, (0)  100  100  0, (0)  100  100 
T2  0, (0)  100  100  0, (0)  100  100 
PL – soft 
tissue 
Presence  0.2, (0-1)  60  100  0.2, (0-1)  90  100 
Shape  0.5, (0-3)  60  90  0.3, (0-2)  90  100 
Enhancement  0.1, (0-1)  90  100  0.1, (0-1)  90  100 
T1  0.4, (0-2)  60  100  0.3, (0-2)  90  100 
T2  0.5, (0-3)  60  90  0.3, (0-2)  90  100 
 
 
 
Inter-rater agreement between the podiatrist (LH) and radiologist (LK) was evaluated on two 
occasions after progressive stages of training. LK was considered the expert reader. A potential 
learning effect was noted and agreement continued to improve to moderate levels with training 
(table 12). Again, the grading or identification of metatarsal erosion and bone marrow oedema 
by LH were reported to be consistently challenging. 
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Table 12: MRI reading inter-reader agreement (LH & LK) 
Where PEA= percentage exact agreement; PCA= percentage close agreement; IM= intermetatarsal 
region; PL= plantar region. For all factors N=10.  
Factor 
After initial training  After additional training 
Mean score 
(range)  PEA  PCA  Mean score 
(range)  PEA  PCA 
Bone erosion  8.15 (2,19)  0  50  7.5, (2-19)  20  40 
Bone oedema  -  -  -  -  -  - 
Synovitis  1.2, (0-4)  30  100  1.1, (0-3)  80  100 
IM – fluid 
Presence  1.7, (0-4)  30  100  1.6, (1-3)  50  100 
Shape  1.8, (0-4)  30  100  1.7, (1-4)  50  90 
Enhancement  1.8, (0-5)  40  90  1, (0-3)  20  100 
T1  3.4, (0-8)  30  90  3.2, (2-6)  50  90 
T2  4.6, (0-10)  20  30  4.8, (0-3)  50  50 
IM - soft 
tissue 
Presence  0.8, (0-3)  20  100  0.9, (0-3)  50  100 
Shape  1.7, (0-3)  30  70  1.8, (0-6)  40  50 
Enhancement  0.7, (0-3)  40  100  0.8, (0-3)  60  100 
T1  1.5, (0-6)  30  80  1.8, (0-6)  50  90 
T2  1.9, (0-9)  20  50  2.1, (0-9)  30  80 
PL – fluid 
Presence  0, (0)  100  100  0, (0)  100  100 
Shape  0, (0)  100  100  0, (0)  100  100 
Enhancement  0, (0)  100  100  0, (0)  100  100 
T1  0, (0)  100  100  0, (0)  100  100 
T2  0, (0)  100  100  0, (0)  100  100 
PL – soft 
tissue 
Presence  0.2, (0-1)  60  100  0.2, (0-1)  90  100 
Shape  0.5, (0-3)  60  90  0.3, (0-2)  90  100 
Enhancement  0, (0-1)  90  100  0.1, (0-1)  90  100 
T1  0.4, (0-2)  60  100  0.3, (0-2)  90  100 
T2  0.5, (0-3)  60  90  0.3, (0-2)  90  100 
 
 
3.7.1.3 Agreement in FPI data 
The FPI requires semi-quantitative scoring of multiple joint alignments to derive a final 
composite score. The subjective nature of scoring alignment may introduce observer bias to the 
study results thus the intra- and inter-reader agreement of FPI scores were established. 
 
A subset of 13 participants, consecutively recruited from the larger study population, was seen 
on two occasions, with a four week interval, by the same researcher (LH). After completion of 
the first three participants differences between scores were reviewed to identify large potential 
discrepancies, although none were identified. Review of the following ten participants was then 
completed. Intra-rater agreement was demonstrated by calculation of the mean difference 
between scores, with the range of disagreement expressed as +/- 2 standard deviations. The 
standard error of the mean was calculated to provide 95% confidence intervals for the likely 
mean disagreement between scores on occasions one and two. The results of the FPI intra-rater 79 
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agreement analysis are presented using Bland-Altman plots in figure 28 (Bland and Altman 
1986). Additional agreement calculations are documented in appendix sections A9 and A10. 
 
 
 
 
Figure 28: FPI Intra-rater reliability 
Bland & Altman plot demonstrating intra-rater (LH) agreement for FPI scores for left and right feet 
combined (Bland and Altman 1986).  
 
 
 
The intra-rater agreement for FPI use is therefore as follows: 
  The standard error mean difference between scores at observation times one and two is 
0.85, across a score range of -24 to 24 
  The 95% confidence interval for this estimation is -2.71 to 1.01, for example 95% of all 
scores are within this limit of agreement 
  All scores are within the upper and lower limits of two standard deviations from the mean, 
suggesting that there is good agreement between observations 
  Agreement appears consistent across all score ranges, although this is a small sample size 
(N=13) 
These results suggest there is good intra-rater agreement, with small potential variation in 
scores of >1, across a range of 24. The potential variation is neither positively nor negatively 
skewed suggesting that this is random error. 
3.7.2 Confounding & interactive effects 
It is possible that spurious relationships, (statistically inferred relationships between two 
variables when in fact no relationship exists), may be demonstrated when investigating 80 
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associations between FFB and explanatory variables, as illustrated in figure 29. Consequently, 
identification of putative risk factors (most likely explanatory variables) and investigation of 
possible confounders (explanatory, equally associated variables) was completed as part of the 
statistical analysis process. 
 
 
 
 
 
Figure 29: The identification of confounding variables 
Where A = Exposure/ risk factor of interest (e.g. bursae presence), B = outcome of interest (e.g. foot pain), 
C = possible putative or confounding risk factor (e.g. presence of localised inflammation). Image author’s 
own. 
 
 
 
Possible putative factors included in association analyses were age, gender, height, weight, 
disease duration, disease activity (DAS 28-CRP or DAS 28-ESR), ESR, CRP, FPI and patient-
reported foot-related disability. The conceptual framework for the definition of interaction, based 
on the homogeneity concept proposed by Szklo et al. (2005a), was adopted to allow for the 
consideration of interactive factors as either positive or negative effect modifiers. An example 
application of this concept to factors explored within this thesis is illustrated in figure 30. 
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Figure 30: The conceptual framework for determining interactive effect 
Where, in this example, it is assumed that RA is the effect modifer as bursae are potentially able to be 
eliminated. Image author’s own; adapted from Campbell and Machin (1999).    
 
3.8 Overview of statistical methodologies 
The following sections provide an overview of the information processing techniques used for 
data entry, checking and analysis. All techniques were completed by the study researcher (LH) 
and reviewed by a senior statistician (DC) or data manager (JM).  
3.8.1 Data preparation & analysis software  
For studies one and two, the relational database Access (version 2, Microsoft Corporation, 
2007) was used for data entry and all forms were configured to reflect that of the data collection 
sheets. The database tables created were: participant demographical data, US assessment, 
podiatry assessment, DAS 28 and FIS. The participant code was used as the primary key 
(unique person identifier) and also selected as the foreign key (used to link individuals across 
different tables). Within the database, the podiatry assessment, DAS 28 and FIS data was 
expressed as a sub-form within the master demographical form. Data was prepared for 
extraction or reporting using concatenated queries (for combining fields), calculated queries (for 
additive outcome variables) and parameter queries (to refine items extracted for analysis). A 
proportion of the collected data was double entered by two researchers (LH and PC), and 
subsequently checked for inconsistencies, outliers and missing information. Identified errors 
were checked against the original hard copy datasheets for clarification. Where information was 
confirmed as missing this was annotated as such within the database. Prior to statistical analysis 82 
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data distribution was checked for normality using histograms or scatter plots, the findings of 
which were used to inform statistical test selection.  
 
For experimental study one, baseline, year-one and year-three datasets were merged using 
SAS
® software (Statistical Analysis System, Version 9.3, SAS Institute Inc.). Statistical analysis 
was completed using either SPSS (Statistical Package for Social Sciences software, version 
18.0, Chicago, Il, 2009) or Stata (version 11.0, Statacorp, College Station, Texas, USA). The 
MRI data collected for studies three and four was entered directly into multiple Excell pages 
(version 14.0, Microsoft Corporation, 2010) to reflect those of the data collection sheets and 
automatically re-configured into a larger single file. Data was checked for inconsistencies, outlier 
and missing information, and where appropriate the original record sheets referred to for 
clarification. The basic algorithm used for the clustering of data throughout this thesis is shown 
in figure 31. Variables of interest were defined at either the episode level (for longitudinal 
analysis), the participant level (for cross-sectional analysis), foot level (for agreement analysis) 
or site level (for FFB MRI characterisation). 
 
 
 
 
Figure 31: Data clustering 
Where FeeTURA = Foot & Ankle Ultrasound studies in Rheumatoid Arthritis, pt = participant, BL = baseline 
data collection point, L = left foot, R = right foot, 1-9 = forefoot sites of interest. N.B. At the participant level 
N=159, however, not all participants have data for BL, year-one and year-three inclusively. Image author’s 
own. 
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3.8.2 Descriptive statistics 
The demographical and clinical characteristics of the study participants are presented as the 
mean or median, and standard deviation (SD) or range, dependent upon data distribution. For 
the reported longitudinal study (Chapter four), participants were coded as either responders 
(participated within follow-up data collection) or non-responders (did not participate). A Levenes 
test was completed to evaluate equality within group variances. Estimations of differences in 
demographic or clinical characteristics between those patients who did or did not respond to 
invitation for inclusion at year-three are presented as mean and 95% confidence intervals. 
Statistically significant differences in measured variables between response groups were 
determined using independent samples t-tests. For the reported comparative cross-sectional 
study (Chapter five), statistically significant differences in demographic characteristics between 
cohorts were determined using independent sample t-tests. 
3.8.3 Inferential statistics  
The following sections provide detail regarding the main statistical techniques used within the 
four experimental thesis chapters, to determine the epidemiology and clinical importance of FFB.  
3.8.3.1 The epidemiology of FFB 
The point prevalence proportion of US-detectable or MRI-detectable FFB was calculated by the 
division of the sum of identified cases by the sum of the total studied population and expressed 
per 100 patients. Longitudinal analysis of FFB was completed using an adjusted study cohort, 
which was inclusive of participants who attended all episodes of data collection only. The 
change in score value used for analysis purposes was an expression of the difference between 
baseline and year three scores. The comparative probability of FFB presence between different 
participant groups was expressed as an odds ratio (and 95% confidence interval), and 
calculated as follows: 
 
  Odds ratio  = (number exposed in pop. A/ number not exposed in pop. A) 
              number exposed in pop. B/ number not exposed in pop. B 
 
  Calculation 3: Odds Ratio (Campbell and Machin 1999, Silman and Macfarlan 1995).  
 
The distribution of FFB across nine predefined forefoot sites was expressed as a percentage of 
the total number of FFB and demonstrated figuratively using chloropleth maps. The nine 
investigated forefoot sites were grouped into medial (sites 1-3), central (sites 4-6) and lateral 
(sites 7-9). Statistically significant differences in the distribution of FFB between participant 
groups or MRI characteristics were evaluated using repeated Chi
2 analyses. Differences in the 
US or MRI appearance of FFB are discussed descriptively. Differences in the presence of FFB 
MRI determined enhancement between fluid and soft tissue lesions, within the same participant, 
across either intermetatarsal of plantar sites were determined using multiple matched-paired t-
tests. 84 
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3.8.3.2 The clinical importance of FFB 
Correlation coefficient analyses were used to determine the statistical significance of potential 
associations between the primary outcome of interest (FFB count), and measured explanatory 
variables (markers of disease activity, foot deformity/function and patient-reported foot-related 
disability) in each participant group.  
 
Multiple linear regression techniques, with ordinary least squares estimation, adjusted for 
demographical data, were used to explore statistical relationships between the primary outcome 
of interest (FFB) and potential explanatory variables. Significant factors were subsequently 
entered into a multiple linear regression model to identify potential confounding or colinearity 
within the study findings. In Chapter five, multiple linear regression techniques were also used to 
explore the predictive value of FFB count, in each participant group, for alternate primary 
outcome measures including disease activity, foot deformity/function or disability. Multinomial 
logistic regression techniques were used to explore the potential relationships between FFB 
distribution and indicators of disease activity, foot deformity/function or disability. Significant 
factors were subsequently entered into a combined multinomial logistic regression model to 
identify potential confounding or colinearity within the study findings. 
3.9 Timescale of research completion 
Data collection for study one started in December 2009 and was completed in December 2010. 
Data collection for study two was completed in two phases; phase one started in June 2010 and 
was completed in January 2011, phase two started in July 2011 and was completed in October 
2011. Data collection for studies three and four started in December 2010 and was completed in 
June 2011. Further detail regarding the timeline for the completion of specific research tasks is 
documented in table 13. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
Tasks 
Year 1 (2009 - 2010)  Year 2 (2010 – 2011)  Year 3 (2011 – 2012) 
O  N  D  J  F  M  A  M  J  J  A  S  O  N  D  J  F  M  A  M  J  J  A  S  O  N  D  J  F  M  A  M  J  J  A  S 
R
A
:
 
S
t
u
d
y
 
1
 
Complete ethical approval                                                                                       
Complete R & D approval                                                                                       
Complete WTCRF application                                                                                      
Intra-rater agreement: FPI                                                                                      
Inter-rater agreement: FPI                                                                                      
Inter-rater agreement: US                                                                         
Participant recruitment: RA                                                                                      
Participant recruitment: f.-up                                                                                      
Data collection                                                                                      
Data entry, cleaning & review                                                                         
Data analysis (1)                                                                                      
Data analysis (2)                                                                         
Write-up: The natural history 
of FFB in RA                                        
                                             
O
A
:
 
S
t
u
d
y
 
2
 
Complete ethical approval                                                                                       
Complete R & D approval                                                                                       
Participant recruitment: OA                                                                                      
Data collection                                                                                      
Data entry, cleaning & review                                                                         
Data analysis (1)                                                                                      
Data analysis (2)                                                                         
Write-up: The prevalence of 
FFB in OA                                        
                                             
H
V
 
:
 
S
t
u
d
y
 
2
 
Complete ethical approval                                                                         
Complete R & D approval                                                                         
Participant recruitment                                                                         
Data collection                                                                         
Data entry, cleaning & review                                                                         
Data analysis                                                                         
Write-up: The prevalence of 
FFB in healthy volunteers                           
                                              
 
   
 
 
 
Table 13: Gantt timeline of study completion 
Tasks 
Year 1 (2009-2010)  Year 2 (2010 – 2011)  Year 3 (2011 – 2012) 
O  N  D  J  F  M  A  M  J  J  A  S  O  N  D  J  F  M  A  M  J  J  A  S  O  N  D  J  F  M  A  M  J  J  A  S 
M
R
I
 
s
c
o
r
e
 
d
e
v
e
l
o
p
m
e
n
t
:
 
S
t
u
d
y
 
3
 
Complete ethical approval                                                                         
Complete R & D approval                                                                         
Complete ethical 
amendment                           
                                             
Participant recruitment                                                                         
Data collection                                                                         
Intra-reader agreement                                                                         
Inter-reader agreement                                                                         
Data analysis planning                                                                         
Pilot image reading                                                                         
Image reading (LK & MT)                                                                         
Image reading (LH)                                                                         
Data entry, cleaning & 
review                           
                                             
Data analysis                                                                          
Write up: Development of 
the FFB score                            
                                             
M
R
I
-
d
e
t
e
c
t
a
b
l
e
 
F
F
B
 
S
t
u
d
y
 
4
 
Data collection                                                                         
Image reading                                                                          
Data preparation                                                                         
Data analysis planning                                                                         
Data analysis                                                                         
Write-up: The 
epidemiology of MRI-
detectable FFB                           
                                             
Research task undertaken   
Preliminary task   
Item associated with research dissemination   
Unanticipated research tasks   87 
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Chapter four  
The epidemiology & clinical importance of US-detectable 
forefoot bursae in patients with rheumatoid arthritis 
 
4.0 Chapter abstract 
Background: Rheumatoid arthritis (RA) is a systemic, complex disease affecting multiple body 
tissues and organs that has a significant impact on the lives of patients and their families. The 
specific impact of RA on the foot is under-reported in comparison to the hand. However, there is 
a growing body of evidence highlighting the epidemiology of foot problems in this patient group. 
In particular forefoot bursae (FFB) have been recently highlighted as potentially clinically 
relevant and associated with RA disease. However, the natural history of FFB in patients with 
RA has not been reported previously. Furthermore, the longitudinal relationship between 
changes in RA disease activity and FFB is unclear. As such, longitudinal investigation of the 
natural history and clinical importance of FFB in patients with RA is warranted.  
Aim: To determine the natural history and clinical importance of FFB in patients with RA. 
Methods: A longitudinal, prospective, cohort study recruited patients with RA from a 
rheumatology outpatient clinic. Data were collected at baseline (N=149), one-year (n=120) and 
three-year follow-ups (n=60). The primary outcome of interest, the presence of forefoot bursae, 
was determined using musculoskeletal ultrasound. Point prevalence (PP) was used to describe 
the occurrence of FFB at each time point. The distribution of FFB across forefoot sites is 
expressed as a percentage of the total observed FFB. The US appearance of FFB is discussed 
descriptively. Correlation coefficient analysis was used to determine the statistical significance of 
potential associations between FFB count and indicators of disease activity or disability at year 
three. Linear regression was used to determine the predictive value of FFB count longitudinally.  
Results: The mean (± SD) age, disease duration and DAS 28-CRP were 64 (±11.8) years, 15.1 
(±10.3) years, and 2.9 (±1.2) respectively. FFB were consistently highly prevalent (baseline PP: 
95 per 100 (mean: 3.58, SD: 2.36, range: 0-8); year 1 PP: 92 per 100 (mean: 3.80, SD: 2.44, 
range: 0-11); year 3 PP: 88 per 100 participants (mean: 3.05, SD: 2.14, range: 0-11)). 
Differences in the US appearance of FFB were noted, ranging from large spherical lesions to 
slit-like cavities. The presence of FFB at year three was significantly associated with metatarsal 
head erosion (r=0.419, p=0.001) but no other indicators of disease activity. A reduction in FFB 
count longitudinally was significantly associated with reduced DAS 28-CRP scores but no other 
indicators of disease activity (r=-0.331, p=0.030). Disease duration and forefoot bursae 
presence were significant prognostic indicators of foot impairment (p=0.009, p=0.012 
respectively), explaining 16% of score variability in the final regression model. Disease duration, 
forefoot bursae and erosion presence were identified as significant prognostic indicators of 88 
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activity limitation (p=0.006, p=0.019, p=0.002 respectively), explaining 35% of score variability in 
the final regression model.  
Conclusion: FFB are highly prevalent and clinically relevant longitudinally in patients with RA. 
FFB may be an indicator of therapeutic efficacy or themselves a therapeutic target, thereby 
improving patient outcome. Future research regarding the potential relationship between FFB 
and biomechanical impairment or inflammation is warranted. 
4.1 Introduction 
There is increasing evidence that foot problems in patients with rheumatoid arthritis (RA) are 
highly prevalent, even when classical measures of disease activity, such as the DAS-28 score, 
suggest clinical remission (van der Leeden et al. 2010, Rome et al. 2009, Otter et al. 2010, Katz 
et al. 2006). A population survey by Otter et al., (2010), demonstrated that this is true for many 
patients with RA, regardless of disease duration or therapy, and may be particularly evident in 
those receiving biologic therapy (Grondal et al. 2008, Nagasawa et al. 2010). It appears that 
despite great advances in disease management, a large proportion of patients remain 
significantly impaired by foot complications (van der Leeden et al. 2007, van der Leeden et al. 
2010). This has a major impact on a patient’s ability to return to work or complete tasks of daily 
living (Klareskog et al. 2009, Katz et al. 2008, Puolakka et al. 2006). Despite recent advances, 
the longitudinal relationship between the prevalence of foot complications, disease state and the 
impact of disease in terms of disability remains unclear (van der Leeden et al. 2008). Previous 
cross-sectional studies have suggested that forefoot bursae (FFB) are associated with RA 
disease activity and disability (Bowen et al. 2009, Bowen et al. 2010c). However, it is unclear 
whether these are spurious relationships, confounding effects or true physiological responses. 
Thus, further longitudinal investigation of the natural history and clinical importance of FFB in 
patients with RA is warranted as this may provide a potential therapeutic target.  
4.1.1 Study aim & objectives 
The main aim of this study was to determine the natural history and clinical importance of FFB in 
patients with RA. To achieve this aim the following objectives were set: 
 
1.  To determine the natural history of US-detectable FFB over three years  
2.  To describe potential differences in the US characteristics of identified FFB 
3.  To determine the clinical importance of US-detectable FFB  
4.2 Materials & methods  
4.2.1 Study design  
A longitudinal, prospective, cohort study comprised of a series of cross-sectional observations at 
baseline, year-one and year-three follow-up time points was completed. Please note, the year-
three follow-up data had been collected by the author for the purposes of this thesis while the 
baseline and year-one follow-up data had been previously collated and published (Bowen et al. 89 
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2010b). Thus, the data collected within this study is used as both a new cross-sectional data set 
and is also merged with data sets to facilitate longitudinal FFB evaluation.  
 
The primary study outcome was an analysis of the presence of US-detected forefoot bursae 
(FFB). All intermetatarsal spaces (x4) and plantar metatarsal regions (x5) were imaged for the 
presence of FFB. The number of observed lesions for both feet was combined, thus a maximum 
score of 18 was possible. Explanatory variables of interest included those related to RA disease 
activity (joint hypertrophy (JH), metatarsal head erosion (ER), serological inflammatory markers 
(ESR, CRP) and disease activity score (DAS 28) or the impact of RA disease in terms of patient-
reported foot-related disability (Foot Impact Score (FIS)). Disease activity was evaluated using 
markers of Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP) and calculation of a 
28 joint Disease Activity Score (DAS 28) (Van der Heijde et al. 1990). Metatarsophalangeal JH 
and metatarsal head ER were determined using US and scored as present or absent for each 
location, thus a maximum score of 10 for either JH or ER was possible. Disability was evaluated 
using the two subscales of the Foot Impairment Score (FIS): 1. (FISIF, 0-21); Foot impairment 
and footwear restriction, 2. (FISAP, 0-29); Activity limitation and participation restriction (Helliwell 
et al. 2005). An elevated FISIF or FISAP score indicates greater foot impairment or activity 
limitation respectively. Explanatory variables were selected based upon the findings of previous 
work, literature review and potential clinical relevance. Detail regarding the selected measures is 
given in Chapters two (section 2.2), and three (section 3.6).  
4.2.2 Study population  
Patients included within this study were those with a consultant confirmed diagnosis of 
rheumatoid arthritis (RA; in accordance with 1987 ACR criteria), who were consecutively, 
prospectively recruited from a general rheumatology out-patient clinic within Southampton, and 
who have returned for all three data collection appointments. Detail regarding the recruitment, 
screening, inclusion/exclusion criteria and sample size determinants is documented in Chapter 3 
(sections 3.4-3.5). 
4.2.3 Protocol for data collection 
The protocol for participant recruitment and data collection is summarised in figure 32.  
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Figure 32: A schematic diagram of the protocol for study one 
Where, FeeTURA = foot and ankle ultrasound research in rheumatoid arthritis; PIS = participant 
information sheet; ID = identification; US = ultrasound; DAS = disease activity score 91 
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4.2.4 Protocol for image collection & interpretation 
Musculoskeletal ultrasound (US) scanning, using a Diasus
® diagnostic scanner (System 8, 
Dynamic imaging, Livingston, Scotland, UK), was completed in B-Mode to provide real-time 
grey-scale images. The return echo signals were automatically processed using Diasus
® 2D 
spline filtering. Image pixilation was standardised at 640 x 440 pixels, the optimum settings for 
fine image resolution available using this software. The overall transmit power and gain were set 
at ≤50 and ≤30 respectively, in accordance with the European League Against Rheumatism 
working group for US in rheumatology, scanning recommendations (Backhaus M. 2001). All 
metatarsophalangeal joints and intermetatarsal spaces, of both feet, were individually imaged 
from both a plantar and dorsal approach, in longitudinal and transverse scanning planes, using 
an 8-16MHz linear array transducer. All intermetatarsal spaces and plantar forefoot regions were 
additionally imaged from a plantar approach, in longitudinal and transverse scanning planes, 
using a 5-10MHz linear array transducer. Where possible the lowest number of focus points was 
used and centred at the level plantar to the deep transverse intermetatarsal ligament for plantar 
foot scans and the upper third of the joint space for dorsal foot scans. All US scanning was 
performed in accordance with the British Medical Ultrasound Society guidelines for safe use 
(Fitzpatrick et al. 1998) and completed by two trained podiatrists (LH and CJB), the reliability of 
which was determined to be substantial (kappa=0.7). Furthermore, the reliability of a podiatrist 
(CJB) and radiologist has been previously demonstrated and reported to be moderate-
substantial  (Bowen et al. 2008).  
 
Intermetatarsal lesions were classified as bursae if a defined region of hypo-echogenicity, 
occurring within the IM spaces, either inferior or superior to the deep transverse intermetatarsal 
ligament, was observed in the perpendicular transverse and longitudinal plantar scanning 
planes. Plantar lesions were classified as bursae if a defined region of hypo-echogenicity, 
occurring inferior to the level of the base of the metatarsal heads, was observed in the 
perpendicular transverse and longitudinal scanning planes. Thus lesions were defined based 
upon location and grey-scale US properties and not size or shape. MTP joint hypertrophy was 
noted as present if distension of the dorsal synovial joint membrane, as a consequence of either 
increase in synovial fluid volume or membrane thickening, extended beyond the proximal or 
distal attachment sites at the metatarsal head or base of the proximal phalanx respectively. 
Metatarsal head erosion was noted as present if a distinct loss in cortical bone was observed in 
two perpendicular scanning planes.  
4.2.5 Analysis   
All analysis was completed using Stata version 11.0 (Stata Corp, College Station, Texas, USA), 
or SPSS version 18.0 (Chicago, Illinois, USA). The sample size for this study was determined 
using Pearsons’ correlation coefficient estimates of association between bursae 
presence/absence and patient reported foot complications (r=0.211; p=0.371), based upon 
previously reported data (Bowen et al. 2009). Prior to analysis, data distribution was checked for 92 
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inconsistencies, outliers and missing information. Histograms and scatter plots were used to 
assess whether the data followed a normal distribution. The demographic and clinical 
characteristics of the study participants are presented as the mean/median, standard deviation 
(SD) and range. Estimations of differences in demographic or clinical characteristics between 
those patients who did or did not respond to invitation for inclusion at year-three are presented 
as mean and 95% confidence intervals. Statistically significant differences in measured variables 
between response groups were determined using independent sample t-tests.  
 
The total number of US-detectable episodes of FFB, JH or ER for both feet combined was 
calculated for each patient; these count scores were treated as continuous variables for the 
purposes of analysis, although were bounded between 0-18 for FFB and 0-10 for JH and ER. 
Point prevalence was used to describe the occurrence of FFB at each time point. The 
distribution of FFB across forefoot sites is expressed as a percentage of the total observed FFB. 
The US appearance of FFB is discussed descriptively. Correlation coefficient analysis was used 
to determine the statistical significance of potential associations between FFB count and 
indicators of disease activity or disability at year three.  
 
Longitudinal analysis was completed using an adjusted study cohort, which was inclusive of 
participants who attended all episodes of data collection only. The ‘change in score’ value used 
for analysis purposes was an expression of the difference between baseline and year three 
scores. Correlation coefficient analysis was used to determine the statistical significance of 
potential associations between changes in the primary outcome of interest (FFB count) and 
changes in other explanatory variables from baseline to year three (markers of disease activity 
and disability). Multiple linear regression techniques with ordinary least squares estimation were 
used to explore statistical relationships between the primary outcomes of interest and potential 
explanatory variables. Significant factors were subsequently entered into a multiple linear 
regression model to identify potential confounding or colinearity within the study findings. A 
pattern analysis technique was used to demonstrate the longitudinal variability of each measure 
of disability, specific to each participant. Participants were categorised based upon the manner 
in which the outcome of interest increased or decreased, by 1 score or more, or remained the 
same across time points, and were subsequently stratified into high (FFB>4) or low (FFB≤3) 
FFB count groups. Differences between groups were explored using Chi
2 analyses.   
4.3 Results 
4.3.1 Study cohort characteristics 
At baseline 149 participants were recruited to the study. Of those, 120 returned at year one and 
of those 60 returned at year three. Five patients died between the year-one and three 
appointments. Respondents unable to attend the year-three appointment cited lack of time 
(n=6), unwillingness to travel (n=4), poor mobility (n=2) or other personal factors (n=5) as 
reasons for non-attendance. A summary of response analysis is shown in table 14. The 93 
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Levenes’ test for equal variance identified that for both weight and DAS 28-CRP variables this 
could not be assumed and therefore adjusted values are reported. 
 
 
 
Table 14: Response analysis 
Results are reported for the comparative evaluation of responders and non-responders between stated 
time points.  
Where BMI = Body Mass Index; CRP = C-reactive protein; ESR = Erythrocyte Sedimentation Rate; DAS = 
Disease Activity Score; FISIF = Foot Impact Score impairment/footwear subscale; FISAP = Foot Impact 
Score activity/participation limitation subscale. 
 
 
BASELINE→YEAR-
THREE  
YEAR-ONE→YEAR-
THREE   BASELINE→YEAR-ONE  
Mean 
difference 
(95% CI) 
p-value 
Mean 
difference 
(95% CI) 
p-value 
Mean 
difference 
(95% CI) 
p-value 
age (years)  1.1 
(-3.0–5.2)  0.592  1.9 
(-2.5-6.3)  0.402  -1.4 
(-6.4-3.7)  0.588 
weight (Kg)  0.2 
(-4.8-5.2)  0.945  -0.9 
(-6.4-4.7)  0.753  3.3 
(-2.9-9.5)  0.297 
BMI (Kg/m
2)  0.3 
(-1.5-2.1)  0.745  -0.9 
(-2.9-1.1)  0.394  1.6 
(-0.9-4.0)  0.203 
disease duration 
(years) 
0.4 
(-3.0-3.9)  0.808  0.2 
(-3.6-4.0)  0.915  1.2 
(-3.0-5.4)  0.570 
CRP (mg/L)  0.6 
(-5.6-6.8)  0.840  2.7 
(-2.8-8.2)  0.333  -0.5 
(-8.2-7.2)  0.900 
ESR (mm/hr)  5.1 
(-1.3-11.5)  0.116  2.0 
(-5.4-9.4)  0.594  2.2 
(-5.8-10.2)  0.580 
DAS 28-CRP  0.5 
(0.1-1.0)  0.029*  0.3 
(-0.2-0.8)  0.256  0.3 
(-0.3-1.0)  0.329 
DAS 28-ESR  0.5 
(0.02-1.0)  0.041*  -0.02 
(-0.6-0.6)  0.938  0.6 
(-0.1-1.2)  0.121 
FIS IF  -0.2 
(-1.9-1.4)  0.794  -0.5 
(-2.3-1.2)  0.543  0.9 
(-1.1-2.9)  0.393 
FIS AP  -0.01 
(-3.1-3.1)  0.993  -0.4 
(-3.9-3.2)  0.837  3.0 
(-0.8-6.8)  0.124 
 
 
 
A further month-by-month summary of response and recruitment rates can be found in appendix 
section A8. Due to the number of participants responding but unable to attend the clinical 
appointment for US review from December 2009-March 2010, the recruitment criteria and 
associated ethical application were revised to allow completion of the FIS questionnaire only if 
patients were unable to attend the hospital. This change was implemented in April 2010. Three 
subsequent study participants completed the FIS questionnaire but did not attend any other 
assessment. At year one no significant differences between responders and non-responders for 
any tested variables were identified. The results of responder analysis at year three suggested 
that those patients with higher disease activity, as indicated by DAS 28-CRP and DAS 28-ESR, 
were more likely to return (p=0.029 and p=0.041 respectively). A summary of the demographic 
and clinical characteristics of the study population at each time point is given in table 15. 
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Table 15: Cohort demographic & clinical characteristics  
N.B. data is reported following adjustment for cases completing all episodes of data collection.  
Where MTP = metatarsophalangeal; DAS = disease activity score; CRP = C-reactive protein; ESR = 
erythrocyte sedimentation rate; FISIF = foot impact score impairment/footwear subscale; FISAP = Foot 
Impact Score activity/participation limitation subscale. 
 
  BASELINE (N=149) 
Mean,  
(SD), Range 
YEAR ONE (n=120) 
Mean,  
(SD), Range 
YEAR THREE (n=60) 
Mean,  
(SD), Range 
age (years)  59.4,  
(12.3), 25-87 
60.7,  
(12.1), 26-88 
62,  
(11.8), 28-89 
height (m)  1.6,  
(0.1), 1.2-2.1 
1.6,  
(0.1), 1.2-2.1 
1.7,  
(0.1), 1.3-2.1 
weight (Kg)  73.3,  
(16.1), 43.8-118.9 
71.9,  
(15.9), 43.8-110.2 
71.0, 
 (13.6), 42.2-108 
BMI (Kg/m
2)  27.2,  
(4.9), 18.5-41.6 
27,  
(5.5), 16.8-48.2 
25.5,  
(3.9), 19.1-33.4 
disease duration 
(years) 
12.3,  
(10.3), 1.0-43.0 
13.1,  
(10.4), 2.0-44.0 
15.1,  
(10.3), 3.0-45.0 
gender  29 (M): 121 (F)  23 (M): 97 (F)  9 (M): 51 (F) 
MTP joint hypertrophy  2.8, 
2.7 (0-10) 
1.7, 
(1.9), 0-7 
2.5, 
(2.8), 0-10 
erosion  3.7, 
(2.6), 0-10 
4.8, 
(3.0), 0-10 
6.0, 
(3.3), 0-10 
CRP (mg/L)  12.1, 
(20.4),  2-100 
12.8, 
(18.8), 1-122 
8.8, 
(13.2), 1-73 
ESR (mm/hr)  20.3, 
(16.5), 2-100 
22.5, 
(16.9), 1-81 
20.1, 
(20.5), 0-111 
DAS 28-CRP  3.1, 
(1.2), 1.1-6.6 
3.1, 
(1.2), 0.5-6.6 
2.9, 
(1.2), 1-5.4 
DAS 28-ESR  3.6, 
(1.3), 1.1-6.5 
4.1, 
(1.5), 0.5-6.6 
3.1, 
(1.3), 0.3-6 
FISIF  10.7, 
(4.8), 0-20 
10.4, 
(5.1), 0-20 
10.4, 
(5.1), 0-20 
FISAP  16.9, 
(10.3), 0-29 
17.3, 
(9.9), 0-30 
17.4, 
(9.8), 0-30 
 
 
 
As shown in table 16, no significant differences in participant markers of RA disease activity 
were reported longitudinally.  
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Table 16: Longitudinal changes in disease activity 
Results are reported for evaluation of difference in scores between time points for the same participant. 
Therefore the maximum possible sample size for comparison with year one and year three data is 120 and 
60 respectively. *= Significant at level of 5% probability (2-tailed). 
 
 
BASELINE→YEAR THREE  YEAR ONE→YEAR 
THREE 
BASELINE→YEAR 
ONE 
 
Mean  
difference 
(95% CI) 
p-value 
Mean  
Difference 
(95% CI) 
p-value 
Mean  
difference 
(95% CI) 
p-value 
MTP joint hypertrophy  -0.9 
(-1.9 – 0.06)  0.066  0.4 
(-0.5 – 1.4)  0.384  1.07 
(0.2 – 1.9)  0.009* 
erosion  1.4 
(-2.5 – -1.4)  0.011*  -2.3 
(-3.2 - -1.4)  0.000*  -1.1 
(-2.0 - -2.0)  0.018* 
DAS 28-CRP  -0.08 
(-0.6 – 0.5)   0.751  0.1 
(-0.4 – 0.7)  0.660  0.14 
(-0.3 – 0.6)  0.534 
CRP (mg/L)  5.8 
(-3.5 – 15.2)  0.217  4.2 
(-2.4 – 10.7)  0.207  -2.8 
(-13.1 – 7.4)  0.580 
ESR (mm/hr)  2.2 
(-4.9 – 9.3)  0.539  -0.1 
(-5.0 – 4.9)  0.977  -1.6 
(-7.3 – 4.1)  0.582 
 
 
 
As demonstrated in table 15, mean FISIF and FISAP scores remained moderate across all time 
points. Longitudinally, the change in mean FISIF score from baseline to year three suggests a 
slight improvement over time, while FISAP deteriorated, although reported changes in disability 
scores between time points were not significantly different. As illustrated in figure 33, few 
patients remained in a stable state of reported disability, with the majority of patients (98%, 
n=59) experiencing some fluctuation, with regards to both improvement and worsening. Overall, 
15% of participants (n=9) reported deterioration in FISIF such that they changed severity 
classification from mild to moderate or from moderate to severe. Conversely, 14% of participants 
(n=8) reported improvement in FISIF such that they changed severity classification from severe 
to moderate or from moderate to mild. Similarly, 22% of participants (n=13) reported 
deterioration in FISAP such that they changed severity classification from mild to moderate or 
from moderate to severe. Conversely, 23% of participants (n=14) reported improvement in FISAP 
such that they changed severity classification from severe to moderate or from moderate to mild. 
Assuming a clinically meaningful change in score of 3 points or more (Turner et al. 2007), thus 
regardless of disability category, 10% of participants (n=6) reported worsening foot impairment 
while 9% of participants (n=15) reported improvement. Similarly, 23% of participants (n=14) 
reported a clinically meaningful increase in activity limitation, while 18% (n=11) reported 
improvement. 
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33a. FISIF  
33b. FISAP  
Figure 33: Frequency of pattern occurrence for changes in reported disability over time 
Where 1=↓↓, 2=↓↑, 3=↑↑, 4=↑↓, 5=↔↓, 6=↔↑, 7=↔↔, 8=↓↔, 9=↑↔; where ↓= reduction in 1 score or more 
between time points, ↑= increase in 1 score or more between time points, ↔ = no change in score between 
time points. FISIF = foot impact score impairment/footwear subscale; FISAP = Foot Impact Score 
activity/participation limitation subscale 
 
 
4.3.2 The natural history of FFB 
The point prevalence of US-detectable FFB at baseline, year one and year three was calculated 
to be as follows:  
  At baseline (N=150), the overall point prevalence of FFB was 93 per 100 RA 
participants (mean: 3.54, SD: 2.22, range: 0-9); (139/150). 
  At year one (N=120), the overall point prevalence of FFB was 93 per 100 RA 
participants (mean: 3.70, SD: 2.20, range: 0-11); (112/120). 97 
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  At year three (N=56), the overall point prevalence of FFB was 88 per 100 RA 
participants (mean: 3.05, SD: 2.14, range: 0-11); (49/56). 
 
However, due to participant drop-out from the study it was considered that adjusted time-
matched point prevalence may be more representative of the true trend in FFB prevalence 
scores over time. The adjusted time-matched prevalence scores are therefore summarised as 
follows: 
  At baseline, the adjusted point prevalence of FFB was 95 per 100 RA participants 
(mean: 3.58, SD: 2.36, range: 0-8); (57/60). 
  At year-one, the adjusted point prevalence of FFB was 92 per 100 RA participants 
(mean: 3.80, SD: 2.44, range: 0-11); (55/60). 
 
Changes in the prevalence of FFB were not statistically significantly different over time, as 
demonstrated in table 17.  
 
 
Table 17: Longitudinal changes in FFB prevalence 
N.B. data included within this analysis includes year-matched cases for whom only baseline, year-one and 
year-three data is available. Therefore the maximum possible sample size for comparison is 60 
participants. However, due to missing data these totals are variable. 
*= Significant at level of 5% probability (2-tailed). 
 
 
  Mean diff 
(95% CI)  P-value 
BASELINE→YEAR-THREE (N=56)  0.8 
(-0.03 – 1.7)  0.058 
YEAR-ONE→YEAR-THREE (N=56)  0.7 
(-0.1 – 1.5)  0.760 
BASELINE→YEAR-ONE (N=60)  -0.07 
(-0.912 – 0.779)  0.875 
 
 
A similar frequency of total FFB occurrence was noted across time points, however, the 
distribution of FFB across forefoot sites varied, as illustrated in figure 34. At baseline a greater 
proportion of the total FFB were located within the intermetatarsal spaces. A similar but less 
distinct trend is observed at year-three, with the greatest notable difference being an increase in 
FFB reported plantar to the first MTP joint with a concomitant reduction within the IM 1-2 space.    
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Figure 34: The distribution of FFB across forefoot sites at each time point 
Values are expressed as percentage of total observed FFB in each location. Values are representative of 
the adjusted cohort of participants who completed all episodes of data collection only. 
Where M1-5 = plantar metatarsophalangeal joint region. 
 
 
 
Overall, bilateral FFB were detected in 87.5% of participants at the year-three follow-up visit 
(N=49)). Of the total FFB observed (n=171), 53.7% of FFB (n=43) were noted within the 
intermetatarsal region, whereas 46.2% of FFB (n=37) were noted plantar to the metatarsal 
heads. The most common location for FFB, when both feet were combined, was the 
intermetatarsal 4-5 space (62.5% of participants, n=35), closely followed by the intermetatarsal 
3-4 space (51.8% of participants, n=29), however a range in distribution across all sites was 
observed. The least common sites for FFB occurrence were plantar to the third and fouth 
metatarsal head regions (14.3%, n=8 and 16.1%, n=9 respectively).  
4.3.3 The US characteristics of FFB 
Examples of intermetatarsal lesions, classified as bursae based on the presence of a defined 
region of hypo-echogenicity occurring within the IM spaces plantar to the DTML, are illustrated in 
figures 35a and b.  
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Figure 35: US appearances of intermetatarsal lesions 
Where 35a illustrates a transverse scan of the right foot with identification of the bases of the metatarsal 
heads (2-4) and an intermetatarsal lesion (*), 35b) illustrates a transverse scan of the left foot with 
identification of the bases of the metatarsal heads (2-4) and an intermetatarsal lesion (*). 
 
 
Differences in the ultrasound appearances of IM lesions were noted; a subset of FFB appeared 
as well defined homogeneously hypoechoic with well-defined and regular borders (figure 28a), 
while an alternate subset appeared as diffuse heterogeneously hypoechoic, containing an 
anechoic centre with irregular borders (figure 28b). 
 
All plantar lesions were noted as being hypoechoic discontinuations within the plantar soft 
tissues of the forefoot, with a compressible, anechoic region at the centre, and were thus 
classified as FFB. However, the appearance of such lesions was also highly variable, ranging 
from superficial slit-like cavities (figure 36a) to larger spherical structures occurring either plantar 
or dorsal to the superficial transverse intermetatarsal ligament (figure 36b). 
 
 
 
 
Figure 36: US appearances of plantar forefoot lesions 
Where 36a illustrates a transverse scan of the left foot with identification of the sesamoids (s) and a slit-like 
fluctuant cavity superficial to the region of the 2
nd metatarsal head, 36b illustrates a transverse scan of the 
right foot with identification of a large fluctuant spherical lesion, with anechoic fluid cavity enveloping a 
hypoechoic free floating central mass, plantar to the intermetatarsal 2-3 space.  
 
 
In addition to lesions being located within the intermetatarsal and plantar metatarsal regions as 
previously reported, bursal-like cavities were also observed in association with and adjacent to 100 
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other forefoot structures. As illustrated in figures 37a and b, a bursal cavity (*) was also noted 
curving around the plantar and tibial borders of the medial sesamoid of the right foot. The lesion 
appears slit-like in figure 37a when viewed without the application of plantar compression. 
However, the same lesion, seen enlarged in figure 37b, demonstrates lateral capsular bulging 
when displaced by applying plantar compression with the ultrasound transducer. This 
exemplifies a number of cases where the still grey-scale image of the bursal cavity was highly 
fluctuant dependent upon operator transducer orientation or contact pressure. 
 
 
 
Figure 37: US appearances of other hypoechoic forefoot lesions 
Where 37a illustrates a transverse scan at the level of the metatarsal heads using the 5-10MHz probe, with 
identification of  the sesamoids  (s)  and  metatarsal  heads 1-3.  The  bursal cavity,  located  plantar  to the 
medial sesamoid (*), appears slit-like without plantar compression with the transducer. However, the same 
lesion  seen  enlarged  in  figure  37b  demonstrates  lateral  capsular  bulging  when  displaced  by  applying 
plantar compression with the transducer (*). 37c Illustrates a longitudinal scan plantar to the 2
nd metatarsal 
head of the right foot using the 8-16MHz probe, with identification of a capsular lesion superficial to the 
flexor digitorum longus tendon (*). 37d Illustrates a longitudinal plantar scan of the 1
st interphalangeal joint 
of the right foot using the 8-16MHz probe, with identification of a lesion superficial to the inserting slip of the 
flexor hallucis longus tendon. DP= distal phalanx, PP= proximal phalanx. 
 
 
The bursal cavity noted plantar to the second metatarsal head in figure 37c, exemplifies an 
instance of lesion occurrence, superficial to but remaining separate from, the underlying flexor 
digitorum longus tendon, which remained homogeneous with no discontinuation to fibrillar 
striation. This was the single detected occurrence of a separate lesion superficial and distinct 
from the tendon, with no interjecting fatty tissue. In all other cases of a possible bursal cavity 
being located immediately plantar to the tendon, scanning in perpendicular planes using the 8-101 
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16 MHz transducer subsequently identified the tissue disruption as regions of tenosynovitis. The 
bursal cavity shown in figure 37d, illustrates the occurrence of a lesion within the soft tissues of 
the hallux, located plantar to the interphalangeal joint, which could be tracked proximally to the 
base of the phalanx. The lesion is separated from the inferior flexor hallucis longus tendon slip 
by fibro-fatty tissue, illustrating the distinct nature of this structure. The lesion appears as a 
heterogeneous hypoechoic mass with regions of total anechogenicity. Instances of plantar 
hallux lesions were noted in two study participants. A summary of all observed lesions is shown 
in figure 38. 
 
 
 
 
 
Figure 38: Forefoot anatomy & identification of observed bursae 
Where FFB 1-5 were previously identified, FFB 6-9 are additionally identified within this study.  
1 = 1-2 intermetatarsal bursa coursing adjacent to adductor hallucis tendon that may extend beyond the 
deep  transverse  intermetatarsal  ligament,  2  =  intermetatarsal  bursae  that  may  become  hypertrophied 
extending beyond the deep transverse intermetatarsal ligament, 3 = bursae associated with neurovascular 
bundle,  4  =  bursae  associated  with  superior  aspect  of  flexor  digitorum  brevis  tendon,  5  =  plantar 
mechanical  bursae,  6  =  large  ‘billowing’  intermetatarsal  bursae  located  plantar  to  the deep  transverse 
intermetatarsal ligament, may appear as either an organised homogeneous hypoechoic mass, or diffuse 
hypoechoic region with or without an anechoic centre, 7 = large spherical encapsulated intermetatarsal 
bursae,  may  appear  as  either  a  hypoechoic  mass  with  or  without  an  anechoic  centre,  8  =  small 
intermetatarsal bursae, appearing as a well-defined region with hypoechoic signal, 9 = large encapsulated 
spherical bursae located plantar to the 1
st MTPJ, often found plantar to the medial sesamoid bone. Image 
author’s own. 
 
  
4.3.4 The clinical importance of FFB 
Increased FFB count was significantly associated with increased metatarsal head erosion 
(r=0.419, p=0.001) but no other indicators of disease activity at year-three. A reduction in FFB 
count longitudinally was associated with reduced DAS 28-CRP scores (r=-0.331, p=0.030), but 
no other indicators of disease activity. 
 
The presence of FFB and disease duration at baseline were determined to be significant 
independent predictors of FISIF scores at year-three, where a high presence of FFB or increased 102 
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disease duration were indicative of worsening foot impairment longitudinally (R
2=0.10, p=0.012; 
R
2=0.11, p=0.009 respectively, table 18a). Similarly the presence of FFB and increased disease 
duration, in addition to the increased presence of ER and disease activity at baseline, were all 
determined to be significant predictors of FISAP at year-three, where a high presence of FFB or 
ER, increased disease duration and increased disease activity were indicative of increased 
activity limitation longitudinally (R
2=0.12, p=0.006; R
2=0.09, p=0.019; R
2=0.16, p=0.002; 
R
2=0.11, p=0.025 respectively, table 18a).  
 
 
Table 18a: Predictors of disability: univariate, adjusted, linear regression analysis  
Reported results were adjusted for age and disease duration.  
FISIF = Foot Impact Score impairment/footwear subscale; FISAP = Foot Impact Score activity/participation 
limitation subscale; CRP = C-reactive protein; ESR = Erythrocyte Sedimentation Rate; DAS = Disease 
Activity Score. 
  Impairment (FISIF)  Activity limitation (FISAP) 
EXPLANATORY 
VARIABLE 
Reg. 
Coeff. 
p-value 
(95% CI)  R
2  F-value  Reg. 
Coeff. 
P-value  
(95% CI)  R
2  F-
value 
forefoot bursae  0.70  0.012 
(0.02 – 1.23)  0.10  6.77  1.47  0.006 
(0.44 – 2.5)  0.12  8.14 
MTP joint 
hypertrophy  0.29 
0.239 
(-0.20 – 
0.78) 
0.02  1.42  0.25  0.608 
(-0.71 – 1.2)  0.004  0.27 
erosion  0.49 
0.053 
(-0.01 – 
0.98) 
0.01  3.89  1.14  0.019 
(0.20 – 2.09)  0.09  5.84 
DAS 28-CRP  1.23 
0.051 
(-0.07 – 
2.47) 
0.09  4.02  2.43  0.025 
(0.32 – 4.54)  0.11  5.40 
DAS 28-ESR  1.13  0.051 
(-0.01 – 2.3)  0.08  4.0  2.12  0.035 
(0.15 – 4.09)  0.09  4.70 
CRP (mg/L)  0.002 
0.941 
(-0.07 – 
0.07) 
0.00  0.01  0.02 
0.802 
(-0.12 – 
0.15) 
0.001  0.06 
ESR (mm/hr)  0.03 
0.467 
(-0.05 – 
0.11) 
0.01  0.54  0.17  0.033 
(0.01 – 0.32)  0.08  4.75 
disease 
duration  0.16  0.009 
(0.04 – 0.27)  0.11  7.20  0.36  0.002 
(0.14 – 0.58)  0.16  10.82 
 
 
 
All identified independently significant explanatory variables were entered into a further 
multivariate regression model, adjusted for age and disease duration, in order to identify 
potential covariate factors. As shown in table 19, the significance of each independent predictor 
variable diminished, suggesting likely colinearity between the included model factors. 
Additionally, in each model, the increased adjusted model R
2 suggests that the colinearity 
between the included model factors may be synergistic in overall effect. 
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Table 19: Predictors of disability: multivariate linear regression analysis  
Where  19a  shows  results  of  multivariate  regression  analysis  for  previously  identified  independent 
predictors of reported foot impairment; 19b shows results of multivariate analysis for previously identified 
predictors of activity limitation.  
FISIF = Foot Impact Score impairment/footwear subscale; FISAP = Foot Impact Score activity/participation 
limitation subscale; CRP = C-reactive protein; ESR = Erythrocyte Sedimentation Rate; DAS = Disease 
Activity Score. 
19a.  Impairment (FISIF) 
EXPLANATORY 
VARIABLE  β  p-value 
(95% CI) 
R
2 
(adj. R
2)  F-value 
forefoot bursae  0.50  0.084 
(-0.07 – 1.06)  0.16 
(0.13)  5.28 
Disease duration  0.12  0.067 
(-0.01 – 0.24) 
 
 
19b.  Activity limitation (FISAP) 
EXPLANATORY 
VARIABLE  β  P-value  
(95% CI) 
R
2 
(adj. R
2)  F-value 
forefoot bursae  0.33  0.552 
(-0.78 – 1.43) 
0.35 
(0.27)  4.22 
erosion  0.87  0.083 
(-0.12 – 1.87) 
DAS28-CRP  2.36  0.026 
(0.30 – 4.43) 
ESR (mm/hr)  0.11  0.136 
(-0.04 – 0.25) 
disease duration  0.18  0.147 
(-0.07 – 0.43) 
 
 
 
Following identification of FFB as a novel predictor of both FISIF and FISAP, data were stratified 
into groups of high (n=25) and low (n=35) FFB count at baseline; where 0-3 was defined as low, 
and 4 or more as high based upon clinical observation and overall observed score range. As 
illustrated in figure 39, a trend towards increased reported disability in those patients with 
increased FFB presence at baseline was observed, however differences between groups were 
not significant. 
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39a. FISIF  
 
39b. FISAP  
Figure 39: FFB & changes in foot-related disability  
Where patients were grouped by high (≥4)/low (≤3) FFB count at baseline. FIS = Foot Impact Score; IF = 
Foot impairment subscale; AP = Activity limitation subscale; BL = baseline; Yr = Year. 
 
 
4.4 Discussion 
This study has uniquely demonstrated the epidemiology of FFB in patients with RA. Differences 
in the US characteristics of observed FFB have been reported. Furthermore the clinical 
importance of FFB in patients with RA has been evaluated. In the studied cohort, FFB were 
consistently highly prevalent, albeit slightly reducing, longitudinally. This observed FFB 
prevalence was determined to be significantly associated with RA disease activity. The findings 
of this study therefore appear to reinforce the hypotheses of previous authors which suggest an 
association between FFB presence and RA disease activity ((Bowen et al. 2009, Bowen et al. 
2010c, Mutlu et al. 2006, Koski 1998)). Uniquely however this study has demonstrated a 
longitudinal association between FFB and RA disease activity.  
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Furthermore, previous authors, such as Turner et al. (Turner et al. 2006, Turner et al. 2008), 
have highlighted the relationship between disease mediated inflammation, structural changes to 
joint integrity and functional decline, and cited these as probable causes for the high prevalence 
of disability observed in RA populations (Woodburn et al. 2002b, van der Leeden et al. 2006, 
van der Leeden et al. 2008). This study has uniquely proposed and demonstrated that FFB may 
additionally be a clinically relevant feature of RA disease related to disability; where the 
presence of FFB at baseline was identified as a significant independent predictor of disability 
after three years in this patient group. Additionally, changes in FFB presence and disease 
activity were both associated with changes in reported disability. Two plausible hypotheses, 
explaining the relationship between FFB presence and foot-related disability in patients with RA, 
have been proposed; 1. FFB synovium is susceptible to disease-mediated inflammatory 
processes in a similar manner to joint synovium, and FFB are therefore representative of 
disease activity (Bossley and Cairney 1980), 2. FFB occur or hypertrophy as a consequence of 
poor forefoot biomechanical function, and are therefore indicative of physical changes in joint 
function (Studler et al. 2008, Ahmed et al. 1994). A combination of both hypotheses is also 
plausible.  
 
The association between FFB and inflammatory disease has been previously documented in 
both histological and cross-sectional imaging studies (1983, 1982, 1998). The identification of a 
synovial membrane within intermetatarsal FFB, with inwardly projecting villi (Hernandez et al. 
1991), or a fibro-collagenous membrane which exhibits some superficial synoviocytic cellular 
elements (Chauveaux et al. 1987, Meenagh et al. 2006), appears to provide support for the 
notion that FFB are directly associated with disease activity. Additionally, a number of cross 
sectional imaging studies reinforce this theory, suggesting that the particular susceptibility of 
FFB, above other synovial structures, makes them a clinically useful, representative feature of 
minimal disease activity  (Koski 1998, 1998, 2003). Conversely, a number of authors propose 
that at least a subset of plantar FFB may be entirely generated as a consequence of mechanical 
irritation (Aguiar et al. 2005, Claustre et al. 1983, Meurman 1982, Studler et al. 2008). Authors 
such as Studler et al. (2008) describe these as slit-like cavities of fluid, lacking a synovial 
membrane, that manifest predominantly in areas of torsional stress. This is perhaps reinforced 
by the findings of Ahmed et al. (1994), who report the development of mechanical bursae at the 
socket interface in four below knee amputees. In such instances mechanical FFB may be 
considered advantageous, allowing compression or torsion between otherwise densely fibrous, 
rigid tissues. The proposed aetiology is mechanically induced separation of the fibro-
collagenous tissues, resulting in the accumulation of extra-cellular fluid in these spaces 
(Hernandez et al. 1991). It is currently unclear to what extent the observed differences in the US 
appearance of FFB demonstrated in this study may reflect alternate subsets of FFB in this 
patient group. Future research that explores the underlying aetiology or patho-physiology of FFB 
in patients with RA would identify future potential therapeutic targets.  106 
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4.4.1 Study limitations  
This study has a number of strengths and potential limitations. The studied population is a 
consecutive sample of well phenotyped patients for whom unique longitudinal data is now 
available, who may be considered as representative of patients with RA attending secondary 
care in England. However, there is some loss to follow-up. None the less, the response analysis 
completed suggests that there is no systematic differential bias in any of the key measured 
variables introduced as a result of this. It is possible that some of the included participants have 
modified their responses regarding foot health as a consequence of inclusion within the study. 
However the reported values for both the primary and secondary outcome measures are 
consistent with those reported in previous works, thereby reducing the likelihood of the presence 
of this effect within the reported results. It is however possible that those patients with minimal 
RA disease, who do not attend a secondary care environment for their rheumatological care, will 
have been selectively omitted from recruitment to this study, resulting in a sampling bias. Given 
the unclear nature of the association between FFB, RA disease activity and biomechanical 
impairment, the likely modification to the external validity of the reported results made by 
omission of this group is unclear. 
 
In order to minimise observer bias in the primary outcome measure, the US examination was 
completed prior to all other clinical assessment of foot health. Additionally the FIS questionnaire 
was graded after the completion of all other data collection activities. Of additional note, the FIS 
score used within this study was not originally intended for longitudinal use. However, in the 
absence of a validated longitudinal scoring system the authors felt that FIS use was appropriate 
in this preliminary work. The development of a clinical tool, sensitive to change and validated for 
use in this population would significantly enhance any subsequent work in this area. The use of 
Power Doppler (PD) for the determination of active inflammation, as an adjunct to US 
examination, would also enhance future work in this area. PD was not available at the time of 
this study and therefore it is not possible to determine whether identified FFB were actively 
inflamed (bursitis). None the less, this does not detract from the significant findings of this study 
which show that the US-detected FFB are indicative of disability and therefore should be 
considered a clinically relevant feature of RA disease.  
 
The reduced sample size of this study may account for the lack of significant difference in 
disability reported between high and low FFB groups, via the introduction of a type II 
misclassification error. However, the upper categorical boundaries were selected based upon 
limited clinical understanding of FFB and as such stringent cut-off margins were selected. Of 
course, review of these boundaries may yield significant differences between groups. It should 
also be noted that, for some participants, inclusion within the study identified a number of 
previously untreated foot impairment and footwear complications at the baseline appointment, 
for which subsequent treatment was offered. This may account for the slight improvement in 
impairment scores reported over time, and therefore the generalisability of these results to 107 
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patients not receiving podiatric care should be considered. Similarly, the rationale for the 
potential association between disability and FFB remains unclear. It is possible that 
improvement in systemic disease activity may lead to an increase in weight bearing activity as 
patients undertake more tasks as part of daily living. Concomitantly with this however, the 
biomechanical stresses placed upon the foot may also be elevated. The relative contribution of 
elevated adverse biomechanical function to FFB prevalence remains unclear. Conversely, it is 
also plausible that a worsening of systemic disease activity may also see concomitant increases 
in the hypertrophy or inflammation of synovially lined structures such as FFB. Again the relative 
contribution of elevated inflammation to FFB prevalence also remains unclear. 
 
Having identified FFB as clinically relevant in patients with RA, further exploration of the 
potential relationships between FFB and biomechanical impairment or disease mediated 
inflammation would improve the current understanding of the biological mechanisms contributing 
to the potentially pathological nature of observed FFB. Evaluation of the presence, distribution 
and characterisation of US-detectable FFB in healthy volunteers, for whom FFB may be 
potentially present but non-pathological, would also contribute to the advancement of knowledge 
in this area of study. 
4.4.2 Conclusion & summary 
This study has uniquely identified that forefoot bursae are highly prevalent and clinically relevant 
longitudinally in patients with RA. The association between reductions in FFB and reduced DAS 
28-CRP longitudinally provides preliminary evidence to support the hypothesis that FFB may be 
a potential indicator of disease activity and long term therapeutic efficacy. Future research 
regarding the potential relationship between FFB and inflammation or biomechanical impairment 
is warranted.  108 
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The epidemiology & clinical importance of US-detectable FFB in patients with 
rheumatoid arthritis 
 
Key points: 
 
  FFB remain highly prevalent in patients with RA longitudinally 
  The US characteristics of FFB in patients with RA are variable 
  Changes in the prevalence of FFB are associated with changes in RA disease 
activity 
  FFB  are  identified  as  a  prognostic  indicator  of  patient  reported  disability  and 
represent a possible novel therapeutic target 
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Chapter five 
The relationship between forefoot bursae & inflammation or 
biomechanical impairment  
 
5.0 Chapter abstract 
Background: Previous research has shown that musculoskeletal ultrasound (US) detectable 
forefoot bursae (FFB) are indicative of foot-related disability longitudinally in patients with RA. 
However, the pathological mechanisms associated with FFB presence in this patient group are 
unclear; two biologically plausible hypotheses have been proposed: 1. FFB are associated with 
biomechanical impairment, 2. FFB are associated with RA disease mediated inflammation.  
Aim: To explore the relationship between US-detectable FFB and biomechanical impairment or 
inflammation in patients with RA.  
Methods: A cross-sectional observational study was completed in three comparative cohorts: 1. 
Healthy volunteers (HV, n=50), 2. patients with medial knee osteoarthritis (OA, n=50), 3. patients 
with rheumatoid arthritis (RA, n=56). HV were selected as a comparative control group. Patients 
with knee OA were selected as a surrogate biomechanically impaired only group. Patients with 
RA were considered representative of a biomechanically impaired and inflammatory group. FFB 
were noted as present if detected in two scanning planes, when viewed with US. Indicators of 
biomechanical function included assessment of foot joint deformity, ranges of motion and overall 
posture. Indicators of inflammation included US-detected metatarsophalangeal joint hypertrophy 
or metatarsal head erosion, systemic serological markers (ESR and CRP) and a composite 
measure of disease activity (DAS 28). The probability of FFB presence was determined for each 
participant group and comparatively expressed as an odds ratio (inclusive of 95% confidence 
interval and p-value). Multiple linear regression analyses were used to determine the 
independent predictors of FFB in each participant group, in addition to the predictive value of 
FFB for impaired biomechanical function or disability. Multinomial logistic regression analyses 
were used to determine the relationship between FFB distribution and indicators of disease 
activity, biomechanical function or disability in each patient group. 
Results: FFB were highly prevalent in both patients with RA and knee OA (PP=88 per 100 
participants; mean=3.05, SD=2.14, range=0-11, and PP=94 per 100 participants; mean=2.8, 
SD=1.5, range=0-5, respectively), compared to HV (PP=56 per 100 participants; mean=1.3, 
SD=1.5, range=0-6). Increased FFB count was associated with biomechanical impairment in HV 
and patients with OA. Conversely in patients with RA FFB count was significantly associated 
with erosion presence only (r=0.42, p≤0.01). Comparatively, HV demonstrated a lateral FFB 
distribution, OA patients an even distribution and RA patients a lateral or central FFB 
distribution. Differences in FFB distribution were significantly different between all groups (RA-110 
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HV: X
2=26.37, p≤0.01; RA-OA:. X
2=15.64, p≤0.01; OA-HV: X
2=16.02, p≤0.01). The distribution 
of FFB in patients with OA was not related to biomechanical impairment or foot-related disability. 
In patients with RA, the distribution of FFB was significantly related to markers of RA disease 
activity but not biomechanical impairment or foot-related disability. 
Conclusion: Uniquely, this study has identified that, in patients with RA, US-detected FFB are 
highly prevalent and related to both inflammation and biomechanical impairment. The 
distribution pattern of FFB, unique to patients with RA, may be clinically relevant and related to 
metatarsal head erosion. The findings of this study suggest that both inflammation and 
biomechanical impairment are related to the prevalence of FFB. Further work is required to 
characterise which FFB are of greatest clinical relevance.  
5.1 Introduction 
Previous studies have demonstrated a high prevalence of musculoskeletal ultrasound (US) 
detected forefoot bursae (FFB) in patients with rheumatoid arthritis (RA) (Bowen et al. 2009, 
Bowen et al. 2010c). FFB prevalence has been demonstrated to be significantly associated with 
increased RA disease activity both in cross-sectional and longitudinal studies (Bowen et al. 
2009, Bowen et al. 2010c, Koski 1998, Palmer 1970). Furthermore, FFB have been 
demonstrated to be a significant prognostic indicator of patient-reported foot-related disability 
longitudinally (Chapter four). However, the biological mechanisms underpinning this relationship 
are currently unclear. Previous researchers have suggested that, in patients with RA, an 
increased prevalence of FFB may be related to increased disease activity. It is hypothesised that 
the synovium, which lines the otherwise inconspicuous intermetatarsal anatomical bursae, is 
hypertrophied as a consequence of excessive inflammation (Koski 1998, Bowen et al. 2010a, 
Chauveaux et al. 1987). Conversely, there is evidence to suggest that an increased prevalence 
of FFB may be related to biomechanical impairment; it is hypothesised that adverse pressure 
and shearing forces result in the accumulation of interstitial fluid within degraded tissues (Ahmed 
et al. 1994, Studler et al. 2008, Aguiar et al. 2005). However, to date, the pathophysiological 
mechanism underpinning the previously reported clinical relevance of US-detected FFB in 
patients with RA is unclear. In order to target and optimise therapeutic intervention, an improved 
understanding of the potential inflammatory or biomechanical mechanisms underpinning the 
clinical importance of FFB in this patient population is required.  
5.1.1 Study aim & objectives 
The main aim of this study was to explore the potential relationship between US-detectable FFB 
and biomechanical impairment or inflammation in patients with RA. To achieve this aim the 
following objectives were set:  
 
1.  To compare the prevalence and distribution of US-detectable FFB between patients with 
medial knee osteoarthritis (OA), as a surrogate biomechanically impaired patient group, 
and healthy volunteers (HV) 111 
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2.  To compare the prevalence and distribution of US-detectable FFB between patients with 
rheumatoid arthritis (RA), as a surrogate inflammatory and biomechanically impaired 
patient group, and HV 
3.  To compare the prevalence and distribution of US-detectable FFB between patients with 
RA and OA 
4.  To explore the potential relationship between FFB distribution and inflammation or 
biomechanical impairment  
5.2 Materials & methods 
5.2.1 Study design 
To achieve the above objectives a comparative, cross-sectional observational study design was 
used. The primary study outcome was an analysis of the presence of US-detected forefoot 
bursae (FFB). All intermetatarsal spaces (x4) and plantar metatarsal regions (x5) were imaged 
for the presence of FFB. The number of observed lesions for both feet was combined, thus a 
maximum score of 18 was possible. Explanatory variables of interest included those related to 
biomechanical foot deformity (foot posture index (FPI), hallux abducto-valgus deformity (HAV), 
lesser digital deformity (LDD)), foot function (ankle, subtalar, midfoot, or metatarsophalangeal 
joint ranges of motion), patient-reported foot-related disability (FIS), or those related to RA 
disease activity (joint hypertrophy (JH), metatarsal head erosion (ER), serological inflammatory 
markers (ESR, CRP) and DAS 28).  
 
The foot posture index was selected as a composite measure of weight-bearing foot joint 
alignment and scored for both feet combined (0-24). Deformity was scored as either present or 
absent for each joint assessed and the accumulative score for each foot combined (0-20). Joint 
range of motion was scored as full, limited or rigid for each joint of interest and the accumulative 
score for each foot combined (0-4). Disability was evaluated using the two subscales of the Foot 
Impairment Score (FIS); 1. (FISIF, 0-21): foot impairment and footwear restriction, 2. (FISAP, 0-
29): activity limitation and participation restriction (Helliwell et al. 2005). An elevated FISIF or 
FISAP score indicates greater foot impairment or activity limitation respectively. 
Metatarsophalangeal JH and metatarsal head ER were determined using US and scored as 
present or absent for each location. An accumulative score for each foot combined was 
calculated (range=0-10). Disease activity was evaluated using markers of erythrocyte 
sedimentation rate (ESR), C-reactive protein (CRP) and calculation of a 28 joint disease activity 
score (DAS 28) (Van der Heijde et al. 1990). Explanatory variables were selected based upon 
the findings of previous work, literature review and potential clinical relevance. Further detail 
regarding the selected measures is given in Chapters two (section 2.2) and three (section 3.6). 
5.2.2 Study population  
The study utilised three comparative cohorts: 1. healthy volunteers (HV; n=50), 2. patients with 
medial knee osteoarthritis (OA; n=50), 3. patients with rheumatoid arthritis (RA; n=56). HV were 112 
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recruited from the staff and student population at the University of Southampton via open 
advertisement. Patients with a consultant confirmed diagnosis of unilateral medial compartment 
knee OA, of Kellgren and Lawrence grade ≥2at the time of recruitment (Kellgren and Lawrence 
1957), or consultant confirmed diagnosis of RA (consistent with 1987 ACR criteria), were 
recruited from known cohorts who had previously participated in either a trial of vitamin D 
supplementation (the ‘VIDEO’ study) or forefoot bursae (the ‘FeeTURA’ study). Participants from 
both the ‘VIDEO’ and ‘FeeTURA’ studies were originally consecutively, prospectively recruited 
from a population of patients attending a UK rheumatology outpatient clinic. Participants from 
the VIDEO study were consecutively, retrospectively identified from those completing the final 
episode of trial data collection until the target sample size was achieved. All FeeTURA study 
participants were invited to take part in this follow-up study. Please note, the participants with 
RA contributing to this study have also contributed to the study findings documented in Chapter 
four. Thus, a proportion of the data presented within this study may be a replication of that 
reported previously. However duplicate data is presented in a contextually different manner to 
that presented previously. Further details regarding the study population are given in Chapter 
three (sections 3.4-3.5). 
5.2.3 Protocol for data collection 
The participant recruitment and data collection protocol is summarised in figure 40.  113 
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Figure 40: A schematic diagram of the study protocol  
Where, VIDEO = Vitamin D in osteoarthritis research trial; FeeTURA = foot and ankle ultrasound research 
in rheumatoid arthritis; PIS = participant information sheet; ID = identification; US = ultrasound; DAS = 
disease activity score. 114 
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5.2.4 Protocol for image collection & interpretation 
Musculoskeletal ultrasound (US) scanning, using a Diasus
® diagnostic scanner (System 8, 
Dynamic imaging, Livingston, Scotland, UK), was completed in B-Mode to provide real-time 
grey-scale images. The return echo signals were automatically processed using Diasus
® 2D 
spline filtering. Image pixilation was standardised at 640 x 440 pixels, the optimum settings for 
fine image resolution available using this software. The overall transmit power and gain were set 
at ≤50 and ≤30 respectively, in accordance with the European League Against Rheumatism 
working group for US in rheumatology scanning recommendations (Backhaus M. 2001). All 
metatarsophalangeal joints and intermetatarsal spaces, of both feet, were individually imaged 
from both a plantar and dorsal approach, in longitudinal and transverse scanning planes, using 
an 8-16MHz linear array transducer. All intermetatarsal spaces and plantar forefoot regions were 
additionally imaged from a plantar approach, in longitudinal and transverse scanning planes, 
using a 5-10MHz linear array transducer (see figure 24, Chapter three, section 3.6.3). Where 
possible the least amount of focus points were used and centred at the level plantar to the deep 
transverse intermetatarsal ligament for plantar foot scans and the upper third of the joint space 
for dorsal foot scans. All US scanning was performed in accordance with the British Medical 
Ultrasound Society guidelines for safe use (Fitzpatrick et al. 1998) and completed by two trained 
podiatrists (LH and CJB), the reliability of which has been previously reported and identified as 
moderate to substantial (kappa=0.7) (Bowen et al. 2008).  
 
Intermetatarsal lesions were classified as bursae if a defined region of hypo-echogenicity, 
occurring within the IM spaces, either inferior or superior to the deep transverse intermetatarsal 
ligament, was observed in the perpendicular transverse and longitudinal plantar scanning 
planes. Plantar lesions were classified as bursae if a defined region of hypo-echogenicity, 
occurring inferior to the level of the base of the metatarsal heads, was observed in the 
perpendicular transverse and longitudinal scanning planes. Thus lesions were defined based 
upon location and grey-scale US properties and not size or shape. MTP joint hypertrophy was 
noted as present if distension of the dorsal synovial joint membrane, as a consequence of either 
increase in synovial fluid volume or membrane thickening, extended beyond the proximal or 
distal attachment sites at the metatarsal head or base of the proximal phalanx respectively. 
Metatarsal head erosion was noted as present if a distinct loss in cortical bone was observed in 
two perpendicular scanning planes.  
5.2.5 Analysis 
All analysis was completed using Stata version 11.0 (Stata Corp, College Station, Texas, USA), 
or SPSS version 18.0 (Chicago, Illinois, USA). Prior to analysis, data distribution was checked 
for inconsistencies, outliers and missing information. Histograms and scatter plots were used to 
assess whether the data followed a normal distribution. The demographic and clinical 
characteristics of the study participants are presented as the mean, standard deviation (SD) and 
range. Statistically significant differences in demographic characteristics between cohorts were 115 
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determined using independent sample t-tests. Statistical significance was reported at the 5% 
confidence level, based upon two-tailed analysis (p≤0.05). 
 
The point prevalence proportion (PP) of US-detectable FFB was calculated by the division of the 
sum of identified cases by the sum of the total studied population and expressed per 100 
patients. The probability of FFB presence was determined for each participant group and 
comparatively expressed as an odds ratio (inclusive of 95% confidence interval and p-value). 
Statistically significant differences in the distribution of FFB across forefoot regions between 
groups were determined using repeated chi squared analyses. Correlation coefficient analysis 
was used to determine the statistical significance of potential associations between the primary 
outcome of interest (FFB count), and measured explanatory variables (markers of foot 
deformity/function, patient-reported foot-related disability and disease activity) in each participant 
group. The total number of US-detectable episodes of FFB, JH or ER for both feet combined 
was calculated for each patient; these count scores were treated as continuous variables for the 
purposes of analysis, although they were bounded between 0-18 for FFB and 0-10 for JH and 
ER. Multiple linear regression techniques, with ordinary least squares estimation, were used to 
explore the predictive value of FFB count, in each patient group, for alternate primary outcome 
measures relating to disease state; including foot deformity/function, patient-reported foot-
related disability and/or disease activity. Further linear regression, with ordinary least squares 
estimation, was used to explore statistical relationships between FFB count as the primary 
outcome of interest and potential explanatory variables. Significant factors were subsequently 
entered into a multiple linear regression model to identify potential confounding or colinearity 
within the study findings. 
 
FFB were grouped into medial (sites 1-3), central (sites 4-6) or lateral (sites 7-9) scores (figure 
41). Trends between medial, central and lateral FFB scores were then coded into one of four 
categories: 1. equal distribution of FFB across all sites, 2. increased distribution laterally, 3. 
increased distribution centrally, 4. other distribution. Categories were selected based upon 
observations of overall trends within the data for each group. It is noteworthy that few patients 
demonstrated an increasing distribution medially therefore this was not included as a category. 
Chi
2 analyses were used to determine statistically significant differences in pattern category 
between patient groups. Age-adjusted, multinomial, logistic regression techniques were used to 
explore the potential relationships between FFB pattern category and indicators of 
biomechanical function, disability or disease state in each patient group. Significant factors were 
subsequently entered into a combined multinomial logistic regression model to identify potential 
confounding or colinearity within the study findings. 
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Figure 41: Lesion site definitions  
Segmentation of intermetatarsal sites is by bisection of the midline of the metatarsal head, relative to the 
short axis of the foot, for medial-lateral boundaries and the base of the lesser metatarsal heads for plantar 
boundaries.  Segmentation  of  plantar  sites  is  by  vertical  bisection  of  the  midline  of  the  intermetatarsal 
space,  relative  to  the  short  axis  of  the  foot,  for  medial-lateral  boundaries  and  the  base  of  the  lesser 
metatarsal heads for dorsal boundaries. 1-9 = derived intermetatarsal and plantar foot segments. Image 
author’s own. 
 
 
5.3 Results 
5.3.1 Study cohort characteristics 
A summary of the demographic and clinical characteristics of the study participants is shown in 
table 20. Participant age was significantly different between all groups (HV-OA p≤0.001; HV-RA 
p≤0.001; OA-RA p=0.006). Additionally, significant differences in participant weight, BMI and 
disease duration between patients with OA and RA were noted (p≤0.001, p≤0.001, p=0.043 
respectively). 
 
 
Table 20: Cohort demographic characteristics 
Where SD = standard deviation, BMI = body mass index.  
 
 
HEALTHY 
VOLUNTEERS 
(N=50) 
KNEE OA  
(N=50) 
RA  
(N=60) 
 
Mean, (SD), Range  Mean, (SD), Range  Mean, (SD), Range 
age (years)  41, (13), 20-65  66.3, (12.2), 53-80  62, (11.8), 28-89 
height (m)  1.7, (0.09), 1.5-1.9  1.7, (0.1), 1.5-1.9  1.7, (0.1), 1.3-2.1 
weight (Kg)  69.5, (13.3), 47-115  81.4, (15), 51.3-120.6  70.7, (13.6), 42.2-108 
BMI  24.6, (4.5), 18.9-38.4  28.6, (5), 19.3-41.5  25.5, (3.9), 19.1-33.4 
disease duration (years)   -   11.2, (9.3), 1-40  15.1, (10.3), 3-45 
 
 
5.3.2 The comparative epidemiology of FFB between HV & patients with knee OA 
The point prevalence of FFB in healthy volunteers and patients with OA was 56 per 100 
participants (mean=1.3, SD=1.5, range=0-6) and 94 per 100 participants (mean=2.8, SD=1.5, 117 
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range=0-5) respectively. Thus, for each patient with OA without FFB, 15.7 patients are likely to 
have at least one FFB (47/3). Conversely, for each HV without FFB, 1.3 people are likely to have 
at least one FFB (28/22). Comparatively, patients with OA are 1.7 times more likely to have at 
least one FFB than HV (0.94/0.56). Similarly when considering the relative odds of occurrence, 
for every OA patient without FFB 2.7 (3.5/1.3) times as many OA patients will have at least one, 
relative to the number of HV with FFB for every HV without; the odds ratio for FFB occurrence 
relative to patients with OA and HV is 0.08 (95% CI=0.022-0.296, p≤0.001). 
 
Significant differences between participant groups were observed in the distribution pattern of 
FFB across forefoot sites (X
2=16.02, p≤0.001). HV had a greater tendency towards a lateral FFB 
distribution, particularly at the IM 4/5 site, while patients with OA had a relatively more even 
distribution across the forefoot, although they also demonstrated a high frequency of FFB in the 
IM 4/5 site (figure 42).  
 
 
Figure 42: The distribution of FFB in HV & patients with OA 
Values are expressed as percentage of sample with FFB in this location.  
Where M1-5 = plantar metatarsophalangeal joint region. 
 
5.3.3 The comparative epidemiology of FFB between HV & patients with RA 
The point prevalence of FFB in HV and patients with RA was 56 per 100 participants (mean=1.3, 
SD=1.5, range=0-6) and 88 per 100 participants (mean=3.05, SD=2.14, range=0-11) 
respectively. Thus, for each patient with RA without FFB, 7 patients are likely to have at least 
one FFB (49/7). Conversely, for each HV without FFB, 1.3 patients are likely to have at least one 
FFB (28/22). Comparatively, patients with RA are 1.6 times more likely to have at least one FFB 
than HV (0.88/0.56). Similarly when considering the relative odds of occurrence, for every RA 
patient without FFB, 5.4 (7/1.3) times as many RA patients will have at least one, relative to the 
number of HV with FFB for every HV without; the odds ratio for FFB occurrence relative to 
patients with RA and HV is 0.18 (95% CI=0.069-0.479, p≤0.001). 118 
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Significant differences between participant groups were observed in the distribution pattern of 
FFB across forefoot sites (X
2=26.37, p≤0.001). HV had a greater tendency towards a lateral FFB 
distribution, particularly at the IM 4/5 site, while patients with RA had a tendency for FFB to also 
occur more centrally (figure 43).  
 
 
Figure 43: The distribution of FFB in healthy volunteers & patients with RA 
Values are expressed as percentage of sample with FFB in this location.  
Where M1-5 = plantar metatarsophalangeal joint region. 
 
5.3.4 The comparative epidemiology of FFB between patients with RA & knee OA 
The point prevalence of FFB in patients with RA and OA was 88 per 100 participants 
(mean=3.05, SD=2.14, range=0-11) and 94 per 100 participants (mean=2.8, SD=1.5, range=0-
5) respectively. Comparatively, patients with OA are 1.1 times more likely to have FFB than 
patients with RA (0.94/0.88). Similarly when considering the relative odds of occurrence, for 
every RA patient without FFB, 0.4 (7/15.7) times as many RA patients will have at least one, 
relative to the number of OA patients with FFB for every OA patient without; the odds ratio for 
FFB occurrence relative to patients with RA and OA is 0.45 (95% CI=0.109-1.831, p=0.328). 
 
Significant differences between participant groups were observed in the distribution pattern of 
FFB across forefoot sites (X
2=15.64, p≤0.001). Patients with RA had a greater frequency of FFB 
occurring within the intermetatarsal spaces or outer margins of the foot while patients with OA 
had a relatively more even distribution across the forefoot and high prevalence at IM 4/5 (figure 
44). 
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Figure 44: The distribution of FFB in patients with RA & OA 
Values are expressed as percentage of sample with FFB in this location.  
Where M1-5 = plantar metatarsophalangeal joint region. 
 
 
5.3.5 The relationship between FFB distribution & inflammation or biomechanical impairment  
In patients with OA, FFB pattern category was not determined to be significantly related to 
indicators of biomechanical impairment or foot-related disability (see appendix section A15 for 
details). In patients with RA, FFB pattern category was determined to be significantly related to 
disease activity; a more central FFB distribution was indicative of increased joint hypertrophy or 
metatarsal head erosion (Pseudo R
2=0.145, p=0.032; Pseudo R
2=0.240, p=0.002 respectively). 
When joint hypertrophy and erosion were entered into a further combined, age-adjusted, 
multinomial regression analysis, the resultant model accounted for 30.4% of the variability in 
FFB pattern category (table 21). FFB pattern category was not significantly related to 
biomechanical impairment or foot-related disability in this patient group (see appendix section 
A15 for details). 
 
 
Table  21:  Predictors  of  FFB  pattern  category:  age-adjusted,  multinomial,  logistic  regression 
analysis (RA) 
Where df = degrees of freedom. * = Significant at the 0.05 level. 
EXPLANATORY 
VARIABLE 
FFB PATTERN CATEGORY 
X
2  df  p-value  Pseudo-R
2 
(Cox & Snell) 
Model p-
value 
constant  9.24  3  0.026 
0.304  0.002 
joint hypertrophy  4.95  3  0.176 
*erosion  11.49  3  0.009 
likelihood score  20.29  6  0.002 
goodness-of-fit  67.02  81  0.868 120 
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5.3.6 The relationship between FFB count & inflammation or biomechanical impairment  
For healthy volunteers, FFB count was significantly associated with increased biomechanical 
impairment; where increased FFB count was significantly associated with poorer foot posture 
(r=0.41, p=0.003), the presence of hallux abducto-valgus deformity (r=0.30, p=0.032) or lesser 
digital deformity (r=0.46, p≤0.001) and reduced foot joint ranges of motion (ankle: r=0.34, 
p=0.014; subtalar: r=0.37, p=0.009; midfoot: r=0.37, p=0.009; metatarsophalangeal: r=0.28, 
p=0.050). For participants with OA, FFB count was significantly associated with reduced ankle 
joint range of motion (r=-0.30, p=0.037). For participants with RA, FFB count was significantly 
associated with increased US-detected metatarsal head erosion (r=0.42, p≤0.001), but no other 
biomechanical or disease related variables (for full association analysis results see Appendix 
A13). 
 
In patients with OA an increased number of FFB significantly predicted reduced ankle joint 
ranges of motion (R
2=0.09, p=0.037) but no other measures of biomechanical impairment or 
foot-related disability. In patients with RA an increased number of FFB significantly predicted 
reduced ankle joint range of motion (R
2=0.08, p=0.039) and increased metatarsal head erosion 
(R
2=0.18, p≤0.001) but no other measures of biomechanical impairment, foot-related disability or 
disease activity (for full regression analysis results see Appendix A14). 
5.3.7 Predicting FFB count in HV & patients with OA or RA  
For HV, indicators of biomechanical function were determined to be significant predictors of FFB 
count. Increased foot posture, HAV, lesser digital deformity scores and reduced ankle, subtalar 
and midfoot joint ranges of motion were determined to be significant independent predictors of 
FFB count, where poorer foot structure and function were indicative of increased FFB count 
(R
2=0.17, p=0.003; R
2=0.10, p=0.024; R
2=0.23, p≤0.001; R
2=0.12, p=0.016; R
2=0.16, p=0.004; 
R
2=0.16, p=0.004 respectively, table 22a; for full results see Appendix A12). All identified 
independently significant explanatory variables were entered into a further multiple regression 
analysis, with the resultant models explaining 24% of the variability in the observed number of 
FFB, of which foot posture and lesser digital deformity significantly accounted for 15% and 77% 
of the variance respectively (table 22b).  
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Table 22: Predictors of FFB count 
Where 22a shows results of linear regression analyses for all dependent variables; 22b shows results of a 
multiple regression analysis for previously identified independent predictors of FFB count.  
Where BMI = body mass index; jROM = joint range of motion; CI = confidence interval. *= Significant at the 
0.05 level. 
22a. Predictors of FFB count: univariate, age-adjusted, linear regression analysis (HV) 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  R
2  F-
value 
*foot posture  0.17  0.003 (0.06-0.27)  0.17  9.53 
*hallux abducto-valgus   0.88  0.024 (0.12-1.63)  0.10  5.44 
*lesser digital deformity  0.53  0.000 (0.25-0.80)  0.23  14.5 
*ankle jROM  1.09  0.016 (0.22-1.97)  0.12  6.29 
*subtalar jROM  1.27  0.004 (0.42-2.12)  0.16  8.91 
*midfoot jROM  1.27  0.004 (0.42-2.12)  0.16  8.91 
 
22b. Predictors of FFB count: multivariate, age-adjusted, linear regression analysis (HV) 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  Adjusted 
R
2 
F-
value 
*foot posture  0.15  0.022 (0.02-0.27) 
0.24  4.16 
*lesser digital deformity  0.77  0.026 (0.1-1.43) 
 
 
 
For patients with knee OA, an increased presence of lesser digital deformity and reduced ankle 
joint range of motion were determined to be significant independent predictors of FFB count 
(R
2=0.07, p=0.057; R
2=0.09, p=0.037 respectively, table 23a). Both explanatory variables 
remained significant when entered into a multiple regression analysis, with the resultant model 
explaining 15% of the variability in the observed number of FFB (table 23b).  
 
 
 
Table 23: Predictors of FFB count (OA) 
a: Results of linear regression analyses for all dependent variables; b: Results of a multiple regression 
analysis for previously identified independent predictors of FFB count. *Significant at the 0.05 level. 
23a. Predictors of FFB count: univariate, adjusted, linear regression analysis (OA) 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  R
2  F-
value 
lesser digital deformity  0.31  0.057 (-0.01-0.64)  0.07  3.79 
*ankle jROM  -0.44  0.037 (-0.85- -0.03)  0.09  4.62 
 
23b. Predictors of FFB count: multivariate linear regression analysis (OA) 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  Adjusted 
R
2 
F-
value 
*lesser digital deformity  0.37  0.022 (0.06-0.68) 
0.15  5.35 
*ankle jROM  -0.50  0.014 (-0.90- -0.11) 
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For patients with RA, an increased presence of metatarsal head erosion and reduced ankle joint 
range of motion were determined to be significant independent predictors of FFB count 
(R
2=0.18, p≤0.001; R
2=0.08, p=0.039 respectively, table 24a). Both explanatory variables 
remained significant when entered into a multiple regression analysis, with the resultant model 
explaining 18% of the variability in the observed number of FFB (table 24b). No further 
biomechanical or disease related explanatory variables were identified as significant predictors 
of FFB count (for full analysis results see Appendix sections A12 to A15).  
 
 
Table 24: Predictors of FFB count (RA) 
Where 24a shows results of multiple linear regression analyses for all dependent variables; 24b shows 
results  of  a  multiple  regression  analysis  for  previously  identified  independent  predictors  of  FFB  count. 
*Significant at the 0.05 level. 
24a.Predictor of FFB count: univariate, adjusted, linear regression analysis (RA) 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  R
2  F-
value 
*erosion  0.27  0.001 (0.11-0.43)  0.18  11.49 
*ankle jROM  0.52  0.039 (0.03-1.01)  0.08  4.47 
 
24b. Predictors of FFB count: multivariate, adjusted linear regression analysis (RA) 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  Adjusted 
R
2 
F-
value 
*erosion  0.24  0.004 (0.08-0.41) 
0.18  7.02 
ankle jROM  0.36  0.137 (-0.12-0.83) 
 
 
 
5.4 Discussion 
This is the first study to comparatively determine the prevalence of US-detectable FFB in 
patients with RA, medial knee OA and healthy volunteers. Uniquely, FFB were determined to be 
highly prevalent in both patients with RA and patients with medial knee OA. The results of this 
study suggest that patients with RA are 1.3 times more likely to have at least one FFB than a 
healthy volunteer, while those with medial knee OA are 1.7 times more likely. Comparatively, 
patients with OA are 1.1 times more likely to have at least one FFB than those with RA.  
 
To our knowledge, there have been no previously reported studies of FFB in patients with 
medial knee OA and as such the surprisingly high prevalence of FFB cannot be compared to 
other works. However, Silva (2008) reported the presence of bursal hypertrophy in the absence 
of active inflammation in patients with biomechanically elicited trochanteric pain. In this work the 
authors hypothesise that biomechanical irritation contributed to bursal hypertrophy and the 
fibrotic changes seen in the associated histopathology of excised tissue. It is possible that a 
similar rationale of biomechanical irritation to the plantar fibro-fat pad of the forefoot, subsequent 123 
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to proximal/distal joint degradation and kinetic dysfunction, may account for the high presence of 
FFB reported in this study (Astephen and Deluzio 2004, Astephen and Deluzio 2005, Astephen 
et al. 2008a). The sensitivity and specificity of US for detecting and differentiating between FFB 
and fibrotic changes within the plantar fat pad has not been established. It is possible therefore, 
that misclassification of FFB and fibrotic lesions could be contributing to an over-reporting of 
FFB presence. Future work which determines the construct validity of US-reported FFB would 
be of significant benefit to this area of study.  
 
The pattern of FFB distribution was significantly different between all groups. Healthy volunteers 
demonstrated a lateral FFB distribution, patients with OA an even distribution and patients with 
RA a lateral or central distribution. However, all groups had the highest prevalence of FFB in the 
4/5 intermetatarsal space. In patients with OA, the distribution of FFB was not related to 
indicators of biomechanical impairment or foot-related disability. However in patients with RA, 
the distribution of FFB was related to MTP joint hypertrophy and metatarsal head erosion but not 
indicators of biomechanical impairment or foot-related disability. These findings suggest that in 
patients with OA, although elevated in number, the distribution of FFB is not clinically indicative. 
However in patients with RA, the distribution of FFB is associated with inflammatory disease 
activity and is potentially a clinically relevant feature in the pathogenesis of RA foot disease. 
Conversely, the high prevalence of FFB seen in all groups, including the healthy volunteers, 
perhaps suggests that a proportion of FFB are present yet clinically ‘silent’. The findings of this 
study therefore appear to reinforce those of previous authors which suggest that different types 
of FFB may exist. Thus, patients with RA potentially demonstrate a number of coexisting FFB 
subtypes related to healthy foot anatomy, biomechanical irritation and disease activity. An 
observer-independent, reliable and valid method of characterising FFB in patients with RA, to 
differentiate between those which are potentially anatomical or pathological, would be of 
significant clinical benefit, providing a framework for future targeted intervention.  
 
In patients with RA, metatarsal head erosion and ankle joint range of motion were both identified 
as significant independent predictors of FFB count. When entered into a multivariate model, the 
significance of ankle joint range of motion diminished, suggesting that these items are potentially 
co-linear. The interpretation of the consistently identified relationship between FFB and erosion 
should therefore be made with caution; it is unclear to what extent erosion should be considered 
as representative of disease activity, disease chronicity or biomechanical impairment of the MTP 
joints in this experimental context. Interestingly this concept is arguably reinforced by the 
findings of Woodburn et al. (2002c), who demonstrate changes in forefoot kinetics associated 
with impaired ankle joint architecture in patients with RA. Future use of Power Doppler (PD) to 
identify active inflammation would enhance subsequent study of the clinical importance of FFB 
in patients with RA. 
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The relative clinical importance of FFB that are associated with inflammation or biomechanical 
impairment remains unclear. Interestingly, a similarly high FFB prevalence between patient 
groups was observed. However, in contrast to patients with RA the relationship between FFB 
prevalence and disability was not evident in patients with OA. Thus, the clinical importance of 
US-detected FFB in terms of foot-related disability in patients with OA, when evaluated with 
outcome measures used in this study, appears negligible. However the prognostic value of FFB 
in patients with medial knee OA does appear to offer further avenues of investigation. Van der 
Leeden et al. (2008), amongst other authors, have previously identified significant reductions in 
weight-bearing activity with the course of RA disease activity (Cho et al. 2012, Hallert et al. 
2012). It is possible that the RA population studied undertake less weight-bearing activity than 
the comparative OA group and therefore acquire less biomechanical irritation to the forefoot 
(Miyoshi et al. 2004). Alternatively, many of the patients with RA also demonstrated a 
generalised loss of plantar fibro-fatty tissue which may limit the extent of the biomechanically 
irritated tissue response that can be observed using US (Falsetti et al. 2006, Budiman-Mak et al. 
1999). Conversely, the kinetic parameters of gait are likely to be significantly different between 
patient groups (van der Leeden et al. 2006, Turner et al. 2008, Turner and Woodburn 2008, 
Khazzam et al. 2007, Huang et al. 2008, Heiden et al. 2009b); previous researchers have 
demonstrated that patients with RA have reduced walking speed, increased stance phase of gait 
and widened base of support (Turner et al. 2008, Turner and Woodburn 2008, Woodburn et al. 
2002b). Conversely patients with medial knee OA have been demonstrated to have a greater 
tendency towards lateral loading of the foot during the stance phase of gait (Huang et al. 2008, 
Heiden et al. 2009a, Astephen et al. 2008a). Such functional differences will have a concomitant 
effect upon the internal loading forces exerted upon joints and soft tissues during gait (Astephen 
and Deluzio 2005, Astephen et al. 2008b). Thus differences in the nature of biomechanical 
impairment between patient groups may account for the variation in FFB count and distribution 
observed. Future work may seek to investigate the relationship between FFB and dynamic 
markers of biomechanical impairment in addition to static markers such as those used within this 
work (Cavanagh et al. 1997).  
5.4.1 Study limitations  
This study has a number of strengths and potential limitations. The patients with OA or RA were 
consecutively, prospectively recruited from an outpatient secondary care setting and as such the 
study findings may be considered as generalisable to such patients within the UK. There is no 
known pathophysiological mechanism that would lead to regional variation in the reported 
prevalence of FFB in such patient groups. However, the generalisability of the study results to 
patients not reviewed within a secondary care setting should be considered (Silman and 
Hochberg 2001). In particular, there has been recent discussion regarding the under-
representation of the elderly or people without a history of health service access within the study 
of OA epidemiology (Hoogeboom et al. 2012, Peat et al. 2011). 
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The patients with OA included within this study had a significantly greater BMI than the 
comparative participant groups. Previous research has suggested a link between elevated BMI 
and biomechanical impairment in terms of both kinematic and kinetic joint loading parameters 
(Goulston et al. 2011, Holliday et al. 2011, Oliveria et al. 1999). The additional loading and 
torsional stress exerted upon the soft tissues of the forefoot as a consequence of elevated BMI 
are unclear although such theoretical links provide a plausible pathophysiological rationale for 
an association between BMI and FFB presence (Astephen and Deluzio 2005). It is possible that 
the overall elevation in BMI present in patients with OA may contribute to the increased 
presence of FFB recorded. It is currently unclear whether elevated BMI may be an aetiological, 
putative or confounding factor in the development of FFB. Improved understanding of the 
relationship between FFB and BMI would help inform the further determination of the clinical 
importance of FFB in differing patient groups.  
 
Throughout the course of data collection the researcher undertaking the US assessment was 
not blinded to the patient group of each participant, and as such there is potential for observer 
bias within the reported results (Silman and Hochberg 2001). However to minimise subjectivity in 
observation, a strict protocol of US procedure and FFB identification was adhered to throughout 
data collection and analysis. Additionally, the researcher undertaking the investigation 
completed a comprehensive formal training programme in the use of US. Inter-rater agreement 
in the use of US between the primary researcher and a second ‘expert’ researcher was 
confirmed as good-excellent on two occasions, suggesting that the likelihood of reporting error is 
minimal (see Chapter three, section 3.7). None the less, there is a need for a reliable and valid 
method of characterising FFB, which can subsequently be used to inform the clinical importance 
of FFB in patients with RA.  
5.4.2 Conclusion & summary 
Uniquely, this study has identified that, in patients with RA, US-detected FFB are highly 
prevalent and related to both inflammation and biomechanical impairment. The distribution 
pattern of FFB, unique to patients with RA, may be clinically relevant and related to metatarsal 
head erosion. The findings of this study suggest that both inflammation and biomechanical 
impairment are related to the prevalence of FFB. Further work is required to characterise which 
FFB are of greatest clinical relevance.  
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The relationship between FFB & Inflammation or biomechanical impairment 
 
Key points: 
  FFB are highly prevalent in patients with RA and medial knee OA  
  In patients with RA, the presence of FFB is associated with inflammation and 
biomechanical impairment  
  The central distribution pattern of FFB, unique to patients with RA, is clinically 
relevant and associated with metatarsal head erosion  
  Further characterisation of FFB is required in order to fully determine their clinical 
importance  127 
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Chapter six  
Detecting forefoot bursae in patients with rheumatoid arthritis 
using MRI: development of the ‘FFB-score’ 
 
6.0 Chapter abstract 
Background: Previous studies have demonstrated a high prevalence of clinically relevant 
forefoot bursae (FFB) in patients with rheumatoid arthritis (RA) using musculoskeletal ultrasound 
(US). However, there is a need for an observer-independent, reliable and valid method of 
characterising FFB. Magnetic Resonance Imaging (MRI) allows improved visualisation and 
characterisation of FFB in multiple imaging planes.  
Aim: To determine the reliability and validity of a novel MRI-based scoring tool for the 
identification and characterisation of FFB in patients with RA. 
Methods: A collaborative process of tool design was completed by a team of rheumatologists, 
radiologists, and a podiatrist from centres within the UK and Germany. In an iterative process of 
tool design, items to be included, grading criteria, overall utility and MRI sequences were 
determined. The FFB-score assesses 9 distinct forefoot regions and contains 5 items; lesion 
presence, shape, enhancement, and T1/T2 characteristics. The final tool was evaluated on 42 
consecutively recruited patients with RA (mean (±SD) age=62.2 (±12) years, disease 
duration=15.3 (±10.3) years, and DAS 28=3.1 (±1.4)), who were recruited from a UK 
rheumatology clinic. Images were obtained using a 1.5T whole body scanner and a 4-channel 
flex extremity coil. The final MRI protocol included coronal T1 and STIR, coronal and sagittal T1 
post-gadolinium, and long axis 3D volumetric sequences. The intra and inter-reader agreement 
was evaluated using percentage exact/close agreement (PEA/PCA) and kappa analyses. 
Content validity was evaluated using Lawshe’s content validity ratio (CVR). Discriminant validity, 
with regard to differentiation between high and low MRI-determined indicators of disease activity 
(erosion, bone marrow oedema and synovitis), clinical markers of disease activity (DAS 28), or 
foot-related disability (foot impact score), was evaluated using receiver operator characteristic 
curves and area under the curve analysis.  
Results: The FFB-score was determine to have substantial overall intra-reader agreement 
(kappa range=5.5-9) and substantial inter-reader agreement (kappa range=4.7-8.7). The FFB-
score was determined to have good content validity (CVR: 0.625) and good discriminant validity 
when differentiating between patients with high/low MRI-determined disease activity local to the 
forefoot (erosion: p=0.011, synovitis: p=0.004, oedema: p=0.018). The FFB-score has good 
discriminant validity when differentiating between patients with high/low foot-related disability 
(foot impairment p=0.006, activity limitation p=0.033).  
Conclusion: The FFB-score is a reliable and valid MRI-based tool for the identification and 
characterisation of FFB in patients with RA. Further investigation of the clinical importance of 128 
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identified FFB characteristics may allow timely and targeted therapeutic intervention. 
Longitudinal validation, assessment of responsiveness and refinement of the scoring system is 
needed in order to maximise its potential utility in clinical trials and epidemiological studies. 
6.1 Introduction 
Previous studies have demonstrated a high prevalence of musculoskeletal ultrasound (US) 
detected forefoot bursae (FFB) in patients with rheumatoid arthritis (RA) (Bowen et al. 2009, 
Bowen et al. 2010c). FFB prevalence has been demonstrated to be significantly associated with 
increased RA disease activity both in cross-sectional and longitudinal studies (Bowen et al. 
2009, Bowen et al. 2010c, Koski 1998, Palmer 1970). Furthermore, FFB have been 
demonstrated to be a significant prognostic indicator of patient-reported foot-related disability 
longitudinally (Chapter four). However, the underlying biological mechanisms linking FFB to 
disease activity or disability are currently unclear. Two plausible hypotheses have been 
suggested and explored in comparative study of patients with primarily inflammatory or 
degenerative arthritis: 1. FFB are associated with biomechanical impairment (Ahmed et al. 1994, 
Studler et al. 2008, Aguiar et al. 2005), 2. FFB are associated with RA disease mediated 
inflammation (Koski 1998, Bowen et al. 2010a). The work presented in Chapter five reinforces 
these disparate hypotheses, demonstrating comparatively different FFB counts and distributions 
between healthy volunteers and patients with predominantly inflammatory or degenerative 
arthritis. The findings of this work suggest that differing clinically relevant FFB distribution 
patterns or characteristics may coexist in patients with RA. Accurately identifying, and 
differentiating between, which FFB are related to inflammation or biomechanical impairment 
would allow better targeted intervention. There is a need for an observer-independent, reliable 
and valid method of identifying and characterising FFB in patients with RA. Magnetic Resonance 
Imaging (MRI) allows improved visualisation and characterisation of FFB in multiple imaging 
planes.  
6.1.1 Study aim & objectives 
The main aim of this study was to determine the reliability and validity of a novel MRI-based 
scoring tool for the identification and characterisation of FFB in patients with RA; the ‘FFB-
score’. The following study objectives were set:  
 
1.  To complete an iterative process of MRI-based semi-quantitative tool design 
2.  To collate an FFB-score reference image atlas  
3.  To determine the reliability and validity of the FFB-score 
6.2 Materials & methods 
6.2.1 Study design 
To achieve the above objectives a collaborative process of score design was completed by a 
team of rheumatologists, radiologists, and a podiatrist from centres within the UK and Germany. 129 
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A cross-sectional cohort study design was used, with repeated image data generation by 
multiple readers. 
6.2.2 Study population 
Patients included within this study were those with a consultant confirmed diagnosis of RA who 
were consecutively recruited from a UK rheumatology out-patient clinic. Those participants who 
completed all stages of the FeeTURA programme (three appointments) were eligible for 
screening into this study. Detail regarding the recruitment, screening, inclusion/exclusion criteria 
and sample size determinants is documented in Chapter three (sections 3.4-3.5).  
6.2.3 Protocol for tool development  
The protocol for score development adhered as closely as possible to the 2009 OMERACT 
recommendations for the MRI-based quantification of RA (Boesen et al. 2009). A schematic 
diagram of the four stages of score development is shown in figure 45. At stage one, selection of 
items initially proposed for inclusion within the FFB tool was based upon literature review, 
clinical utility, and agreed via panel consensus (panel members=LK, MT, FR, NA, CE and LH). 
Features determined as key following panel discussion included FFB anatomical location, size, 
shape, enhancement, and MR appearance. The categorisation of FFB based upon anatomical 
location, rather than perceived aetiology or clinical importance, was considered to be the most 
objective approach to documentation and is consistent with principles of radiological 
investigation. At stage two, image acquisition protocols were refined by the study senior 
radiographer (NR) in conjunction with the research team until an optimal sequence protocol was 
achieved. Image acquisition and interpretation were reviewed in conjunction with the proposed 
tool items for completeness, comprehensibility, time taken to complete, feasibility of clinical use 
and appropriateness of scoring ranges and criteria. At stages three and four the final version of 
the proposed tool was evaluated for reader agreement and validity. 
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Figure 45: Protocol for FFB-score development 
 
 
6.2.4 Protocol for data collection  
The protocol for participant recruitment and MRI data acquisition is illustrated in figure 46. 
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Figure 46: A schematic diagram of the protocol for MRI data acquisition 
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acquisition 
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Image transfer 
  RA participants who had taken part in the year-three FeeTURA study visit were eligible for screening 
for possible inclusion within this research. Patient’s medical notes were screened for contraindications 
for the completion of MRI with gadolinium. 
  Eligible participants were sent a letter of invitation with i) reply slip, ii) return stamped addressed 
envelope and iii) PIS. 
  The researcher was available to answer any queries regarding participation within this study 
  A second letter of invitation (with supporting documents) was sent to those patients who had not 
responded to the first after 4 weeks. There was no further contact with patients who had not 
responded after this time. 
  Responding patients were contacted. Suitability for inclusion and contraindications to participation 
were reviewed and confirmed with the patient. An appointment was then agreed.  
  A letter confirming the appointment date, time and location was sent to the participant. Additionally, 
participants were sent written information about the procedure and how to prepare for having a scan. 
  Participants were greeted at the Radiology department by reception staff 
  A member of the research team reviewed the protocol for data collection with the participant and 
formal consent was obtained 
  A trained radiologist completed a safety protocol, inclusive of metal checking and test of renal function.  
  Participants were asked to lay supine on the plinth of the scanner, with their knees flexed at a 45 
degree position. Foam packing was used to help stabilise and rest the legs in this position. 
  Participants were encouraged to allow the feet to rest in a comfortable position. 
  A receiver RF coil was positioned around both feet and packed with foam to minimise movement of the 
feet after fitting and orientating them within the scanning plane 
  An intra-venous line was secured prior to scanning to minimise potential participant movement 
between pre & post-gadolinium scanning sequences 
  Participants were then manoeuvred into the magnet and orientated appropriately with the aid of a light 
localiser. Only the lower third of the leg was placed within the magnet bore. 
  Participants were given an emergency squeeze bulb with advice on how and when this should be used 
  Participants were issued with either headphones and music or earplugs at their preference 
  System adjustment and calibration were completed by the radiologist/radiographer  
  Localiser sequences were completed and slice orientations confirmed. Sagittal and coronal axes were 
orientated relative to participant bony anatomical landmarks 
  5 x Pre-defined sequences & slice selections were then completed 
  Images were transferred onto CD in preparation for reading 
  Participants were invited to leave the scanning room and attend a reception area where a drink of 
their choice was offered 
  Any further questions were answered by a member of the research team and the session concluded 132 
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A 1.5 Tesla (T) whole body scanner (Siemens Avanto Syngo
® MR B15, Siemens AG Medical 
Solutions, Erlangen, Germany) was used for all MRI acquisition. A four channel flex extremity 
radio frequency (RF) surface coil (Siemens, Siemens AG Medical Solutions; circularly polarised 
array) was used to image the mid and forefoot region only. Prior to data collection, initial 
capacitor tuning was completed to ensure that the RF coil frequency was synchronised with the 
magnetic field (B0). System calibration was completed as per the standard protocol for the 
radiology department.   
 
Overall, two-dimensional and three-dimensional sequences, of between 29 and 96 slices with 
0.6mm to 3mm slice thickness respectively, were completed after orientation with a T1 sagittal 
locator image. Alignment and positioning were manually orientated by the radiologist; coronal 
scans were orientated with the metatarsal parabola, sagittal scans were orientated 
approximately perpendicular to the coronal slice profile and with the shaft of the third metatarsal. 
The field of view (FoV) in the read direction was determined as the base of the first metatarsal to 
the distal aspect of the hallux. The FoV in the phase-encode direction was defined as extending 
from the medial to the lateral foot borders. The TE/TR ratios were adjusted in an iterative 
process by the study senior radiographer until appropriate image clarity or contrast was 
achieved (dependent upon sequence and intended use). Further details regarding the protocol 
for image acquisition are documented in Chapter three, section 3.6.4, (including ROI 
definition/participant placement, mapping k-space and SNR management). A summary and 
rationale for the final MRI sequence protocol are given in table 25.  
 
 
Table 25: Summary & rationale for MRI sequences  
Where T1=Isocromat relaxation time; Cor=coronal; se=spin echo; STIR=short tau inversion recovery; fs=fat 
saturated; gad=gadolinium; Sag=sagittal; Ax=axial; pd=proton dense; sp=space. 
 
Sequence 
number  Description  Abbreviation  Primary use 
1  T1 weighted coronal spin 
echo pulse sequence  Cor_T1_se  Identification of bone erosion 
and anatomical landmarks 
2  Coronal Short Tau 
Inversion Recovery  Cor_STIR  Differentiation between tissue 
types (fluid/fat/fibrous tissue) 
3  T1 weighted fat saturated 
post-contrast coronal  Cor_T1_fs_(post-gad)  Identification of highly 
vascularised regions 
4  T1 weighted fat saturated 
post-contrast sagittal  Sag_T1_fs_(post-gad)  Identification of highly 
vascularised regions 
5 
Long axis proton dense fat 
saturated three-
dimensional volumetric 
space  
Ax_pd_sp  Reconstructed calculation of 
lesion volume 
 
 
 
The final MRI sequence protocol used in data acquisition is shown in table 26.   
 
 
 
 
 
 
 
Table 26: MRI sequence protocol used in data acquisition 
Where TR=relaxation time, TE=echo time, FoV=field of view; Cor=coronal; se=spin echo; STIR=short tau inversion recovery; fs=fat saturated; gad=gadolinium; 
Sag=sagittal; Ax=axial; pd=proton dense; sp=space. 
 
Sequence  TR/TE 
(ms) 
FoV 
(mm) 
Acquisition 
matrix 
Pixel size 
(mm)  Flip angle  Slice thickness 
(mm) 
Inter-slice 
gap (mm) 
Number of 
slices 
Acquisition 
time 
1 
Cor_T1_Se 
TR : 656 
TE :15  200  384 x 182  0.7 x 0.5  90  3.0  1.5  29  2.04 
2 
Cor_STIR 
TR : 4000 
TE :15  200  384 x 160  0.7 x 0.5  150  3.0  1.5  29  2.46 
3 
Cor_T1_fs 
(post-gad) 
TR:620 
TE :15  200  384 x 182  0.7 x 0.5  90  3.0  1.5  29  3.53 
4 
Sag_T1_fs 
(post-gad) 
TR :579 
TE :18  200  384 x 140  0.9 x 0.5  90  3.0  1.0  2 x 19  5.26 
5 
Ax_PD_Sp 
TR :1300 
TE :37  180  320 x 278  0.6 x 0.6 x 
0.6  160  0.6  N/A  96  4.35 
                Total  17.64 
 
Sequence key: 1: Coronal T1, 2: Coronal STIR, 3: Coronal T1 post-gadolinium fat saturated, 4: Sagittal T1 post-gadolinium fat-saturated, 5: Long axis proton dense 3D 
volumetric.  
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6.2.5 Protocol for image reading 
Images were viewed using Siemens Syngo
© Fast view software for Dicom images (Siemens AG 
2004-2006). They were reviewed for anomalous findings by a consultant radiologist (LK) at the 
time of acquisition in order to conform to safety and quality control checking procedures. The 
first three complete sets of acquired images were read by two consultant radiologists (LK and 
MT) simultaneously. Image interpretation and scoring were discussed and agreed during this 
time. A further five images were read by each radiologist independently. Findings, scoring 
criteria and grading systems were reviewed for consistency and efficacy. The findings of this 
initial reading exercise were discussed by a panel of three national and international radiologists 
(LK, MT and FR), two consultant rheumatologists (NA and CE) and a podiatrist (LH). Consensus 
regarding image interpretation, item inclusion and grading criteria or ranges was sought. The 
itemised scoring tool was subsequently adjusted in response to this process. The remaining 
images were scored by each radiologist reader independently (LK and MT). A podiatrist (LH) 
underwent MRI image interpretation and scoring mentorship with the chief radiologist for the 
study (LK) over a period of 12 months, in addition to completing an adjunctive taught training 
course on MRI principles and practice. The podiatrist re-read and scored the first five complete 
sets of acquired images. Image interpretation and agreement between the podiatrist and a 
radiologist (LK) were evaluated. Further mentorship occurred over a six month period after 
which a supervised re-reading session, between LH and LK, of the original five complete sets of 
images, was completed to improve areas where inconsistency or poor-moderate agreement 
were identified. The following five complete sets of acquired images were then re-read by LH 
and a second evaluation of agreement between the LH and LK completed. Good agreement 
between the podiatrist (LH) and radiologist (LK) was established (see Chapter three, section 
3.7.2 for details). All remaining images were subsequently independently re-read and scored by 
the podiatrist. All image readers (LK, MT and LH) were not blinded to the name of the study 
participant, however they were blinded to other reader findings, unless explicitly stated as part of 
the training, agreement analysis or expert consensus exercises. Both radiologists were blinded 
to the corresponding patient clinical data at the time of image reading. 
 
Identified FFB were categorised to a single pre-defined site only (see figure 41, Chapter five, 
section 5.2.4). In the event of observed FFB extending across the pre-defined anatomical 
boundaries, the site in which the majority of the FFB was located was recorded. Differentiation 
between fluid and soft tissue lesions was determined by differences in T1/T2 contrast. However, 
after initial reading, it was observed that complex fibrous lesions with fluid elements were 
apparent. Fluid collection was therefore defined as a homogeneous hyperintense mass with 
fluid-equivalent signal on pd/T2 sequence and homogenous hypointensity in contrast to true 
‘mass’, defined as non-fluid equivalent/intermediate signal on T1 and T2. Differentiation between 
fluid/fibrous intermetatarsal lesions and neuroma was determined primarily by anatomical 135 
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location, in addition to review of lesion margins and T1/T2 characteristics as described 
previously. 
6.2.6 Protocol for image atlas development 
Images considered to be of suitable quality and representative of each item grade were collated 
by LH for potential inclusion within the image atlas. Each was reviewed for quality, 
representativeness, site and grade. Included images were selected by panel consensus (LH, 
LK, MT, FR, NA and CE).  
6.2.7 Analysis 
All analysis was completed using Stata version 11.0 (Stata Corp, College Station, Texas, USA) 
or SPSS version 18.0 (Chicago, Illinois, USA). Prior to analysis, data distribution was checked 
for inconsistencies, outliers and missing information. Histograms and scatter plots were used to 
assess whether the data followed a normal distribution. The demographic and clinical 
characteristics of the study participants are presented as the mean, standard deviation (SD) and 
range. The arrangement and clustering of study data used for FFB analysis purposes is shown 
in figure 47. 
 
 
 
 
Figure 47: Data clustering map 
Where Pt = patient, R1/2/3 = reader one to three, L = left, R = right, IM = intermetatarsal lesion, PL = 
plantar  lesion,  ST  =  soft  tissue  lesion,  FL  =  fluid  lesion,  P/A  =  present/absent,  Sh  =  shape,  En  = 
Enhancement, T1 = MRI T1 characteristic, T2 = MRI T2 characteristic. N.B. The number of sites present 
(level seven) is dependent upon location (level 4), where intermetatarsal lesions have four possible sites 
and plantar forefoot lesions have five possible sites. 136 
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The radiologist combined and radiologist/podiatrist combined mean score (and range) for each 
item was calculated. Intra-reader and inter-reader agreement were evaluated using estimations 
of percentage exact agreement (PEA) and percentage close agreement (PCA=within ± 2 
scores) for all items and Kappa agreement for the determination of FFB presence or absence.  
 
Content validity, defined as the extent to which a tool accounts for/includes all likely contributing 
components, was evaluated using Lawshe’s content validity ratio (CVR). CVR was calculated for 
all items. The discriminant validity of the FFB-score, defined as the degree to which two total 
scores can reliably differentiate between two distinct groups or characteristics, was evaluated 
using receiver operator characteristics (ROC) curves plotted using Mann Whitney-U statistics 
and corresponding area under the curve analysis. The discriminant validity of the FFB-score to 
differentiate between patients with high/low disease activity or patient-reported foot-related 
disability was also assessed in this way. MRI-determined disease activity local to the forefoot 
was assessed via observations of metatarsal head and phalangeal base erosion or bone 
marrow oedema and MTP joint synovitis. Participants with erosion score ≥20, bone marrow 
oedema score ≥11 and synovitis score ≥2 were classified as having high disease activity. The 
margins for erosion and oedema were defined as 25% of the observed maximum score. The 
margin for synovitis was defined as being what was considered clinically meaningful by the 
expert consensus panel. Systemic disease activity was assessed using DAS 28. The margins 
for systemic disease activity were defined as per the previously validated DAS disease 
categories (Wolfe et al. 2001). Patient-reported foot-related disability was assessed using the 
two subscales of the foot impact score (FIS): 1. (FISIF, 0-21); foot impairment and footwear 
restriction, 2. (FISAP, 0-29): activity limitation and participation restriction (Helliwell et al. 2005). 
Participants with FISIF score ≥7 and FISAP score ≥10 were classified as having high foot 
impairment or activity limitation respectively. The margins for disability were pragmatically 
derived, as high, moderate or low, at 33% increments of the total score. The discriminant validity 
of the seven derived FFB-score items was assessed and included: 1. total FFB count, 2. total 
predominantly fluid lesion count, 3. total predominantly soft tissue lesion count, 4. total FFB 
enhancement, 5. total fluid lesion enhancement, 6. total soft tissue lesion enhancement, and 7. 
FFB shape.  
6.3 Results 
6.3.1 Study cohort characteristics 
All invited patients took part in the study. A summary of the demographic and clinical 
characteristics of the study cohort (N=42) is given in table 27. A total of 840 joints and 1,512 
possible FFB sites were reviewed by each reader.  
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Table 27: Cohort demographic & clinical characteristics 
Where  CRP=C-reactive  protein,  ESR=erythrocyte  sedimentation  rate,  DAS=disease  activity  score; 
FISIF=foot  impact  score  impairment/footwear  subscale;  FISAP=foot  impact  score  activity/participation 
limitation subscale; US=musculoskeletal ultrasound; FFB=forefoot bursae. 
 
  Mean, (SD), Range 
age (years)  62.2, (12), 28-89 
height (m)  1.7, (0.1), 1.3-1.9 
weight (Kg)  71, (13.7), 42.2-108 
BMI (Kg/m
2)  26, (4.4), 19.1-39 
disease duration 
(years)  15.3, (10.3), 4-42 
CRP (mg/L)  9.3, (14.9), 1-73 
ESR (mm/hr)  20.8, (21.9), 0-111 
DAS 28-CRP  3.5, (4.6), 1-31 
DAS 28-ESR  3.1, (1.4), 0.3-6 
erosion  17.9, (17.4), 0-77 
bone marrow oedema  10, (9.6), 0-44 
synovitis  3.5, (4.7), 0-20 
FISIF  3, (2.2), 0-8 
FISAP  7, (3.2), 0-10 
US-detectable FFB  3, (2.9), 0-10 
 
 
6.3.2 The ‘FFB-score’  
All originally proposed items and scoring criteria were included within the final version of the tool, 
with the exception of size for which the semi-quantitative reporting of values was highly 
inconsistent between readers due to difficulties in clear structural visualisation in three imaging 
planes. Four possible enhancement grading options were proposed and trialled during phases 
one-three of score development:  
 
  Option 1: The scale is 0-3. Score 0 is no enhancement and scores 1-3 (mild, moderate, 
severe) are by thirds of the presumed maximum volume of enhancing tissue within the 
identified lesion 
  Option 2: The scale is 0-2. Score 0=no enhancement, 1=patchy, 2=solid 
  Option 3: The scale is 0-2. Score 0=no enhancement, 1=less than 2mm thickness, 
2=greater than 2mm thickness (when measured from the widest portion of peripheral 
enhancement, avoiding partial voluming effect) 
  Option 4: The scale is 0-4. Score 0=no enhancement, 1=1-25%, 2=26-50%, 3=51-75%, 
4=76-100% of the presumed maximum volume of the potential enhancing tissue within the 
identified lesion 
 
After completion of tool development stages 1-3, option two was selected as the most 
appropriate score for use. The final proposed FFB-score items, definitions and grading criteria 138 
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are presented in table 28. The FFB-score record sheet with user guide can be found in the 
appendix section A19.  
 
Table 28: FFB-score items, definitions & grading criteria 
Factor  Definition  Scoring 
Fluid collection 
A fluid collection is defined as a 
homogeneous hyperintense extra-articular 
mass with a fluid-equivalent signal on PD/T2 
weighted sequences, to be judged relative to 
synovial joint fluid. 
Present (1)/Absent (0) 
Extra articular 
soft tissue 
lesion 
A fluid collection is defined as a 
homogeneous hyperintense extra-articular 
mass with a fluid-equivalent signal on PD/T2 
weighted sequences, to be judged relative to 
synovial joint fluid. 
Present (1)/Absent (0) 
Shape 
Intermetatarsal lesions: 
Lesions with an extended height and narrow 
width are described as linear. Lesions with 
bulbous rounded dorsal/plantar margins are 
described as ‘dumb-bell’. Lesions with 
bulbous rounded plantar margins are 
described as ‘teardrop’. 
Plantar lesions: 
Lesions with an extended width and narrow 
height are described as linear. Lesions with 
irregular borders projecting both in the 
transverse and frontal planes are described 
as reticular. Lesions with regular borders of 
near equal projection in both the transverse 
and frontal planes are described as mass-
like. 
Intermetatarsal lesions: 
Linear (1)/Dumb-bell 
(2)/Teardrop (3) 
 
Plantar lesions: 
Linear (1)/Reticular (2)/Mass-
like (3) 
Enhancement 
Enhancement is judged by comparison of T1 
weighted images obtained before and after 
intravenous gadolinium contrast. 
No enhancement (0)/Patchy 
(1)/Solid (2) 
MR 
characteristics 
Lesions are defined as hypointense (Hypo) 
when appearing darker relative to muscle 
imaged within the same slice, Isointense 
(Iso) when appearing grey-scale equivalent 
or hyperintense (hyper) when appearing 
brighter. 
Hypointense (1)/Isointense 
(2)/Hyperintense (3) 
Intermetatarsal 
location 
Lesions are defined as occurring within the 
intermetatarsal spaces if the major 
proportion of the lesion is located dorsal to 
the deep transverse intermetatarsal 
ligament. 
IM 1-2/IM 2-3/IM 3-4/IM 4-5 
Plantar 
metatarsal 
location 
Lesions are defined as occurring plantarly if 
the major proportion of the lesion is located 
plantar to the deep transverse 
intermetatarsal ligament. The plantar area of 
the foot is divided into fifths in accordance 
with the area underlying each metatarsal 
head. The plantar intermetatarsal space is 
bisected in a line perpendicular to the 
sagittal image plane, equi-distant from each 
metatarsal head. 
1/2/3/4/5 
 139 
 
  Chapter 6: Development of the ‘FFB-Score’ 
6.3.3 FFB-score image atlas 
Figure 48 illustrates the collated images considered to be representative of item grading for the 
FFB-score. Each image set has a locator image in order to help orientate the user towards the 
area of interest. 
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48a. Intermetatarsal lesions: enhancement & T1/ STIR characteristics 
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48b. Intermetatarsal lesions: shape141 
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48c. Plantar lesions: enhancement & T1/STIR characteristics 
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48d. Plantar lesions: shape 
 
Figure 48: The FFB-score image atlas 
See table 28 for item grading definitions 
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6.3.4 FFB-score values & ranges 
The combined mean score (and range) for all FFB-score items when evaluated both between 
radiologist readers and between a radiologist and podiatrist reader were similar (table 29).  
 
 
Table 29: FFB-Score mean values & ranges 
Lesion 
type  Factor 
Radiologist 
combined  
mean score, 
(range) 
Adjusted radiologist & 
podiatrist combined  
mean score (range) 
I
n
t
e
r
m
e
t
a
t
a
r
s
a
l
 
F
l
u
i
d
 
Count  3 (0-8)  3 (0-8) 
Shape  4 (0-14)  4 (0-14) 
Enhancement  1 (0-9)  1 (0-9) 
MRI T1  7 (0-14)  7 (0-14) 
MRI T2  10 (0-24)  10 (0-24) 
S
o
f
t
 
t
i
s
s
u
e
  Count  1 (0-5)  1 (0-9) 
Shape  0 (0-6)  1 (0-6) 
Enhancement  1 (0-6)  1 (0-8) 
MRI T1  2 (0-10)  2 (0-10) 
MRI T2  2 (0-12)  2 (0-12) 
P
l
a
n
t
a
r
 
l
e
s
i
o
n
 
F
l
u
i
d
 
Count  0 (0-2)  0 (0-2) 
Shape  6 (0-15)  5 (0-15) 
Enhancement  0 (0-3)  0 (0-3) 
MRI T1  0 (0-4)  0 (0-4) 
MRI T2  0 (0-6)  0 (0-6) 
S
o
f
t
 
t
i
s
s
u
e
  Count  5 (0-10)  4 (0-10) 
Shape  11 (0-25)  9 (0-25) 
Enhancement  1 (0-7)  1 (0-7) 
MRI T1  10 (0-20)  8 (0-20) 
MRI T2  12 (0-29)  10 (0-29) 
 
 
6.3.5 Intra & inter-reader agreement 
Overall, the FFB-score was demonstrated to have substantial intra-reader agreement. The 
detection of intermetatarsal fluid lesions was moderate (k=5.5), plantar fluid lesions excellent 
(k=7.5-8) and intermetatarsal and plantar soft tissue lesions substantial (k=9, k=7-8 
respectively). Further agreement result details are tabulated in appendix section A16. Overall, 
the FFB-score was demonstrated to have substantial inter-reader agreement, with the exception 
of plantar soft tissue lesion shape and T1/T2 characteristics between readers LK and MT, for 
which agreement was poor-moderate. The detection of intermetatarsal fluid lesions was 
moderate (k=4.7-4.9), plantar fluid lesions substantial to excellent (k=6.6-8.7) and 
intermetatarsal and plantar soft tissue lesions substantial (k=7.3-7.5, k=6.4 respectively). Further 
agreement result details are tabulated in appendix section A16.  
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6.3.6 FFB-score validity  
Estimations of FFB-score content validity, calculated using Lawshe’s CVR, determined that all 
items have good validity (0.625; where N=5 and Ne=5 for all items). The FFB-score had poor 
discriminant validity for the differentiation of patients with high/low systemic disease activity 
(further discriminant validity result details are tabulated in appendix section A17). Conversely, 
FFB count and enhancement characteristics demonstrated good discriminant validity for the 
differentiation of patients with high/low MRI-determined disease activity local to the foot. 
Specifically, FFB fluid lesion count, FFB enhancement and soft tissue lesion enhancement 
significantly discriminated between high/low erosion scores (AUC= 0.281, p=0.022; AUC=0.741, 
p=0.011; AUC=0.744, p=0.011 respectively; figure 49a). FFB enhancement and soft tissue 
lesion enhancement significantly differentiated between high/low bone marrow oedema scores 
(AUC= 0.718, p=0.018; AUC=0.681, p=0.048 respectively; figure 49b). FFB enhancement and 
fluid lesion enhancement significantly differentiated between high/low synovitis scores (AUC= 
0.759, p=0.004; AUC=0.697, p=0.031 respectively; figure 49c). Further discriminant validity 
result details are tabulated in appendix sections A17 and A18. 
 
 
 
   
49a. Metatarsophalangeal joint erosion 
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49b. Bone marrow oedema 
 
 
49c. Metatarsophalangeal joint synovitis 
Figure 49: FFB-score discriminant validity: disease activity 
Where 49a shows  discriminant  validity  for high/low  erosion  scores,  49b shows  discriminant  validity  for 
high/low bone marrow oedema scores, 49c shows discriminant validity for high/low synovitis scores. FFB = 
forefoot bursae; FL = fluid lesion; ST = soft tissue lesion; en = enhancement. 
 
 
 
The FFB-score was also determined to have good discriminant validity when differentiating 
between patients with high/low foot-related disability. Specifically, FFB count and FFB soft tissue 
lesion count significantly discriminated between high/low foot impairment (AUC=0.198, p=0.006; 146 
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AUC=0.274, p=0.040 respectively; figure 50a). FFB count and FFB fluid lesion count 
significantly differentiated between high/low activity limitation (AUC=0.288, p=0.033; 
AUC=0.260, p=0.016 respectively; figure 50b).  
 
 
 
50a. FISIF 
 
 
50b. FISAP 
Figure 50: FFB-score discriminant validity: foot-related disability 
Where 50a shows discriminant validity for high/low foot impairment scores, 50b shows discriminant validity 
for high/low activity limitation scores. FFB = forefoot bursae; FL = fluid lesion; ST = soft tissue lesion; en = 
enhancement;  FISIF  =  foot  impact  score  impairment/footwear  subscale;  FISAP  =  foot  impact  score 
activity/participation limitation subscale 
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6.4 Discussion 
To our knowledge, this study is the first to propose a systematic method for the semi-quantitative 
characterisation of FFB in patients with RA. The FFB-score, created and evaluated in a multi-
step process consistent with OMERACT recommendations, appears to have good content 
validity (OMERACT filter 1), discriminant validity (OMERACT filter 2) and feasibility of use 
(OMERACT filter 3) based upon the preliminary analyses completed in this work (Boesen et al. 
2009, Tugwell et al. 2007). In particular, the FFB-score appears to have good discriminant 
validity when differentiating between patients with high/low foot-related disability or forefoot 
disease activity. The FFB-score also appeared to demonstrate good intra and inter-reader 
reliability for all score dimensions. The findings of this study therefore provide preliminary 
evidence in support of the use of this score for the identification and characterisation of 
potentially clinically relevant bursa-like lesions of the forefoot in patients with RA. The 
accompanying image atlas and user guide provides reference material that may aid the uptake 
and use of the FFB-score in future work.  
 
The evaluation of FFB, completed as part of the FFB-score development, identified differences 
in the tissue characteristics of observed lesions. Previous authors have suggested that such 
differences are related to the FFB aetiology (Studler et al. 2008, Koski 1998), although 
characterisation by pathological or aetiological means has arguably contributed to confusion 
within the literature. It is therefore proposed that the FFB-score can be utilised to characterise a 
range of forefoot bursa-like lesions without assumption or bias towards their potential aetiology 
and clinical importance. However, it should be noted that despite all identified lesions meeting 
our study definition of bursa (fluid filled cavity), a range of bursa-like lesions were observed. Of 
particular note, are the complex lesions occurring within the plantar fibro-fatty tissues of the 
forefoot that demonstrated a mixture of enhanced synovium and dense fibrotic tissue around a 
fluid cavity. The clinical significance of the range of bursa-like lesions observed remains unclear 
and warrants further investigation. Further evaluation of the clinical importance of MRI-detected 
FFB, and the characteristics thereof, in patients with RA is also warranted. 
 
The reduced agreement reported for intermetatarsal fluid lesions was attributed to difficulty in 
accurately differentiating between nerve, fibrous or synovial tissue and bursa. The close 
anatomical association between the intermetatarsal neurovascular bundles and FFB, evident 
throughout the course of this work, potentially confounds the symptomatic nature of lesions 
identified within this anatomical region (Theumann et al. 2001). Future work, systematically 
exploring the prevalence and histopathology of co-existing FFB and neuroma, may provide 
beneficial insight regarding the pathogenesis of such lesions (Zielaskowski et al. 2000, Mutlu et 
al. 2006, Zanetti et al. 1997).  
 
Significant differences in FFB enhancement, related to RA disease activity, were noted. Thus, 
the score developed in this study has potential clinical value in identifying and characterising 148 
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bursa-like lesions of the forefoot that may be indicative of RA disease activity; it is feasible that 
FFB characterised using the FFB-score represent a surrogate indicator of disease activity within 
the forefoot. However, the mechanisms underpinning this relationship remain unclear.  
6.4.1 Study limitations 
This study has a number of strengths and potential limitations. The studied population is a 
consecutive sample of well phenotyped patients with established RA, receiving ongoing 
rheumatological care. As such, the generalisability of the study findings to those patients with 
early disease or high disease activity needs to be explored. It should also be noted that the 
measures of MRI-determined localised disease activity used within this study have not been 
previously validated for use within the forefoot, although they have been demonstrated to be 
reproducible at this site (Baan et al. 2011). It is unclear at this time whether the elevated 
proportion of localised disease activity identified within this cohort is due to measurement error 
or is a true indication of ongoing minimal disease activity within the forefoot. The evaluation of 
disease activity local to the foot, but not detected with traditional composite measures such as 
the DAS 28, is of particular clinical importance in the ongoing care of foot health in patients with 
RA. This work provides further evidence which supports the need for the future development of 
a reliable and valid tool for the evaluation of RA disease activity in the forefoot.  
 
Kappa values were used to determine the agreement between readers for the overall presence 
or absence of a lesion. However, this method does not account for instances where the same 
lesion may be observed by each reader but scored as occurring in neighbouring locations, 
thereby reducing absolute agreement. As such, the kappa values reported are potentially an 
under-estimation of actual presence/absence agreement between readers. Evaluation of lesion 
size was omitted from the analysis of this study due to poor agreement between readers in the 
early iterative stages of score development. However, this should not be taken to infer that 
lesion size is of little clinical relevance. Moreover, the collaborators of this study agreed that the 
FFB-score may be enhanced with the inclusion of lesion size although the identification of 
alternate semi-quantitative methods to achieve this requires further work. Additionally, 
assessment of responsiveness and criterion validity (inclusive of predictive validity) and 
refinement of the scoring system are needed in order to maximise its’ potential utility in clinical 
trials and epidemiological studies (Silman and Hochberg 2001). Furthermore, the construct 
validity of all identified bursa-like lesions could be developed with the completion of a concurrent 
histopathological investigation. 
6.4.2 Conclusion & summary 
The FFB-score is a reliable and valid MRI-based tool for the detection and evaluation of FFB in 
patients with RA. The proposed tool has potential to be used clinically to locate and characterise 
FFB. Additional investigation of the clinical importance of identified FFB characteristics would 
potentially allow timely and targeted therapeutic intervention. Further longitudinal validation, 149 
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assessment of responsiveness and refinement of the scoring system is needed in order to 
maximise its potential utility in clinical trials and epidemiological studies. 
 
 
Detecting forefoot bursae using MRI: development of the ‘FFB-score’ 
 
Key points: 
 
  The FFB-score is reliable and valid for the identification and characterisation of 
FFB in patients with RA 
  The FFB-score can be used in future epidemiological studies of FFB in patients 
with RA 
  Further longitudinal evaluation of the FFB-score is required 150 
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Chapter seven 
The epidemiology & clinical importance of MRI-detectable 
forefoot bursae in patients with rheumatoid arthritis 
 
7.0 Chapter abstract 
Background: Previous studies have demonstrated a high prevalence of clinically relevant 
musculoskeletal ultrasound (US) detected forefoot bursae (FFB) in patients with rheumatoid 
arthritis (RA). Both increased inflammation and biomechanical impairment have been cited as 
potential pathophysiological mechanisms underpinning the clinical importance of FFB. However, 
further characterisation of FFB is required to better explore this hypotheses. The recently 
derived magnetic resonance imaging (MRI) based FFB-score allows improved identification and 
characterisation of FFB in multiple imaging planes, such that determination of the epidemiology 
and clinical importance of MRI-detectable FFB, and specific characteristics thereof, is feasible.  
Aim: To determine the epidemiology and clinical importance of MRI-detectable FFB in patients 
with RA.  
Methods: A cross-sectional observational study of FFB was completed in patients with a 
consultant confirmed diagnosis of RA recruited from a UK rheumatology clinic. The primary 
outcome of interest, the presence of FFB, was determined using a 1.5T whole body MRI 
scanner and 4-channel flex extremity coil. The MRI protocol included coronal T1 and STIR, 
coronal and sagittal T1 post-gadolinium, and long axis 3D volumetric sequences. The point 
prevalence proportion (PP) of FFB was calculated by the division of the sum of identified cases 
(FFB ≥1) by the sum of the total studied population and expressed per 100 patients. The 
distribution of FFB across 9 pre-defined forefoot sites was expressed as a percentage of the 
total observed FFB. The MRI-determined characterisation of FFB is discussed descriptively. 
Correlation coefficient analysis was used to determine the statistical significance of potential 
associations between FFB count, or characteristics thereof, and indicators of systemic (ESR, 
CRP, DAS 28) or localised disease activity (MRI-detected MTP joint synovitis, erosion or bone 
marrow oedema), biomechanical impairment (FPI, Joint range of motion), or patient-reported 
foot-related disability (FIS questionnaire).  
Results: The mean participant (± SD) age, disease duration and DAS 28 was 62.2 (±12) years, 
15.3 (±10.3) years and 3.1 (±1.4) respectively. MRI-detectable FFB were highly prevalent in this 
patient cohort (PP=100 per 100, mean=7.7, SD=3.9, range=1-18). Of all observed FFB (n=324), 
41.7% were characterised as predominantly fluid and 58.3% as predominantly soft tissue 
lesions. Fluid lesions were typically distributed within the intermetatarsal spaces while soft tissue 
lesions were typically distributed across the plantar forefoot. An increased presence of plantar 
fluid lesions was associated with elevated systemic markers of disease activity as were 152 
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reductions in the presence of soft tissue lesions. An increased presence of intermetatarsal soft 
tissue lesions was associated with the presence of MTP joint synovitis. An increased presence 
of soft tissue lesions (predominantly plantar) was associated with markers of biomechanical 
impairment. A trend towards an association between Increased FFB enhancement and disease 
chronicity or greater patient-reported foot impairment was noted. 
Conclusion: MRI-detectable FFB are highly prevalent in patients with RA. Characterisation of 
MRI-detected FFB is helpful in identifying those lesions of greatest clinical relevance; there is 
preliminary evidence to suggest that the presence of intermetatarsal soft tissue lesions and 
plantar fluid lesions are associated with RA disease activity, while plantar soft tissue lesions are 
associated with biomechanical impairment. Importantly, a trend towards an association between 
increased FFB enhancement and increased foot impairment was noted.  
7.1 Introduction 
Previous studies have demonstrated a high prevalence of musculoskeletal ultrasound (US) 
detected forefoot bursae (FFB) in patients with rheumatoid arthritis (RA) (Bowen et al. 2009, 
Bowen et al. 2010c). FFB prevalence has been demonstrated to be significantly associated with 
increased RA disease activity both in cross-sectional and longitudinal studies (Bowen et al. 
2009, Bowen et al. 2010c, Koski 1998, Palmer 1970). Furthermore, FFB have been 
demonstrated to be a significant prognostic indicator of patient-reported foot-related disability 
longitudinally (Chapter four). Both increased inflammation and biomechanical impairment have 
been cited as potential pathophysiological mechanisms underpinning the clinical relevance of 
US-detectable FFB (Ahmed et al. 1994, Studler et al. 2008, Aguiar et al. 2005, Koski 1998, 
Harper 2003, Hernandez et al. 1991). The work presented in Chapter five has reinforced this 
hypothesis, demonstrating comparatively different FFB distributions between healthy volunteers 
and patients with predominantly inflammatory or degenerative arthritis. The findings of this work 
suggest that differing clinically relevant FFB distribution patterns or characteristics may coexist 
in patients with RA. The recently derived MRI-based FFB-score, unlike US, allows observer-
independent, multi-planar, identification and characterisation of FFB in patients with RA (Chapter 
six). This study therefore aims to utilise the FFB-score to determine the epidemiology and 
clinical importance of MRI-detectable FFB, and characteristics thereof, in patients with RA.  
7.1.1 Study aim & objectives 
The main aim of this study was to determine the epidemiology and clinical importance of MRI-
detectable FFB in patients with RA. To achieve this aim the following objectives were set: 
  
1.  To determine the prevalence of MRI-detectable FFB  
2.  To describe differences in the MRI characteristics of identified FFB 
3.  To determine the clinical importance of MRI-detectable FFB in patients with RA 153 
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7.2 Materials & methods 
7.2.1 Study design  
To achieve the above objectives a cross-sectional observational study design was used. The 
primary study outcome was an analysis of the presence of MRI-detected forefoot bursae (FFB), 
and their MRI characteristics. All intermetatarsal spaces (x4) and plantar metatarsal regions (x5) 
were imaged for the presence of FFB and characterised according to the ‘FFB-score’. The 
number of observed FFB for both feet was combined (0-18). Explanatory variables of interest 
included those related to systemic RA disease activity (serological inflammatory markers and 
composite disease activity score), disease activity localised to the forefoot (MRI-detected 
activity), biomechanical foot deformity (foot posture index (FPI), hallux abducto-valgus deformity 
(HAV), lesser digital deformity (LDD)), foot function (ankle, subtalar, midfoot, or 
metatarsophalangeal joint ranges of motion), or disease impact in terms of patient-reported foot-
related disability (Foot Impact Score).  
 
Systemic disease activity was evaluated using markers of erythrocyte sedimentation rate (ESR), 
C-reactive protein (CRP) and calculation of a 28 joint disease activity score (DAS 28) (Van der 
Heijde et al. 1990).  Disease activity localised to the forefoot was evaluated using MRI-detected 
metatarsophalangeal joint synovitis (SY), bone marrow oedema (OE), and metatarsophalangeal 
joint erosion (ER). Synovitis was graded 0-3 (normal, mild, moderate or severe), bone marrow 
oedema as 0-3 (by 33% volume increments) and erosion as 0-10 (by 10% volume increments), 
as per the recommendations for the EULAR-OMERACT ‘RAMRIS’ score for the hand 
(Conaghan et al. 2005a). The foot posture index was selected as a composite measure of 
weight-bearing foot joint alignment and scored for both feet combined (0-24). Deformity was 
scored as either present or absent for each joint assessed and the accumulative score for each 
foot combined (0-20). Joint range of motion was scored as full, limited or rigid for each joint of 
interest and the accumulative score for each foot combined (0-4). Disability was evaluated using 
the two subscales of the foot impairment score (FIS): 1. (FISIF, 0-21); foot impairment and 
footwear restriction, 2. (FISAP, 0-29); activity limitation and participation restriction (Helliwell et al. 
2005). An elevated FISIF or FISAP score indicates greater foot impairment or activity limitation 
respectively. Explanatory variables were selected based upon the findings of previous work, 
literature review and potential clinical relevance. Detail regarding the selected measures is given 
in Chapter two (section 2.2) and Chapter three (section 3.6). 
7.2.2 Study population  
Patients included within this study were those with a consultant confirmed diagnosis of RA who 
were consecutively recruited from a UK rheumatology out-patient clinic. All participants who 
completed the year-three ‘FeeTURA’ study were eligible for screening to this study. Further 
detail regarding the recruitment, screening, inclusion/exclusion criteria and sample size 
determinants is documented in Chapter three (sections 3.4-3.5).  154 
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7.2.3 Protocol for data collection 
The protocol for participant recruitment and MRI data acquisition is illustrated in figure 51. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 51: A schematic diagram of the protocol for MRI data acquisition 
 
Participant 
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(1) 
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(2) 
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Image 
acquisition 
Close 
Image transfer 
  RA participants who had participated within the year-three FeeTURA study visit were eligible for 
screening for inclusion within this study. Patient’s medical notes were screened for contraindications 
for the completion of MRI with gadolinium 
  Eligible participants were sent a letter of invitation with i) reply slip, ii) return stamped addressed 
envelope & iii) PIS 
  The researcher was available to answer any queries regarding participation within this study 
  A second letter of invitation (with supporting documents) was sent to those patients who had not 
responded to the first after 4 weeks. There was no further contact with patients who had not 
responded after this time. 
  Responding patients were contacted. Suitability for inclusion and contraindications to participation 
were reviewed and confirmed with the patient. An appointment was then agreed.  
  A letter confirming the appointment date, time and location was sent to the participant. Additionally, 
participants were sent written information about the procedure and how to prepare for having a scan. 
  Participants were greeted at the Radiology department by reception staff 
  A member of the research team reviewed the protocol for data collection with the participant and 
formal consent was obtained 
  A trained radiologist completed a safety protocol, inclusive of metal checking and test of renal function  
  Participants were asked to lay supine on the plinth of the scanner, with their knees flexed at a 45 
degree position. Foam packing was used to help stabilise and rest the legs in this position. 
  Participants were encouraged to allow the feet to rest in a comfortable position 
  A RF coil was positioned around both feet and packed with foam to minimise movement of the feet 
after fitting and orientation of the feet within the scanning plane 
  An intra-venous line was secured prior to scanning to minimise potential participant movement 
between pre and post-gadolinium scanning sequences 
  Participants were then manoeuvred into the magnet and orientated appropriately with the aid of a light 
localiser. The lower third of the leg was placed within the magnet bore only. 
  Participants were given an emergency squeeze bulb with advice on how and when this should be used 
  Participants were issued with either headphones and music or earplugs at their preference 
  System adjustment and calibration was completed by the radiologist/radiographer  
  Localiser sequences were completed and slice orientations confirmed. Sagittal and coronal axes were 
orientated relative to participant bony anatomical landmarks.  
  5 x Pre-defined sequences and slice selections were completed 
  Images were transferred onto CD in preparation for reading 
  Participants were invited to leave the scanning room and attend a reception area where a drink of 
their choice was offered 
  Any further questions were answered by a member of the research team and the session concluded 155 
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A 1.5 Tesla (T) whole body scanner (Siemens Avanto Syngo
® MR B15, Siemens AG Medical 
Solutions, Erlangen, Germany) was used for all MRI acquisition. A four channel flex extremity 
radio frequency (RF) surface coil (Siemens, Siemens AG Medical Solutions; with circularly 
polarised array) was used to image the mid and forefoot region only. Prior to data collection 
initial capacitor tuning was completed to ensure that the RF coil frequency was synchronised 
with the magnetic field (B0). System calibration was completed as per the standard protocol for 
the radiology department. 
   
Five sequences were completed after orientation with a T1-weighted sagittal locator image: 1. 
T1 weighted coronal spin echo pulse sequence, 2. Coronal short Tau inversion recovery 
sequence, 3. T1-weighted fat-saturated post-gadolinium coronal, 4. T1-weighted fat-saturated 
post-gadolinium sagittal, 5. Long axis proton-dense fat-saturated 3D voxel sequence. Alignment 
and positioning was manually orientated by the radiologist; coronal scans were orientated with 
the metatarsal parabola, sagittal scans were approximately orientated perpendicular to the 
coronal slice profile and with the shaft of the third metatarsal. The field of view (FoV) in the read 
direction was determined as the base of 1
st metatarsal to the distal aspect of the hallux. The FoV 
in the phase-encode direction was defined as extending from the medial to the lateral foot 
borders. Further details regarding the protocol for image acquisition is documented in Chapter 
three (section 3.6.4).  
7.2.4 Protocol for image acquisition & reading 
FFB images were scored according to previously derived FFB-score and graded for all items 
including presence/absence of a lesion, lesion location (intermetatarsal/plantar), tissue type 
(fluid/soft tissue), shape (linear/reticular/mass or linear/dumb-bell/teardrop), and enhancement 
(0-2) (Chapter 6). The metatarsophalangeal joints of the forefoot were scored for synovitis, bone 
marrow oedema and erosion. Synovitis was graded 0-3 (normal, mild, moderate or severe), 
bone marrow oedema as 0-3 (by 33% volume increments) and erosion as 0-10 (by 10% volume 
increments), as per the recommendations for the EULAR-OMERACT ‘RAMRIS’ score for the 
hand (Conaghan et al. 2005a). Images were viewed using Siemens Syngo
© fast view software 
for Dicom images (Siemens AG 2004-2006). Images were reviewed for anomalous findings by a 
consultant radiologist (LK) at the time of acquisition in order to conform to safety and quality 
control checking procedures. All MRI images were read and scored by a consultant radiologist 
(LK), familiar with the FFB-score, who was blinded to the patient’s clinical presentation and 
disease state.  
7.2.5 Analysis 
All analysis was completed using Stata version 11.0 (Stata Corp, College Station, Texas, USA) 
or SPSS version 18.0 (Chicago, Illinois, USA). Prior to analysis, data distribution was checked 
for inconsistencies, outliers and missing information. Histograms and scatter plots were used to 
assess whether the data followed a normal distribution. The demographic and clinical 156 
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characteristics of the study participants are presented as the mean, standard deviation (SD) and 
range. 
 
The point prevalence proportion of MRI-detectable FFB was calculated by the division of the 
sum of identified cases by the sum of the total studied population and expressed per 100 
patients. The observed FFB presence mean, SD and range were also calculated. For the 
purposes of distribution analyses, MRI-detected FFB were grouped according to the 
predominant tissue characteristic of the observed lesion; group 1: predominantly fluid, group 2: 
predominantly soft tissue. The nine investigated forefoot sites were grouped into medial (sites 1-
3), central (sites 4-6) and lateral (sites 7-9), (figure 41, Chapter five, section 5.2.4). Statistically 
significant differences in the distribution of FFB across forefoot regions between fluid and soft 
tissue lesions were explored using chi squared analyses. Differences in the MRI appearance of 
FFB are discussed descriptively. Differences in the presence of FFB enhancement between fluid 
and soft tissue lesions, within the same participant, across either intermetatarsal of plantar sites 
were determined using multiple matched-paired t-tests. Correlation coefficient analysis was used 
to determine the statistical significance of potential associations between the primary outcome of 
interest (FFB count), and measured explanatory variables (markers of systemic disease activity, 
local disease activity, biomechanical function and patient-reported foot-related disability). The 
total number of MRI-detectable episodes of FFB, JH or ER for both feet combined was 
calculated for each patient; these count scores were treated as continuous variables for the 
purposes of analysis, although were bounded between 0-18 for FFB and 0-10 for SY, OE and 
ER. For the purposes of clinical importance analyses, participants were pragmatically stratified 
into high (FISIF>5; ~25% of maximum score) or low (FISIF≤4) reported foot impairment and high 
(FISAP>8; ~25% of maximum score) or low (FISAP≤7) reported activity limitation. Statistically 
significant differences in total observed FFB, or characteristics thereof, between high and low 
levels of patient-reported foot impairment or activity limitation was subsequently determined 
using Chi
2 analysis. 
7.3 Results 
7.3.1 Study cohort characteristics 
All invited patients participated within the study. A summary of the demographic and clinical 
characteristics of the study cohort (N=42) is given in table 30. A total of 840 joints and 1,512 
possible FFB sites were reviewed.  
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Table 30: Cohort demographic & clinical characteristics 
Where  CRP=C  -  reactive  protein,  ESR=erythrocyte  sedimentation  rate,  DAS=disease  activity  score; 
FISIF=foot  impact  score  impairment/footwear  subscale;  FISAP=foot  impact  score  activity/participation 
limitation subscale. 
  Mean, (SD), Range 
age (years)  62.2, (12), 28-89 
height (m)  1.7, (0.1), 1.3-1.9 
weight (Kg)  71, (13.7), 42.2-108 
BMI (Kg/m
2)  26, (4.4), 19.1-39 
disease duration (years)  15.3, (10.3), 4-42 
CRP (mg/L)  9.3, (14.9), 1-73 
ESR (mm/hr)  20.8, (21.9), 0-111 
DAS 28-CRP  3.5, (4.6), 1-31 
DAS 28-ESR  3.1, (1.4), 0.3-6 
synovitis  3.5, (4.7), 0-20 
bone marrow oedema  10, (19.6), 0-44 
erosion  17.9, (17.4), 0-77 
FIS IF  3, (2.2), 0-8 
FIS AP  7, (3.2), 0-10 
 
 
7.3.2 The prevalence of MRI-detectable FFB in patients with RA 
MRI-detectable FFB were highly prevalent in patients with RA (table 31). Of all observed FFB, a 
greater number were detected within the plantar metatarsal region compared to the 
intermetatarsal region. Of all observed FFB, a greater number of observed lesions were 
predominantly soft tissue compared to fluid (table 31).  
 
 
Table 31: The prevalence of MRI-detectable FFB  
  Point prevalence 
(per 100 participants)  Mean, (SD), Range 
Total observed FFB  100   7.7, (3.9), 1-18 
Intermetatarsal FFB  88.1  4.1, (2.6), 0-11 
Plantar FFB  92.9  3.6, (2.3), 0-10 
Fluid FFB  83.3  3.2, (2.2), 0-7 
Fluid intermetatarsal FFB  83.3  3.1, (2.1), 0-7 
Fluid plantar FFB  7.1  0.1, (0.3), 0-1 
Soft tissue FFB  97.6  4.5, (2.7), 0-11 
Soft tissue intermetatarsal 
FFB  52.4  0.9, (1.2), 0-5 
Soft tissue plantar FFB  92.9  3.6, (2.3), 0-10 
 
 
 
The distribution of MRI-detectable FFB is shown in figure 52. A significant difference between 
the distribution of predominantly fluid and soft tissue lesions was observed (X
2=72.8, p≤0.001); 158 
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fluid lesions were distributed across the medial and central intermetatarsal spaces, while soft 
tissue lesions were distributed across the plantar forefoot region (figure 52).  
 
 
 
Figure 52: The distribution of MRI-detectable FFB & FFB-subtypes across the forefoot 
Values are expressed as percentage of sample with FFB in this location.  
Where M1-5 = plantar metatarsophalangeal joint region. 
 
 
7.3.3 The MRI characteristics of FFB in patients with RA 
Differences in the shape of observed FFB, for both fluid and soft tissue lesions, in both 
intermetatarsal and plantar metatarsal regions were observed (figure 53). Additionally both fluid 
and soft tissue lesions demonstrated ranges of enhancement (figure 54). No significant 
difference in enhancement between intermetatarsal fluid and soft tissue lesions was determined 
(t=0.815, p=0.420). However, a significant difference in enhancement between plantar fluid and 
soft tissue lesions was determined (t=-3.65, p≤0.001), where predominantly soft tissue lesions 
were significantly more inflamed than predominantly fluid lesions.  
 
  
 
 
 
 
 
 
Figure 53a: Differences in MRI-detectable FFB shape 
 
 
 
 
 
 
  
 
   
 
 
 
Figure 53b: Differences in plantar lesion shape 
Where 53a illustrates differences in observed intermetatarsal lesion shape, 53b illustrates differences in observed plantar lesion shape. Areas of interest are denoted by 
an interrupted white line. 
 
 
 
 
  
 
 
 
 
 
 
Figure 54a: Differences in MRI-detectable FFB enhancement: intermetatarsal lesions 
 
 
 
 
 
 
  
 
   
 
 
 
 
Figure 54b: Differences in MRI-detectable FFB enhancement: plantar lesions 
Where 54a illustrates differences in observed intermetatarsal lesion shape, 54b illustrates differences in observed plantar lesion shape. Areas of interest are denoted by 
an interrupted white line. 163 
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7.3.4 The clinical importance of FFB in patients with RA 
An increased number of plantar fluid lesions and reduced numbers of all soft tissue lesions (and 
specifically plantar soft tissue lesions) was significantly associated with increased CRP (r=0.33, 
p=0.035; r=-0.38, p=0.015; r=-0.34, p=0.029 respectively). Increased plantar soft tissue lesion 
enhancement was significantly associated with longer disease duration (r=0.38, p=0.015). No 
further FFB characteristics were associated with systemic markers of disease activity.  
 
An increase in the number of intermetatarsal soft tissue lesions was significantly associated with 
metatarsophalangeal joint synovitis (r=0.37, p=0.017). Increased intermetatarsal fluid lesion 
enhancement was also approaching a significant correlation with synovitis (r=0.3, p=0.053). No 
further FFB characteristics were associated with localised markers of disease activity.  
 
An increase in the number of soft tissue lesions was significantly associated with poorer foot 
posture (r=0.36, p=0.019) and reduced ankle joint range of motion (r=0.35, p=0.025). No further 
FFB characteristics were associated with markers of biomechanical impairment. Please note, 
disease duration, CRP, ESR, DAS 28-CRP and MRI-detected SY, OE and ER were all 
determined to be negatively skewed and as such Spearman’s Rank association analyses are 
reported for these variables.  
 
Participants were grouped according to low (<25% of maximum score) or high (≥25% of 
maximum score) erosion, bone marrow oedema, synovitis or reported foot-related disability. 
Significant differences in plantar soft tissue lesion enhancement were noted between those 
patients with low or high erosion scores (p=0.03, t=1.97, 95% CI=-0.02 – 1.31). Similarly, 
significant differences in plantar soft tissue lesion enhancement and the number of 
intermetatarsal soft tissue lesions were noted between patients with low or high bone marrow 
oedema scores (p=0.03, t=2.22, 95% CI=0.06-1.24; p=0.048, t=-2.07, 95% CI=-1.62-0.01 
respectively). No significant differences in any MRI characteristics were noted between patients 
with low or high synovitis or foot-related disability. However a trend towards an increase in all 
MRI enhancement characteristic scores in those patients with greater foot impairment (FISIF) 
was noted. Additional detail related to the completed association analyses is presented in 
appendix section A20. 
7.4 Discussion 
To our knowledge, this study has uniquely reported the high prevalence of MRI-detected FFB in 
patients with RA. Furthermore, differences in the MRI characteristics of identified FFB in this 
patient group were demonstrated in this work. Identified bursa-like lesions appeared to exhibit a 
range of inflammatory and fibrotic tissue characteristics. Predominantly soft tissue lesions within 
the plantar tissue were the most prevalent lesion type (PP=92.9 per 100), followed by fluid and 
soft tissue lesions within the intermetatarsal spaces (PP=83.3 per 100, PP=52.4 per 100 
respectively), with fluid lesions within the plantar tissue being the least prevalent (PP=7.1 per 164 
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100). Distribution analysis further revealed a trend for fluid lesions to be predominantly located 
within the intermetatarsal 1/2, 2/3 and 3/4 spaces, while soft tissue lesions were mainly 
distributed across the plantar forefoot regions. Thus the findings of this study suggest that two 
distinct and predominant groups of FFB may coexist in patients with RA: 1. intermetatarsal 
predominantly fluid lesions, 2. plantar predominantly soft tissue lesions. However, these groups 
are not absolute and do not represent those lesions of greatest potential clinical importance. 
This research has generated preliminary evidence to suggest that the presence of 
intermetatarsal soft tissue lesions and plantar fluid lesions are associated with RA disease 
activity, while plantar soft tissue lesions are associated with biomechanical impairment. 
 
Previous authors have suggested that an increased presence of plantar soft tissue lesions is 
attributable to biomechanical irritation; it is hypothesised that repetitive and adverse 
biomechanical irritation distorts the structural integrity of the plantar fibro-fat pad and elevates a 
mechanism of tissue fibrosis (Ahmed et al. 1994, Studler et al. 2008, Lohman et al. 2001, 
Bottger et al. 1998, Cameron 1963). Overall, the findings of this study therefore appear to 
support this hypothesis. However, uniquely this work has also identified a significant association 
between inflamed plantar soft tissue lesions and elevated bone marrow oedema in patients with 
RA. The implications of this finding are unclear; it is possible that these findings illustrate a 
mechanism whereby repetitive biomechanical irritation results in the perpetuation of 
inflammation within the forefoot as suggested by Studler et al. (2008). Conversely, these 
findings may illustrate a mechanism whereby minimal disease activity within the forefoot is 
driving the development of fibrotic/synovial lesions within the plantar tissues or vice versa 
(Boutry et al. 2003a, Canoso and Yood 1979b, Hernandez et al. 1991, Zielaskowski et al. 2000). 
It would appear that majority of plantar soft tissue lesions are associated with biomechanical 
impairment, however a few, which can be differentiated via their MRI enhancement 
characteristics, appear to be related to RA disease activity.  
 
The presence of intermetatarsal soft tissue lesions was also noted to be significantly associated 
with elevated counts of bone erosion. This would initially appear to reinforce the hypothesis that 
intermetatarsal soft tissue FFB are related to inflammation, perhaps by a process of synovial 
hypertrophy, and not biomechanical impairment (Awerbuch et al. 1982, Jaganathan et al. 2012, 
Boutry et al. 2003a). However, the biomechanical function of the intermetatarsal tissues remains 
unclear. This is arguably potentially relevant in patients with notable lesser digital deformity and 
potential rupture of the plantar plate or adjacent ligaments which may destabilise the forefoot 
during loading activity (Fuhrmann et al. 2005, Siddle et al. 2012). It is possible therefore, that 
biomechanical impairment may be a confounding driver for both intermetatarsal soft tissue 
hypertrophy and joint deterioration. The methods of identifying biomechanical impairment in this 
study largely focus’s upon static measures of joint alignment and therefore may not be sensitive 
to the biomechanical stresses exerted upon the tissues of the forefoot. However, the presence 
of intermetatarsal soft tissue lesions was also noted to be significantly associated with MTP joint 165 
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synovitis, arguably reinforcing the inflammatory driven hypothesis of FFB hypertrophy. Future 
work that evaluates the pathogenesis of MRI-detectable FFB longitudinally, within an inception 
cohort without notable changes to the biomechanical structure and integrity of the foot, would 
significantly benefit study in this area. An improved understanding of the pathological 
mechanisms underpinning this relationship between FFB characteristics and RA disease will 
help evidence the clinical importance of FFB further.  
 
It may however, be misleading to consider differences in the MRI characteristics of FFB to be 
indicative of distinct subtypes of bursa-like lesion. For the purposes of analysis, the identified 
FFB were categorised in this way, however a number of complex bursa-like lesions were 
observed with ranging fluid/soft tissue or enhancement presentation. It is plausible that the 
differing MRI characteristics observed may be representative of a range in the stages of lesion 
development rather than discrete subtypes of FFB (Studler et al. 2008, Awerbuch et al. 1982, 
Mutlu et al. 2006). Longitudinal evaluation of the pathogenesis of MRI-detectable FFB with 
concomitant histological examination would provide additional evidence in support of refute of 
this hypothesis. In particular further evaluation of the clinical importance of FFB enhancement 
may help direct future therapeutic strategies. 
7.4.1 Study limitations 
This study has a number of strengths and limitations. The studied population is a consecutive 
sample of well phenotyped patients with established RA, receiving ongoing rheumatological 
care. As such, the generalisability of the study findings to those patients with early disease or 
high disease activity needs to be explored. It should also be noted that the measures of MRI-
determined localised disease activity used within this study have not been previously validated 
for use within the forefoot, although have been demonstrated to be reproducible at this site 
(Baan et al. 2011).  
 
No previous investigations of the prevalence of MRI-detectable FFB have been reported to date. 
As such the sample size of this study was estimated based upon the proportional difference in 
US-detectable FFB presence/absence previously identified (Chapter four). Despite a high 
prevalence of FFB subsequently being observed within this study cohort, the statistical power to 
stratify FFB data based upon MRI characteristics should be questioned. For this reason the 
inferential statistics completed within this study have been limited to association analysis only 
(Bland and Altman 2009, Bland and Altman 1994a). Although completion of additional 
regression analyses, in order to identify clinically meaningful relationships between FFB 
characteristics and RA disease, would have benefit (Silman and Hochberg 2001). Furthermore, 
the identification of potential confounders or interactive effects within the reported data, such as 
treatment regimen/drug use, is required. Previous research has reported significant associations 
between methotrexate use and tissue fibrosis, although the exact mechanisms for this remain 
unclear (DiFrancesco et al. 1994, Mutlu et al. 2006, Matsushita et al. 2006, Patatanian and 166 
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Thompson 2002, Williams et al. 1998). None the less, there is potential biological plausibility to 
the suggestion that drug use may affect FFB prevalence in patients with RA.  
 
In order to minimise reporting bias in the primary outcome measure, the MRI image sets were 
read without prior knowledge of the corresponding patient-reported foot-related disability scores. 
However, it was not possible to blind the reading researcher (LH) to the name of the study 
participant to whom the image set corresponded. As such it is possible that the reader may have 
been familiar with the participant’s clinical characteristics in the 4-6 weeks previous to the scan 
being completed. However, inter-reader reliability with an experienced radiologist, blinded to the 
clinical history of the study participants, has been previously established and reported as good 
to excellent (Chapter six). The good inter-reader agreement reported previously suggests that 
there is minimal evidence of systematic observer bias as a consequence of familiarity with the 
clinical history of the study participants.  
7.4.2 Conclusion & summary 
MRI-detectable FFB are highly prevalent in patients with RA. Characterisation of MRI-detected 
FFB is helpful in identifying those lesions of greatest clinical relevance; there is preliminary 
evidence to suggest that the presence of intermetatarsal soft tissue lesions and plantar fluid 
lesions are associated with RA disease activity, while plantar soft tissue lesions are associated 
with biomechanical impairment. Importantly, a trend towards an association between increased 
FFB enhancement and increased foot impairment was noted.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The epidemiology & clinical importance of MRI-detectable FFB in patients with 
rheumatoid arthritis 
 
Key points: 
 
  MRI-detectable FFB are highly prevalent in patients with RA 
  41.7% of observed FFB were characterised as predominantly fluid & 58.3% as 
predominantly soft tissue 
  An increased presence of intermetatarsal soft tissue FFB and plantar fluid FFB is 
associated with increased RA disease activity 
  An increased presence of soft tissue FFB within the plantar fat pad is associated 
with biomechanical impairment, however these FFB can themselves become 
inflamed  
  A trend towards those patients with the greatest number of inflamed FFB also 
reporting the greatest foot impairment was observed 167 
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Chapter eight 
Discussion, conclusions & future research 
 
8.0 Introduction 
The preceding chapters have presented a series of four experimental studies that explore the 
epidemiology and clinical importance of US-detectable or MRI-detectable FFB in patients with 
RA. This chapter aims to draw together the findings of these four experimental studies and to 
discuss the presented body of work as an integrated programme of research. The advancement 
in knowledge and contribution towards clinical practice made by this research programme is 
considered. The conclusion is made that ‘FFB are clinically relevant in patients with RA’ and the 
alternate thesis hypothesis, originally outlined in Chapter two, is accepted. Limitations within the 
reported studies are acknowledged and recommendations for future research proposed.  
8.1 The epidemiology & clinical importance of forefoot bursae in patients with RA 
 
This programme of research has identified a high prevalence of FFB in patients with RA. Results 
from the longitudinal US evaluation suggest that the high prevalence of FFB is largely sustained 
over a period of time however some fluctuations in FFB number can occur. The disability status 
of a patient with RA can be predicted by the number of FFB that they have. However, further 
comparative evaluation of FFB between patients with predominantly inflammatory or 
degenerative arthritis suggests, that while the number of FFB may be clinically relevant, their 
location may also be clinically meaningful. Evaluation of FFB in healthy volunteers suggests that 
approximately 50% of those FFB identified in patients with RA may not be clinically relevant, in 
particular those identified in the intermetatarsal 4/5 space. Characterisation of the remaining 
FFB using MRI, suggests that some FFB are related to RA disease activity while others are 
related to biomechanical impairment. Specifically, plantar fluid lesions and intermetatarsal soft 
tissue lesions appear to be associated with disease activity, while plantar soft tissue lesions 
appear to be associated with biomechanical impairment. It is also noteworthy that, a trend 
towards an association between elevated FFB inflammation and patient-reported foot 
impairment was also observed.  
8.2 Summary of advancement of knowledge 
This programme of research has utilised novel US and MRI imaging techniques to determine the 
epidemiology and clinical importance of FFB in patients with RA. The advances in knowledge 
made by the research studies forming this thesis have been discussed in the corresponding 
experimental chapters. However, key advances in knowledge may by this programme of 
research include: 
1.  US-detectable FFB remain highly prevalent in patients with RA longitudinally 
2.  The US characteristics of FFB in patients with RA are variable 168 
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3.  Changes in the presence of US-detectable FFB are associated with changes in RA 
disease activity 
4.  US-detectable FFB are identified as a prognostic indicator of patient reported disability 
and represent a possible novel therapeutic target 
5.  US-detectable FFB are highly prevalent in patients with RA and medial knee OA 
compared to healthy volunteers 
6.  In patients with RA, the presence of US-detectable FFB is associated with inflammation 
and biomechanical impairment  
7.  The central distribution pattern of US-detectable FFB, unique to patients with RA, is 
clinically relevant and associated with metatarsal head erosion  
8.  The FFB-score is reliable and valid for the identification and characterisation of FFB in 
patients with RA 
9.  MRI-detectable FFB are highly prevalent in patients with RA, of which 41.7% of MRI-
detected FFB were characterised as predominantly fluid & 58.3% as predominantly soft 
tissue 
10. The characterisation of FFB using MRI can identify bursa-like lesions of differing clinical 
importance: 
o  An increased presence of MRI-detected plantar fluid and intermetatarsal soft 
tissue FFB is associated with increased RA disease activity 
o  An increased presence of MRI-detected soft tissue FFB within the plantar fat 
pad is associated with biomechanical impairment, however these FFB can 
themselves become inflamed  
o  A trend towards those patients with the greatest number of inflamed FFB also 
reporting the greatest foot impairment was observed 
 
It can be concluded therefore that FFB are highly prevalent and clinically relevant in patients 
with RA, thus the alternate thesis hypothesis can be accepted and the null hypothesis rejected. 
Furthermore, clinically relevant FFB can be reliably identified and characterised using the FFB-
score. The rationale for the clinical importance of subsets of FFB remains unclear however, this 
thesis has provided support for the hypothesis that both disease mediated inflammation and 
biomechanical impairment are relevant factors in the genesis of FFB. These findings are 
summarised figuratively in figure 55. 
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Figure 55: An illustrated summary of the main research findings 
 
 
8.3 Implications for clinical practice 
Overall, the completion of this body of work has led to the identification of a range of FFB 
characteristics that are evident in patients with RA, the clinical value of which differs. Clear 
distinction should be drawn however between what can be interpreted as the direct clinical 
importance of FFB (for example their pathological state) and the clinical value that can be 
gained from the study of FFB (for example what observing FFB can tell us about our patients).  
 
From the findings of this programme of research it is not possible to conclusively determine to 
what extent FFB directly contribute to the burden of foot disease in patients with RA. There is 
however preliminary data that appears to support this hypothesis, for example the number of 
MRI enhancing FFB observed is new documentation of inflammation within the soft tissues 
outside of the forefoot joints in patients with RA (Chapter seven). It is possible that selectively 
targeting therapeutic intervention at inflamed FFB may ease the burden of foot complications in 
this patient group. Kanbe et al. (2006) and Huang et al. (2011) have demonstrated significant 
clinical benefit following the surgical excision of inflamed bursae. However, there is limited 
additional evidence documented to date advocating the targeted management of inflamed FFB, 
other than that which is hypothetically proposed (Koski 1998, Harper 2003, Awerbuch et al. 
1982, Boutry et al. 2005). Future research is required to demonstrate the efficacy of selectively 
treating FFB.  170 
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None the less, the findings of this programme of research have highlighted the prognostic 
clinical value of US-detected FFB for the determination of foot-related disability longitudinally 
(Chapter four). It is possible to conclude that those patients identified as having four or more US-
detectable FFB have greater likelihood of worsening foot-related disability over three years. 
Thus, the evaluation of US-detectable FFB presence can be used as a clinical adjunct to the 
assessment of foot health in patients with RA. It is also noteworthy that the study findings 
suggest that US-detectable FFB presence, as well as foot-related disability, is fluctuant. 
Therapeutically, this suggests that both factors have potential to be modified and improved. 
However, additional insight into the mechanisms underpinning this relationship is required 
before a process of targeted intervention and evaluation can be developed. 
 
The study of MRI-detected FFB suggests that a subset of FFB, (inflamed soft tissue lesions), is 
associated with disease duration (Chapter seven). The rationale for this is unknown; it is unclear 
whether this is related to disease chronicity, disease aggression or biomechanical impairment, 
as suggested by previous authors (Studler et al. 2008, Harper 2003, Canoso and Yood 1979b, 
Awerbuch et al. 1982, Koski 1998, Bottger et al. 1998). Koski et al. (1998), amongst other 
authors (Awerbuch et al. 1982, Bowen et al. 2010c, Boutry et al. 2003a, OBrien et al. 1997, 
Scutellari and Orzincolo 1998), has suggested that FFB become inflamed as a consequence of 
RA disease affecting the synovial lining of these lesions. However, the presence of synoviocytes 
within plantar FFB has not been reported to date. The nature of the plantar tissues identified as 
inflamed within this study is currently unclear and future histological examination needed. An 
improved understanding of the mechanisms driving inflammation in this tissue, that was 
previously considered clinically unimportant or adventitial in healthy volunteers (Studler et al. 
2008), may improve our understanding of the pathogenesis of RA disease within the forefoot. 
 
Additionally, plantar fluid lesions were determined to be significantly associated with systemic 
markers of RA disease activity (Chapter seven). Again, this finding appears contradictory to the 
hypothesis associated with plantar FFB suggested by previous authors; plantar fluid FFB were 
thought to arise as a consequence of repetitive, excessive linear and torsional biomechanical 
stress to the fibro-fat pad that resulted in separation of the fibro-collagenous tissue layers and 
accumulation of slit-like cavities of fluid (Studler et al. 2008, Ahmed et al. 1994). Perhaps this 
aetiological assumption is correct, but in patients with RA, the inflammation accompanying this 
repetitive micro-trauma is poorly regulated, becoming excessive at these sites. Conversely, 
these lesions may indeed be directly related to RA disease activity; the direct effect of excessive 
disease-mediated inflammation may not be limited to the synovial tissue of the forefoot. 
Moreover, RA disease activity may directly affect the structure and proliferation of fibro-
collagenous tissue within the plantar forefoot (Mutlu et al. 2006, Matsushita et al. 2006, 
Zielaskowski et al. 2000, Sanders et al. 1998, Oloff-Solomon et al. 1984). Future evaluation of 
the pathogenesis of different FFB characteristics would further inform the understanding of their 171 
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clinical value. None the less, the use of the FFB-score is demonstrated to be a potentially 
beneficial clinical adjunct in the evaluation of RA disease activity.  
 
As highlighted by Khan et al. (2012) the identification of minimal disease activity is a growing 
clinical concern. There is a need for improved clinical indicators of continued disease activity 
because a number of patients continue to report ongoing complications despite up-regulation of 
pharmacological therapy (Aletaha and Smolen 2011, Aletaha et al. 2011, Wells et al. 2009). This 
is evidenced within the RA cohort contributing to this body of research; although not a primary 
focus of this work, the findings of the study in Chapter six suggest that a number of patients 
(n=25) continue to have ongoing minimal disease activity within the forefoot (identified using 
MRI) despite receiving biologic intervention and achieving remission from disease according to 
DAS 28 evaluation. Arguably, the evaluation of FFB in patients with RA, using the FFB-score, is 
therefore advocated. Use of the FFB-score provides clinically relevant information regarding the 
perpetuation of inflammatory disease within the forefoot in patients with RA beyond that which is 
detected using current methods of assessment. It is therefore possible that a number of patients 
who require further up-regulation of treatment, that would otherwise not be reviewed, will be 
identified with the use of the FFB-score. Future work, which cross-validates the findings of the 
MRI-based FFB-score with US-detected FFB, would reduce the time and financial burden of 
FFB evaluation, potentially improving the clinical utility of an US-based FFB-score. The long 
term economic impact of improved identification of minimal disease activity, via evaluation of 
FFB, is also warranted.  
8.4 Limitations 
The specific limitations of each study are explored within the discussion section of the 
corresponding chapter. However there are a number of limitations that are applicable to all the 
documented works, which warrant further comment.  
 
A single measure of the impact of FFB was used throughout this programme of research only, 
the FIS questionnaire (Helliwell et al. 2005). At the time of research, this was the only tool that 
had been previously validated for use in patients with RA and was therefore selected for this 
reason. However, the FIS questionnaire has not been validated for longitudinal use, although 
Turner et al. (2007) suggested that a score change of three or more, in either direction, was 
clinically meaningful. As such, these margins of change were adopted in this work. 
Consequently, the reported estimations of disability impact associated with FFB may be biased 
by measurement inaccuracy. Such bias is likely to be systematic throughout the reported results, 
however the direction (e.g. over/under estimation) is unknown. Use of secondary measures, that 
identify concurrent validity between items, would improve the certainty of an accurate 
assessment of disability (Silman and Hochberg 2001). Validation of FIS longitudinally would also 
be of benefit in improving the construct validity of these reported measures. Thus, the variation 
in disability reported in Chapter four, may be a consequence of measurement error. The 172 
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additional use of margins of clinically meaningful change in disability, suggested by Turner et al. 
(2007), potentially increased the stringency of evaluation of change, thereby minimising the 
effect of measurement error. Conversely, the loss of sensitivity to change, introduced through 
the grouping of continuous data, may have resulted in an underestimation of clinically 
meaningful fluctuation in disability (Altman and Bland 1999, Bland and Altman 1996).  
 
The differences in longitudinal disability demonstrated between patients with high/low FFB count 
are also of interest. Foot impairment improved for both patients with high and low FFB at 
baseline, with the reported impairment converging between groups at year-three. This may 
represent an overall regression to the mean disability level for the studied cohort (Bland and 
Altman 1994b). Alternatively, patients entering the study at baseline were offered podiatric care 
if required and thus the reduction in impairment may represent a treatment effect (Campbell and 
Machin 1999). Furthermore, it is possible that those patients with an elevated burden of foot 
disease, to which FFB presence may be contributing, preferentially sought intervention 
accounting for the greater reduction in impairment shown in this group. Additional post-hoc 
analysis of treatment provision would benefit the interpretation of these results (Campbell and 
Machin 1999). It is also plausible to suggest that those patients with a pre-existing foot 
complication were more likely to participate within this study and as such the burden of foot 
disease may be over represented within this cohort. Future inclusion of recruitment analyses 
may provide further insight into this potential bias. However, the prevalence of reported foot 
impairment and activity limitation within this study is consistent with those reported by previous 
authors (Helliwell et al. 2005; Turner et al. 2007). However it should be noted, that the same 
preferential bias for recruitment may also be evident within these comparative investigations. 
 
It is interesting, that in contrast to improved foot impairment, reported activity limitation 
increased. It is plausible that in a treated cohort, patients who feel better and have less foot 
impairment attempt to undertake more weight-bearing tasks of daily living (Campbell et al. 2012, 
Platto et al. 1991). Such patients may become increasingly aware of activity limitations that were 
otherwise masked by comorbid disease or other social influences/distractions (Bjork et al. 2011). 
Conversely, while foot impairment may be modifiable and can improve, factors contributing to 
activity limitation perhaps accumulate only (van der Leeden et al. 2007, van der Leeden et al. 
2008). Therefore it may not be possible for improvements in foot impairment to be mirrored with 
improvements in foot-related activity limitation. In this instance, the assessment of FFB presence 
may be a useful indicator of potential activity limitation; FFB assessment could be used clinically 
to identify those patients at greatest risk of worsening activity limitation and to whom 
management should be targeted.  
 
The degree and impact of pain associated with FFB has not been evaluated in this programme 
of research. This is a key omission and the potential influence of pain or pain related anxiety, as 
a confounding or colinear factor, should be considered (Otter et al. 2011, Mustafa et al. 2012, 173 
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McWilliams et al. 2012, Campbell et al. 2012). Interestingly, Otter et al. (2011) note a positive 
correlation between reported pain and healthcare access. Furthermore, various authors have 
reported a high incidence of foot specific pain associated with the development of soft tissue 
lesions of the forefoot (Koski 1998, Iagnocco et al. 2001, Ashman et al. 2001, Zielaskowski et al. 
2000). Thus, if longitudinal differences in reported disability are to be considered as a treatment 
effect, the presence of pain associated with FFB may further confound differences in disability 
observed between high/low FFB count groups.  
 
A number of investigative techniques have been used to evaluate the mechanical function of the 
foot. Clinically used static postural measures include navicular height, arch height and valgus 
index [86, 87]. However, these have been demonstrated to have significantly different inter-rata 
reliability (p = 0.001- 0.005) even when evaluated in non-pathological populations (Weiner-
Ogilvie and Rome 1998; Menz et al. 2005). The foot posture index (FPI) was the only clinical 
static postural tool validated for use for patients with RA.at the time of this study (Redmond et al. 
2006). The authors acknowledge that the FPI was only able to predict 64% of the variance in 
static standing position and 41% of the postural variance during the stance phase of gait in this 
patient group (Redmond et al. 2006). None the less, this has been shown to have good internal 
consistency (Cronbachs alpha=0.83) and allows simple multi-segment, multi-plane evaluation in 
a clinical setting and as such has clear advantages over the alternative postural tools. 
 
However, it should be noted that when applied in this work, substantial inter-rater variation was 
recorded, even after two episodes of dedicated researcher training. As such, and despite 
moderate agreement subsequently being demonstrated, the findings of this score should be 
treated with caution; there is likely to be some reporter bias within the recorded results. 
Furthermore, the clinical relevance of a static measure of alignment is yet to be demonstrated. It 
has previously been hypothesised that variations in static weight bearing alignment can be 
related to dynamic biomechanical stress (Hicks 1953; Root et al. 1977; Dananberg 2000, Fuller 
2000; Kirby 2001). However there is much contention surrounding the theoretical underpinning 
of this inferred relationship (Wold et al.2008). None the less, the results of the work completed 
as part of this thesis do appear to suggest that, despite these limitations, the FPI score may 
have clinical relevance when considering the relationship between static foot alignment and FFB 
prevalence. Further work is required to fully determine the nature of this association.  
 
The provision of ongoing rheumatological care, concurrent to the longitudinal study completed in 
Chapter four, may introduce treatment effect as a possible confounder within the reported 
results. Changes in the provision of pharmacological care were not reported or analysed within 
the scope of this investigation. However, it is plausible that a number of patients will be in receipt 
of disease modifying anti-rheumatic drugs, such as Methotrexate, which have been previously 
linked with soft tissue change and nodulosis, or will have had an escalation in drug therapy to 
include newer biologic therapies, the secondary effects of which remain unknown. As such, 174 
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future work which clearly evaluates the potential contributory or colinear effect that differing 
treatment regimens may have on the soft tissue structures of the foot is warranted.  
 
The FFB-score was validated for use in patients with RA against MRI-determined measures of 
disease activity within the forefoot, adopted from the RAMRIS score (Ostergaard et al. 2003). 
However, these measures have been validated for application to the metacarpophalangeal joints 
and not the metatarsophalangeal joints (Lassere et al. 2003). None the less, there is biological 
plausibility to the application of this tool to these forefoot joints, although the accuracy of 
localised disease activity assessment, within the reported validation study in Chapter six, should 
be considered. 
8.4.1 Management of bias 
There are a number of potential biases within the reported study findings. The following text 
therefore summarises such potential sources of bias and considers the methodological 
adjustments used to manage this where possible. The implications of such biases to the 
conclusions of this work are considered.  
 
Selection bias, the introduction of error due to systematic differences in the characteristics 
between those selected or not selected to participate within the study, may be evident within the 
represented sample population (Silman and Macfarlan 1995). Those patients attending a 
rheumatology outpatient clinic, within a secondary care setting, were consecutively invited to 
participate within the baseline study reported in Chapters four and five. As such, the target 
samples are likely to include those patients with chronic or more active disease and may not be 
representative of all patients with a rheumatological diagnosis. Indeed, the demographical 
analysis completed appears to suggest that those patients with more established RA disease 
are represented within the studied population (Bland and Altman 1994b). The applicability of the 
study findings to those patients with early disease should therefore be questioned. Future work, 
that includes an inception cohort, would benefit further study in this area. Post-hoc response 
analyses were completed for the longitudinal study completed in Chapter four, the findings of 
which suggest that there may be a systematic difference in those patients willing to return for 
follow-up assessment and those who withdrew from the study. As such, systematic bias in the 
inclusion of those patients with the greatest burden of foot or inflammatory disease may result in 
an over-representation of these or associated characteristics within the study findings. The 
generalisability of the results of this work the broader population should therefore be considered.  
 
Prevalence bias, the restriction of studied cases to those with only the disease state of interest, 
was minimised by the recruitment strategy chosen, and is therefore unlikely to be evident within 
the studied population; Included participants were not recruited based upon the presence or 
absence of FFB, the primary outcome of interest (Silman and Macfarlan 1997).  
 175 
 
  Chapter 8: Discussion 
Survival bias, the exclusion of cases no longer able to participate within the studied population 
arising from factors related to the primary outcome of interest, may be evident within the 
represented sample population (Silman and Macfarlan 1997). It is plausible to suggest that 
those patients with a greater burden of foot disease and related mobility limitation may be 
restricted from attending follow-up study visits. Quantification of such bias was attempted via the 
completion of the response analyses reported in Chapter four (Bland and Altman 1994b). 
Furthermore, a methodological adjustment to recruitment was introduced subsequent to initial 
poor response rates at the year three follow-up visit.  Eligible participants were offered an option 
to complete a postal questionnaire only, negating any need for physical attendance at a hospital 
examination appointment. However, changes to response rates were negligible following this 
amendment and as such, the likely role of disability as an inhibitor to response can be 
questioned.  
 
Participant recall bias, differences in a patient’s ability to recall information of relevance, may be 
evident within the represented sample population (Silman and Macfarlan 1994b; Silman and 
Hochberg 2001). The duration and severity of episodes of poor foot heath may influence the 
degree of foot-related disability reported by study participants. Similarly, the impact of poor foot 
health may be more readily recalled if recent life events have been modified as a consequence; 
the period of time between FIS questionnaire completion and an episode of poor foot health may 
impact the patient’s ability to recall pertinent information. To overcome this, participants were 
encouraged to consider their responses, and answer based upon their experiences of foot 
health over the previous week only. Additionally, details of surgical history, previous episodes of 
poor foot health or related disease activity were cross references and verified by review of the 
patient’s medical notes by the study researcher. However, it remains plausible that FIS scores 
may be over or underestimated dependent upon a patient’s ability to recall related information.         
 
Participant reporting bias, error in response that is dependent upon the willingness of a 
participant to provide a true response or disclose information of relevance, may be evident within 
the represented sample population when considering reported foot impairment or activity 
limitation (Silman and Macfarlan 1994b). However, the primary outcome of interest, FFB, was 
determined based upon US analysis and is therefore unlikely to be influenced by such reporting 
bias. To negate potential reporting bias, the researchers were cautious not to demonstrate any 
preference towards the identification or absence of disability or foot complications.  
 
Researcher observer bias, the systematic error in the researcher’s measurement, reporting or 
documentation of the phenomena of interest, may be evident within the study findings (Silman 
and Macfarlan 1994b). The identification or FFB using US or MRI may be altered as a 
consequence of interest or improving familiarity with the image sets. To minimise such bias, all 
researchers completed assessment skills training prior to the undertaking of data collection. Intra 
and inter-reader agreement for all methods of FFB identification were completed and the 176 
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findings of the study researcher (LH) referenced against the findings of an ‘expert’ reader 
(LK/CB). Thus, the relative accuracy of all researchers for the identification and characterisation 
of FFB has been quantifiably demonstrated to be good, subsequent to agreement analyses. 
However, it is of note that a learning effect was reported by the main researcher (LH) who was 
novice to MRI reading at the start of this study. As such, the data reported by LH was not used 
until consistently high image agreement with an expert reader was achieved, thereby minimising 
potential reporting inaccuracy. In study two, (Chapter five) there remains however some risk of 
non-directional misclassification bias when comparing observed phenomena between groups; 
equal observer bias may occur in both study population. However, the researcher is not blinded 
to the group from which the participant originates and thus observational bias may potentially be 
systematic and directional in nature.  
 
It was not feasible to blind the researcher to the patients clinical history in studies one, three and 
four (Chapters four, six and seven) or patient group in study two (Chapter five). However the 
comparative expert readers were blinded to the patient’s disease status at the time of image 
acquisition. Thus any potential systematic reporting bias by the main study researcher would be 
evident within the completed agreement analysis. Thus, there is minimal indication there may be 
any systematic reporting bias by the main researcher (LH) in the reading of US or MRI images 
and subsequent FFB prevalence reporting. 
8.5 Implications for future research 
The completion of this programme of research has led to the identification of a number of areas 
of future research that warrant further investigation: 
 
1.  The assessment of FFB 
a.  An investigation of the relative sensitivity and specificity of MRI and US for the 
detection of FFB subtypes would be of benefit. The use of MRI to identify and 
characterise FFB has been demonstrated, however application of this new 
knowledge to inform and direct the use of US would potentially reduce the time and 
economic burden of FFB evaluation  
b.  The inflammatory state of FFB, identified using MRI, has been shown to be clinically 
relevant. Investigation of the efficacy of Power Doppler use as an adjunct to US 
evaluation may improve the clinical efficacy of this method of FFB assessment.  
c.  The FFB-score has been validated for use at a single time point. Longitudinal 
validation of FFB-score, with assessment of item responsiveness/sensitivity to 
change and criterion validity would improve the clinical utility of this score. 
d.  The content and discriminant of the FFB-score have been demonstrated. The 
investigation of FFB-score construct validity, with concurrent histological 
examination, would improve our understanding of the clinical relevance of this 
score.  177 
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2.  The clinical importance of FFB 
a.  Evaluation of FFB size was omitted from the current research programme due to 
difficulties in reducing measurement error. However, the study completed in Chapter 
six evidenced strong expert consensus regarding the importance of evaluating FFB 
size in future research.  
b.  Pain associated with FFB or other foot complications has been identified as a 
potential confounder/collinear factor, which may influence the current understanding 
of the clinical importance of FFB. Future investigation of the relationship between 
FFB and pain is therefore warranted.  
c.  FFB have been shown to be associated with impaired ankle joint range of motion in 
patients with medial knee OA, based upon cross section evaluation. Future 
research investigating the prognostic value of FFB in this patient group may be of 
clinical benefit. Additionally, the rationale for association between FFB, ankle joint 
function and medial knee OA remains unclear. There is limited evidence that 
demonstrates an association between changes in the forefoot and medial knee OA. 
However the findings of this research suggest that there is efficacy in exploring 
potential associations between these regions further.  
 
3.  Understanding the mechanisms by which FFB may be pathological 
a.  Biomechanical impairment has been shown to be significantly related to FFB count. 
Biomechanical impairment has been assessed using predominantly static 
measures. However, recent research suggests that static measures are poor 
indicators of biomechanical impairment compared to dynamic functional measures 
(Muller et al. 2012, Sell 2012, McPoil and Cornwall 1996, Allen et al. 2004). 
Therefore, further evaluation of the relationship between FFB and dynamic 
measures of biomechanical impairment may provide additional insight into their 
pathogenesis.  
b.  Biomechanical impairment has been determined using estimations of joint 
biomechanical function. However, direct investigation of biomechanical function and 
impairment to the tissues of the forefoot would be of greater theoretical efficacy 
c.  Evaluation of the local inflammatory infiltrate surrounding and within enhancing FFB 
tissue would provide addition insight into the cellular mechanisms regulating 
inflammation within these tissues. An improved understanding of these cellular 
mechanisms can be used to inform targeted therapeutic intervention.  
d.  Patients with medial knee OA were noted as having significantly elevated BMI 
scores. BMI was therefore identified as a potential confounder within the reported 
results. The relative contribution of elevated BMI to FFB development in patients 
with medial knee OA would improve current understanding of the clinical importance 
of FFB in this patient group.  178 
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4.  The management of FFB 
a.  The findings of this programme of research cannot be used to conclusively 
advocate the treatment of FFB. However, the preliminary results presented in 
Chapter seven, suggest that a subset of FFB are related to disease activity or are 
inflamed. Trials of interventions that seek to reduce the number or inflammatory 
state of these FFB in particular might demonstrate clinical benefit.  
b.  Using the FFB-score a number of FFB were identified as associated with RA 
disease activity. Longitudinal evaluation of these lesions would demonstrate their 
potential responsiveness to fluctuations in disease state or disease management. 
Investigation of the value of FFB as an indicator of therapeutic efficacy is warranted 
and could inform improved timely management of RA disease activity.  
 
5.  The assessment of disease activity within the foot 
a.  Although not a primary focus of this body of work, a number of patients were 
identified as having active disease within the forefoot, despite receiving biologic 
therapy and systemic or composite markers of disease activity suggesting remission 
(n=25). This has highlighted an unmet need for improved evaluation of disease 
activity within the forefoot.  
b.  There are currently no MRI-based scores that have been validated for use in the 
evaluation of RA disease activity within the forefoot. As such, the RAMRIS score, 
validated for use in the hand, was applied to forefoot to allow an evaluation of 
disease activity within these joints. However development of a validated score, for 
the evaluation of RA disease activity within the forefoot, is needed.  
8.6 Summary 
This thesis has uniquely identified the natural history of US-detectable FFB in patients with RA. 
The presence of FFB at baseline was determined to be a significant prognostic indicator of foot-
related disability after three-years. The rationale for this remained unclear at the time of study. 
Two plausible hypotheses, explaining the relationship between FFB presence and foot-related 
disability in patients with RA, were extrapolated from the literature: 1. FFB synovium is 
susceptible to disease-mediated inflammatory processes in a similar manner to joint synovium, 
and FFB are therefore representative of disease activity (Bossley and Cairney 1980), 2. FFB 
occur or hypertrophy as a consequence of biomechanical impairment of the forefoot, and are 
therefore indicative of physical changes in joint and associated tissue function (Studler et al. 
2008, Ahmed et al. 1994). Observed differences in the US characteristics of FFB supported a 
further hypothesis that subtypes of FFB, related to either inflammation or biomechanical 
impairment, may co-exist in patients with RA. Subsequently, FFB were determined to be 
relatively highly prevalent in patients with primary inflammatory or degenerative arthritis 
compared to healthy volunteers. Furthermore, US-detectable FFB presence was determined to 179 
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be associated with both inflammation and biomechanical impairment. The findings of this study 
appeared to reinforce the hypothesis that subtypes of FFB, related to both inflammation and 
biomechanical impairment, coexist in patients with RA. However, the need for a user-
independent, reliable and valid method of characterising FFB in patients with RA was identified. 
In response, the MRI-based FFB-score was created, evaluated and validated for use in the 
identification and characterisation of bursa-like lesions of the forefoot in patients with RA. The 
tool was subsequently applied and the high prevalence of MRI-detectable FFB uniquely 
reported. The characterisation of MRI-detected FFB has been identified as helpful in identifying 
those lesions of greatest clinical relevance; there is preliminary evidence to suggest that an 
increased presence of intermetatarsal soft tissue FFB and plantar fluid FFB is related to 
increased inflammation. Conversely, an increased presence of soft tissue FFB within the plantar 
fat pad appears to be related to biomechanical impairment; however these lesions can 
themselves become inflamed. A trend towards those patients with the greatest number of 
inflamed FFB also reporting the greatest foot impairment was observed.  180 
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The epidemiology & clinical importance of forefoot bursae in patients with 
rheumatoid arthritis 
 
Key points: 
 
  US-detectable and MRI-detectable FFB are highly prevalent  
  US-detectable FFB presence is associated with both inflammation and 
biomechanical impairment  
 
  FFB can be characterised as predominantly fluid, occurring within the 
intermetatarsal spaces, or soft tissue, occurring within the plantar fat pad 
  An increased presence of intermetatarsal soft tissue FFB and plantar fluid FFB is 
related to increased inflammation  
  An increased presence of soft tissue FFB within the plantar fat pad is related to 
biomechanical impairment, however these can themselves become inflamed  
 
  US-detectable FFB are prognostic indicators of patient-reported foot-related 
disability  
  A trend towards those patients with the greatest number of inflamed FFB also 
reporting the greatest foot impairment was observed. 181 
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A4: Participant consent form 
 
 
 
Rheumatology Research Unit 
Mailpoint 63, Level G, West Wing 
Southampton General Hospital,  
Tremona Road, Southampton.  
SO16 6YD 
Tel: 02380 796711/ 5279 
Fax: 02380 796711 
Email: lindsey.hooper@suht.swest.nhs.uk 
 
NRES code: 09/H0504/93 
SUHT Study Number: RHM MED 0871 
 
CONSENT FORM – CLINICAL ASSESSMENT 
 
Project title: The importance of pedal bursae in patients with Rheumatoid Arthritis 
(FeeTURA
3) 
 
Name of Principal Investigator: Miss Lindsey Hooper 
 
I  confirm  that  I  have  read  and  understand  the  information  sheet  (V4.  21/10/09-a) 
provided for the above study and have had the opportunity to ask questions related to 
this. These questions have been answered satisfactorily. 
 
I understand that my participation is voluntary and that I am free to withdraw at any 
time, without giving any reason, without my medical care or legal rights being affected.  
 
I understand responsible individuals from the University of Southampton, Southampton 
University Hospitals’ NHS Trust (SUHT) or from regulatory authorities where review is 
relevant to the above research study, may look at sections of my medical notes. I give 
permission for these individuals to have access to my records.  
 
I agree to blood and urine samples being taken and analysed for the purposes of this 
study and in potential future studies with ethical approval. 
 
I agree to take part in the above study. 
 
 
…………………………            ……………………….        ………………………… 
Name of patient      Date        Signature 
 
 
…………………………           …………………………     ………………………… 
Name of person taking consent   Date        Signature 
(If different from researcher) 
 
 
…………………………          …………………………       ………………………… 
Researcher        Date        Signature  
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Rheumatology Research Unit 
Mailpoint 63, Level G, West Wing 
Southampton General Hospital,  
Tremona Road, Southampton.  
SO16 6YD 
Tel: 02380 796711/ 5279 
Fax: 02380 796711 
Email: lindsey.hooper@suht.swest.nhs.uk 
 
NRES Code: 09/H0504/93 
SUHT study number: RHM MED0871  
 
PARTICIPANT INFORMATION SHEET – FeeTURA
3 Clinical assessment
  
 
You are being invited to take part in a research study. Before you decide if you would like to take 
part it is important for you to understand why the research is being done and what it will involve. 
Please take time to read this information carefully and discuss it with others if you wish. 
If you are happy to participate you will be asked to sign a consent form. 
 
Part 1 tells you about the purpose of the study and that will happen to you if you take part 
Part 2 gives you more detailed information about the conduct of the study.  
 
Please ask us if there is anything that is unclear or if you would like more information. Take time 
to decide whether or not you wish to take part.  
 
Thank you for reading this. 
 
Part 1 
1. What is the research about? 
This study is a follow-up study to a previous piece of research conducted at Southampton called 
the FeeTURA study. You may have been a participant in some of this research already. The 
main purpose of this current study is to investigate swelling (inflammation) in the feet of patients 
with Rheumatoid Arthritis (RA) or other inflammatory arthritis.  
 
Inflammatory arthritis can cause pain and damage to many joints. The joints most likely to be 
involved are in the feet and hands. However, most studies have concentrated on problems in 
the hands, and relatively little is known about the feet. The results from the first FeeTURA study 
have shown that the swelling in the feet can be very important. In particular, this swelling can be 
related to increased foot pain and also reduced walking ability. Bursae (small fluid filled sacks), 
which  can  become  inflamed  with  these  types  of  arthritis  were  found  to  be  of  particular 
importance. Being able to see such bursae using ultrasound or MRI and see how they change 
over time when you attend your rheumatology outpatients or podiatry appointments would help 
us to decide on the best course of treatment for you and for future patients. For example, this 
may involve deciding on what medicines and/or doses to use, or providing you with/adjusting 
existing insoles, to help prevent further pain, deformity or walking disability now or in the future.  
 
2. Why have I been chosen? 
You have been chosen either because you took part in the first FeeTURA study and we would 
like to know how your feet have changed in the 3-years since your taking part or because you 
have been newly diagnosed with an inflammatory arthritis and we would like to know how your 
feet are at the moment.  You  were  initially chosen  because  you  have a  type  of arthritis and 
attended/ are due to attend The Department of Rheumatology at Southampton General Hospital 
as part of your usual care. 
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3. Do I have to take part? 
It is your choice if you decide to take part or not. If you do decide to take part you will be asked 
to sign a consent form. You are still free to stop your involvement in the study at any time and 
without having to provide any explanation. A decision to withdraw at any time, or decision not to 
take part, will not affect any care that you will normally receive. 
 
4. What will happen to me if I take part? 
If  you  agree  to  participate  in  this  study  you  will  be  asked  to  attend  a  clinical  assessment 
appointment at Southampton General Hospital. During your appointment we will scan the sole of 
your  foot  using  a  diagnostic  ultrasound  scanner  in  the  same  way  that  unborn  babies  are 
scanned within the womb. This will mean that you will be asked to sit on a couch with your feet 
facing the investigator. The investigator will scan the soles of both your feet and record any 
areas of swelling (inflammation). A clinical examination of your feet will involve the investigator 
looking at and feeling the shape, any swelling, lesions or marks on your feet and this information 
will be noted by the researcher.  
 
Foot pressure measurements will be recorded by a computerised system called the F-Scan. 
This involves placing specialist insoles into your shoes, which are attached to the computer via a 
long cable. The insoles are very thin and so fit easily into the shoe without causing rubbing or 
discomfort.  To  avoid  any  possibility  of  trips  you  will  be  guided  by  the  investigator  along  a 
walkway  away  from  any  free  trailing  cables  that  connect  the  insoles  to  the  computer.  The 
computer automatically records the amount of pressure occurring under the soles of your feet 
during each footstep.  
 
You will also be asked to complete 2 short questionnaires that ask you about foot pain and 
walking ability. These questionnaires will take you approximately 10 minutes to complete.  
 
You will also be asked to provide a blood and urine sample. These will be collected by a fully 
trained  research  nurse,  stored  securely  and  used  only  for  the  purposes  of  research.  Some 
discomfort or a small bruising may occur at the site on your arm from where the blood sample 
has been taken. However, every effort will be made to minimise this and only fully trained staff 
will complete collection of this blood sample.  
 
It is expected that this appointment will last approximately 1 hour.  
 
Finally, you will be asked to have an MRI scan of your feet. This will mean walking along the 
corridor to the radiology department where a radiologist will assist you. You will be asked to lie 
down and still for approx. 30 minutes while the machine takes pictures of the structures inside 
your feet. 
 
5. What do I have to do? 
Taking part in the study does not alter any of your standards of care. You do not need to alter 
your lifestyle or diet in any way.  
 
6. What are the benefits of taking part? 
The information that we get from this study may help us to treat patients with foot problems 
associated with Rheumatoid or Inflammatory Arthritis better in the future. There may not be any 
direct benefit to you associated with taking part in this study however; your taking part helps us 
to identify swelling, bursae and other foot complications within the feet which contribute to the 
development of more targeted and timely treatments. 
 
7. What are the possible disadvantages and risks of taking part? 
In laboratory trials some risk of ultrasound exposure damage to tissues has been documented. 
This risk however,  is suggested to  be due to levels of exposure that  are  never used  within 
clinical practice. An excellent safety record for ultrasound use exists and after many years of use 
there has been no documented instance of related human injury. During clinical assessments 
with new ultrasound equipment such as that used in this study, the total ultrasound exposure is 
kept as low as reasonable achievable and this is known as the ALARA principle. Implementing 195 
 
  Appendices 
ALARA within the study has required the investigators to receive training in ultrasound use, and 
further support is available from the radiology department at Southampton General Hospital.  
 
It is possible that the foot pressure measurements recorded by the FScan
® machine may pose 
some risk of trip or fall as the insoles are connected to the computer via long cables. There is 
also a minor risk of you walking too far and toppling over the FScan
® system. To avoid these 
hazards, the exact distance of the walkway will be explained and demonstrated to you and you 
will be supervised by the investigator at all times during this activity. 
 
 
 
8. What if there is a problem? 
Any complaint about the way you have been treated during the study or any possible harm you 
might suffer will be addressed. The detailed information on this is given in part 2.  
 
The  contact  number  for  any  complaints  is:  Dr  Martina  Dorward,  Research  Support  Office, 
University  of  Southampton,  Building  27,  Highfield  Campus,  Southampton.  SO17  1BJ. 
Telephone: 02380 59 8848 
 
9. Will my taking part in this study be kept confidential? 
Yes. All the information about your participation in this study will be kept confidential. The details 
are included in Part 2, however your GP may be informed about your participation in this study. 
 
10. Contact for further information 
Further information can be obtained from: 
 
Principal  Investigator:  Miss  Lindsey  Hooper,  Rheumatology  Research  Unit,  Southampton 
University  Hospitals’  Trust,  at  Southampton  General  Hospital.  Telephone:  02380  777  222 
extension 5279. 
 
And/or 
Chief  Investigator:  Professor  Nigel  Arden,  Department  of  Rheumatology,  Southampton 
University Hospitals’ Trust, at Southampton General Hospital. Telephone: 02380 79 8723 / 8523 
/ 6711. 
 
 
 
Thank you for reading this. 
 
This completes Part 1 of the Information Sheet.  
If the information in Part 1 has been of interest to you and you are considering taking part 
please continue to read Part 2 before making any decision. 
 
 
PARTICIPANT INFORMATION SHEET 
 
Part 2 
11. What will happen if I don’t want to carry on with the study? 
You can withdraw from the study at any time without any need to provide a reason for doing so. 
Your choice to withdraw will have no effect on the care that you normally receive. If you are in 
agreement images or information gathered up to the point at which you withdraw might still be 
used.  
 
12. What if there is a problem or something goes wrong? 
It is extremely unlikely that taking part in this research project will harm you. If this did occur 
however there are no special compensation arrangements. If you are harmed due to someone’s’ 
negligence,  then  you  may  have  grounds  for  a  legal  action  for  compensation  against  (The 
University of Southampton or Southampton University Hospitals Trust) but you may have to pay 
your own legal costs. The normal National Health Service complaints mechanisms will still be 
available to you.  196 
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Regardless of this, if you have a concern about any aspect of this study you should ask to speak 
with  investigator  who  will  do  their  best  to  answer  your  questions  (Telephone  02380  777222 
extension 5279). If you remain unhappy and wish to complain formally, you can do this through 
the NHS Complaints Procedure. Details can be obtained form the Patient Advice and Liaison 
Service  (PALS)  information  point  within  the  hospital  or  you  can  telephone  them  on  02380 
798498 or email PALS@suht.swest.nhs.uk 
 
Alternatively, the consumers for ethics in research (CERES) website: http://www.ceres.org.uk/ is 
a recommended third independent participant support body.  
 
13. Will my taking part in this study be kept confidential? 
All information that is collected about you during the course of the research will be kept strictly 
confidential. Any information about you that leaves the hospital will be coded so that at no time 
will any of your personal details be revealed. The procedures for handling, processing storage 
and destruction of any data collected during this study are compliant with the Data Protection 
Act 1998 and in line with the Southampton University Hospitals NHS Trust Policy.  
 
14. What will happen to the results of the research study? 
We hope the results are useful and we intend to publish them in a rheumatological journal and 
to present them at scientific conferences & meetings. The results will also be utilised by the 
Principal Investigator as contribution towards her  PhD thesis,  which  will  be submitted to the 
University of Southampton. You will not be identifiable in any publications arising from this work.  
 
15. Who is organising and funding the research? 
The study is sponsored by Southampton University Hospitals’ Trust (SUHT) and cosponsored by 
Southampton University. The research is organised by investigators from both SUHT and the 
School of Health Sciences within Southampton University.  
 
16. Who has reviewed the study? 
The study has been peer reviewed by the research division of the School of Health Sciences, 
Southampton  University  and  the  SUHT  Research  and  Development  Department.  The  South 
West Hampshire Local Research Ethics Committee has also reviewed the study.  
 
 
 
 
 
 
 
If you agree to take part you will be given a copy of this information sheet and a signed consent 
form  to  keep.  If  you  have  read  this  information  sheet  and  are  happy  to  participate  in  the 
proposed study please sign the reply slip attached to the invitation letter and return it in the 
stamped  address  envelope  provided  or  to  rheumatology  reception  at  your  next  outpatient 
appointment.  
 
 
 
 
 
Thank you for considering taking part and taking time to tread this information sheet. 
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A6: Participant letter of invitation & reply slip 
 
 
 
Rheumatology Research Unit 
Mailpoint 63, Level G, West Wing 
Southampton General Hospital,  
Tremona Road, Southampton.  
SO16 6YD 
Tel: 02380 796711/ 5279 
Fax: 02380 796711 
Email: lindsey.hooper@suht.swest.nhs.uk 
 
NRES code: 09/H0504/93 
SUHT Study Number: RHM MED0871 
 
Dear…………………………………….. 
 
Re: The FeeTURA
3 study – Clinical assessment – ‘The importance of foot bursae in patients 
with RA and UIA’ 
 
You are being invited to take part in a research study involving the investigation of foot problems 
in patients with Rheumatoid Arthritis (RA) or Undifferentiated Inflammatory Arthritis (UIA). This is 
a follow-up investigation to a previous study (FeeTURA) in which you may have already been 
involved. Professor Nigel Arden, Consultant Rheumatologist, remains as the main supervisor of 
this  follow-up  investigation  and  Miss  Lindsey  Hooper  is  the  lead  researcher  (Principal 
Investigator). 
 
We  know  that  inflammatory  arthritis  commonly  affects  the  feet,  and  have  also  begun  to 
understand more about the associations of swelling, pain and walking ability with RA, following 
the initial FeeTURA study.  
 
These  results  of  this  study  have  shown  that  swelling  in  the  feet  can  vary  greatly  and  can 
significantly affect a persons’ ability to walk or complete daily living tasks. This follow-up study 
has therefore been designed to investigate how these swellings might change over a 3 year 
period  in  patients  with  established  RA  or  over  a  6-month  period  in  those  patients  newly 
diagnosed  with  UIA.  This  will  be  investigated  using  questionnaires,  ultrasound,  MRI  and 
pressure-sensitive insoles. 
 
Before you decide if you would like to take part it is important that you fully understand why this 
research is being done and what it will involve. Please find enclosed a copy of the ‘participant 
information sheet’ for this study. Please take time to read this information carefully and discuss it 
with others if you wish.  
 
If you are interested in taking part in the study please complete the enclosed reply slip and 
return  it  in  the  stamped  addressed  envelope  also  provided.  If  you  have  any  concerns  or 
questions regarding this study please feel free to contact Professor Nigel Arden or myself on the 
details above at any time. 
 
Thank you for taking time to read this information,  
 
Yours sincerely,  
 
 
 
Miss Lindsey Hooper 
Principal Investigator for this study. 198 
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Rheumatology Research Unit 
Mailpoint 63, Level G, West Wing 
Southampton General Hospital,  
Tremona Road, Southampton.  
SO16 6YD 
Tel: 02380 796711/ 5279 
Fax: 02380 796711 
Email: lindsey.hooper@suht.swest.nhs.uk 
 
NRES code: 09/G0504/93 
SUHT Study Number: RHM MED0871 
 
 
 
 
 
Dear Miss Hooper,  
 
I am happy to be contacted to discuss my willingness to be considered for the following study 
further: 
 
Study:  FeeTURA
3  study  –  Clinical  assessment  –  ‘The  importance  of  forefoot  bursae  in 
patients with RA and UIA’ 
 
 
 
…………………………………   ……………………………….     ………………………………. 
Name of patient (printed)  Signature      Date 
 
 
My contact telephone number is:………………………………………………………………….. 
 
 
The date of my next Rheumatology Outpatients Appointment is: ……………………………… 
 
 
Please return this reply slip using the self-addressed envelope provided.  
 
 
Thank you. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Lead Researcher contact details: 
Miss Lindsey Hooper 
Address: As above. 
Tel: 02380 777 222 extension: 5279 
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A7: Data collection forms  
A7a: Participant demographic data assessment form (1) 
 
Participant Demographic Data 
 
1.                 
                 
 
 
 
 
 
 
 
 
2.  Date of visit:  ........./............./.......... 
 
 
 
3.  Age:..................yrs   Weight:..................kgs  Height...................cms
   
 
 
4.  Hand dominance:  Left    Right   
 
 
 
Question 
Yes   No 
(please tick if 
appropriate) 
5  Does the patient have and ACR diagnosis of Rheumatoid 
arthritis? 
   
6  Is Rheumatoid factor present?     
7  Are anti-CCP antibodies present?     
8  Does this patient have a diagnosis of osteoarthritis?     
9  Has this patient received any IV steroid in the last 8 weeks?     
10  Has this patient received any intra-muscular steroid in the last 8 
weeks? 
   
11  Is this patient currently receiving oral steroid therapy?     
11b  If yes, please provide details: 
 
12  Has this patient received any intra-articular steroid (or other) 
injections to the foot or ankle within the last 8 weeks? 
   
12b  If yes, please provide details: 
 
13  Is this patient receiving anti-TNF therapy currently?     
13b  If yes please provide details: 
 
14  Is this patient currently taking Methotrexate?     
14b  If yes, please provide details: 
 
Patient Addressograph  Patient Code: 
………………..… 
Participant no: 
……………..…… 
Year diagnosed:  
………….………. 
Arthritis duration: 
………………... 
Main sites affected: ………………... 
……………………………...……………
…..........................................................
..............................................................
........... 200 
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                                                                                                                   Yes      No 
14c  Has this patient taken Methotrexate previously?     
14d  If yes, please provide details: 
 
15  Is this patient currently taking Leflunomide?     
16  Is this patient currently taking Sulphasalazine?     
17  Is this patient currently taking Azathioprine?     
18  Is this patient currently taking Amitriptyline?     
19  Is this patient currently taking any other DMARD?     
19b  If yes, please provide details: 
 
19c  Has this patient taken any of these medications previously?     
19d  If yes, please provide details: 
 
20  Is this patient currently taking or using any other forms of 
analgesia? 
   
20b  If yes, please provide details: 
 
21  Has this patient ever had lower limb or foot surgery?     
21b  If yes please provide details (including date): 
 
22  Does this patient currently visit a podiatrist?     
22b  If no has this patient ever visited a podiatrist?     
22c  If yes, please provide details: 
 
23  Is there any documentation of foot complications in the patients’ 
medical records? 
   
23b  If yes, please provide details: 
 
 
 
 
Investigator Signature: ................................................   
 
Print name: ................................................................... 
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A7b: Participant demographic data collection form (2) 
 
Participant Demographic Data  
 
1.                 
                 
 
 
 
 
 
 
 
2.  Date of visit:  ........./............./.......... 
 
3.  Age:..................yrs   Weight:..................kgs  Height...................cms
   
 
4.  Hand dominance:  Left    Right   
 
Question  Yes   No 
(please tick if 
appropriate) 
5  Can you confirm this participant has no arthritis?     
6  Has this participant received any IV steroid in the last 8 weeks?     
7  Has this participant received any intra-muscular steroid in the 
last 8 weeks? 
   
8  Is this participant currently receiving oral steroid therapy?     
8b  If yes, please provide details: 
 
9  Has this participant received any intra-articular steroid (or other) 
injections to the foot or ankle within the last 8 weeks? 
   
9b  If yes, please provide details: 
 
10  Is the participant currently using any forms of analgesia?     
10b  If yes, please provide details 
 
11  Has this participant ever had lower limb or foot surgery?     
11b  If yes, please provide details 
 
12  Does this participant currently visit a podiatrist/chiropodist?     
12b  If no, has this participant ever visited a podiatrist/chiropodist?     
12c  If yes, please provide details 
 
13  Does this patient report any foot complications at present or 
previously? 
   
13b  If yes, please provide details 
 
 
Investigator Signature:................................................   
 
Print name:......................................... 
Participant address details 
Participant Code: 
…………………………………… 202 
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A7c: Musculoskeletal ultrasound assessment form 
 
Participant Ultrasound Assessment – Right Foot 
 
Participant Code: ......................................   Date: ............................................... 
 
Anatomical 
location 
Synovial hypertrophy 
present?  
If yes please specify 
thickness & grade 
Synovial hypertrophy 
with Doppler Activity? 
If yes please specify 
volume 
Bone Erosion present? 
If yes please specify 
MTPJ 1   
     
MTPJ 2   
     
MTPJ 3   
     
MTPJ 4   
     
MTPJ 5   
     
 
Anatomical 
location 
Bursae present?  
If yes please specify wall 
thickness & size 
Bursae present with Doppler Activity? 
If yes please specify volume 
Sub met 1   
   
Inter met 1 / 2   
   
Sub met 2    
   
Inter met 2 / 3   
   
Sub met 3   
   
Inter met 3 / 4 
     
Sub met 4 
     
Inter met 4 / 5 
     
Sub met 5 
     
 
 
 
Dorsal aspect 
Plantar aspect 
Please mark location of bursae 
Comments: 203 
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A7d: Podiatric assessment form 
 
Participant Podiatric Assessment  
 
Participant Code:......................................   Date: ............................................... 
 
  Component 
Score 
Left 
(-2 to +2) 
Right 
(-2 to +2) 
Rearfoot 
Talar head palpation     
Curves above and below lateral 
malleoli     
Inversion/ eversion of Calcaneus     
Midfoot 
Bulge in the region of TNJ     
Congruence of medial longitudinal 
arch     
Forefoot  Adduction/abduction of the forefoot 
relative to the rearfoot     
  Total     
 
 
 
 
Foot Structure Assessment (Mark as appropriate)    Right      Left 
 
Hallux Abducto Valgus:    present / absent      present / absent 
5
th MPJ Exostosis:      present / absent      present / absent 
Lesser Toe Deformity:    present / absent      present / absent 
MPJ Subluxation:      present / absent      present / absent 
 
Joint Assessment (ROM) (Mark as appropriate)    Right      Left 
Ankle Joint:                    Full / Limited / Rigid            Full / Limited / Rigid 
Sub Talar Joint:              Full / Limited / Rigid            Full / Limited / Rigid 
Mid Tarsal Joint:              Full / Limited / Rigid            Full / Limited / Rigid 
1
st MPJ:                    Full / Limited / Rigid            Full / Limited / Rigid 
Other:  
Footwear: ……………………. Orthoses: …………………. Ulceration: …………………… 
 
Other comments: ………………………………………………………………………… 
Refer for biomechanical assessment?    Yes / No     
Refer to Consultant / GP?        Yes / No 
Refer for vascular / neurological assessment?  Yes / No 
Refer to Orthotist?          Yes/ No 
Refer for podiatric treatment?       Regular Appointment / SR / SOS / Annual 
Recall / No 
Researcher’s Signature: ...................................   Date: …………………………………… 
Temporal gait parameters           Right      Left 
Location of peak pressure (A-F):  ………………………..   .……………………….. 
Value of peak pressure:    ………………………..   ……………………….. 
Time of peak pressure:    ………………………..   ……………………….. 
Total footstep time:      ………………………..   ……………………….. 
Mean force:        ………………………..   ………………………..  
   
A7e: Disease activity assessment form 
 
 
   
 
 
 
 
 
               
   
   
   
       
 
                  
 
 
       
 
 
L  R 
         
 
       
       
       
       
       
       
       
       
       
     
Which joints are swollen? (Please tick) 
ESR………………Date:……….. 
CRP………………Date:……….. 
DAS………………Date:……….. 
Global VAS: Overall wellbeing: please indicate on the scale below 
 
        0                               100 
          ----------------------------------------------------------------------- 
Best Imaginable                                            Worst Imaginable 
Health State                                   Health State 
 
                     
Which joints are tender? (Please tick) 
Patient ID _______________________ 
     
 
 
 
   
 
 
 
 
 
               
   
   
   
         
            
 
 
       
 
 
L  R 
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A7f: Foot Impact Scale – Self completed questionnaire 
 
 
 
FOOT IMPACT SCALE 
 
On the following pages you will find some statements that have been made by people 
who have arthritis in their feet.  We would like you to tick "true" if the statement applies 
to you, and tick "not true" if it does not.           
Please choose the response that applies best to you at the moment.  
 
 
                          TRUE             NOT TRUE 
 
1.  My feet get painful when I'm standing……………… 
 
2.  My feet hurt me……………………………………… 
 
3.  I find the pain in my feet frustrating………………… 
 
4.  The pain is worse when I've been on my feet all        
  day…………………………………………………… 
 
5.  At the end of the day there is pain and tension       
  in my feet……………………………………………. 
 
I never get rid of the stiffness in the background……. 
 
 
Please remember to read each statement thinking about your feet.  
Please choose the response that applies best to you at the moment.  
 
                          TRUE             NOT TRUE 
 
7.  My feet throb at night………………………………..   
 
8.  My feet wake me up at night…………………………  
 
9.  I feel as though I've got pebbles in my shoes…………   
 
10.  I get pain every time I put my foot down……………. 
 
11.  I get a burning sensation all the time…………………   
 
12.  I cry with pain………………………………………… 
 
 
Please check you have ticked a box for every statement on this page 
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Please remember to read each statement thinking about your feet.  
Please choose the response that applies best to you at the moment.  
           
                 TRUE           NOT TRUE
                     
13.  I can only walk in certain shoes……………………..       
                   
14.  I need shoes with plenty of room in them…………….. 
 
15.  I am limited in my choice of shoes……………………     
       
16.  I need a wider fit of shoes…………………………….. 
 
17.  I feel I need a lot of padding under my feet…………... 
 
18.  My footwear always feels heavy……………………… 
 
19.  I have to keep swapping and changing my shoes……… 
 
20.  I can't get any shoes on………………………………...   
 
21.  I walk bare foot all the time……………………………   
 
 
 
Please remember to read each statement thinking about your feet.  
Please choose the response that applies best to you at the moment.  
 
 
 
                TRUE           NOT TRUE 
 
22.  I feel unsafe on my feet……………………………… 
 
23.  I have to walk for a bit and sit for a bit……………….. 
 
24.  I can’t run……………………………………………. 
 
25.  I find I shuffle around……………………………….. 
 
26.  I am limping about all the time……………………… 
 
27.  I have to use a walking stick or walking frame……… 
 
 
 
 
Please check you have ticked a box for every statement on this page 
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Please remember to read each statement thinking about your feet.  
Please choose the response that applies best to you at the moment.  
 
 
                TRUE          NOT TRUE 
 
28.  It takes me all my time to climb the stairs…………… 
 
29.  I need help to climb stairs……………………………   
 
30.  I can't walk on cobbles………………………………. 
 
31.  I am unsteady on uneven surfaces…………………… 
 
32.  I can't walk as far as I would like to…………………       
           
33.  It takes me longer to do things……………………….      
           
34.  My whole life has been adapted……………………… 
 
 
 
Please remember to read each statement thinking about your feet.  
Please choose the response that applies best to you at the moment.  
 
                TRUE           NOT TRUE 
 
35.  My feet restrict my movement………………………       
               
36.  I get annoyed because I'm slower…………………….     
               
37.  I get frustrated because I can't do things so quickly…. 
 
38.  My whole life has slowed down………………………      
             
39.  It's reduced the range of things I can do……………..     
               
40.  I have to plan everything out…………………………      
           
41.  I can't keep up like I used to………………………….      
               
42.  Socially it’s affected me a lot………………………….       
             
43.  I am ashamed of how I walk………………………….  
 
44.   I'm nervous of missing a curb edge…………………..   
 
 
 
Please check you have ticked a box for every statement on this page 208 
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Please remember to read each statement thinking about your feet.    
Please choose the response that applies best to you at the moment.  
   
 
       
                TRUE          NOT TRUE
       
45.  I feel isolated because I can't go very far………………     
           
46.  I feel I slow other people down………………………..     
           
47.  I can't do some of the things I take for granted…………     
                     
48.  I can't go for walks with the people close to me………..     
                     
49.  I'm finding it difficult to be independent……………….     
           
50.  I dread finishing up in a wheelchair…………………….     
             
51.  I get frustrated because I can't do things for myself……     
       
               
Please check you have ticked a box for every statement on this page 
 
           
 
 
 
 
 
THANK YOU FOR COMPLETING THIS QUESTIONNAIRE 
 
 
 
 
 
     
 
 
FOR OFFICE USE ONLY 
 
 
 
Score 1 =   Score 2 =  209 
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A8: Year-three follow-up study response & recruitment rates 
 
 
 
 
 
Month   
(Sample size) 
Response 
Y/N 
Recruited 
Y/N 
Response 
Y/N 
Recruited Y/N 
1
st invitation  2
nd invitation 
Y 
N 
Jan 
N=31 
19 
12 
15 
4 
4 
8 
2 
2 
N 
Y 
N 
Y 
Y 
N 
Y 
N 
Y 
N 
Y 
Y 
N 
ᶧ91%, *55% 
ᶧ74%, *55% 
ᶧ40%, *40% 
ᶧ57%, *43% 
Y 
N 
Dec  
N=11 
7 
4 
4 
3 
3 
1 
2 
1 
N 
No = 1 x leg ulceration, 2 x RIP, 1 x travel, 2 x unspecified 
No = 1 x RIP, 2 x unspecified 
No = N/A 
Y 
N 
Y 
Y 
N 
Feb 
N=10 
4 
6 
4 
0 
0 
6 
0 
0 
N 
No = 1 x difficulty walking  
Mar 
N=7 
3 
4 
2 
1 
1 
3 
1 
0 
N 210 
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N 
Month   
(Sample size) 
Response 
Y/N 
Recruited 
Y/N 
Response 
Y/N 
Recruited Y/N 
1
st invitation  2
nd invitation 
Y 
N 
Y 
N 
Y 
Y 
N 
Y 
Y 
N 
Y 
Y 
N 
Y 
Y 
N 
Jul 
N=8 
3 
5 
2 
1 
1 
4 
0 
1 
N 
0 
0 
0 
0 
ᶧ50%, *38% 
ᶧ88%, *75% 
ᶧ100%, *100% 
ᶧ50%, *25% 
May N=8 
5 
3 
4 
1 
2 
1 
2 
Y  N  Apr  
N=8 
3 
5 
2 
1 
1 
4 
1 (FIS) 
Y 
N 
Y 
Y  Jun 
N=6 
5 
1 
5 
0 
1 
1  N 
N 
N 
N 
N 
N 
Y 
Y 
No = 1 x time 
No = 1 x time  
No = N/A 
No = 1 x time, 1 x unspecified 211 
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  Month   
(Sample size) 
Response 
Y/N 
Recruited 
Y/N 
Response 
Y/N 
Recruited Y/N 
1
st invitation  2
nd invitation 
Sep 
N=3 
1 
2 
1 
0 
2 
0 
2 
0 
N 
Y 
Y 
N 
Y 
Y 
N 
Y 
N 
Y 
N 
Aug  
N=1 
1 
0 
1 
0  N 
Y 
N 
Y 
Nov 
N=11 
5 
6 
5 
0 
0 
6 
N 
ᶧ100%, *100% 
ᶧ100%, *100% 
ᶧ36%, *36% 
ᶧ45%, *45% 
Y 
N 
N 
Y 
No = 1 x time, 1 x unspecified 
No = N/A 
No = 1 x travel 
No = N/A 
Y 
N 
Y 
Y 
N 
N  Oct 
N=11 
2 
9 
2 
0 
2 
7 
2 (LFIS) 
0 212 
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A9: Calculation of intra-rater FPI reliability – Bland & Altman plots 
Intra-rater reliability – demonstration of B-A plots for FPI agreement – Right foot only 
 
Mean difference: -0.62 
Standard error of mean difference: 0.46 
95% confidence interval for mean difference: -1.62 → 0.39 
Degrees of freedom: 12 
 
Intra-rater reliability – demonstration of B-A plots for FPI agreement – Left foot only 
 
Mean difference: -0.23 
Standard error of mean difference: 0.43 
95% confidence interval for mean difference: -1.16 → 0.7 
Degrees of freedom: 12 213 
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Intra-rater reliability – demonstration of B-A plots for FPI agreement – Both feet combined 
scores 
 
 
Mean difference: -0.85 
Standard error of mean difference: 0.85 
95% confidence interval for mean difference: -2.71 → 1.01 
Degrees of freedom: 12 
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A10: Calculation of inter-rater FPI reliability – Bland & Altman plots 
 
Inter-rater reliability – demonstration of B-A plots for FPI agreement – Right foot only 
 
Mean difference: -0.9 
Standard error of mean difference: 0.57 
95% confidence interval for mean difference: -2.18 → 0.38 
Degrees of freedom: 9 
 
Inter-rater reliability – demonstration of B-A plots for FPI agreement – Left foot only 
 
Mean difference: -0.3 
Standard error of mean difference: 0.56 
95% confidence interval for mean difference: -1.56 → 0.96 
Degrees of freedom: 9 215 
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Inter-rater reliability – demonstration of B-A plots for FPI agreement – Both feet combined 
scores 
 
 
 
Mean difference: -1.2 
Standard error of mean difference: 1.07 
95% confidence interval for mean difference: -3.63 → 1.23 
Degrees of freedom: 216 
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A11: Association analysis 
 
 
Table A11: FFB count association analysis (RA) 
Where ᶧ = non-parametric data; *= Significant at the 0.05 level. 
 
 
NUMBER OF FFB 
r  p-value 
age  -0.150  0.270 
BMI  -0.020  0.888 
foot posture  0.149  0.272 
hallux abducto-valgus  0.230  0.088 
lesser digital deformity  0.184  0.174 
*ankle jROM  0.277  0.039 
subtalar jROM  0.215  0.111 
midfoot jROM  0.228  0.090 
metatarsophalangeal jROM  0.238  0.077 
disease duration  -0.027  0.843 
MTP joint hypertrophy  0.184  0.175 
*erosion  0.419  0.001 
ESR  0.015  0.914 
CRP  0.050  0.716 
DAS 28-ESR  -0.009  0.947 
DAS 28-CRP  -0.049  0.718 
FISIF  0.100  0.509 
FISAP  0.161  0.284 217 
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A12: Linear regression analysis – FFB as dependent variable 
 
 
Table A12a: FFB count regression analysis (HV) 
i:  Results  of  multiple  linear  regression  analyses  for  all  dependent  variables;  ii:  Results  of  multivariate 
regression analysis for previously identified independent predictors of FFB count.  
Where  CI=  confidence  interval;  BMI=Body  mass  index;  jROM=  joint  range  of  motion;  DAS=  Disease 
Activity Score. *= Significant at the 0.05 level. 
i. 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  R
2  F-
value 
age  0.01  0.763 (-0.03-0.04)  0.00  0.092 
weight  -0.02  0.175 (-0.06-0.01)  0.04  1.9 
BMI  -0.004  0.934 (-0.10-0.09)  0.00  0.01 
MTP joint hypertrophy  0.88  0.107 (-0.2-2.0)  0.05  2.7 
erosion  0.41  0.072 (-0.04-0.86)  0.07  3.38 
*foot posture  0.17  0.003* (0.06-0.27)  0.17  9.53 
*hallux abducto-valgus   0.88  0.024* (0.12-1.63)  0.10  5.44 
*lesser digital deformity  0.53  0.000* (0.25-0.80)  0.23  14.5 
*snkle jROM  1.09  0.016* (0.22-1.97)  0.12  6.29 
*subtalar jROM  1.27  0.004* (0.42-2.12)  0.16  8.91 
*midfoot jROM  1.27  0.004* (0.42-2.12)  0.16  8.91 
 metatarsophalangeal 
jROM  0.61  0.084 (-0.08-1.3)  0.06  3.12 
 
ii. 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  Adjusted 
R
2 
F-
value 
*foot posture  0.15  0.022* (0.02-0.27) 
0.24  4.16 
hallux abducto-valgus  -0.42  0.398 (-1.4-0.57) 
*lesser digital deformity  0.77  0.026* (0.1-1.43) 
ankle jROM  -0.20  0.742 (-1.4-1.0) 
subtalar jROM     
midfoot jROM  -0.77  0.343 (-2.4-0.85) 
 
 
Table A12b: FFB count regression analysis (OA) 
i:  Results  of  multiple  linear  regression  analyses  for  all  dependent  variables;  ii:  Results  of  multivariate 
regression analysis for previously identified independent predictors of FFB count.  
i. 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  R
2  F-
value 
age  -0.05  0.070 (-0.41-0.004)  0.07  3.43 
weight  -0.004  0.786 (-0.04-0.03)  0.00  0.08 
BMI  -0.00  0.948 (-0.09-0.09)  0.00  0.00 
MTP joint hypertrophy  -0.01  0.979 (-0.48-0.47)  0.00  0.00 
erosion  0.03  0.766 (-0.20-0.26)  0.00  0.09 
foot posture  -0.04  0.497 (-0.15-0.07)  0.10  0.47 218 
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hallux abducto-valgus   -0.22  0.334 (-0.66-0.23)  0.02  0.95 
*lesser digital deformity  0.31  0.057 (-0.01-0.64)  0.07  3.79 
*snkle jROM  -0.44  0.037 (-0.85- -0.03)  0.09  4.62 
subtalar jROM  -0.05  0.829 (-0.51-0.41)  0.00  0.05 
midfoot jROM  0.09  0.675 (-0.33-0.50)  0.00  0.18 
 metatarsophalangeal 
jROM  0.20  0.302 (-0.18-0.58)  0.02  1.09 
 
ii. 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  Adjusted 
R
2 
F-
value 
*lesser digital deformity  0.37  0.022 (0.06-0.68) 
0.15  5.35 
*ankle jROM  -0.50  0.014 (-0.90- -0.11) 
 
 
Table A12c: FFB count regression analysis (RA) 
i:  Results  of  multiple  linear  regression  analyses  for  all  dependent  variables;  ii:  Results  of  multivariate 
regression analysis for previously identified independent predictors of FFB count.  
i. 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  R
2  F-
value 
age  -0.03  0.270 (-0.07)  0.02  1.24 
weight  -0.02  0.269 (-0.07-0.02)  0.02  1.25 
BMI  -0.01  0.888 (-0.17-0.14)  0.00  0.02 
ESR  0.001  0.933 (-0.03-0.03)  0.00  0.01 
CRP  -0.01  0.576 (-0.06-0.03)  0.01  0.32 
DAS 28-ESR  -0.02  0.947 (-0.46-0.43)  0.00  0.01 
DAS 28-CRP  -0.09  0.718 (-0.59-0.01)  0.00  0.13 
MTP joint hypertrophy  0.14  0.175 (-0.06-0.34)  0.03  1.89 
*erosion  0.27  0.001 (0.11-0.43)  0.18  11.49 
foot posture  0.04  0.272 (-0.03-0.11)  0.02  1.23 
hallux abducto-valgus   0.50  0.088 (-0.08-1.07)  0.05  3.03 
lesser digital deformity  0.23  0.174 (-0.10-0.56)  0.03  1.90 
*ankle jROM  0.52  0.039 (0.03-1.01)  0.08  4.47 
subtalar jROM  0.41  0.111 (-0.10-0.92)  0.05  2.62 
midfoot jROM  0.35  0.090 (-0.06-0.76)  0.05  2.97 
 metatarsophalangeal 
jROM  0.40  0.077 (-0.05-0.84)  0.06  3.24 
 
ii. 
EXPLANATORY  
VARIABLE 
NUMBER OF FFB 
Coefficient  p-value (95% CI)  Adjusted 
R
2 
F-
value 
*erosion  0.24  0.004 (0.08-0.41) 
0.18  7.02 
ankle jROM  0.36  0.137 (-0.12-0.83) 
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A13: Association analysis 
 
 
Table 13a: FFB count association analysis (HV) 
Where ᶧ = non-parametric data; *= Significant at the 0.05 level. 
 
 
NUMBER OF FFB 
r  p-value 
age  0.046  0.763 
BMI  -0.013  0.934 
*foot posture  0.407  0.003 
*ᶧhallux abducto-valgus  0.304  0.032 
*ᶧlesser digital deformity  0.460  0.001 
*ᶧankle jROM  0.344  0.014 
*ᶧsubtalar jROM  0.366  0.009 
*ᶧmidfoot jROM  0.366  0.009 
*ᶧmetatarsophalangeal jROM  0.279  0.050 
 
 
Table A13b: FFB count association analysis (OA) 
 
NUMBER OF FFB 
r  p-value 
age  -0.261  0.070 
BMI  -0.011  0.948 
foot posture  -0.098  0.497 
hallux abducto-valgus  -0.139  0.334 
lesser digital deformity  0.270  0.057 
*ankle jROM  -0.296  0.037 
subtalar jROM  -0.031  0.829 
ᶧmidfoot jROM  0.071  0.625 
ᶧmetatarsophalangeal jROM  0.117  0.419 
disease duration  -0.007  0.962 
MTP joint hypertrophy  -0.004  0.979 
erosion  0.043  0.766 
FISIF  0.140  0.333 
FISAP  0.055  0.703 
 
 
Table A13c: FFB count association analysis (RA) 
 
NUMBER OF FFB 
r  p-value 
age  -0.150  0.270 
BMI  -0.020  0.888 
foot posture  0.149  0.272 
hallux abducto-valgus  0.230  0.088 
lesser digital deformity  0.184  0.174 
*ankle jROM  0.277  0.039 
subtalar jROM  0.215  0.111 220 
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midfoot jROM  0.228  0.090 
metatarsophalangeal jROM  0.238  0.077 
disease duration  -0.027  0.843 
MTP joint hypertrophy  0.184  0.175 
*erosion  0.419  0.001 
ᶧESR  0.015  0.914 
ᶧCRP  0.050  0.716 
DAS 28-ESR  -0.009  0.947 
DAS 28-CRP  -0.049  0.718 
FISIF  0.100  0.509 
FISAP  0.161  0.284 
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A14: Linear regression analysis – FFB as explanatory variable 
 
 
Table A14a: FFB count regression analysis (HV) 
Where HV=healthy volunteer; OA= osteoarthritis; RA= rheumatoid arthritis; FFB= forefoot bursae; FPI= 
foot  posture  index;  HAV=  hallux  abducto  valgus  deformity;  LDD=  lesser  digital  deformity;  jROM=  joint 
range of motion; FISIF= foot impact score impairment subscale; FISAP= foot impact score activity limitation 
subscale; DAS= disease activity score; CRP= C-reactive protein; ESR= erythrocyte sedimentation rate; 
JH= joint hypertrophy; ER= erosion; *= Significant at the 0.05 level. 
 
EXPLANATORY 
VARIABLE: FFB 
COUNT 
DEPENDENT VARIABLE (BIOMECHANICAL) 
FPI*  HAV*  LDD*  ankle 
jROM* 
subtalar 
jROM* 
midfoot 
jROM* 
MTP 
jROM 
Coefficient  0.999  0.116  0.442  0.106  0.123  0.123  0.100 
p-value  0.003  0.024  0.000  0.016  0.004  0.004  0.084 
R
2  0.17  0.10  0.23  0.12  0.16  0.16  0.06 
F-value  9.53  5.44  14.50  6.29  8.91  8.91  3.12 
 
 
Table A14b: FFB count regression analysis (OA) 
 
EXPLANATORY 
VARIABLE: FFB 
COUNT 
DEPENDENT VARIABLE (BIOMECHANICAL) 
FPI  HAV  LDD  ankle 
jROM* 
subtalar 
jROM 
midfoot 
jROM 
MTP 
jROM 
Coefficient  -0.262  -0.090  0.233  -0.199  -0.020  0.042  0.113 
p-value  0.497  0.334  0.057  0.037  0.829  0.675  0.302 
R
2  0.01  0.02  0.07  0.09  0.001  0.004  0.02 
F-value  0.47  0.95  3.79  4.62  0.05  0.18  1.09 
 
 
EXPLANATORY 
VARIABLE: FFB 
COUNT 
DEPENDENT VARIABLE 
(DISABILITY) 
FISIF  FISAP 
Coefficient  0.451  0.318 
p-value  0.333  0.703 
R
2  0.02  0.003 
F-value  0.96  0.15 
 
 
Table A14c: FFB count regression analysis (RA) 
 
EXPLANATORY 
VARIABLE: FFB 
COUNT 
DEPENDENT VARIABLE (BIOMECHANICAL) 
FPI  HAV  LDD  ankle 
jROM* 
subtalar 
jROM 
midfoot 
jROM 
MTP 
jROM 
Coefficient  0.559  0.106  0.149  0.148  0.113  0.148  0.143 
p-value   0.272  0.088  0.174  0.039  0.111  0.090  0.077 
R
2  0.02  0.05  0.03  0.08  0.05  0.05  0.06 
F-value  1.23  3.03  1.90  4.47  2.62  2.97  3.24 
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EXPLANATORY 
VARIABLE: FFB 
COUNT 
DEPENDENT VARIABLE 
(DISABILITY) 
FISIF  FISAP 
Coefficient  0.217  0.768 
p-value   0.509  0.284 
R
2  0.01  0.03 
F-value  0.44  1.18 
 
EXPLANATORY 
VARIABLE: FFB 
COUNT 
DEPENDENT VARIABLE (RA DISEASE) 
DAS 28-CRP  DAS 28-
ESR  CRP  ESR  JH  ER* 
Coefficient  -0.027  -0.006  -0.469  0.110  0.244  0.643 
p-value   0.718  0.947  0.576  0.933  0.175  0.001 
R
2  0.002  0.000  0.01  0.000  0.03  0.18 
F-value  0.13  0.005  0.32  0.01  1.89  11.49 
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A15: Multinomial regression analysis 
 
 
Table A15a: Multinomial regression analysis (OA) 
Where HV=healthy volunteer; OA= osteoarthritis; RA= rheumatoid arthritis; FFB= forefoot bursae; FPI= 
foot  posture  index;  HAV=  hallux  abducto  valgus  deformity;  LDD=  lesser  digital  deformity;  jROM=  joint 
range of motion; FISIF= foot impact score impairment subscale; FISAP= foot impact score activity limitation 
subscale; DAS= disease activity score; CRP= C-reactive protein; ESR= erythrocyte sedimentation rate; 
JH= joint hypertrophy; ER= erosion; *= Significant at the 0.05 level.  
 
EXPLANATORY 
VARIABLE 
FFB PATTERN CATEGORY 
X
2  df  p-value  Pseudo-R
2 
(Cox & Snell) 
MTP joint hypertrophy  0.31  3  0.957  0.006 
erosion  7.24  3  0.065  0.135 
FPI  0.51  3  0.915  0.010 
LDD  2.03  3  0.567  0.040 
FISIF  1.88  3  0.597  0.037 
FISAP  5.07  3  0.167  0.096 
 
 
Table A15b: Multinomial regression analysis (RA) 
 
EXPLANATORY 
VARIABLE 
FFB PATTERN CATEGORY 
X
2  df  p-value  Pseudo-R
2 
(Cox & Snell) 
MTP joint hypertrophy  8.80  3  0.032  0.145 
erosion  15.35  3  0.002  0.240 
DAS 28-CRP  4.26  3  0.235  0.073 
DAS 28-ESR  0.86  3  0.836  0.015 
FPI  1.90  3  0.593  0.033 
LDD  3.05  3  0.384  0.053 
FISIF  2.94  3  0.400  0.051 
FISAP  0.84  3  0.841  0.015 
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A16: FFB-score intra-reader & inter-reader agreement analysis 
 
 
Table A16a: FFB-score intra-reader agreement 
Lesion 
type  Factor  PEA  PCA  Kappa 
(Left: right) 
I
n
t
e
r
m
e
t
a
t
a
r
s
a
l
 
F
l
u
i
d
 
Count  50  100  5.5: 5.5 
Shape  50  90   
Enhancement  20  100   
MR T1  50  90   
MR T2  50  50   
S
o
f
t
 
t
i
s
s
u
e
  Count  50  100  7.5: 8 
Shape  40  50   
Enhancement  50  100   
MR T1  60  90   
MR T2  30  80   
P
l
a
n
t
a
r
 
l
e
s
i
o
n
 
F
l
u
i
d
 
Count  100  100  9: 9 
Shape  100  100   
Enhancement  100  100   
MRI T1  100  100   
MRI T2  100  100   
S
o
f
t
 
t
i
s
s
u
e
  Count  90  100  8: 7 
Shape  90  100   
Enhancement  90  100   
MRI T1  90  100   
MRI T2  90  100   
 
 
 
 
 Table A16b: FFB-score inter-reader agreement 
 
Lesion 
type  Factor 
PEA  PCA  Kappa  
(left: right) 
LK-MT  LK-LH  LK-MT  LK-LH  LK-LH 
I
n
t
e
r
m
e
t
a
t
a
r
s
a
l
 
F
l
u
i
d
 
Count  31  50  86  100  4.7: 4.9 
Shape  21  50  79  90   
Enhancement  71  90  95  100   
MRI T1  26  50  57  100   
MRI T2  19  50  55  50   
S
o
f
t
 
t
i
s
s
u
e
  Count  71  100  95  100  7.5: 7.3 
Shape  86  100  90  100   
Enhancement  81  100  95  100   
MRI T1  64  100  86  100   
MRI T2  62  80  74  100   
P
l
a
n
t
a
r
 
l
e
s
i
o
n
 
F
l
u
i
d
 
Count  93  100  100  100  8.7: 6.6 
Shape  17  100  50  100   
Enhancement  88  90  98  100   
MRI T1  90  100  95  100   
MRI T2  90  100  100  100   225 
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S
o
f
t
 
t
i
s
s
u
e
  Count  19  70  52  100  6.4: 6.4 
Shape  10  40  26  70   
Enhancement  40  100  88  100   
MRI T1  10  60  33  100   
MRI T2  14  40  29  100   
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A17: FFB-score discriminant validity analysis – localised markers of disease activity 
 
 
Table A17a: FFB-score discriminant validity – MRI-determined disease activity in the forefoot 
Where FFB = Forefoot bursae; FL = fluid lesion; ST = soft tissue lesion; Sh = shape; En = enhancement; 
FISIF = foot-related impairment; FISAP foot-related activity limitation. 
*Significant at the 0.05 level. 
 
Test item  AUC  Significance  95% Confidence 
Interval 
E
r
o
s
i
o
n
 
FFB count  0.333  0.081  0.16-0.51 
FFB FL  0.281  0.022*  0.12-0.45 
FFB ST  0.491  0.922  0.31-0.67 
FFB sh  0.384  0.224  0.21-0.56 
FFB en  0.741  0.011*  0.57-0.91 
FFB FL en  0.523  0.812  0.34-0.71 
FFB ST en  0.744  0.011*  0.57-0.92 
O
e
d
e
m
a
 
FFB count  0.464  0.691  0.29-0.64 
FFB FL  0.507  0.939  0.33-0.69 
FFB ST  0.462  0.682  0.28-0.64 
FFB sh  0.478  0.808  0.30-0.65 
FFB en  0.718  0.018*  0.56-0.88 
FFB FL en  0.607  0.244  0.43-0.78 
FFB ST en  0.681  0.048*  0.51-0.86 
S
y
n
o
v
i
t
i
s
 
FFB count  0.470  0.741  0.29-0.65 
FFB FL  0.561  0.501  0.39-0.74 
FFB ST  0.410  0.322  0.24-0.59 
FFB sh  0.440  0.509  0.26-0.62 
FFB en  0.759  0.004*  0.61-0.91 
FFB FL en  0.697  0.031*  0.53-0.86 
FFB ST en  0.671  0.060  0.50-0.84 
 
 
Table A17b: FFB-score discriminant validity – patient-reported foot-related disability  
 
Test item  AUC  Significance  95% Confidence 
Interval 
F
I
S
I
F
 
FFB count  0.195  0.006*  0.06-0.33 
FFB FL  0.301  0.071  0.14-0.47 
FFB ST  0.274  0.040*  0.09-0.45 
FFB sh  0.387  0.304  0.16-0.61 
FFB en  0.527  0.806  0.30-0.76 
FFB FL en  0.490  0.927  0.27-0.72 
FFB ST en  0.502  0.988  0.30-0.70 
F
I
S
A
P
 
FFB count  0.288  0.033*  0.12-0.45 
FFB FL  0.260  0.016*  0.11-0.42 
FFB ST  0.385  0.248  0.20-0.57 
FFB sh  0.460  0.686  0.27-0.65 
FFB en  0.472  0.781  0.27-0.68 
FFB FL en  0.338  0.103  0.15-0.53 
FFB ST en  0.576  0.444  0.38-0.77 227 
 
             Appendices 
 
A18: FFB-score discriminant validity – serological/clinical markers of disease activity  
 
 
 
Where FFB = Forefoot bursae; FL = fluid lesion; ST = soft tissue lesion; Sh = shape; En = enhancement; 
CRP = C-Reactive Protein, ESR = Erythrocyte Sedimentation Rate, DAS = Disease Activity Score. 
 
Table A19a. Differentiation between moderate and high disease activity 
 
Test item  AUC  Significance  95% Confidence 
Interval 
D
A
S
 
2
8
-
C
R
P
 
FFB count  0.404  0.582  0.09-0.72 
FFB FL  0.482  0.920  0.20-0.77 
FFB ST  0.386  0.515  0.06-0.71 
FFB sh  0.228  0.121  0.00-0.47 
FFB en  0.219  0.109  0.04-0.40 
FFB FL en  0.316  0.293  0.08-0.55 
FFB ST en  0.281  0.211  0.06-0.50 
D
A
S
 
2
8
-
E
S
R
 
FFB count  0.360  0.277  0.11-0.61 
FFB FL  0.398  0.428  0.18-0.61 
FFB ST  0.376  0.338  0.14-0.61 
FFB sh  0.274  0.08  0.04-0.50 
FFB en  0.338  0.210  0.13-0.55 
FFB FL en  0.376  0.338  0.17-0.59 
FFB ST en  0.398  0.428  0.18-0.62 
C
R
P
 
FFB count  0.088  0.163  0.00-0.18 
FFB FL  0.075  0.151  0.00-0.19 
FFB ST  0.275  0.447  0.13-0.42 
FFB sh  0.225  0.353  0.09-0.36 
FFB en  0.575  0.800  0.40-0.75 
FFB FL en  0.325  0.554  0.00-0.72 
FFB ST en  0.700  0.499  0.54-0.87 
E
S
R
 
FFB count  0.487  0.952  0.00-1.00 
FFB FL  0.250  0.238  0.00-0.52 
FFB ST  0.615  0.586  0.14-1.00 
FFB sh  0.577  0.717  0.09-1.00 
FFB en  0.359  0.506  0.04-0.68 
FFB FL en  0.321  0.397  0.04-0.60 
FFB ST en  0.442  0.785  0.06-0.83 
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A18b. Differentiation between low & moderate disease activity 
 
Test item  AUC  Significance  95% Confidence 
Interval 
D
A
S
 
2
8
-
C
R
P
 
FFB count  0.482  0.847  0.30-0.67 
FFB FL  0.509  0.923  0.32-0.70 
FFB ST  0.477  0.804  0.29-0.66 
FFB sh  0.451  0.600  0.26-0.64 
FFB en  0.439  0.516  0.25-0.62 
FFB FL en  0.477  0.804  0.29-0.66 
FFB ST en  0.422  0.408  0.24-0.60 
D
A
S
 
2
8
-
E
S
R
 
FFB count  0.486  0.881  0.30-0.67 
FFB FL  0.422  0.399  0.24-0.60 
FFB ST  0.548  0.605  0.37-0.73 
FFB sh  0.505  0.957  0.32-0.69 
FFB en  0.378  0.187  0.20-0.56 
FFB FL en  0.422  0.399  0.24-0.60 
FFB ST en  0.380  0.197  0.20-0.56 
C
R
P
 
FFB count  0.443  0.539  0.26-0.62 
FFB FL  0.373  0.173  0.20-0.55 
FFB ST  0.536  0.698  0.36-0.72 
FFB sh  0.483  0.852  0.29-0.68 
FFB en  0.438  0.504  0.25-0.62 
FFB FL en  0.368  0.157  0.19-0.54 
FFB ST en  0.484  0.862  0.30-0.67 
E
S
R
 
FFB count  0.385  0.206  0.21-0.56 
FFB FL  0.360  0.124  0.19-0.53 
FFB ST  0.439  0.506  0.26-0.61 
FFB sh  0.421  0.389  0.24-0.60 
FFB en  0.426  0.419  0.25-0.60 
FFB FL en  0.367  0.144  0.19-0.54 
FFB ST en  0.444  0.540  0.27-0.62 
 
  229 
 
       
A19: The FFB-score grading sheet 
 
 
Intermetatarsal (IM) lesions 
 
 
 
 
 
  Factor  IM 
1-2 
IM 
2-3 
IM 
3-4 
IM 
4-5 
Fluid collection:(y/n) 
       
 
Size: (HxWxD, mm) 
       
 
Shape: (linear/ reticular/ circular) 
       
 
Enhancement: (0-2) 
       
 
MR characteristics (T1): (Hypo, Iso, Hyper) 
       
 
MR characteristics (T2): (Hypo, Iso, Hyper) 
       
Soft tissue lesion: (y/n) 
       
 
Size: (H x W x D, mm) 
       
 
Shape: (linear/ reticular/ circular) 
       
 
Enhancement: (0-2) 
       
 
MR characteristics (T1): (Hypo,Iso,Hyper) 
       
 
MR characteristics (T2): (Hypo,Iso,Hyper) 
       
Circle as appropriate: 
Left foot / Right foot 230 
 
   
 
 
 
Plantar forefoot lesions 
 
 
 
 
 
Factor  Head of 
metatarsal 1 
Head of 
metatarsal 2 
Head of 
metatarsal 3 
Head of 
metatarsal 4 
Head of 
metatarsal 5 
Fluid collection:(y/n) 
         
 
Size: (HxWxD, mm) 
         
 
Shape: (linear/ reticular/ circular) 
         
 
Enhancement: (0-2) 
         
 
MR characteristics (T1): (Hypo, Iso, Hyper) 
         
 
MR characteristics (T2): (Hypo, Iso, Hyper) 
         
Soft tissue lesion: (y/n) 
         
 
Size: (H x W x D, mm) 
         
 
Shape: (linear/ reticular/ circular) 
         
 
Enhancement: (0-2) 
         
 
MR characteristics (T1): (Hypo,Iso,Hyper) 
         
 
MR characteristics (T2): (Hypo,Iso,Hyper) 
         
Circle as appropriate: 
Left foot / Right foot 231 
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A20: Association analysis: the clinical importance of MRI-detectable FFB  
 
 
Table A20a: Association between systemic disease activity and FFB-subtypes 
Where DAS = Disease Activity Score; CRP= C-reactive protein, ESR= Erythrocyte sedimentation rate; 
FFB= forefoot bursae; IM= intermetatarsal; FL= fluid lesion; EN= enhancement; ST= soft tissue lesion. 
  SYSTEMIC DISEASE ACTIVITY 
r (p-value) 
DAS 28-CRP  DAS 28-ESR  CRP  ESR  Disease 
duration 
FFB count  -0.10, (0.537)  -0.05, (0.758)  -0.01, (0.949)  -0.00, (0.992)  0.15, (0.339) 
IM  -0.03, (0.831)  0.05, (0.754)  0.12, (0.459)  -0.00, (0.993)  0.15, (0.337) 
IM_FL  0.01, (0.958)  0.09, (0.583)  0.12, (0.460)  -0.02, (0.901)  0.04, (0.828) 
IM_FL_EN  -0.15, (0.338)  -0.12, (0.463)  -0.20, (0.221)  -0.09, (0.557)  -0.22, (0.158) 
IM_ST  -0.07, (0.661)  -0.04, (0.797)  0.06, (0.701)  0.00, (0.996)  0.22, (0.166) 
IM_ST_EN  -0.23, (0.154)  -0.26, (0.100)  -0.22, (0.163)  -0.08, (0.636)  0.02 (0.913) 
IM_EN  0.06, (0.723)  -0.01, (0.966)  0.08, (0.611)  0.12, (0.474)  0.27, (0.079) 
PL  -0.13, (0.420)  -0.16, (0.330)  -0.30, (0.055)  -0.01, (0.971)  0.01, (0.934) 
PL_FL  0.20, (0.206)  0.08, (0.611)  0.33, (0.035*)  0.25, (0.121)  0.02, (0.885) 
PL_FL_EN  -0.01, (0.942)  -0.07, (0.688)  0.01, (0.960)  0.10, (0.526)  -0.07, (0.683) 
PL_ST  -0.15, (0.350)  -0.17, (0.285)  -0.34, (0.029*)  -0.03, (0.877)  0.00, (0.984) 
PL_ST_EN  -0.15, (0.343)  0.02, (0.923)  -0.03, (0.863)  0.27, (0.083)  0.38, (0.015*) 
PL_EN  -0.18, (0.272)  -0.24, (0.139)  -0.24, (0.124)  -0.04, (0.803)  0.23, (0.144) 
FL  0.03, (0.847)  0.10, (0.552)  0.08, (0.636)  0.01, (0.932)  0.037, (0.818) 
FL_EN  -0.02, (0.894)  0.01, (0.966)  0.09, (0.592)  0.10, (0.531)  0.22, (0.153) 
ST  -0.16, (0.307)  -0.15, (0.351)  -0.38, (0.015*)  -0.03, (0.879)  0.23, (0.137) 
ST_EN  -0.11, (0.496)  -0.16, (0.328)  -0.21, (0.186)  -0.03, (0.849)  0.13, (0.404) 
 
Table A20b: Association between localised disease activity and FFB-subtypes 
  LOCALISED DISEASE ACTIVITY 
 (r (p-value) 
Synovitis  Bone marrow 
oedema  Erosion 
FFB count  0.23, (0.142)  0.01, (0.951)  0.10, (0.542) 
IM  0.22, (0.166)  0.11, (0.501)  0.18, (0.254) 
IM_FL  0.12, (0.450)  0.02, (0.908)  0.09, (0.582) 
IM_FL_EN  0.30, (0.053)  0.17, (0.271)  0.02, (0.905) 
IM_ST  0.37, (0.017*)  0.20, (0.216)  0.20, (0.208) 
IM_ST_EN  0.21, (0.188)  0.15, (0.351)  0.14, (0.387) 
IM_EN  0.18, (0.251)  0.13, (0.424)  0.12, (0.433) 
PL  -0.15, (0.355)  0.01, (0.932)  -0.12, (0.454) 
PL_FL  0.20, (0.216)  0.11, (0.492)  0.23, (0.151) 
PL_FL_EN  0.06, (0.694)  0.28, (0.077)  0.08, (0.612) 
PL_ST  -0.18, (0.259)  0.00, (0.998)  -0.15, (0.349) 
PL_ST_EN  0.13, (0.421)  0.10, (0.535)  0.23, (0.145) 
PL_EN  -0.12, (0.439)  -0.02, (0.878)  -0.12, (0.443) 
FL  0.04, (0.786)  0.13, (0.422)  0.12, (0.469) 
FL_EN  0.06, (0.722)  0.02, (0.903)  0.05, (0.750) 
ST  -0.08, (0.633)  0.12, (0.452)  -0.05, (0.740) 
ST_EN  -0.02, (0.919)  0.22, (0.158)  -0.02, (0.889) 232 
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Table A20c: Association between biomechanical impairment and FFB-subtypes 
 
  BIOMECHANICAL IMPAIRMENT 
r (p-value) 
FPI  LDD  HAV  Ankle jROM  ST jROM  MF jROM 
MTPl jROM 
FFB count  -0.11, (0.477)  0.12, (0.441)  0.13, (0.424)  -0.11, (0.477)  -0.12, (0.446)  0.15, (0.366)  0.01, (0.941) 
IM  -0.15, (0.363)  0.07, (0.683)  0.06, (0.692)  -0.13, (0.410)  -0.14, (0.381)  0.12, (0.466)  -0.10, (0.518) 
IM_FL  0.03, (0.858)  0.03, (0.872)  0.17, (0.288)  0.04, (0.818)  -0.02, (0.917)  0.16, (0.313)  0.03, (0.855) 
IM_FL_EN  -0.07, (0.664)  0.01, (0.963)  0.12, (0.443)  -0.28, (0.081)  -0.28, (0.079)  -0.13, (0.411)  -0.12, (0.451) 
IM_ST  -0.36, (0.019*)  0.10, (0.550)  -0.16, (0.317)  -0.35, (0.025*)  -0.27, (0.085)  -0.03, (0.848)  -0.28, (0.082) 
IM_ST_EN  -0.08, (0.617)  -0.04, (0.783)  0.05, (0.762)  -0.05, (0.738)  0.03, (0.851)  -0.07, (0.646)  -0.20, (0.206) 
IM_EN  -0.25, (0.116)  0.13, (0.432)  -0.11, (0.480)  -0.17, (0.303)  -0.11, (0.498)  0.10, (0.548)  -0.16, (0.306) 
PL  -0.02, (0.895)  0.14, (0.383)  0.15, (0.347)  -0.04, (0.809)  -0.04, (0.790)  0.11, (0.480)  0.15, (0.340) 
PL_FL  -0.09, (0.560)  -0.01, (0.951)  0.27, (0.091)  0.03, (0.837)  0.06, (0.703)  0.25, (0.110)  0.23, (0.146) 
PL_FL_EN  -0.03, (0.876)  -0.01, (0.962)  0.06, (0.722)  -0.22, (0.170)  -0.22, (0.170)  -0.02, (0.918)  -0.05, (0.775) 
PL_ST  -0.01, (0.951)  0.15, (0.365)  0.12, (0.452)  -0.04, (0.783)  -0.05, (0.746)  0.08, (0.600)  0.13, (0.426) 
PL_ST_EN  0.12, (0.442)  0.15, (0.337)  0.30, (0.060)  0.13, (0.403)  0.17, (0.295)  0.31, (0.052)  0.20, (0.221) 
PL_EN  -0.12, (0.447)  -0.03, (0.843)  0.01, (0.941)  -0.22, (0.159)  -0.20, (0.221)  -0.08, (0.612)  0.02, (0.890) 
FL  0.02, (0.916)  0.02, (0.881)  0.20, (0.216)  0.04, (0.804)  -0.01, (0.955)  0.19, (0.241)  0.06, (0.728) 
FL_EN  -0.18, (0.272)  0.04, (0.785)  -0.06, (0.711)  -0.09, (0.570)  -0.06, (0.734)  0.09, (0.574)  -0.12, (0.444) 
ST  -0.18, (0.249)  0.13, (0.434)  -0.10, (0.536)  -0.27, (0.084)  -0.17, (0.277)  0.05, (0.745)  -0.03, (0.847) 
ST_EN  -0.25, (0.116)  0.16, (0.310)  0.02, (0.907)  -0.20, (0.200)  -0.21, (0.181)  -0.00, (0.996)  -0.10, (0.542) 
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Table A20d: Association between patient-reported foot-related disability and FFB-subtypes 
 
  DISABILITY 
r (p-value) 
FISIF  FISAP 
FFB count  -0.06, (0.729)  -0.05, (0.764) 
IM  -0.04, (0.806)  -0.09, (0.568) 
IM_FL  -0.01, (0.937)  -0.01, (0.969) 
IM_FL_EN  0.02, (0.912)  -0.05, (0.760) 
IM_ST  -0.06, (0.698)  -0.18, (0.246) 
IM_ST_EN  -0.11, (0.504)  -0.20, (0.209) 
IM_EN  -0.05, (0.742)  -0.04, (0.787) 
PL  -0.05, (0.767)  0.02, (0.880) 
PL_FL  0.17, (0.270)  0.25, (0.113) 
PL_FL_EN  0.01, (0.936)  0.03, (0.832) 
PL_ST  -0.07, (0.667)  -0.00, (0.980) 
PL_ST_EN  -0.08, (0.630)  0.18, (0.264) 
PL_EN  -0.27, (0.089)  -0.06, (0.716) 
FL  0.01, (0.958)  0.02, (0.883) 
FL_EN  -0.10, (0.533)  -0.03, (0.875) 
ST  -0.09, (0.588)  -0.09, (0.580) 
ST_EN  -0.12, (0.469)  -0.07, (0.662)  
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